{"text":"An 8-week , randomized , parallel-group , double-blind international trial comparing the once-daily single-pill combination of telmisartan 80 mg and amlodipine 10 mg ( T/A ; n = 352 ) with once-daily amlodipine 10 mg ( A ; n = 354 ) in patients with type 2 diabetes mellitus and stage 1 or 2 hypertension ( systolic BP [ SBP ] > 150 mm Hg ) .","paragraph":"<h3><u>Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.</u></h3>Hypertensive patients with diabetes often require combination therapy to achieve a blood pressure (BP) goal, and evidence suggests that time to BP goal is crucial to decrease cardiovascular risk. ### objective The aim of the study was to investigate whether the single-pill combination of <b style='color:Tomato;'><i>telmisartan</i></b> and <b style='color:Tomato;'><i>amlodipine</i></b> was superior to <b style='color:Tomato;'><i>amlodipine</i></b> alone as initial antihypertensive therapy in patients with diabetes and hypertension. ### methods <b style='color:DodgerBlue;'><i>An</i></b> <b style='color:DodgerBlue;'><i>8-week</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>parallel-group</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>international</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>once-daily</i></b> <b style='color:DodgerBlue;'><i>single-pill</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>telmisartan</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>T/A</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>352</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>once-daily</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>354</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>type</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>diabetes</i></b> <b style='color:DodgerBlue;'><i>mellitus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>hypertension</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>systolic</i></b> <b style='color:DodgerBlue;'><i>BP</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>SBP</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>150</i></b> <b style='color:DodgerBlue;'><i>mm</i></b> <b style='color:DodgerBlue;'><i>Hg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Patient demographics were similar between treatment groups, with an mean (SD) age of 60.5 (10.1) years; 51.7% were male, the mean (SD) body mass index was 32.0 (6.1) and the mean (SD) duration of hypertension was 8.8 (7.9) years. After 8 weeks (primary end point) as well as after 1, 2, and 4 weeks (key secondary end points), significantly greater decreases in the in-clinic mean seated trough cuff SBP with T/A versus A were achieved (-29.0 mm Hg vs -22.9 mm Hg at 8 weeks; P < 0.0001). After 8 weeks, 71.4% versus 53.8% of patients achieved the BP goal (<140/90 mm Hg) with T/A versus A, with mean SBPs of 131.9 and 137.9 mm Hg, respectively. Similar results were observed in the obese (metabolic syndrome) subpopulation. The more stringent goal (<130/80 mm Hg) was achieved by 36.4% and 17.9% patients in the T/A and A groups, respectively. The most common adverse events were peripheral edema, headache, and dizziness. ### conclusions In this selected population of patients with diabetes and hypertension, T/A provided prompt and greater BP decreases compared with A monotherapy, with the majority of patients achieving the BP goal (<140/90 mm Hg).","tokens":[{"text":"An","start":0,"end":2,"id":0,"ws":true},{"text":"8-week","start":3,"end":9,"id":1,"ws":true},{"text":",","start":10,"end":11,"id":2,"ws":true},{"text":"randomized","start":12,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"parallel-group","start":25,"end":39,"id":5,"ws":true},{"text":",","start":40,"end":41,"id":6,"ws":true},{"text":"double-blind","start":42,"end":54,"id":7,"ws":true},{"text":"international","start":55,"end":68,"id":8,"ws":true},{"text":"trial","start":69,"end":74,"id":9,"ws":true},{"text":"comparing","start":75,"end":84,"id":10,"ws":true},{"text":"the","start":85,"end":88,"id":11,"ws":true},{"text":"once-daily","start":89,"end":99,"id":12,"ws":true},{"text":"single-pill","start":100,"end":111,"id":13,"ws":true},{"text":"combination","start":112,"end":123,"id":14,"ws":true},{"text":"of","start":124,"end":126,"id":15,"ws":true},{"text":"telmisartan","start":127,"end":138,"id":16,"ws":true},{"text":"80","start":139,"end":141,"id":17,"ws":true},{"text":"mg","start":142,"end":144,"id":18,"ws":true},{"text":"and","start":145,"end":148,"id":19,"ws":true},{"text":"amlodipine","start":149,"end":159,"id":20,"ws":true},{"text":"10","start":160,"end":162,"id":21,"ws":true},{"text":"mg","start":163,"end":165,"id":22,"ws":true},{"text":"(","start":166,"end":167,"id":23,"ws":true},{"text":"T/A","start":168,"end":171,"id":24,"ws":true},{"text":";","start":172,"end":173,"id":25,"ws":true},{"text":"n","start":174,"end":175,"id":26,"ws":true},{"text":"=","start":176,"end":177,"id":27,"ws":true},{"text":"352","start":178,"end":181,"id":28,"ws":true},{"text":")","start":182,"end":183,"id":29,"ws":true},{"text":"with","start":184,"end":188,"id":30,"ws":true},{"text":"once-daily","start":189,"end":199,"id":31,"ws":true},{"text":"amlodipine","start":200,"end":210,"id":32,"ws":true},{"text":"10","start":211,"end":213,"id":33,"ws":true},{"text":"mg","start":214,"end":216,"id":34,"ws":true},{"text":"(","start":217,"end":218,"id":35,"ws":true},{"text":"A","start":219,"end":220,"id":36,"ws":true},{"text":";","start":221,"end":222,"id":37,"ws":true},{"text":"n","start":223,"end":224,"id":38,"ws":true},{"text":"=","start":225,"end":226,"id":39,"ws":true},{"text":"354","start":227,"end":230,"id":40,"ws":true},{"text":")","start":231,"end":232,"id":41,"ws":true},{"text":"in","start":233,"end":235,"id":42,"ws":true},{"text":"patients","start":236,"end":244,"id":43,"ws":true},{"text":"with","start":245,"end":249,"id":44,"ws":true},{"text":"type","start":250,"end":254,"id":45,"ws":true},{"text":"2","start":255,"end":256,"id":46,"ws":true},{"text":"diabetes","start":257,"end":265,"id":47,"ws":true},{"text":"mellitus","start":266,"end":274,"id":48,"ws":true},{"text":"and","start":275,"end":278,"id":49,"ws":true},{"text":"stage","start":279,"end":284,"id":50,"ws":true},{"text":"1","start":285,"end":286,"id":51,"ws":true},{"text":"or","start":287,"end":289,"id":52,"ws":true},{"text":"2","start":290,"end":291,"id":53,"ws":true},{"text":"hypertension","start":292,"end":304,"id":54,"ws":true},{"text":"(","start":305,"end":306,"id":55,"ws":true},{"text":"systolic","start":307,"end":315,"id":56,"ws":true},{"text":"BP","start":316,"end":318,"id":57,"ws":true},{"text":"[","start":319,"end":320,"id":58,"ws":true},{"text":"SBP","start":321,"end":324,"id":59,"ws":true},{"text":"]","start":325,"end":326,"id":60,"ws":true},{"text":">","start":327,"end":328,"id":61,"ws":true},{"text":"150","start":329,"end":332,"id":62,"ws":true},{"text":"mm","start":333,"end":335,"id":63,"ws":true},{"text":"Hg","start":336,"end":338,"id":64,"ws":true},{"text":")","start":339,"end":340,"id":65,"ws":true},{"text":".","start":341,"end":342,"id":66,"ws":false}],"spans":[{"start":127,"end":138,"token_start":16,"token_end":16,"label":"DRUG"},{"start":149,"end":159,"token_start":20,"token_end":20,"label":"DRUG"},{"start":200,"end":210,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22386829/","_input_hash":1420509013,"_task_hash":-220521991,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":16,"child":20,"head_span":{"start":127,"end":138,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":149,"end":159,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Pharmacokinetic studies evaluating the concurrent use of tenofovir and didanosine have been performed in healthy volunteers .","paragraph":"<h3><u>Effect of tenofovir on didanosine absorption in patients with HIV.</u></h3>To evaluate the pharmacokinetic interaction between <b style='color:Tomato;'><i>tenofovir</i></b> and <b style='color:Tomato;'><i>didanosine</i></b> when used in combination as a highly active antiretroviral therapy regimen. ### Data Sources Literature retrieval was accessed through MEDLINE (1966-January 2003) using the terms <b style='color:Tomato;'><i>tenofovir</i></b> and <b style='color:Tomato;'><i>didanosine</i></b>. Abstracts from recent meetings, including the International AIDS Society, Interscience Conference on Antimicrobial Agents and Chemotherapy, and the Infectious Diseases Society of America, were reviewed for relevant abstracts and poster presentations. ### Data Synthesis <b style='color:DodgerBlue;'><i>Pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>evaluating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concurrent</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tenofovir</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>didanosine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>healthy</i></b> <b style='color:DodgerBlue;'><i>volunteers</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>tenofovir</i></b> 300 mg administered concurrently with 400 mg <b style='color:Tomato;'><i>didanosine</i></b> results in a 48-64% increase in the <b style='color:Tomato;'><i>didanosine</i></b> maximum plasma concentration and AUC with no significant alterations in the <b style='color:Tomato;'><i>tenofovir</i></b> pharmacokinetic parameters. <b style='color:Tomato;'><i>tenofovir</i></b> 300 mg and <b style='color:Tomato;'><i>didanosine</i></b> 250 mg has been compared with <b style='color:Tomato;'><i>didanosine</i></b> 400 mg alone. The results demonstrated equivalent <b style='color:Tomato;'><i>didanosine</i></b> AUCs. ### conclusions When used concurrently, <b style='color:Tomato;'><i>tenofovir</i></b> significantly increases the maximum plasma concentration and the AUC of <b style='color:Tomato;'><i>didanosine</i></b>. Additional data in HIV-infected patients are needed to determine the long-term toxicities of this combination therapy. <b style='color:Tomato;'><i>didanosine</i></b> dose reduction should be considered when these 2 agents are used concurrently.","tokens":[{"text":"Pharmacokinetic","start":0,"end":15,"id":0,"ws":true},{"text":"studies","start":16,"end":23,"id":1,"ws":true},{"text":"evaluating","start":24,"end":34,"id":2,"ws":true},{"text":"the","start":35,"end":38,"id":3,"ws":true},{"text":"concurrent","start":39,"end":49,"id":4,"ws":true},{"text":"use","start":50,"end":53,"id":5,"ws":true},{"text":"of","start":54,"end":56,"id":6,"ws":true},{"text":"tenofovir","start":57,"end":66,"id":7,"ws":true},{"text":"and","start":67,"end":70,"id":8,"ws":true},{"text":"didanosine","start":71,"end":81,"id":9,"ws":true},{"text":"have","start":82,"end":86,"id":10,"ws":true},{"text":"been","start":87,"end":91,"id":11,"ws":true},{"text":"performed","start":92,"end":101,"id":12,"ws":true},{"text":"in","start":102,"end":104,"id":13,"ws":true},{"text":"healthy","start":105,"end":112,"id":14,"ws":true},{"text":"volunteers","start":113,"end":123,"id":15,"ws":true},{"text":".","start":124,"end":125,"id":16,"ws":false}],"spans":[{"start":57,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},{"start":71,"end":81,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12921517/","_input_hash":810721498,"_task_hash":1472186623,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":57,"end":66,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":71,"end":81,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"This comparative phase III trial of mitoxantrone+vinorelbine ( MV ) versus 5-fluorouracil+cyclophosphamide+either doxorubicin or epirubicin ( FAC/FEC ) in the treatment of metastatic breast cancer was conducted to determine whether MV would produce equivalent efficacy , while resulting in an improved tolerance in relation to alopecia and nausea/vomiting .","paragraph":"<h3><u>Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.</u></h3> <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mitoxantrone+vinorelbine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil+cyclophosphamide+either</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FAC/FEC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:DodgerBlue;'><i>MV</i></b> <b style='color:DodgerBlue;'><i>would</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>equivalent</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>resulting</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>tolerance</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>relation</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>alopecia</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>nausea/vomiting</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This multicentre study recruited and randomised 281 patients with metastatic breast cancer; 280 were evaluable for response survival and toxicity (138 received FAC/FEC, 142 received MV). Patient characteristics were matched in each arm and stratification for prior exposure to adjuvant therapy was made prospectively. The overall response rate (ORR) was equivalent in the two arms (33.3% for FAC/FEC versus 34.5% for MV), but MV was more effective in patients who had received prior adjuvant therapy (13% (95% confidence interval (CI) 3-23) for FAC/FEC versus 33% (95% CI 20-47) for MV P=0.025) with a better progression-free survival (PFS) (5 months (range 1-18 months) versus 8 months (range 1-27 months); P=0.0007 for FAC/FEC versus MV, respectively) while FAC/FEC was more effective in previously untreated patients (ORR 43% (95% CI 33-53) versus 35% (95% CI 25-45), P=0.26; PFS 9 months (range 0-29 months) versus 6 months (range 0-26 months) P=0.014). Toxicity was monitored through the initial six cycles of therapy; febrile neutropenia and delayed haematological recovery was more frequent for MV (P=0.001), while nausea/vomiting of grades 3-4 was greater for FAC/FEC (P=0.031), as was alopecia (P=0.0001), cardiotoxicity was the same for the two regimens. MV represents a chemotherapy combination with equivalent efficacy to standard FAC/FEC and improved results for patients who have previously received adjuvant chemotherapy. Toxicity must be balanced to allow for increased haematological suppression and risk of febrile neutropenia with MV compared with a higher risk of subjectively unpleasant side-effects such as nausea/vomiting and alopecia with FAC/FEC.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"comparative","start":5,"end":16,"id":1,"ws":true},{"text":"phase","start":17,"end":22,"id":2,"ws":true},{"text":"III","start":23,"end":26,"id":3,"ws":true},{"text":"trial","start":27,"end":32,"id":4,"ws":true},{"text":"of","start":33,"end":35,"id":5,"ws":true},{"text":"mitoxantrone+vinorelbine","start":36,"end":60,"id":6,"ws":true},{"text":"(","start":61,"end":62,"id":7,"ws":true},{"text":"MV","start":63,"end":65,"id":8,"ws":true},{"text":")","start":66,"end":67,"id":9,"ws":true},{"text":"versus","start":68,"end":74,"id":10,"ws":true},{"text":"5-fluorouracil+cyclophosphamide+either","start":75,"end":113,"id":11,"ws":true},{"text":"doxorubicin","start":114,"end":125,"id":12,"ws":true},{"text":"or","start":126,"end":128,"id":13,"ws":true},{"text":"epirubicin","start":129,"end":139,"id":14,"ws":true},{"text":"(","start":140,"end":141,"id":15,"ws":true},{"text":"FAC/FEC","start":142,"end":149,"id":16,"ws":true},{"text":")","start":150,"end":151,"id":17,"ws":true},{"text":"in","start":152,"end":154,"id":18,"ws":true},{"text":"the","start":155,"end":158,"id":19,"ws":true},{"text":"treatment","start":159,"end":168,"id":20,"ws":true},{"text":"of","start":169,"end":171,"id":21,"ws":true},{"text":"metastatic","start":172,"end":182,"id":22,"ws":true},{"text":"breast","start":183,"end":189,"id":23,"ws":true},{"text":"cancer","start":190,"end":196,"id":24,"ws":true},{"text":"was","start":197,"end":200,"id":25,"ws":true},{"text":"conducted","start":201,"end":210,"id":26,"ws":true},{"text":"to","start":211,"end":213,"id":27,"ws":true},{"text":"determine","start":214,"end":223,"id":28,"ws":true},{"text":"whether","start":224,"end":231,"id":29,"ws":true},{"text":"MV","start":232,"end":234,"id":30,"ws":true},{"text":"would","start":235,"end":240,"id":31,"ws":true},{"text":"produce","start":241,"end":248,"id":32,"ws":true},{"text":"equivalent","start":249,"end":259,"id":33,"ws":true},{"text":"efficacy","start":260,"end":268,"id":34,"ws":true},{"text":",","start":269,"end":270,"id":35,"ws":true},{"text":"while","start":271,"end":276,"id":36,"ws":true},{"text":"resulting","start":277,"end":286,"id":37,"ws":true},{"text":"in","start":287,"end":289,"id":38,"ws":true},{"text":"an","start":290,"end":292,"id":39,"ws":true},{"text":"improved","start":293,"end":301,"id":40,"ws":true},{"text":"tolerance","start":302,"end":311,"id":41,"ws":true},{"text":"in","start":312,"end":314,"id":42,"ws":true},{"text":"relation","start":315,"end":323,"id":43,"ws":true},{"text":"to","start":324,"end":326,"id":44,"ws":true},{"text":"alopecia","start":327,"end":335,"id":45,"ws":true},{"text":"and","start":336,"end":339,"id":46,"ws":true},{"text":"nausea/vomiting","start":340,"end":355,"id":47,"ws":true},{"text":".","start":356,"end":357,"id":48,"ws":false}],"spans":[{"start":114,"end":125,"token_start":12,"token_end":12,"label":"DRUG"},{"start":129,"end":139,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11378344/","_input_hash":966972887,"_task_hash":576970413,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Overnight urinary oxytocin and vasopressin levels were obtained from 62 healthy males ( age range : 18 - 26 years ) to compare with trait measures of trust and aggressive behavior .","paragraph":"<h3><u>Oxytocin, vasopressin and trust: Associations with aggressive behavior in healthy young males.</u></h3><b style='color:Tomato;'><i>oxytocin</i></b> enhances trust during social interactions and reduces the tendency for social betrayal. Animal studies have revealed that <b style='color:Tomato;'><i>oxytocin</i></b> is also an important factor in the establishment and regulation of aggression, for which social interaction is a critical precondition. In humans, however, the effects of <b style='color:Tomato;'><i>oxytocin</i></b> appear more nuanced and influenced by social context and personality traits. Moreover, the pro-social effects of <b style='color:Tomato;'><i>oxytocin</i></b> are not mirrored by <b style='color:Tomato;'><i>vasopressin</i></b>, despite their high chemical similarity. Rather, <b style='color:Tomato;'><i>vasopressin</i></b> has been associated with an increase of aggressive responses. Therefore, we sought to investigate the association of <b style='color:Tomato;'><i>oxytocin</i></b> and <b style='color:Tomato;'><i>vasopressin</i></b> with trust and aggressive behavior. <b style='color:DodgerBlue;'><i>Overnight</i></b> <b style='color:DodgerBlue;'><i>urinary</i></b> <b style='color:MediumOrchid;'><i>oxytocin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vasopressin</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>obtained</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>62</i></b> <b style='color:DodgerBlue;'><i>healthy</i></b> <b style='color:DodgerBlue;'><i>males</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>range</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>26</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>trait</i></b> <b style='color:DodgerBlue;'><i>measures</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>trust</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>aggressive</i></b> <b style='color:DodgerBlue;'><i>behavior</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We found a significant interaction of <b style='color:Tomato;'><i>oxytocin</i></b> and trust on aggression in which low trait measures of trust, in combination with low levels of <b style='color:Tomato;'><i>oxytocin</i></b>, were associated with a history of aggressive behavior. Notably, we found no significant associations for <b style='color:Tomato;'><i>vasopressin</i></b>. Although both <b style='color:Tomato;'><i>oxytocin</i></b> and <b style='color:Tomato;'><i>vasopressin</i></b> have been shown to be important in the emergence of violent behavior, our study suggests that <b style='color:Tomato;'><i>oxytocin</i></b> may be particularly modified by affiliative behaviors. These findings provide insights into the neuropsychological influences of <b style='color:Tomato;'><i>oxytocin</i></b>, and highlights the potential for clinical translation regarding the treatment of patients who exhibit recurrent aggressive behavior.","tokens":[{"text":"Overnight","start":0,"end":9,"id":0,"ws":true},{"text":"urinary","start":10,"end":17,"id":1,"ws":true},{"text":"oxytocin","start":18,"end":26,"id":2,"ws":true},{"text":"and","start":27,"end":30,"id":3,"ws":true},{"text":"vasopressin","start":31,"end":42,"id":4,"ws":true},{"text":"levels","start":43,"end":49,"id":5,"ws":true},{"text":"were","start":50,"end":54,"id":6,"ws":true},{"text":"obtained","start":55,"end":63,"id":7,"ws":true},{"text":"from","start":64,"end":68,"id":8,"ws":true},{"text":"62","start":69,"end":71,"id":9,"ws":true},{"text":"healthy","start":72,"end":79,"id":10,"ws":true},{"text":"males","start":80,"end":85,"id":11,"ws":true},{"text":"(","start":86,"end":87,"id":12,"ws":true},{"text":"age","start":88,"end":91,"id":13,"ws":true},{"text":"range","start":92,"end":97,"id":14,"ws":true},{"text":":","start":98,"end":99,"id":15,"ws":true},{"text":"18","start":100,"end":102,"id":16,"ws":true},{"text":"-","start":103,"end":104,"id":17,"ws":true},{"text":"26","start":105,"end":107,"id":18,"ws":true},{"text":"years","start":108,"end":113,"id":19,"ws":true},{"text":")","start":114,"end":115,"id":20,"ws":true},{"text":"to","start":116,"end":118,"id":21,"ws":true},{"text":"compare","start":119,"end":126,"id":22,"ws":true},{"text":"with","start":127,"end":131,"id":23,"ws":true},{"text":"trait","start":132,"end":137,"id":24,"ws":true},{"text":"measures","start":138,"end":146,"id":25,"ws":true},{"text":"of","start":147,"end":149,"id":26,"ws":true},{"text":"trust","start":150,"end":155,"id":27,"ws":true},{"text":"and","start":156,"end":159,"id":28,"ws":true},{"text":"aggressive","start":160,"end":170,"id":29,"ws":true},{"text":"behavior","start":171,"end":179,"id":30,"ws":true},{"text":".","start":180,"end":181,"id":31,"ws":false}],"spans":[{"start":18,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},{"start":31,"end":42,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30802507/","_input_hash":852254592,"_task_hash":-940615028,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Additionally , the combined effect of Lapatinib together with Herceptin or Cetuximab on cell-mediated cytotoxicity was evaluated .","paragraph":"<h3><u>Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.</u></h3><b style='color:Tomato;'><i>lapatinib</i></b> is a dual tyrosine kinase inhibitor of the EGFR and HER2 tyrosine kinase domains. EGFR is expressed in 33.3% and HER2 in 30.3% of esophageal squamous cell carcinomas (ESCCs). To explore the potential utility of <b style='color:Tomato;'><i>lapatinib</i></b> for therapy of ESCC patients, we evaluated the effect of <b style='color:Tomato;'><i>lapatinib</i></b> on a panel of ESCC cell lines. EGFR and HER2 expression by the cell lines was established, and the effects of <b style='color:Tomato;'><i>lapatinib</i></b> on inhibition of the phosphorylation of HER2, antiproliferative effect, apoptosis-inducing activity and accumulation of HER2 and EGFR on cell surface were evaluated. <b style='color:DodgerBlue;'><i>Additionally</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Lapatinib</i></b> <b style='color:DodgerBlue;'><i>together</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Herceptin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>Cetuximab</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>cell-mediated</i></b> <b style='color:DodgerBlue;'><i>cytotoxicity</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>lapatinib</i></b> inhibited HER2 phosphorylation in HER2-overexpressing, HER2 gene amplification positive ESCC cell line. <b style='color:Tomato;'><i>lapatinib</i></b> also inhibited cell proliferation, induced apoptosis and caused the surface accumulation of HER2 and EGFR in ESCC cell lines. Addition of <b style='color:Tomato;'><i>lapatinib</i></b> increased Herceptin-mediated antibody-dependent cell-mediated cytotoxicity by 15-25% with three ESCC target cell lines. Similarly, <b style='color:Tomato;'><i>cetuximab</i></b>-mediated antibody-dependent cell-mediated cytotoxicity also increased by 15-30% in two ESCC cell lines on addition of <b style='color:Tomato;'><i>lapatinib</i></b>. Cumulatively, the data indicate that <b style='color:Tomato;'><i>lapatinib</i></b> has activity in EGFR- and/or HER2-expressing ESCC cells, and the combination therapy of <b style='color:Tomato;'><i>lapatinib</i></b> and <b style='color:Tomato;'><i>cetuximab</i></b>/Herceptin is a promising strategy in ESCC.","tokens":[{"text":"Additionally","start":0,"end":12,"id":0,"ws":true},{"text":",","start":13,"end":14,"id":1,"ws":true},{"text":"the","start":15,"end":18,"id":2,"ws":true},{"text":"combined","start":19,"end":27,"id":3,"ws":true},{"text":"effect","start":28,"end":34,"id":4,"ws":true},{"text":"of","start":35,"end":37,"id":5,"ws":true},{"text":"Lapatinib","start":38,"end":47,"id":6,"ws":true},{"text":"together","start":48,"end":56,"id":7,"ws":true},{"text":"with","start":57,"end":61,"id":8,"ws":true},{"text":"Herceptin","start":62,"end":71,"id":9,"ws":true},{"text":"or","start":72,"end":74,"id":10,"ws":true},{"text":"Cetuximab","start":75,"end":84,"id":11,"ws":true},{"text":"on","start":85,"end":87,"id":12,"ws":true},{"text":"cell-mediated","start":88,"end":101,"id":13,"ws":true},{"text":"cytotoxicity","start":102,"end":114,"id":14,"ws":true},{"text":"was","start":115,"end":118,"id":15,"ws":true},{"text":"evaluated","start":119,"end":128,"id":16,"ws":true},{"text":".","start":129,"end":130,"id":17,"ws":false}],"spans":[{"start":38,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},{"start":62,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},{"start":75,"end":84,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21207425/","_input_hash":-45206025,"_task_hash":-1333586876,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":6,"child":9,"head_span":{"start":38,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":62,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":11,"head_span":{"start":38,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":75,"end":84,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"In a case-control study , we compared 52 consecutive patients undergoing isolated CABG on aspirin and clopidogrel 75mg/d versus 50 controls on aspirin monotherapy .","paragraph":"<h3><u>Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery.</u></h3>Patients scheduled for coronary artery bypass graft surgery (CABG) are commonly treated with <b style='color:Tomato;'><i>clopidogrel</i></b>. We sought to assess the relation between preoperative platelet aggregation and bleeds in CABG patients on <b style='color:Tomato;'><i>clopidogrel</i></b>. ### Material And Methods <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>case-control</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>52</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>undergoing</i></b> <b style='color:DodgerBlue;'><i>isolated</i></b> <b style='color:DodgerBlue;'><i>CABG</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>75mg/d</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>controls</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Platelet aggregation induced by 10\u03bcmol/l adenosine di-phosphate (ADP) in platelet-rich plasma was measured in subjects on <b style='color:Tomato;'><i>clopidogrel</i></b> within 5days prior to surgery. ADP-induced aggregation of \u226550% was used to define subjects with satisfactory inhibition of platelet reactivity. ### results In 29 patients with preoperative ADP-induced aggregation \u226550%, compared with 23 subjects with aggregation <50%, lower chest-tube drainage volumes (after 6h, p=0.002; and 12h, p=0.001) and fewer rethoracotomies were observed (p=0.03). The former group was characterized with lower transfusion rates of packed red blood cells (p=0.009), platelet concentrate (p=0.04) and fresh frozen plasma (p=0.001). Patients with ADP-induced aggregation \u226550% did not differ from untreated controls regarding the postoperative drainage, transfusions and rethoracotomy. The incidence of thromboembolic events and death during perioperative period were similar in all groups. Multivariate logistic regression identified ADP-induced aggregation <50% as the only independent predictor of rethoracotomy (OR=2.94 [1.12-7.75], p=0.029). ### conclusions Patients on <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> <5days before CABG who had preoperative ADP-induced platelet aggregation \u226550% have bleeding risk similar to those receiving <b style='color:Tomato;'><i>aspirin</i></b> monotherapy. Reduced platelet reactivity to ADP can predict postoperative bleeding in CABG patients on dual antiplatelet therapy.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"a","start":3,"end":4,"id":1,"ws":true},{"text":"case-control","start":5,"end":17,"id":2,"ws":true},{"text":"study","start":18,"end":23,"id":3,"ws":true},{"text":",","start":24,"end":25,"id":4,"ws":true},{"text":"we","start":26,"end":28,"id":5,"ws":true},{"text":"compared","start":29,"end":37,"id":6,"ws":true},{"text":"52","start":38,"end":40,"id":7,"ws":true},{"text":"consecutive","start":41,"end":52,"id":8,"ws":true},{"text":"patients","start":53,"end":61,"id":9,"ws":true},{"text":"undergoing","start":62,"end":72,"id":10,"ws":true},{"text":"isolated","start":73,"end":81,"id":11,"ws":true},{"text":"CABG","start":82,"end":86,"id":12,"ws":true},{"text":"on","start":87,"end":89,"id":13,"ws":true},{"text":"aspirin","start":90,"end":97,"id":14,"ws":true},{"text":"and","start":98,"end":101,"id":15,"ws":true},{"text":"clopidogrel","start":102,"end":113,"id":16,"ws":true},{"text":"75mg/d","start":114,"end":120,"id":17,"ws":true},{"text":"versus","start":121,"end":127,"id":18,"ws":true},{"text":"50","start":128,"end":130,"id":19,"ws":true},{"text":"controls","start":131,"end":139,"id":20,"ws":true},{"text":"on","start":140,"end":142,"id":21,"ws":true},{"text":"aspirin","start":143,"end":150,"id":22,"ws":true},{"text":"monotherapy","start":151,"end":162,"id":23,"ws":true},{"text":".","start":163,"end":164,"id":24,"ws":false}],"spans":[{"start":90,"end":97,"token_start":14,"token_end":14,"label":"DRUG"},{"start":102,"end":113,"token_start":16,"token_end":16,"label":"DRUG"},{"start":143,"end":150,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26003782/","_input_hash":-891249684,"_task_hash":1955769063,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":90,"end":97,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":102,"end":113,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"The MBCs were 1 to 2 tubes higher than the broth dilution MICs for levofloxacin , 1 to 3 tubes higher than the broth dilution MICs for ofloxacin , 1 to 3 tubes higher than the broth dilution MICs for erythromycin , and the same as the broth dilution MICs for rifampin .","paragraph":"<h3><u>Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.</u></h3>The susceptibilities of 56 Legionella pneumophila isolates (43 clinical and 15 environmental isolates) to <b style='color:Tomato;'><i>levofloxacin</i></b>, ofloxacin, <b style='color:Tomato;'><i>erythromycin</i></b>, and <b style='color:Tomato;'><i>rifampin</i></b> were studied with buffered charcoal yeast extract (BCYE) agar (inoculum, 10(4) CFU per spot), and the susceptibilities of five isolates were studied with buffered yeast extract (BYE) broth (inoculum, 10(5) CFU/ml). The MICs inhibiting 90% of strains tested on BCYE agar were 0.125, 0.25, 1.0, and < or = 0.004 micrograms/ml for <b style='color:Tomato;'><i>levofloxacin</i></b>, ofloxacin, <b style='color:Tomato;'><i>erythromycin</i></b>, and <b style='color:Tomato;'><i>rifampin</i></b>, respectively. The MICs by the BYE broth dilution method were 1 to 3, 2, 1 to 2, and 1 tube lower than those by the agar dilution method for <b style='color:Tomato;'><i>levofloxacin</i></b>, ofloxacin, <b style='color:Tomato;'><i>erythromycin</i></b>, and <b style='color:Tomato;'><i>rifampin</i></b>, respectively. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>MBCs</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>tubes</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>tubes</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>ofloxacin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>tubes</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>erythromycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>dilution</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>rifampin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In kinetic time-kill curve studies, at drug concentrations of 1.0 and 2.0 times the MIC, the most active drugs were <b style='color:Tomato;'><i>levofloxacin</i></b> and <b style='color:Tomato;'><i>rifampin</i></b>. At 72 h, concentrations of <b style='color:Tomato;'><i>levofloxacin</i></b> and <b style='color:Tomato;'><i>rifampin</i></b> of 2.0 times the MIC demonstrated a bactericidal effect against L. pneumophila. In contrast, at concentrations of 1.0 and 2.0 times the MICs regrowth was observed with ofloxacin and only a gradual decrease in the numbers of CFU per milliliter was observed with <b style='color:Tomato;'><i>erythromycin</i></b>. Only a minor inhibitory effect was observed with 0.25 or 0.5 time the MICs of all drugs at 24 to 48 h, with regrowth occurring at 72 h. In contrast to <b style='color:Tomato;'><i>erythromycin</i></b> or ofloxacin plus <b style='color:Tomato;'><i>rifampin</i></b> at 0.25 time the MICs, only <b style='color:Tomato;'><i>levofloxacin</i></b> plus <b style='color:Tomato;'><i>rifampin</i></b> demonstrated synergy. Thus, <b style='color:Tomato;'><i>levofloxacin</i></b> demonstrated the best inhibitory and bactericidal effects against L. pneumophila when it was studied alone or in a combination with <b style='color:Tomato;'><i>rifampin</i></b>.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"MBCs","start":4,"end":8,"id":1,"ws":true},{"text":"were","start":9,"end":13,"id":2,"ws":true},{"text":"1","start":14,"end":15,"id":3,"ws":true},{"text":"to","start":16,"end":18,"id":4,"ws":true},{"text":"2","start":19,"end":20,"id":5,"ws":true},{"text":"tubes","start":21,"end":26,"id":6,"ws":true},{"text":"higher","start":27,"end":33,"id":7,"ws":true},{"text":"than","start":34,"end":38,"id":8,"ws":true},{"text":"the","start":39,"end":42,"id":9,"ws":true},{"text":"broth","start":43,"end":48,"id":10,"ws":true},{"text":"dilution","start":49,"end":57,"id":11,"ws":true},{"text":"MICs","start":58,"end":62,"id":12,"ws":true},{"text":"for","start":63,"end":66,"id":13,"ws":true},{"text":"levofloxacin","start":67,"end":79,"id":14,"ws":true},{"text":",","start":80,"end":81,"id":15,"ws":true},{"text":"1","start":82,"end":83,"id":16,"ws":true},{"text":"to","start":84,"end":86,"id":17,"ws":true},{"text":"3","start":87,"end":88,"id":18,"ws":true},{"text":"tubes","start":89,"end":94,"id":19,"ws":true},{"text":"higher","start":95,"end":101,"id":20,"ws":true},{"text":"than","start":102,"end":106,"id":21,"ws":true},{"text":"the","start":107,"end":110,"id":22,"ws":true},{"text":"broth","start":111,"end":116,"id":23,"ws":true},{"text":"dilution","start":117,"end":125,"id":24,"ws":true},{"text":"MICs","start":126,"end":130,"id":25,"ws":true},{"text":"for","start":131,"end":134,"id":26,"ws":true},{"text":"ofloxacin","start":135,"end":144,"id":27,"ws":true},{"text":",","start":145,"end":146,"id":28,"ws":true},{"text":"1","start":147,"end":148,"id":29,"ws":true},{"text":"to","start":149,"end":151,"id":30,"ws":true},{"text":"3","start":152,"end":153,"id":31,"ws":true},{"text":"tubes","start":154,"end":159,"id":32,"ws":true},{"text":"higher","start":160,"end":166,"id":33,"ws":true},{"text":"than","start":167,"end":171,"id":34,"ws":true},{"text":"the","start":172,"end":175,"id":35,"ws":true},{"text":"broth","start":176,"end":181,"id":36,"ws":true},{"text":"dilution","start":182,"end":190,"id":37,"ws":true},{"text":"MICs","start":191,"end":195,"id":38,"ws":true},{"text":"for","start":196,"end":199,"id":39,"ws":true},{"text":"erythromycin","start":200,"end":212,"id":40,"ws":true},{"text":",","start":213,"end":214,"id":41,"ws":true},{"text":"and","start":215,"end":218,"id":42,"ws":true},{"text":"the","start":219,"end":222,"id":43,"ws":true},{"text":"same","start":223,"end":227,"id":44,"ws":true},{"text":"as","start":228,"end":230,"id":45,"ws":true},{"text":"the","start":231,"end":234,"id":46,"ws":true},{"text":"broth","start":235,"end":240,"id":47,"ws":true},{"text":"dilution","start":241,"end":249,"id":48,"ws":true},{"text":"MICs","start":250,"end":254,"id":49,"ws":true},{"text":"for","start":255,"end":258,"id":50,"ws":true},{"text":"rifampin","start":259,"end":267,"id":51,"ws":true},{"text":".","start":268,"end":269,"id":52,"ws":false}],"spans":[{"start":67,"end":79,"token_start":14,"token_end":14,"label":"DRUG"},{"start":200,"end":212,"token_start":40,"token_end":40,"label":"DRUG"},{"start":259,"end":267,"token_start":51,"token_end":51,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7486896/","_input_hash":2130824282,"_task_hash":-706415713,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Ketanserin ( a 5-HT2 antagonist , 10 mumol/L ) and tropisetron ( a 5-HT3 antagonist , 1 mumol/L ) had no effect .","paragraph":"<h3><u>Ketotifen modulates noncholinergic contraction in guinea pig airways in vitro by a prejunctional nonhistamine receptor.</u></h3>In guinea pig airways, electrical field stimulation (50 V, 0.5 msec, 8 Hz for 20 seconds) produces a rapid contraction, which is followed by a long-lasting contraction, at least in the lower part of the trachea and in the bronchi. The latter contraction is due to the release of neuropeptides from airway sensory nerves. <b style='color:Tomato;'><i>ketotifen</i></b> fumarate has been demonstrated to inhibit the noncholinergic contraction in guinea pig airways in vitro, but no attempt has been made to identify the receptor type. Therefore we have performed an in vitro study to investigate which receptor is responsible for the inhibitory effects of <b style='color:Tomato;'><i>ketotifen</i></b> on noncholinergic contraction in guinea pig airways. <b style='color:Tomato;'><i>ketotifen</i></b> (3 to 100 mumol/L) produced a concentration-dependent inhibition of the noncholinergic contraction, with a maximum inhibition of 74% +/- 7% at 8 Hz stimulation (p < 0.001; n = 5). Pretreatment of the tissues with either <b style='color:Tomato;'><i>cimetidine</i></b> (10 mumol/L) or thioperamide (10 mumol/L) or <b style='color:Tomato;'><i>phentolamine</i></b> (10 mumol/L) did not prevent the inhibitory effect of <b style='color:Tomato;'><i>ketotifen</i></b> (10 mumol/L). <b style='color:Tomato;'><i>cetirizine</i></b> (10 mumol/L), on the other hand, produced no inhibition of the noncholinergic contraction at all. Metitepine (0.1 mumol/L) and <b style='color:Tomato;'><i>methysergide</i></b> (1 mumol/L), both 5-HT1 antagonists, attenuated the inhibitory effect of <b style='color:Tomato;'><i>ketotifen</i></b> (10 mumol/L). <b style='color:MediumOrchid;'><i>Ketanserin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5-HT2</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mumol/L</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tropisetron</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>5-HT3</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>mumol/L</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Ketoifen (100 mumol/L) did not affect the cumulative dose-response relationship to exogenous substance P (0.01 mumol/L to 10 mmol/L).(ABSTRACT TRUNCATED AT 250 WORDS)","tokens":[{"text":"Ketanserin","start":0,"end":10,"id":0,"ws":true},{"text":"(","start":11,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"5-HT2","start":15,"end":20,"id":3,"ws":true},{"text":"antagonist","start":21,"end":31,"id":4,"ws":true},{"text":",","start":32,"end":33,"id":5,"ws":true},{"text":"10","start":34,"end":36,"id":6,"ws":true},{"text":"mumol/L","start":37,"end":44,"id":7,"ws":true},{"text":")","start":45,"end":46,"id":8,"ws":true},{"text":"and","start":47,"end":50,"id":9,"ws":true},{"text":"tropisetron","start":51,"end":62,"id":10,"ws":true},{"text":"(","start":63,"end":64,"id":11,"ws":true},{"text":"a","start":65,"end":66,"id":12,"ws":true},{"text":"5-HT3","start":67,"end":72,"id":13,"ws":true},{"text":"antagonist","start":73,"end":83,"id":14,"ws":true},{"text":",","start":84,"end":85,"id":15,"ws":true},{"text":"1","start":86,"end":87,"id":16,"ws":true},{"text":"mumol/L","start":88,"end":95,"id":17,"ws":true},{"text":")","start":96,"end":97,"id":18,"ws":true},{"text":"had","start":98,"end":101,"id":19,"ws":true},{"text":"no","start":102,"end":104,"id":20,"ws":true},{"text":"effect","start":105,"end":111,"id":21,"ws":true},{"text":".","start":112,"end":113,"id":22,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":51,"end":62,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8064073/","_input_hash":302106594,"_task_hash":-1626692204,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"This three-phase study was designed to determine if a pharmacokinetic drug-drug interaction exists between zidovudine and oxazepam .","paragraph":"<h3><u>Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient.</u></h3> <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>three-phase</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>drug-drug</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>exists</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>zidovudine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxazepam</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Six individuals infected with human immunodeficiency virus (HIV) and receiving <b style='color:Tomato;'><i>zidovudine</i></b> at 500 mg daily, with normal renal and hepatic function, were enrolled. During phase I, <b style='color:Tomato;'><i>zidovudine</i></b> pharmacokinetics were studied after steady-state oral administration (100 mg every 4 h) and after a single dose (70 mg) of intravenous <b style='color:Tomato;'><i>zidovudine</i></b>. Phase II consisted of a single oral dose (30 mg) of <b style='color:Tomato;'><i>oxazepam</i></b> followed by a 48-h blood sampling period. Phase III began with 48 h of concomitant <b style='color:Tomato;'><i>zidovudine</i></b>, 100 mg orally every 4 h, and <b style='color:Tomato;'><i>oxazepam</i></b>, 15 mg orally every 8 h, followed by concomitant dosing of intravenous <b style='color:Tomato;'><i>zidovudine</i></b> and oral <b style='color:Tomato;'><i>oxazepam</i></b>. <b style='color:Tomato;'><i>zidovudine</i></b> concentrations were determined by radioimmunoassay. <b style='color:Tomato;'><i>oxazepam</i></b> concentrations were determined with use of a fluorescence polarization immunoassay. The calculated bioavailability was 0.61 for <b style='color:Tomato;'><i>zidovudine</i></b> alone and 0.75 when administered in combination with <b style='color:Tomato;'><i>oxazepam</i></b> (p = 0.16). Plasma half-life for oral <b style='color:Tomato;'><i>zidovudine</i></b> alone and in combination with <b style='color:Tomato;'><i>oxazepam</i></b> was 1.17 h versus 0.99 h, respectively (p = 0.25), and 1.38 h versus 1.15 h (p = 0.38) for intravenous <b style='color:Tomato;'><i>zidovudine</i></b> during single and combination therapy, respectively. Total body clearance of <b style='color:Tomato;'><i>zidovudine</i></b> was not significantly altered by <b style='color:Tomato;'><i>oxazepam</i></b> (93 L/h vs. 109 L/h, p = 0.16). The mean pharmacokinetic parameters determined for a single 30-mg dose of <b style='color:Tomato;'><i>oxazepam</i></b> for oral clearance, apparent volume of distribution, and plasma half-life were 9.8 L/h, 65.7 L, and 5.1 h, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"three-phase","start":5,"end":16,"id":1,"ws":true},{"text":"study","start":17,"end":22,"id":2,"ws":true},{"text":"was","start":23,"end":26,"id":3,"ws":true},{"text":"designed","start":27,"end":35,"id":4,"ws":true},{"text":"to","start":36,"end":38,"id":5,"ws":true},{"text":"determine","start":39,"end":48,"id":6,"ws":true},{"text":"if","start":49,"end":51,"id":7,"ws":true},{"text":"a","start":52,"end":53,"id":8,"ws":true},{"text":"pharmacokinetic","start":54,"end":69,"id":9,"ws":true},{"text":"drug-drug","start":70,"end":79,"id":10,"ws":true},{"text":"interaction","start":80,"end":91,"id":11,"ws":true},{"text":"exists","start":92,"end":98,"id":12,"ws":true},{"text":"between","start":99,"end":106,"id":13,"ws":true},{"text":"zidovudine","start":107,"end":117,"id":14,"ws":true},{"text":"and","start":118,"end":121,"id":15,"ws":true},{"text":"oxazepam","start":122,"end":130,"id":16,"ws":true},{"text":".","start":131,"end":132,"id":17,"ws":false}],"spans":[{"start":107,"end":117,"token_start":14,"token_end":14,"label":"DRUG"},{"start":122,"end":130,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8417175/","_input_hash":-1195466658,"_task_hash":-883831583,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":107,"end":117,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":122,"end":130,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Patients with apical CFTR protein showed higher residual chloride secretion than those without ( amiloride to isoprenaline value of 4.59 and 0.56 mV , respectively , p = 0.01 ) .","paragraph":"<h3><u>Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis.</u></h3>In cystic fibrosis (CF), the clinical condition of patients correlates poorly with genotype. One possible explanation is that clinical status is influenced by net preserved chloride secretion rather than the CF mutation. We tested the relationships between residual chloride secretion, as measured by nasal potential difference (PD) and the type of mutation (genotypes expressing apical cystic fibrosis transmembrane conductance regulator (CFTR) protein versus those that do not) and clinical status. Twenty two CF patients (mean age 25.7 yrs, 11 females and 11 males, mean forced expiratory volume in one second (FEV1) 53.1% of predicted) with defined genotypes were recruited. Nasal PD was measured using a standard protocol involving the perfusion of the nasal epithelium with a sodium channel blocker (<b style='color:Tomato;'><i>amiloride</i></b>), followed by a solution of low chloride and finally with <b style='color:Tomato;'><i>isoprenaline</i></b>. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>apical</i></b> <b style='color:DodgerBlue;'><i>CFTR</i></b> <b style='color:DodgerBlue;'><i>protein</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>residual</i></b> <b style='color:DodgerBlue;'><i>chloride</i></b> <b style='color:DodgerBlue;'><i>secretion</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>amiloride</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>isoprenaline</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>4.59</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.56</i></b> <b style='color:DodgerBlue;'><i>mV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.01</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There was no correlation between mutation type and clinical condition. When these patients were recategorized as \"high\" (> 10 mV <b style='color:Tomato;'><i>amiloride</i></b> to <b style='color:Tomato;'><i>isoprenaline</i></b> response) or \"low\" (10 mV or less) chloride secretors, we found that the former group had a significantly higher FEV1 (67.7 versus 48.3% pred) and a better pulmonary radiological score (4.14 versus 7.07, by Northern scoring system). These results suggest that some cystic fibrosis patients, regardless of genotype, have an ability to secrete chloride when stimulated with chloride secretatagogues, and this is correlated with a better lung function. These results also have implications for the use of potential difference measurements in novel cystic fibrosis transmembrane conductance regulator replacement trials.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"with","start":9,"end":13,"id":1,"ws":true},{"text":"apical","start":14,"end":20,"id":2,"ws":true},{"text":"CFTR","start":21,"end":25,"id":3,"ws":true},{"text":"protein","start":26,"end":33,"id":4,"ws":true},{"text":"showed","start":34,"end":40,"id":5,"ws":true},{"text":"higher","start":41,"end":47,"id":6,"ws":true},{"text":"residual","start":48,"end":56,"id":7,"ws":true},{"text":"chloride","start":57,"end":65,"id":8,"ws":true},{"text":"secretion","start":66,"end":75,"id":9,"ws":true},{"text":"than","start":76,"end":80,"id":10,"ws":true},{"text":"those","start":81,"end":86,"id":11,"ws":true},{"text":"without","start":87,"end":94,"id":12,"ws":true},{"text":"(","start":95,"end":96,"id":13,"ws":true},{"text":"amiloride","start":97,"end":106,"id":14,"ws":true},{"text":"to","start":107,"end":109,"id":15,"ws":true},{"text":"isoprenaline","start":110,"end":122,"id":16,"ws":true},{"text":"value","start":123,"end":128,"id":17,"ws":true},{"text":"of","start":129,"end":131,"id":18,"ws":true},{"text":"4.59","start":132,"end":136,"id":19,"ws":true},{"text":"and","start":137,"end":140,"id":20,"ws":true},{"text":"0.56","start":141,"end":145,"id":21,"ws":true},{"text":"mV","start":146,"end":148,"id":22,"ws":true},{"text":",","start":149,"end":150,"id":23,"ws":true},{"text":"respectively","start":151,"end":163,"id":24,"ws":true},{"text":",","start":164,"end":165,"id":25,"ws":true},{"text":"p","start":166,"end":167,"id":26,"ws":true},{"text":"=","start":168,"end":169,"id":27,"ws":true},{"text":"0.01","start":170,"end":174,"id":28,"ws":true},{"text":")","start":175,"end":176,"id":29,"ws":true},{"text":".","start":177,"end":178,"id":30,"ws":false}],"spans":[{"start":97,"end":106,"token_start":14,"token_end":14,"label":"DRUG"},{"start":110,"end":122,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9311495/","_input_hash":637326166,"_task_hash":23831742,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"African American men were more likely to receive ketoconazole than abiraterone , enzalutamide , or docetaxel ( AME , 2.8 % ; 95 % CI , 0.7%-4.9 % ) .","paragraph":"<h3><u>Factors influencing treatment of veterans with advanced prostate cancer.</u></h3>Treatments for metastatic castration-resistant prostate cancer (CRPC) differ in toxicity, administration, and evidence. In this study, clinical and nonclinical factors associated with the first-line treatment for CRPC in a national delivery system were evaluated. ### methods National electronic laboratory and clinical data from the Veterans Health Administration were used to identify patients with CRPC (ie, rising prostate-specific antigen [PSA] on androgen deprivation) who received <b style='color:Tomato;'><i>abiraterone</i></b>, <b style='color:Tomato;'><i>enzalutamide</i></b>, <b style='color:Tomato;'><i>docetaxel</i></b>, or <b style='color:Tomato;'><i>ketoconazole</i></b> from 2010 through 2017. It was determined whether clinical (eg, PSA) and nonclinical factors (eg, race, facility) were associated with the first-line treatment selection using multilevel, multinomial logistic regression. The average marginal effects (AMEs) were calculated of patient, disease, and facility characteristics on <b style='color:Tomato;'><i>ketoconazole</i></b> versus more appropriate CRPC therapy. ### results There were 4998 patients identified with CRPC who received first-line <b style='color:Tomato;'><i>ketoconazole</i></b>, <b style='color:Tomato;'><i>docetaxel</i></b>, <b style='color:Tomato;'><i>abiraterone</i></b>, or <b style='color:Tomato;'><i>enzalutamide</i></b>. After adjustment, increasing age was associated with receipt of <b style='color:Tomato;'><i>abiraterone</i></b> (adjusted odds ratio [aOR], 1.07; 95% credible interval [CrI], 1.06-1.09) or <b style='color:Tomato;'><i>enzalutamide</i></b> (aOR, 1.10; 95% CrI, 1.08-1.11) versus <b style='color:Tomato;'><i>docetaxel</i></b>. Greater preexisting comorbidity was associated with <b style='color:Tomato;'><i>enzalutamide</i></b> versus <b style='color:Tomato;'><i>abiraterone</i></b> (aOR, 1.53; 95% CrI, 1.23-1.91). Patients with higher PSA values at the start of treatment were more likely to receive <b style='color:Tomato;'><i>docetaxel</i></b> than oral agents and less likely to receive <b style='color:Tomato;'><i>ketoconazole</i></b> than other oral agents. <b style='color:DodgerBlue;'><i>African</i></b> <b style='color:DodgerBlue;'><i>American</i></b> <b style='color:DodgerBlue;'><i>men</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>likely</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:MediumOrchid;'><i>ketoconazole</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AME</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2.8</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>95</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>CI</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.7%-4.9</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This effect was attenuated when adjusting for facility characteristics (AME, 1.9%; 95% CI, -0.4% to 4.1%). ### conclusions Clinical factors had an expected effect on the first-line treatment selection. Race may be associated with the receipt of a guideline-discordant first-line treatment.","tokens":[{"text":"African","start":0,"end":7,"id":0,"ws":true},{"text":"American","start":8,"end":16,"id":1,"ws":true},{"text":"men","start":17,"end":20,"id":2,"ws":true},{"text":"were","start":21,"end":25,"id":3,"ws":true},{"text":"more","start":26,"end":30,"id":4,"ws":true},{"text":"likely","start":31,"end":37,"id":5,"ws":true},{"text":"to","start":38,"end":40,"id":6,"ws":true},{"text":"receive","start":41,"end":48,"id":7,"ws":true},{"text":"ketoconazole","start":49,"end":61,"id":8,"ws":true},{"text":"than","start":62,"end":66,"id":9,"ws":true},{"text":"abiraterone","start":67,"end":78,"id":10,"ws":true},{"text":",","start":79,"end":80,"id":11,"ws":true},{"text":"enzalutamide","start":81,"end":93,"id":12,"ws":true},{"text":",","start":94,"end":95,"id":13,"ws":true},{"text":"or","start":96,"end":98,"id":14,"ws":true},{"text":"docetaxel","start":99,"end":108,"id":15,"ws":true},{"text":"(","start":109,"end":110,"id":16,"ws":true},{"text":"AME","start":111,"end":114,"id":17,"ws":true},{"text":",","start":115,"end":116,"id":18,"ws":true},{"text":"2.8","start":117,"end":120,"id":19,"ws":true},{"text":"%","start":121,"end":122,"id":20,"ws":true},{"text":";","start":123,"end":124,"id":21,"ws":true},{"text":"95","start":125,"end":127,"id":22,"ws":true},{"text":"%","start":128,"end":129,"id":23,"ws":true},{"text":"CI","start":130,"end":132,"id":24,"ws":true},{"text":",","start":133,"end":134,"id":25,"ws":true},{"text":"0.7%-4.9","start":135,"end":143,"id":26,"ws":true},{"text":"%","start":144,"end":145,"id":27,"ws":true},{"text":")","start":146,"end":147,"id":28,"ws":true},{"text":".","start":148,"end":149,"id":29,"ws":false}],"spans":[{"start":49,"end":61,"token_start":8,"token_end":8,"label":"DRUG"},{"start":67,"end":78,"token_start":10,"token_end":10,"label":"DRUG"},{"start":81,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},{"start":99,"end":108,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33764537/","_input_hash":-986323573,"_task_hash":-904230234,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These observations are important in the development of vorinostat , and may have clinical implications on other cancer and noncancer drugs that are UGT2B17 substrates such as exemestane and ibuprofen .","paragraph":"<h3><u>Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.</u></h3><b style='color:Tomato;'><i>vorinostat</i></b>, a histone deacetylase inhibitor being actively evaluated in solid tumors, is metabolized by UGT2B17. UGT2B17 null genotype (UGT2B17*2) has been shown in vitro to reduce UGT2B17 activity. This variant is common in Asians but rare in Caucasians, and we studied its impact on <b style='color:Tomato;'><i>vorinostat</i></b> pharmacokinetics and pharmacodynamics in a clinical study in Asian patients with metastatic breast cancer. ### methods Eligible patients received 400 mg of <b style='color:Tomato;'><i>vorinostat</i></b> monotherapy daily in a lead-in phase I followed by a phase II study. Patients were genotyped for UGT2B17*2, which was correlated with <b style='color:Tomato;'><i>vorinostat</i></b> pharmacokinetics and clinical outcomes. ### results Twenty-six patients were treated with no complete response, one partial response, six stable disease lasting for 12 weeks or more, and 19 progressive disease. Sixteen patients (62%) were UGT2B17*2 homozygotes and had significantly lower mean area under the curve ratio of <b style='color:Tomato;'><i>vorinostat</i></b>-O-glucuronide/<b style='color:Tomato;'><i>vorinostat</i></b> (1.84 vs. 2.51 on day 1, P=0.02; 1.63 vs. 2.38 on day 15, P=0.028), and trended toward having higher <b style='color:Tomato;'><i>vorinostat</i></b> area under the curve (399.02 vs. 318.40, P=0.188), more serious adverse events (31 vs. 0%, P=0.121), higher clinical benefit rate (40 vs. 10%, P=0.179), and longer median progression-free survival (3.0 vs. 1.5 months, P=0.087) than patients with at least one wild-type allele. ### conclusion UGT2B17*2 genotype reduces <b style='color:Tomato;'><i>vorinostat</i></b> glucuronidation and may increase <b style='color:Tomato;'><i>vorinostat</i></b> efficacy and toxicity. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>observations</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>important</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>development</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vorinostat</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>implications</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>noncancer</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>UGT2B17</i></b> <b style='color:DodgerBlue;'><i>substrates</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ibuprofen</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"observations","start":6,"end":18,"id":1,"ws":true},{"text":"are","start":19,"end":22,"id":2,"ws":true},{"text":"important","start":23,"end":32,"id":3,"ws":true},{"text":"in","start":33,"end":35,"id":4,"ws":true},{"text":"the","start":36,"end":39,"id":5,"ws":true},{"text":"development","start":40,"end":51,"id":6,"ws":true},{"text":"of","start":52,"end":54,"id":7,"ws":true},{"text":"vorinostat","start":55,"end":65,"id":8,"ws":true},{"text":",","start":66,"end":67,"id":9,"ws":true},{"text":"and","start":68,"end":71,"id":10,"ws":true},{"text":"may","start":72,"end":75,"id":11,"ws":true},{"text":"have","start":76,"end":80,"id":12,"ws":true},{"text":"clinical","start":81,"end":89,"id":13,"ws":true},{"text":"implications","start":90,"end":102,"id":14,"ws":true},{"text":"on","start":103,"end":105,"id":15,"ws":true},{"text":"other","start":106,"end":111,"id":16,"ws":true},{"text":"cancer","start":112,"end":118,"id":17,"ws":true},{"text":"and","start":119,"end":122,"id":18,"ws":true},{"text":"noncancer","start":123,"end":132,"id":19,"ws":true},{"text":"drugs","start":133,"end":138,"id":20,"ws":true},{"text":"that","start":139,"end":143,"id":21,"ws":true},{"text":"are","start":144,"end":147,"id":22,"ws":true},{"text":"UGT2B17","start":148,"end":155,"id":23,"ws":true},{"text":"substrates","start":156,"end":166,"id":24,"ws":true},{"text":"such","start":167,"end":171,"id":25,"ws":true},{"text":"as","start":172,"end":174,"id":26,"ws":true},{"text":"exemestane","start":175,"end":185,"id":27,"ws":true},{"text":"and","start":186,"end":189,"id":28,"ws":true},{"text":"ibuprofen","start":190,"end":199,"id":29,"ws":true},{"text":".","start":200,"end":201,"id":30,"ws":false}],"spans":[{"start":55,"end":65,"token_start":8,"token_end":8,"label":"DRUG"},{"start":175,"end":185,"token_start":27,"token_end":27,"label":"DRUG"},{"start":190,"end":199,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21849928/","_input_hash":1897274692,"_task_hash":1201564489,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Additional results from MTT cell viability assays demonstrated that H1975 cell proliferation was not significantly decreased after Wnt inhibition by XAV939 , but combination treatment with everolimus ( mTOR inhibitor ) and erlotinib resulted in synergistic cell growth inhibition .","paragraph":"<h3><u>Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.</u></h3>Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when administered individually or in combination to non-small cell lung cancer (NSCLC) patients. However, the overall efficacies of TKIs are limited due to the development of drug resistance. Therefore, it is important to elucidate mechanisms of EGFR and c-Met TKI resistance in order to develop more effective therapies. Model NSCLC cell lines H1975 and H2170 were used to study the similarities and differences in mechanisms of EGFR/c-Met TKI resistance. H1975 cells are positive for the T790M EGFR mutation, which confers resistance to current EGFR TKI therapies, while H2170 cells are EGFR wild-type. Previously, H2170 cells were made resistant to the EGFR TKI <b style='color:Tomato;'><i>erlotinib</i></b> and the c-Met TKI SU11274 by exposure to progressively increasing concentrations of TKIs. In H2170 and H1975 TKI-resistant cells, key Wnt and mTOR proteins were found to be differentially modulated. Wnt signaling transducer, active \u03b2-catenin was upregulated in TKI-resistant H2170 cells when compared to parental cells. GATA-6, a transcriptional activator of Wnt, was also found to be upregulated in resistant H2170 cells. In H2170 <b style='color:Tomato;'><i>erlotinib</i></b> resistant cells, upregulation of inactive GSK3\u03b2 (p-GSK3\u03b2) was observed, indicating activation of Wnt and mTOR pathways which are otherwise inhibited by its active form. However, in H1975 cells, Wnt modulators such as active \u03b2-catenin, GATA-6 and p-GSK3\u03b2 were downregulated. <b style='color:DodgerBlue;'><i>Additional</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>MTT</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>viability</i></b> <b style='color:DodgerBlue;'><i>assays</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>H1975</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>proliferation</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>Wnt</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>XAV939</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mTOR</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Thus, in H2170 cells and H1975 cells, simultaneous inhibition of key Wnt or mTOR pathway proteins in addition to EGFR and c-Met may be a promising strategy for overcoming EGFR and c-Met TKI resistance in NSCLC patients.","tokens":[{"text":"Additional","start":0,"end":10,"id":0,"ws":true},{"text":"results","start":11,"end":18,"id":1,"ws":true},{"text":"from","start":19,"end":23,"id":2,"ws":true},{"text":"MTT","start":24,"end":27,"id":3,"ws":true},{"text":"cell","start":28,"end":32,"id":4,"ws":true},{"text":"viability","start":33,"end":42,"id":5,"ws":true},{"text":"assays","start":43,"end":49,"id":6,"ws":true},{"text":"demonstrated","start":50,"end":62,"id":7,"ws":true},{"text":"that","start":63,"end":67,"id":8,"ws":true},{"text":"H1975","start":68,"end":73,"id":9,"ws":true},{"text":"cell","start":74,"end":78,"id":10,"ws":true},{"text":"proliferation","start":79,"end":92,"id":11,"ws":true},{"text":"was","start":93,"end":96,"id":12,"ws":true},{"text":"not","start":97,"end":100,"id":13,"ws":true},{"text":"significantly","start":101,"end":114,"id":14,"ws":true},{"text":"decreased","start":115,"end":124,"id":15,"ws":true},{"text":"after","start":125,"end":130,"id":16,"ws":true},{"text":"Wnt","start":131,"end":134,"id":17,"ws":true},{"text":"inhibition","start":135,"end":145,"id":18,"ws":true},{"text":"by","start":146,"end":148,"id":19,"ws":true},{"text":"XAV939","start":149,"end":155,"id":20,"ws":true},{"text":",","start":156,"end":157,"id":21,"ws":true},{"text":"but","start":158,"end":161,"id":22,"ws":true},{"text":"combination","start":162,"end":173,"id":23,"ws":true},{"text":"treatment","start":174,"end":183,"id":24,"ws":true},{"text":"with","start":184,"end":188,"id":25,"ws":true},{"text":"everolimus","start":189,"end":199,"id":26,"ws":true},{"text":"(","start":200,"end":201,"id":27,"ws":true},{"text":"mTOR","start":202,"end":206,"id":28,"ws":true},{"text":"inhibitor","start":207,"end":216,"id":29,"ws":true},{"text":")","start":217,"end":218,"id":30,"ws":true},{"text":"and","start":219,"end":222,"id":31,"ws":true},{"text":"erlotinib","start":223,"end":232,"id":32,"ws":true},{"text":"resulted","start":233,"end":241,"id":33,"ws":true},{"text":"in","start":242,"end":244,"id":34,"ws":true},{"text":"synergistic","start":245,"end":256,"id":35,"ws":true},{"text":"cell","start":257,"end":261,"id":36,"ws":true},{"text":"growth","start":262,"end":268,"id":37,"ws":true},{"text":"inhibition","start":269,"end":279,"id":38,"ws":true},{"text":".","start":280,"end":281,"id":39,"ws":false}],"spans":[{"start":149,"end":155,"token_start":20,"token_end":20,"label":"DRUG"},{"start":189,"end":199,"token_start":26,"token_end":26,"label":"DRUG"},{"start":223,"end":232,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26301867/","_input_hash":-1669066164,"_task_hash":1355258483,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":20,"child":26,"head_span":{"start":149,"end":155,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":189,"end":199,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":20,"child":32,"head_span":{"start":149,"end":155,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":223,"end":232,"token_start":32,"token_end":32,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"The addition of dexmedetomidine to bupivacaine 0.5 % in EUS-CPN demonstrated beneficial effects as regards the degree and duration of pain relieve with negligible effect on the patient survival .","paragraph":"<h3><u>Value of Adding Dexmedetomidine in Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis for Treatment of Pancreatic Cancer-Associated Pain.</u></h3>Abdominal and back pain is present in up to 80% of patients with pancreatic cancer and represents a significant cause of morbidity. Celiac plexus neurolysis (CPN) demonstrated good results in relief of pain of upper abdominal malignancy. Dexme<b style='color:Tomato;'><i>detomidine</i></b> is alpha-2 adrenoceptor highly selective agonist approved for procedural sedation use. ### Patients And Methods Fifty patients divided in two groups with locally advanced pancreatic cancer-associated abdominal pain underwent endoscopic ultrasound (EUS)-guided CPN using <b style='color:Tomato;'><i>bupivacaine</i></b> 0.5% alone with alcohol for the first group and <b style='color:Tomato;'><i>bupivacaine</i></b> 0.5% plus dexme<b style='color:Tomato;'><i>detomidine</i></b> in the second. Patients scored their pain according to the Numeric Rating Scale (NRS-11) before, 2, 4, 6, 8, 12, 16, and 24\u00a0week after the procedure. ### results The study has included 50 patient in two groups. There was no significant difference between the two groups as regards medical, laboratory, or tumor characters. The median pain score decreases from 8.32\u2009\u00b1\u20090.75 before the procedure to 3.75\u2009\u00b1\u20093.72 24\u00a0week after the procedure in group 1 and from 8.08\u2009\u00b1\u20090.86 before to 1.67\u2009\u00b1\u20092.3 24\u00a0week after the procedure in group 2. However, there was no significant difference between the two groups in the median pain score during the first 4\u00a0weeks. There was no statistically significant difference between the two groups as regards the median survival time. ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dexmedetomidine</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>EUS-CPN</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>regards</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>degree</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>duration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>relieve</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>negligible</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"addition","start":4,"end":12,"id":1,"ws":true},{"text":"of","start":13,"end":15,"id":2,"ws":true},{"text":"dexmedetomidine","start":16,"end":31,"id":3,"ws":true},{"text":"to","start":32,"end":34,"id":4,"ws":true},{"text":"bupivacaine","start":35,"end":46,"id":5,"ws":true},{"text":"0.5","start":47,"end":50,"id":6,"ws":true},{"text":"%","start":51,"end":52,"id":7,"ws":true},{"text":"in","start":53,"end":55,"id":8,"ws":true},{"text":"EUS-CPN","start":56,"end":63,"id":9,"ws":true},{"text":"demonstrated","start":64,"end":76,"id":10,"ws":true},{"text":"beneficial","start":77,"end":87,"id":11,"ws":true},{"text":"effects","start":88,"end":95,"id":12,"ws":true},{"text":"as","start":96,"end":98,"id":13,"ws":true},{"text":"regards","start":99,"end":106,"id":14,"ws":true},{"text":"the","start":107,"end":110,"id":15,"ws":true},{"text":"degree","start":111,"end":117,"id":16,"ws":true},{"text":"and","start":118,"end":121,"id":17,"ws":true},{"text":"duration","start":122,"end":130,"id":18,"ws":true},{"text":"of","start":131,"end":133,"id":19,"ws":true},{"text":"pain","start":134,"end":138,"id":20,"ws":true},{"text":"relieve","start":139,"end":146,"id":21,"ws":true},{"text":"with","start":147,"end":151,"id":22,"ws":true},{"text":"negligible","start":152,"end":162,"id":23,"ws":true},{"text":"effect","start":163,"end":169,"id":24,"ws":true},{"text":"on","start":170,"end":172,"id":25,"ws":true},{"text":"the","start":173,"end":176,"id":26,"ws":true},{"text":"patient","start":177,"end":184,"id":27,"ws":true},{"text":"survival","start":185,"end":193,"id":28,"ws":true},{"text":".","start":194,"end":195,"id":29,"ws":false}],"spans":[{"start":16,"end":31,"token_start":3,"token_end":3,"label":"DRUG"},{"start":35,"end":46,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32621112/","_input_hash":-1100243710,"_task_hash":1787770347,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":16,"end":31,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":35,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS20"],"answer":"accept"}
{"text":"The incidence of carcinoma , confirmed microscopically , was : control 14/20 ( 70 % ) ; high-dose gefitinib , 7/20 ( 35 % ) ; low-dose gefitinib , 7/20 ( 35 % ) ; high-dose meloxicam 7/21 ( 33 % ) ; and low-dose meloxicam , 12/20 ( 60 % ) .","paragraph":"<h3><u>Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis.</u></h3>To examine the chemopreventive effects of a selective cyclooxygenase (COX)-2 inhibitor, <b style='color:Tomato;'><i>meloxicam</i></b>, and a selective epidermal growth factor (EGF)-receptor tyrosine kinase inhibitor, <b style='color:Tomato;'><i>gefitinib</i></b> (as a single agent) on a carcinogen-induced rodent bladder carcinogenesis model. ### Materials And Methods The study comprised 103 male Fisher-344 rats (8 weeks old); after initial carcinogen treatment for 8 weeks with 0.05%N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in drinking water, the rats were divided into five groups, i.e. group 1, control (vehicle only); group 2, <b style='color:Tomato;'><i>gefitinib</i></b> high-dose (15 mg/kg by gavage once daily); group 3, <b style='color:Tomato;'><i>gefitinib</i></b> low-dose (5 mg/kg); group 4, <b style='color:Tomato;'><i>meloxicam</i></b> high-dose (1.8 mg/kg by gavage once daily); and group 5, <b style='color:Tomato;'><i>meloxicam</i></b> low-dose (0.6 mg/kg). Twelve weeks later the rats were killed; after fixing the bladder in 10% formalin, the number and size of hyperplasia and carcinoma foci were recorded microscopically in sections stained with haematoxylin and eosin, submitted entirely as multiple strips. ### results <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>incidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>confirmed</i></b> <b style='color:DodgerBlue;'><i>microscopically</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>14/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>70</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>7/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>low-dose</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>7/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>meloxicam</i></b> <b style='color:DodgerBlue;'><i>7/21</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>33</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>low-dose</i></b> <b style='color:MediumOrchid;'><i>meloxicam</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>12/20</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The mean numbers of carcinomas per bladder in groups 1-5 were 1.2, 0.5, 0.4, 0.5 and 1.1, respectively. The incidence and the mean number of carcinomas per bladder were significantly lower in the treatment groups (P < 0.05) than in the control group, except in the low-dose <b style='color:Tomato;'><i>meloxicam</i></b> group. There were no significant adverse effects. ### conclusion Both <b style='color:Tomato;'><i>meloxicam</i></b> and <b style='color:Tomato;'><i>gefitinib</i></b> have inhibitory effects on rat bladder carcinogenesis with no significant adverse effects. A combination of these drugs would be worth studying for their synergistic effects.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"incidence","start":4,"end":13,"id":1,"ws":true},{"text":"of","start":14,"end":16,"id":2,"ws":true},{"text":"carcinoma","start":17,"end":26,"id":3,"ws":true},{"text":",","start":27,"end":28,"id":4,"ws":true},{"text":"confirmed","start":29,"end":38,"id":5,"ws":true},{"text":"microscopically","start":39,"end":54,"id":6,"ws":true},{"text":",","start":55,"end":56,"id":7,"ws":true},{"text":"was","start":57,"end":60,"id":8,"ws":true},{"text":":","start":61,"end":62,"id":9,"ws":true},{"text":"control","start":63,"end":70,"id":10,"ws":true},{"text":"14/20","start":71,"end":76,"id":11,"ws":true},{"text":"(","start":77,"end":78,"id":12,"ws":true},{"text":"70","start":79,"end":81,"id":13,"ws":true},{"text":"%","start":82,"end":83,"id":14,"ws":true},{"text":")","start":84,"end":85,"id":15,"ws":true},{"text":";","start":86,"end":87,"id":16,"ws":true},{"text":"high-dose","start":88,"end":97,"id":17,"ws":true},{"text":"gefitinib","start":98,"end":107,"id":18,"ws":true},{"text":",","start":108,"end":109,"id":19,"ws":true},{"text":"7/20","start":110,"end":114,"id":20,"ws":true},{"text":"(","start":115,"end":116,"id":21,"ws":true},{"text":"35","start":117,"end":119,"id":22,"ws":true},{"text":"%","start":120,"end":121,"id":23,"ws":true},{"text":")","start":122,"end":123,"id":24,"ws":true},{"text":";","start":124,"end":125,"id":25,"ws":true},{"text":"low-dose","start":126,"end":134,"id":26,"ws":true},{"text":"gefitinib","start":135,"end":144,"id":27,"ws":true},{"text":",","start":145,"end":146,"id":28,"ws":true},{"text":"7/20","start":147,"end":151,"id":29,"ws":true},{"text":"(","start":152,"end":153,"id":30,"ws":true},{"text":"35","start":154,"end":156,"id":31,"ws":true},{"text":"%","start":157,"end":158,"id":32,"ws":true},{"text":")","start":159,"end":160,"id":33,"ws":true},{"text":";","start":161,"end":162,"id":34,"ws":true},{"text":"high-dose","start":163,"end":172,"id":35,"ws":true},{"text":"meloxicam","start":173,"end":182,"id":36,"ws":true},{"text":"7/21","start":183,"end":187,"id":37,"ws":true},{"text":"(","start":188,"end":189,"id":38,"ws":true},{"text":"33","start":190,"end":192,"id":39,"ws":true},{"text":"%","start":193,"end":194,"id":40,"ws":true},{"text":")","start":195,"end":196,"id":41,"ws":true},{"text":";","start":197,"end":198,"id":42,"ws":true},{"text":"and","start":199,"end":202,"id":43,"ws":true},{"text":"low-dose","start":203,"end":211,"id":44,"ws":true},{"text":"meloxicam","start":212,"end":221,"id":45,"ws":true},{"text":",","start":222,"end":223,"id":46,"ws":true},{"text":"12/20","start":224,"end":229,"id":47,"ws":true},{"text":"(","start":230,"end":231,"id":48,"ws":true},{"text":"60","start":232,"end":234,"id":49,"ws":true},{"text":"%","start":235,"end":236,"id":50,"ws":true},{"text":")","start":237,"end":238,"id":51,"ws":true},{"text":".","start":239,"end":240,"id":52,"ws":false}],"spans":[{"start":98,"end":107,"token_start":18,"token_end":18,"label":"DRUG"},{"start":135,"end":144,"token_start":27,"token_end":27,"label":"DRUG"},{"start":173,"end":182,"token_start":36,"token_end":36,"label":"DRUG"},{"start":212,"end":221,"token_start":45,"token_end":45,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16469040/","_input_hash":1104357333,"_task_hash":1209744864,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Patients with incurable cancer causing chronic pain rated above 6/10 on a numerical scale while receiving high-dose opioid therapy ( more than 200 mg/d of oral morphine equivalent ) and/or exhibiting severe opioid-related adverse events received intrathecal infusions of ziconotide combined with morphine , ropivacaine , and clonidine .","paragraph":"<h3><u>Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.</u></h3>Ziconotide is a new analgesic agent administered intrathecally. It is challenging to use and can induce several and sometimes serious adverse events. A low initial dosage followed by slow titration may reduce serious adverse events. ### objective To determine whether a low starting dosage of ziconotide, followed by slow titration, decreases the incidence of major adverse events associated with ziconotide when used for intractable cancer pain. ### Study Design Observational cohort study. ### setting Three French cancer centers. ### methods <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>incurable</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>causing</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>rated</i></b> <b style='color:DodgerBlue;'><i>above</i></b> <b style='color:DodgerBlue;'><i>6/10</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>numerical</i></b> <b style='color:DodgerBlue;'><i>scale</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:DodgerBlue;'><i>opioid</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/d</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>morphine</i></b> <b style='color:DodgerBlue;'><i>equivalent</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:DodgerBlue;'><i>exhibiting</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>opioid-related</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>infusions</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ziconotide</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>morphine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ropivacaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Seventy-seven patients were included. Adverse events were recorded in 57% of them; moderate adverse events occurred in 51%. Adverse events required treatment discontinuation in 7  (9%) including 5  (6%) for whom a causal role for ziconotide was highly likely; among them 4  (5%) were serious. All patients experienced a significant and lasting decrease in pain intensity  (by 48%) in response to intrathecal analgesic therapy that included ziconotide. ### limitations Limitations include the nonrandomized, observational nature of the study. Determining the relative contributions of each drug to adverse events was difficult, and some of the adverse events manifested as clinical symptoms of a subjective nature. ### conclusions The rates of minor and moderate adverse events were consistent with previous reports. However, the rate of serious adverse events was substantially lower. Our study confirms the efficacy of intrathecal analgesia with ziconotide for relieving refractory cancer pain. These results indicate that multimodal intrathecal analgesia in patients with cancer pain should include ziconotide from the outset in order to provide time for subsequent slow titration.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"with","start":9,"end":13,"id":1,"ws":true},{"text":"incurable","start":14,"end":23,"id":2,"ws":true},{"text":"cancer","start":24,"end":30,"id":3,"ws":true},{"text":"causing","start":31,"end":38,"id":4,"ws":true},{"text":"chronic","start":39,"end":46,"id":5,"ws":true},{"text":"pain","start":47,"end":51,"id":6,"ws":true},{"text":"rated","start":52,"end":57,"id":7,"ws":true},{"text":"above","start":58,"end":63,"id":8,"ws":true},{"text":"6/10","start":64,"end":68,"id":9,"ws":true},{"text":"on","start":69,"end":71,"id":10,"ws":true},{"text":"a","start":72,"end":73,"id":11,"ws":true},{"text":"numerical","start":74,"end":83,"id":12,"ws":true},{"text":"scale","start":84,"end":89,"id":13,"ws":true},{"text":"while","start":90,"end":95,"id":14,"ws":true},{"text":"receiving","start":96,"end":105,"id":15,"ws":true},{"text":"high-dose","start":106,"end":115,"id":16,"ws":true},{"text":"opioid","start":116,"end":122,"id":17,"ws":true},{"text":"therapy","start":123,"end":130,"id":18,"ws":true},{"text":"(","start":131,"end":132,"id":19,"ws":true},{"text":"more","start":133,"end":137,"id":20,"ws":true},{"text":"than","start":138,"end":142,"id":21,"ws":true},{"text":"200","start":143,"end":146,"id":22,"ws":true},{"text":"mg/d","start":147,"end":151,"id":23,"ws":true},{"text":"of","start":152,"end":154,"id":24,"ws":true},{"text":"oral","start":155,"end":159,"id":25,"ws":true},{"text":"morphine","start":160,"end":168,"id":26,"ws":true},{"text":"equivalent","start":169,"end":179,"id":27,"ws":true},{"text":")","start":180,"end":181,"id":28,"ws":true},{"text":"and/or","start":182,"end":188,"id":29,"ws":true},{"text":"exhibiting","start":189,"end":199,"id":30,"ws":true},{"text":"severe","start":200,"end":206,"id":31,"ws":true},{"text":"opioid-related","start":207,"end":221,"id":32,"ws":true},{"text":"adverse","start":222,"end":229,"id":33,"ws":true},{"text":"events","start":230,"end":236,"id":34,"ws":true},{"text":"received","start":237,"end":245,"id":35,"ws":true},{"text":"intrathecal","start":246,"end":257,"id":36,"ws":true},{"text":"infusions","start":258,"end":267,"id":37,"ws":true},{"text":"of","start":268,"end":270,"id":38,"ws":true},{"text":"ziconotide","start":271,"end":281,"id":39,"ws":true},{"text":"combined","start":282,"end":290,"id":40,"ws":true},{"text":"with","start":291,"end":295,"id":41,"ws":true},{"text":"morphine","start":296,"end":304,"id":42,"ws":true},{"text":",","start":305,"end":306,"id":43,"ws":true},{"text":"ropivacaine","start":307,"end":318,"id":44,"ws":true},{"text":",","start":319,"end":320,"id":45,"ws":true},{"text":"and","start":321,"end":324,"id":46,"ws":true},{"text":"clonidine","start":325,"end":334,"id":47,"ws":true},{"text":".","start":335,"end":336,"id":48,"ws":false}],"spans":[{"start":271,"end":281,"token_start":39,"token_end":39,"label":"DRUG"},{"start":296,"end":304,"token_start":42,"token_end":42,"label":"DRUG"},{"start":307,"end":318,"token_start":44,"token_end":44,"label":"DRUG"},{"start":325,"end":334,"token_start":47,"token_end":47,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22996851/","_input_hash":-1775288786,"_task_hash":-1814032713,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":39,"child":42,"head_span":{"start":271,"end":281,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":296,"end":304,"token_start":42,"token_end":42,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":42,"child":44,"head_span":{"start":296,"end":304,"token_start":42,"token_end":42,"label":"DRUG"},"child_span":{"start":307,"end":318,"token_start":44,"token_end":44,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":44,"child":47,"head_span":{"start":307,"end":318,"token_start":44,"token_end":44,"label":"DRUG"},"child_span":{"start":325,"end":334,"token_start":47,"token_end":47,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"Both adalimumab and etanercept were more effective than methotrexate in slowing radiographic joint damage .","paragraph":"<h3><u>A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.</u></h3>This report reviews the clinical effectiveness and cost-effectiveness of <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b> and <b style='color:Tomato;'><i>infliximab</i></b>, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in the treatment of rheumatoid arthritis (RA) in adults. ### Data Sources Electronic databases were searched up to February 2005. ### Review Methods Systematic reviews of the literature on effectiveness and cost-effectiveness were undertaken and industry submissions to the National Institute for Health and Clinical Excellence (NICE) were reviewed. Meta-analyses of effectiveness data were also undertaken for each agent. The Birmingham Rheumatoid Arthritis Model (BRAM), a simulation model, was further developed and used to produce an incremental cost-effectiveness analysis. ### results Twenty-nine randomised controlled trials (RCTs), most of high quality, were included. The only head-to-head comparisons were against <b style='color:Tomato;'><i>methotrexate</i></b>. For patients with short disease duration (<or=3 years) who were na\u00efve to <b style='color:Tomato;'><i>methotrexate</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b> was marginally less and <b style='color:Tomato;'><i>etanercept</i></b> was marginally more effective than <b style='color:Tomato;'><i>methotrexate</i></b> in reducing symptoms of RA. <b style='color:Tomato;'><i>etanercept</i></b> was better tolerated than <b style='color:Tomato;'><i>methotrexate</i></b>. <b style='color:DodgerBlue;'><i>Both</i></b> <b style='color:MediumOrchid;'><i>adalimumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etanercept</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>slowing</i></b> <b style='color:DodgerBlue;'><i>radiographic</i></b> <b style='color:DodgerBlue;'><i>joint</i></b> <b style='color:DodgerBlue;'><i>damage</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>etanercept</i></b> was also marginally more effective and better tolerated than <b style='color:Tomato;'><i>methotrexate</i></b> in patients with longer disease durations who had not failed <b style='color:Tomato;'><i>methotrexate</i></b> treatment. <b style='color:Tomato;'><i>infliximab</i></b> is only licensed for use with <b style='color:Tomato;'><i>methotrexate</i></b>. All three agents, either alone (where so licensed) or in combination with ongoing disease-modifying antirheumatic drugs (DMARDs), were effective in reducing the symptoms and signs of RA in patients with established disease. At the licensed dose, the numbers needed to treat (NNTs) (95% CI) required to produce an American College for Rheumatology (ACR) response compared with placebo were: ACR20: <b style='color:Tomato;'><i>adalimumab</i></b> 3.6 (3.1 to 4.2), <b style='color:Tomato;'><i>etanercept</i></b> 2.1 (1.9 to 2.4), <b style='color:Tomato;'><i>infliximab</i></b> 3.2 (2.7 to 4.0); ACR50: <b style='color:Tomato;'><i>adalimumab</i></b> 4.2 (3.7 to 5.0), <b style='color:Tomato;'><i>etanercept</i></b> 3.1 (2.7 to 3.6), <b style='color:Tomato;'><i>infliximab</i></b> 5.0 (3.8 to 6.7); and ACR70: <b style='color:Tomato;'><i>adalimumab</i></b> 7.7 (5.9 to 11.1), <b style='color:Tomato;'><i>etanercept</i></b> 7.7 (6.3 to 10.0), <b style='color:Tomato;'><i>infliximab</i></b> 11.1 (7.7 to 20.0). In patients who were na\u00efve to <b style='color:Tomato;'><i>methotrexate</i></b>, or who had not previously failed <b style='color:Tomato;'><i>methotrexate</i></b> treatment, a TNF inhibitor combined with <b style='color:Tomato;'><i>methotrexate</i></b> was significantly more effective than <b style='color:Tomato;'><i>methotrexate</i></b> alone. <b style='color:Tomato;'><i>infliximab</i></b> combined with <b style='color:Tomato;'><i>methotrexate</i></b> had an increased risk of serious infections. All ten published economic evaluations met standard criteria for quality, but the incremental cost-effectiveness ratios (ICERs) ranged from being within established thresholds to being very high because of varying assumptions and parameters. All three sponsors who submitted economic models made assumptions favourable to their product. BRAM incorporates improvements in quality of life and mortality, but assumes no effect of TNF inhibitors on joint replacement. For use in accordance with current NICE guidance as the third DMARD in a sequence of DMARDs, the base-case ICER was around pound30,000 per quality-adjusted life-year (QALY) in early RA and pound50,000 per QALY in late RA. Sensitivity analyses showed that the results were sensitive to the estimates of Health Assessment Questionnaire (HAQ) progression while on TNF inhibitors and the effectiveness of DMARDs, but not to changes in mortality ratios per unit HAQ. TNF inhibitors are most cost-effective when used last. The ICER for <b style='color:Tomato;'><i>etanercept</i></b> used last is pound24,000 per QALY, substantially lower than for <b style='color:Tomato;'><i>adalimumab</i></b> ( pound30,000 per QALY) or <b style='color:Tomato;'><i>infliximab</i></b> ( pound38,000 per QALY). First line use as monotherapy generates ICERs around pound50,000 per QALY for <b style='color:Tomato;'><i>adalimumab</i></b> and <b style='color:Tomato;'><i>etanercept</i></b>. Using the combination of <b style='color:Tomato;'><i>methotrexate</i></b> and a TNF inhibitor as first line treatment generates much higher ICERs, as it precludes subsequent use of <b style='color:Tomato;'><i>methotrexate</i></b>, which is cheap. The ICERs for sequential use are of the same order as using the TNF inhibitor alone. ### conclusions <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>etanercept</i></b> and <b style='color:Tomato;'><i>infliximab</i></b> are effective treatments compared with placebo for RA patients who are not well controlled by conventional DMARDs, improving control of symptoms, improving physical function, and slowing radiographic changes in joints. The combination of a TNF inhibitor with <b style='color:Tomato;'><i>methotrexate</i></b> was more effective than <b style='color:Tomato;'><i>methotrexate</i></b> alone in early RA, although the clinical relevance of this additional benefit is yet to be established, particularly in view of the well-established effectiveness of MTX alone. An increased risk of serious infection cannot be ruled out for the combination of <b style='color:Tomato;'><i>methotrexate</i></b> with <b style='color:Tomato;'><i>adalimumab</i></b> or <b style='color:Tomato;'><i>infliximab</i></b>. The results of the economic evaluation based on BRAM are consistent with the observations from the review of clinical effectiveness, including the ranking of treatments. TNF inhibitors are most cost-effective when used as last active therapy. In this analysis, other things being equal, <b style='color:Tomato;'><i>etanercept</i></b> may be the TNF inhibitor of choice, although this may also depend on patient preference as to route of administration. The next most cost-effective use of TNF inhibitors is third line, as recommended in the 2002 NICE guidance. Direct comparative RCTs of TNF inhibitors against each other and against other DMARDs, and sequential use in patients who have failed a previous TNF inhibitor, are needed. Longer term studies of the quality of life in patients with RA and the impact of DMARDs on this are needed, as are longer studies that directly assess effects on joint replacement, other morbidity and mortality.","tokens":[{"text":"Both","start":0,"end":4,"id":0,"ws":true},{"text":"adalimumab","start":5,"end":15,"id":1,"ws":true},{"text":"and","start":16,"end":19,"id":2,"ws":true},{"text":"etanercept","start":20,"end":30,"id":3,"ws":true},{"text":"were","start":31,"end":35,"id":4,"ws":true},{"text":"more","start":36,"end":40,"id":5,"ws":true},{"text":"effective","start":41,"end":50,"id":6,"ws":true},{"text":"than","start":51,"end":55,"id":7,"ws":true},{"text":"methotrexate","start":56,"end":68,"id":8,"ws":true},{"text":"in","start":69,"end":71,"id":9,"ws":true},{"text":"slowing","start":72,"end":79,"id":10,"ws":true},{"text":"radiographic","start":80,"end":92,"id":11,"ws":true},{"text":"joint","start":93,"end":98,"id":12,"ws":true},{"text":"damage","start":99,"end":105,"id":13,"ws":true},{"text":".","start":106,"end":107,"id":14,"ws":false}],"spans":[{"start":5,"end":15,"token_start":1,"token_end":1,"label":"DRUG"},{"start":20,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},{"start":56,"end":68,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17049139/","_input_hash":-141818609,"_task_hash":654054989,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Combination chemotherapy with gemcitabine ( Gem ) , doxorubicin ( Dox ) , and paclitaxel ( Pac ) ( GAT ) has been considered attractive as first-line treatment in metastatic breast cancer .","paragraph":"<h3><u>Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines.</u></h3> <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Gem</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Dox</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Pac</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>GAT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>attractive</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We compared the potential of various schedules of GAT to induce apoptosis on MDA-MB-231, MCF7, and T47D human breast cancer cell lines. The extent of apoptotic induction was analyzed by flow cytometry with 7-aminoactinomycin D (7AAD) staining. Differences between various schedules in terms of apoptotic induction were statistically significant (P < 0.05). The most effective apoptotic induction regimen was achieved by the sequence: Dox for 16 h followed by Pac + Gem. Schedules employing a 16-h interval between drug administrations induced higher levels of apoptosis in human breast cancer cell lines compared with schedules using a 4-h interval. The therapeutic efficacy of the experimental results shown in this paper has been clinically corroborated in a phase II trial in metastatic breast cancer patients.","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"chemotherapy","start":12,"end":24,"id":1,"ws":true},{"text":"with","start":25,"end":29,"id":2,"ws":true},{"text":"gemcitabine","start":30,"end":41,"id":3,"ws":true},{"text":"(","start":42,"end":43,"id":4,"ws":true},{"text":"Gem","start":44,"end":47,"id":5,"ws":true},{"text":")","start":48,"end":49,"id":6,"ws":true},{"text":",","start":50,"end":51,"id":7,"ws":true},{"text":"doxorubicin","start":52,"end":63,"id":8,"ws":true},{"text":"(","start":64,"end":65,"id":9,"ws":true},{"text":"Dox","start":66,"end":69,"id":10,"ws":true},{"text":")","start":70,"end":71,"id":11,"ws":true},{"text":",","start":72,"end":73,"id":12,"ws":true},{"text":"and","start":74,"end":77,"id":13,"ws":true},{"text":"paclitaxel","start":78,"end":88,"id":14,"ws":true},{"text":"(","start":89,"end":90,"id":15,"ws":true},{"text":"Pac","start":91,"end":94,"id":16,"ws":true},{"text":")","start":95,"end":96,"id":17,"ws":true},{"text":"(","start":97,"end":98,"id":18,"ws":true},{"text":"GAT","start":99,"end":102,"id":19,"ws":true},{"text":")","start":103,"end":104,"id":20,"ws":true},{"text":"has","start":105,"end":108,"id":21,"ws":true},{"text":"been","start":109,"end":113,"id":22,"ws":true},{"text":"considered","start":114,"end":124,"id":23,"ws":true},{"text":"attractive","start":125,"end":135,"id":24,"ws":true},{"text":"as","start":136,"end":138,"id":25,"ws":true},{"text":"first-line","start":139,"end":149,"id":26,"ws":true},{"text":"treatment","start":150,"end":159,"id":27,"ws":true},{"text":"in","start":160,"end":162,"id":28,"ws":true},{"text":"metastatic","start":163,"end":173,"id":29,"ws":true},{"text":"breast","start":174,"end":180,"id":30,"ws":true},{"text":"cancer","start":181,"end":187,"id":31,"ws":true},{"text":".","start":188,"end":189,"id":32,"ws":false}],"spans":[{"start":30,"end":41,"token_start":3,"token_end":3,"label":"DRUG"},{"start":52,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},{"start":78,"end":88,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12036452/","_input_hash":-151814940,"_task_hash":1801711831,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":3,"child":8,"head_span":{"start":30,"end":41,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":52,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":14,"head_span":{"start":52,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":78,"end":88,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Anti-cancer agents like adriamycin , mitomycin-C , bleomycin , and etoposide express their cell-killing activity partly through oxygen radicals .","paragraph":"<h3><u>Overcoming of cross-resistance to the cell-killing activity of oxygen radicals in VCR-resistant hematologic cell lines with cyclosporin-A.</u></h3> <b style='color:DodgerBlue;'><i>Anti-cancer</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>like</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>mitomycin-C</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>express</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>cell-killing</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>partly</i></b> <b style='color:DodgerBlue;'><i>through</i></b> <b style='color:DodgerBlue;'><i>oxygen</i></b> <b style='color:DodgerBlue;'><i>radicals</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Since <b style='color:Tomato;'><i>vincristine</i></b> (VCR)-resistant cells show cross-resistance to oxygen radicals, this study was designed to study whether the combined effects of oxygen radicals derived from hypoxanthine-xanthine oxidase plus enhancers of anti-cancer drugs such as <b style='color:Tomato;'><i>verapamil</i></b> (Ver), <b style='color:Tomato;'><i>dipyridamole</i></b> (Dip), and <b style='color:Tomato;'><i>cyclosporin</i></b>-A (Cy-A) overcome the cross-resistance for oxygen radicals in VCR-resistant human leukemia/lymphoma cell lines. We found that 3 micrograms/mL Cy-A enhances the cidal effect of oxygen radicals on two of five types of wild type and two of five VCR-resistant cell lines and it could overcome the cross-resistance to oxygen radicals in VCR-resistant cells. Neither Ver nor Dip showed any effect on the cidal activity of oxygen radicals. Thus, it was suggested that Cy-A works with different mechanisms from those of Ver or Dip, and Cy-A may be useful in reducing the doses of anti-neoplastic agents that exert their activity via oxygen radicals in the clinical treatment.","tokens":[{"text":"Anti-cancer","start":0,"end":11,"id":0,"ws":true},{"text":"agents","start":12,"end":18,"id":1,"ws":true},{"text":"like","start":19,"end":23,"id":2,"ws":true},{"text":"adriamycin","start":24,"end":34,"id":3,"ws":true},{"text":",","start":35,"end":36,"id":4,"ws":true},{"text":"mitomycin-C","start":37,"end":48,"id":5,"ws":true},{"text":",","start":49,"end":50,"id":6,"ws":true},{"text":"bleomycin","start":51,"end":60,"id":7,"ws":true},{"text":",","start":61,"end":62,"id":8,"ws":true},{"text":"and","start":63,"end":66,"id":9,"ws":true},{"text":"etoposide","start":67,"end":76,"id":10,"ws":true},{"text":"express","start":77,"end":84,"id":11,"ws":true},{"text":"their","start":85,"end":90,"id":12,"ws":true},{"text":"cell-killing","start":91,"end":103,"id":13,"ws":true},{"text":"activity","start":104,"end":112,"id":14,"ws":true},{"text":"partly","start":113,"end":119,"id":15,"ws":true},{"text":"through","start":120,"end":127,"id":16,"ws":true},{"text":"oxygen","start":128,"end":134,"id":17,"ws":true},{"text":"radicals","start":135,"end":143,"id":18,"ws":true},{"text":".","start":144,"end":145,"id":19,"ws":false}],"spans":[{"start":24,"end":34,"token_start":3,"token_end":3,"label":"DRUG"},{"start":37,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},{"start":51,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":67,"end":76,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9673368/","_input_hash":-676357944,"_task_hash":1952396913,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>isepamicin</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>amikacin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>intra-abdominal</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This multicentre, randomised, open-label, parallel group study compared the efficacy and safety of <b style='color:Tomato;'><i>isepamicin</i></b> (15 mg/kg once daily) and <b style='color:Tomato;'><i>amikacin</i></b> (7.5 mg/kg twice daily) when given intravenously in combination with <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b> to 267 hospitalised adults with intra-abdominal infections. Clinical cure or improvement was achieved in 96.3% (130/135) evaluable patients (efficacy population) in the <b style='color:Tomato;'><i>isepamicin</i></b> group and 94.3% (66/70) patients in the <b style='color:Tomato;'><i>amikacin</i></b> group. Bacteriological elimination occurred in 93.3% (126/135) evaluable <b style='color:Tomato;'><i>isepamicin</i></b> patients and 95.7% (67/170) <b style='color:Tomato;'><i>amikacin</i></b> patients. there was not statistically significant differences between the groups. Adverse events were reported by 9% of patients in the <b style='color:Tomato;'><i>isepamicin</i></b> group (16/178) and 10% of patients in the <b style='color:Tomato;'><i>amikacin</i></b> group (9/89). Events considered to be related to treatment occurred in 6% of patients in both groups. The most frequent adverse events were diarrhoea, nausea and vomiting. Renal problems caused three patients (2 <b style='color:Tomato;'><i>isepamicin</i></b>, 1 <b style='color:Tomato;'><i>amikacin</i></b>) to withdraw from the study. Ototoxicity (detected by audiometric testing) occurred in one patient (treated with <b style='color:Tomato;'><i>isepamicin</i></b>). In conclusion, <b style='color:Tomato;'><i>isepamicin</i></b> at a dose of 15 mg/kg once daily was shown to be as effective as <b style='color:Tomato;'><i>amikacin</i></b> (7.5 mg/kg twice daily) in the treatment of intra-abdominal infections in hospitalised adults also treated with <b style='color:Tomato;'><i>met<b style='color:Tomato;'><i>ronidazole</i></b></i></b>. Both treatments were well tolerated.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"efficacy","start":4,"end":12,"id":1,"ws":true},{"text":"and","start":13,"end":16,"id":2,"ws":true},{"text":"safety","start":17,"end":23,"id":3,"ws":true},{"text":"of","start":24,"end":26,"id":4,"ws":true},{"text":"isepamicin","start":27,"end":37,"id":5,"ws":true},{"text":"compared","start":38,"end":46,"id":6,"ws":true},{"text":"with","start":47,"end":51,"id":7,"ws":true},{"text":"amikacin","start":52,"end":60,"id":8,"ws":true},{"text":"in","start":61,"end":63,"id":9,"ws":true},{"text":"the","start":64,"end":67,"id":10,"ws":true},{"text":"treatment","start":68,"end":77,"id":11,"ws":true},{"text":"of","start":78,"end":80,"id":12,"ws":true},{"text":"intra-abdominal","start":81,"end":96,"id":13,"ws":true},{"text":"infections","start":97,"end":107,"id":14,"ws":true},{"text":".","start":108,"end":109,"id":15,"ws":false}],"spans":[{"start":27,"end":37,"token_start":5,"token_end":5,"label":"DRUG"},{"start":52,"end":60,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8622103/","_input_hash":-1423308203,"_task_hash":454917263,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Imipenem was compared with nafcillin and with penicillin plus gentamicin in the therapy of experimental endocarditis induced in rabbits by Staph . aureus and Str . faecalis , respectively .","paragraph":"<h3><u>Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis.</u></h3><b style='color:Tomato;'><i>imipenem</i></b> was very active in vitro against 36 Staphylococcus aureus isolates from cases of infective endocarditis; the MBC90 was 0.06 mg/l (four- to eight-fold more active than <b style='color:Tomato;'><i>nafcillin</i></b>). The in-vitro activity of <b style='color:Tomato;'><i>imipenem</i></b> against 22 Streptococcus faecalis isolates from proven endocarditis cases was similar to that of penicillin G (MBC90 = 8 mg/l). <b style='color:MediumOrchid;'><i>Imipenem</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>nafcillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>endocarditis</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>rabbits</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>Staph</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>aureus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Str</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>faecalis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The dosages were chosen to simulate closely serum antibiotic concentrations found in humans receiving standard parenteral regimens. <b style='color:Tomato;'><i>imipenem</i></b> was more rapidly bactericidal than <b style='color:Tomato;'><i>nafcillin</i></b> in experimental staphylococcal endocarditis. The mean +/- S.D. Staph. aureus concentrations within aortic valve vegetations (log10 cfu/g) after 5 days of therapy were as follows: <b style='color:Tomato;'><i>imipenem</i></b> = 1.39 +/- 0.61 versus <b style='color:Tomato;'><i>nafcillin</i></b> 2.39 +/- 0.36 (P less than 0.02). Both the <b style='color:Tomato;'><i>imipenem</i></b> and <b style='color:Tomato;'><i>nafcillin</i></b> regimens resulted in 'sterile' vegetations in congruent to 50% of rabbits with experimental staphylococcal endocarditis after 5 days of therapy (P greater than 0.05). <b style='color:Tomato;'><i>imipenem</i></b> was also equivalent to penicillin plus <b style='color:Tomato;'><i>gentamicin</i></b> in the therapy of experimental enterococcal endocarditis for 5 days, as assessed by the mean cfu/g vegetation and the percentage of vegetations rendered sterile. However, 7 days of therapy cured experimental enterococcal endocarditis in 72% of rabbits receiving penicillin plus <b style='color:Tomato;'><i>gentamicin</i></b> versus 20% for <b style='color:Tomato;'><i>imipenem</i></b> alone (P less than 0.05). <b style='color:Tomato;'><i>imipenem</i></b> deserves further evaluation in the therapy of infective endocarditis, both in experimental animal models of infection and in humans. This agent may prove useful in the therapy of staphylococcal endocarditis in a variety of difficult clinical situations. Therapy of enterococcal endocarditis with <b style='color:Tomato;'><i>imipenem</i></b> alone is not advisable, pending further data.","tokens":[{"text":"Imipenem","start":0,"end":8,"id":0,"ws":true},{"text":"was","start":9,"end":12,"id":1,"ws":true},{"text":"compared","start":13,"end":21,"id":2,"ws":true},{"text":"with","start":22,"end":26,"id":3,"ws":true},{"text":"nafcillin","start":27,"end":36,"id":4,"ws":true},{"text":"and","start":37,"end":40,"id":5,"ws":true},{"text":"with","start":41,"end":45,"id":6,"ws":true},{"text":"penicillin","start":46,"end":56,"id":7,"ws":true},{"text":"plus","start":57,"end":61,"id":8,"ws":true},{"text":"gentamicin","start":62,"end":72,"id":9,"ws":true},{"text":"in","start":73,"end":75,"id":10,"ws":true},{"text":"the","start":76,"end":79,"id":11,"ws":true},{"text":"therapy","start":80,"end":87,"id":12,"ws":true},{"text":"of","start":88,"end":90,"id":13,"ws":true},{"text":"experimental","start":91,"end":103,"id":14,"ws":true},{"text":"endocarditis","start":104,"end":116,"id":15,"ws":true},{"text":"induced","start":117,"end":124,"id":16,"ws":true},{"text":"in","start":125,"end":127,"id":17,"ws":true},{"text":"rabbits","start":128,"end":135,"id":18,"ws":true},{"text":"by","start":136,"end":138,"id":19,"ws":true},{"text":"Staph","start":139,"end":144,"id":20,"ws":true},{"text":".","start":145,"end":146,"id":21,"ws":true},{"text":"aureus","start":147,"end":153,"id":22,"ws":true},{"text":"and","start":154,"end":157,"id":23,"ws":true},{"text":"Str","start":158,"end":161,"id":24,"ws":true},{"text":".","start":162,"end":163,"id":25,"ws":true},{"text":"faecalis","start":164,"end":172,"id":26,"ws":true},{"text":",","start":173,"end":174,"id":27,"ws":true},{"text":"respectively","start":175,"end":187,"id":28,"ws":true},{"text":".","start":188,"end":189,"id":29,"ws":false}],"spans":[{"start":0,"end":8,"token_start":0,"token_end":0,"label":"DRUG"},{"start":27,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},{"start":46,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},{"start":62,"end":72,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6421794/","_input_hash":1926321652,"_task_hash":653025822,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":46,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":62,"end":72,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The total dose of paclitaxel ( 175 - 200 mg/m2 ) ; cisplatin ( 75 mg/m2 ) ; and etoposide ( 175 - 200 mg/m2 ) was divided into five daily doses administered over 3 h with cycles repeated at 21 - 28 days .","paragraph":"<h3><u>Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer.</u></h3>In this phase II study, <b style='color:Tomato;'><i>paclitaxel</i></b> was added to the combination of <b style='color:Tomato;'><i>cisplatin</i></b> and <b style='color:Tomato;'><i>etoposide</i></b> (TPE regimen), in 37 patients with advanced non-small cell lung cancer, using a multifractionated dosing schedule. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>divided</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>28</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>.</i></b> 15 patients had stage III A or B disease and 22 stage IV disease. 32 patients were evaluable for toxicity and 37 for response. Neutropenia was the most prominent toxicity. Grade 3 or grade 4 neutropenia was observed in 12 (38%) and 9 (25%) of the patients, respectively and 11 patients required hospitalisation. 3 patients died secondary to chemotherapy related sepsis. Diarrhoea (grade 3, 3 patients; grade 4, 2 patients) was the only other significant non-haematological acute toxicity. The optimal dose rate for this multifractionated regimen was <b style='color:Tomato;'><i>paclitaxel</i></b> 35 or 40 mg/m2/fraction; <b style='color:Tomato;'><i>cisplatin</i></b> 15 mg/m2/fraction; <b style='color:Tomato;'><i>etoposide</i></b> 35 or 40 mg/m2/fraction. Responses were observed in 28 of 37 evaluable patients (3 complete response; 25 partial responses [76%]. 22 patients are alive; 8 with stage III B disease received radiation or surgery (3 had minimal or no tumour in the pathology specimen). TPE is a highly active regimen for non-small cell lung cancer and multifractionated dose scheduling is a feasible and well tolerated system.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"total","start":4,"end":9,"id":1,"ws":true},{"text":"dose","start":10,"end":14,"id":2,"ws":true},{"text":"of","start":15,"end":17,"id":3,"ws":true},{"text":"paclitaxel","start":18,"end":28,"id":4,"ws":true},{"text":"(","start":29,"end":30,"id":5,"ws":true},{"text":"175","start":31,"end":34,"id":6,"ws":true},{"text":"-","start":35,"end":36,"id":7,"ws":true},{"text":"200","start":37,"end":40,"id":8,"ws":true},{"text":"mg/m2","start":41,"end":46,"id":9,"ws":true},{"text":")","start":47,"end":48,"id":10,"ws":true},{"text":";","start":49,"end":50,"id":11,"ws":true},{"text":"cisplatin","start":51,"end":60,"id":12,"ws":true},{"text":"(","start":61,"end":62,"id":13,"ws":true},{"text":"75","start":63,"end":65,"id":14,"ws":true},{"text":"mg/m2","start":66,"end":71,"id":15,"ws":true},{"text":")","start":72,"end":73,"id":16,"ws":true},{"text":";","start":74,"end":75,"id":17,"ws":true},{"text":"and","start":76,"end":79,"id":18,"ws":true},{"text":"etoposide","start":80,"end":89,"id":19,"ws":true},{"text":"(","start":90,"end":91,"id":20,"ws":true},{"text":"175","start":92,"end":95,"id":21,"ws":true},{"text":"-","start":96,"end":97,"id":22,"ws":true},{"text":"200","start":98,"end":101,"id":23,"ws":true},{"text":"mg/m2","start":102,"end":107,"id":24,"ws":true},{"text":")","start":108,"end":109,"id":25,"ws":true},{"text":"was","start":110,"end":113,"id":26,"ws":true},{"text":"divided","start":114,"end":121,"id":27,"ws":true},{"text":"into","start":122,"end":126,"id":28,"ws":true},{"text":"five","start":127,"end":131,"id":29,"ws":true},{"text":"daily","start":132,"end":137,"id":30,"ws":true},{"text":"doses","start":138,"end":143,"id":31,"ws":true},{"text":"administered","start":144,"end":156,"id":32,"ws":true},{"text":"over","start":157,"end":161,"id":33,"ws":true},{"text":"3","start":162,"end":163,"id":34,"ws":true},{"text":"h","start":164,"end":165,"id":35,"ws":true},{"text":"with","start":166,"end":170,"id":36,"ws":true},{"text":"cycles","start":171,"end":177,"id":37,"ws":true},{"text":"repeated","start":178,"end":186,"id":38,"ws":true},{"text":"at","start":187,"end":189,"id":39,"ws":true},{"text":"21","start":190,"end":192,"id":40,"ws":true},{"text":"-","start":193,"end":194,"id":41,"ws":true},{"text":"28","start":195,"end":197,"id":42,"ws":true},{"text":"days","start":198,"end":202,"id":43,"ws":true},{"text":".","start":203,"end":204,"id":44,"ws":false}],"spans":[{"start":18,"end":28,"token_start":4,"token_end":4,"label":"DRUG"},{"start":51,"end":60,"token_start":12,"token_end":12,"label":"DRUG"},{"start":80,"end":89,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9713270/","_input_hash":1052186597,"_task_hash":-1846717707,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":4,"child":12,"head_span":{"start":18,"end":28,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":51,"end":60,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":19,"head_span":{"start":51,"end":60,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":80,"end":89,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In this phase 3 trial , we randomly assigned ( in a 1:1:1 ratio ) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib ( 20 mg orally once daily ) plus pembrolizumab ( 200 mg intravenously once every 3 weeks ) , lenvatinib ( 18 mg orally once daily ) plus everolimus ( 5 mg orally once daily ) , or sunitinib ( 50 mg orally once daily , alternating 4 weeks receiving treatment and 2 weeks without treatment ) .","paragraph":"<h3><u>Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.</u></h3><b style='color:Tomato;'><i>lenvatinib</i></b> in combination with <b style='color:Tomato;'><i>pembrolizumab</i></b> or <b style='color:Tomato;'><i>everolimus</i></b> has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of <b style='color:Tomato;'><i>sunitinib</i></b> is unclear. ### methods <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>1:1:1</i></b> <b style='color:DodgerBlue;'><i>ratio</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>previous</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:MediumOrchid;'><i>lenvatinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>lenvatinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated. ### results A total of 1069 patients were randomly assigned to receive <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> (355 patients), <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b> (357), or <b style='color:Tomato;'><i>sunitinib</i></b> (357). Progression-free survival was longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P<0.001) and was longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (median, 14.7 vs. 9.2 months; hazard ratio, 0.65; 95% CI, 0.53 to 0.80; P<0.001). Overall survival was longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (hazard ratio for death, 0.66; 95% CI, 0.49 to 0.88; P\u2009=\u20090.005) but was not longer with <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b> than with <b style='color:Tomato;'><i>sunitinib</i></b> (hazard ratio, 1.15; 95% CI, 0.88 to 1.50; P\u2009=\u20090.30). Grade 3 or higher adverse events emerged or worsened during treatment in 82.4% of the patients who received <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b>, 83.1% of those who received <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>everolimus</i></b>, and 71.8% of those who received <b style='color:Tomato;'><i>sunitinib</i></b>. Grade 3 or higher adverse events occurring in at least 10% of the patients in any group included hypertension, diarrhea, and elevated lipase levels. ### conclusions <b style='color:Tomato;'><i>lenvatinib</i></b> plus <b style='color:Tomato;'><i>pembrolizumab</i></b> was associated with significantly longer progression-free survival and overall survival than <b style='color:Tomato;'><i>sunitinib</i></b>. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"this","start":3,"end":7,"id":1,"ws":true},{"text":"phase","start":8,"end":13,"id":2,"ws":true},{"text":"3","start":14,"end":15,"id":3,"ws":true},{"text":"trial","start":16,"end":21,"id":4,"ws":true},{"text":",","start":22,"end":23,"id":5,"ws":true},{"text":"we","start":24,"end":26,"id":6,"ws":true},{"text":"randomly","start":27,"end":35,"id":7,"ws":true},{"text":"assigned","start":36,"end":44,"id":8,"ws":true},{"text":"(","start":45,"end":46,"id":9,"ws":true},{"text":"in","start":47,"end":49,"id":10,"ws":true},{"text":"a","start":50,"end":51,"id":11,"ws":true},{"text":"1:1:1","start":52,"end":57,"id":12,"ws":true},{"text":"ratio","start":58,"end":63,"id":13,"ws":true},{"text":")","start":64,"end":65,"id":14,"ws":true},{"text":"patients","start":66,"end":74,"id":15,"ws":true},{"text":"with","start":75,"end":79,"id":16,"ws":true},{"text":"advanced","start":80,"end":88,"id":17,"ws":true},{"text":"renal","start":89,"end":94,"id":18,"ws":true},{"text":"cell","start":95,"end":99,"id":19,"ws":true},{"text":"carcinoma","start":100,"end":109,"id":20,"ws":true},{"text":"and","start":110,"end":113,"id":21,"ws":true},{"text":"no","start":114,"end":116,"id":22,"ws":true},{"text":"previous","start":117,"end":125,"id":23,"ws":true},{"text":"systemic","start":126,"end":134,"id":24,"ws":true},{"text":"therapy","start":135,"end":142,"id":25,"ws":true},{"text":"to","start":143,"end":145,"id":26,"ws":true},{"text":"receive","start":146,"end":153,"id":27,"ws":true},{"text":"lenvatinib","start":154,"end":164,"id":28,"ws":true},{"text":"(","start":165,"end":166,"id":29,"ws":true},{"text":"20","start":167,"end":169,"id":30,"ws":true},{"text":"mg","start":170,"end":172,"id":31,"ws":true},{"text":"orally","start":173,"end":179,"id":32,"ws":true},{"text":"once","start":180,"end":184,"id":33,"ws":true},{"text":"daily","start":185,"end":190,"id":34,"ws":true},{"text":")","start":191,"end":192,"id":35,"ws":true},{"text":"plus","start":193,"end":197,"id":36,"ws":true},{"text":"pembrolizumab","start":198,"end":211,"id":37,"ws":true},{"text":"(","start":212,"end":213,"id":38,"ws":true},{"text":"200","start":214,"end":217,"id":39,"ws":true},{"text":"mg","start":218,"end":220,"id":40,"ws":true},{"text":"intravenously","start":221,"end":234,"id":41,"ws":true},{"text":"once","start":235,"end":239,"id":42,"ws":true},{"text":"every","start":240,"end":245,"id":43,"ws":true},{"text":"3","start":246,"end":247,"id":44,"ws":true},{"text":"weeks","start":248,"end":253,"id":45,"ws":true},{"text":")","start":254,"end":255,"id":46,"ws":true},{"text":",","start":256,"end":257,"id":47,"ws":true},{"text":"lenvatinib","start":258,"end":268,"id":48,"ws":true},{"text":"(","start":269,"end":270,"id":49,"ws":true},{"text":"18","start":271,"end":273,"id":50,"ws":true},{"text":"mg","start":274,"end":276,"id":51,"ws":true},{"text":"orally","start":277,"end":283,"id":52,"ws":true},{"text":"once","start":284,"end":288,"id":53,"ws":true},{"text":"daily","start":289,"end":294,"id":54,"ws":true},{"text":")","start":295,"end":296,"id":55,"ws":true},{"text":"plus","start":297,"end":301,"id":56,"ws":true},{"text":"everolimus","start":302,"end":312,"id":57,"ws":true},{"text":"(","start":313,"end":314,"id":58,"ws":true},{"text":"5","start":315,"end":316,"id":59,"ws":true},{"text":"mg","start":317,"end":319,"id":60,"ws":true},{"text":"orally","start":320,"end":326,"id":61,"ws":true},{"text":"once","start":327,"end":331,"id":62,"ws":true},{"text":"daily","start":332,"end":337,"id":63,"ws":true},{"text":")","start":338,"end":339,"id":64,"ws":true},{"text":",","start":340,"end":341,"id":65,"ws":true},{"text":"or","start":342,"end":344,"id":66,"ws":true},{"text":"sunitinib","start":345,"end":354,"id":67,"ws":true},{"text":"(","start":355,"end":356,"id":68,"ws":true},{"text":"50","start":357,"end":359,"id":69,"ws":true},{"text":"mg","start":360,"end":362,"id":70,"ws":true},{"text":"orally","start":363,"end":369,"id":71,"ws":true},{"text":"once","start":370,"end":374,"id":72,"ws":true},{"text":"daily","start":375,"end":380,"id":73,"ws":true},{"text":",","start":381,"end":382,"id":74,"ws":true},{"text":"alternating","start":383,"end":394,"id":75,"ws":true},{"text":"4","start":395,"end":396,"id":76,"ws":true},{"text":"weeks","start":397,"end":402,"id":77,"ws":true},{"text":"receiving","start":403,"end":412,"id":78,"ws":true},{"text":"treatment","start":413,"end":422,"id":79,"ws":true},{"text":"and","start":423,"end":426,"id":80,"ws":true},{"text":"2","start":427,"end":428,"id":81,"ws":true},{"text":"weeks","start":429,"end":434,"id":82,"ws":true},{"text":"without","start":435,"end":442,"id":83,"ws":true},{"text":"treatment","start":443,"end":452,"id":84,"ws":true},{"text":")","start":453,"end":454,"id":85,"ws":true},{"text":".","start":455,"end":456,"id":86,"ws":false}],"spans":[{"start":154,"end":164,"token_start":28,"token_end":28,"label":"DRUG"},{"start":198,"end":211,"token_start":37,"token_end":37,"label":"DRUG"},{"start":258,"end":268,"token_start":48,"token_end":48,"label":"DRUG"},{"start":302,"end":312,"token_start":57,"token_end":57,"label":"DRUG"},{"start":345,"end":354,"token_start":67,"token_end":67,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33616314/","_input_hash":-318641375,"_task_hash":-1256770653,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":28,"child":37,"head_span":{"start":154,"end":164,"token_start":28,"token_end":28,"label":"DRUG"},"child_span":{"start":198,"end":211,"token_start":37,"token_end":37,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":48,"child":57,"head_span":{"start":258,"end":268,"token_start":48,"token_end":48,"label":"DRUG"},"child_span":{"start":302,"end":312,"token_start":57,"token_end":57,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["POS11","NEG11"],"answer":"accept"}
{"text":"Only chemotherapy by intravenous administration of 2 courses of 120 - 150 mg ACNU ( 1.7 - 2.2 mg/kg ) and 4 mg vincristine ( 0.06 mg/kg ) with intrathecal administration of methotrexate was given at this time .","paragraph":"<h3><u>A long surviving case of recurrent medulloblastoma displaying effectiveness of ACNU/vincristine chemotherapy.</u></h3>A favorable case of recurrent medulloblastoma, in which 19 years has elapsed with combination therapy due to surgery, radiation and chemotherapy since the initial operation, is reported. The case was a male of age 12 who was admitted due to medulloblastoma of the classical type. Tumor recurrences were observed 3 times within 7 years after the initial operation and radiation treatment. At the 3rd recurrence, a large tumor was found in the cerebellar vermis and left cerebellar hemisphere on CT with CSF dissemination and a high NSE level in the CSF (62 ng/ml). <b style='color:DodgerBlue;'><i>Only</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>courses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>150</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>ACNU</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1.7</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2.2</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.06</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The tumor image and gait disturbance with radicular pain disappeared completely and the NSE level in the CSF improved to within the normal range (5.4 ng/ml). The patient continues in complete remission, with a Karnovsky performance status of 100% at 4 years after the 3rd recurrence. We report full details of this case in which active treatments consisting mainly of chemotherapy proved to be effective for recurrent medulloblastoma, even though its prognosis is generally very unfavorable.","tokens":[{"text":"Only","start":0,"end":4,"id":0,"ws":true},{"text":"chemotherapy","start":5,"end":17,"id":1,"ws":true},{"text":"by","start":18,"end":20,"id":2,"ws":true},{"text":"intravenous","start":21,"end":32,"id":3,"ws":true},{"text":"administration","start":33,"end":47,"id":4,"ws":true},{"text":"of","start":48,"end":50,"id":5,"ws":true},{"text":"2","start":51,"end":52,"id":6,"ws":true},{"text":"courses","start":53,"end":60,"id":7,"ws":true},{"text":"of","start":61,"end":63,"id":8,"ws":true},{"text":"120","start":64,"end":67,"id":9,"ws":true},{"text":"-","start":68,"end":69,"id":10,"ws":true},{"text":"150","start":70,"end":73,"id":11,"ws":true},{"text":"mg","start":74,"end":76,"id":12,"ws":true},{"text":"ACNU","start":77,"end":81,"id":13,"ws":true},{"text":"(","start":82,"end":83,"id":14,"ws":true},{"text":"1.7","start":84,"end":87,"id":15,"ws":true},{"text":"-","start":88,"end":89,"id":16,"ws":true},{"text":"2.2","start":90,"end":93,"id":17,"ws":true},{"text":"mg/kg","start":94,"end":99,"id":18,"ws":true},{"text":")","start":100,"end":101,"id":19,"ws":true},{"text":"and","start":102,"end":105,"id":20,"ws":true},{"text":"4","start":106,"end":107,"id":21,"ws":true},{"text":"mg","start":108,"end":110,"id":22,"ws":true},{"text":"vincristine","start":111,"end":122,"id":23,"ws":true},{"text":"(","start":123,"end":124,"id":24,"ws":true},{"text":"0.06","start":125,"end":129,"id":25,"ws":true},{"text":"mg/kg","start":130,"end":135,"id":26,"ws":true},{"text":")","start":136,"end":137,"id":27,"ws":true},{"text":"with","start":138,"end":142,"id":28,"ws":true},{"text":"intrathecal","start":143,"end":154,"id":29,"ws":true},{"text":"administration","start":155,"end":169,"id":30,"ws":true},{"text":"of","start":170,"end":172,"id":31,"ws":true},{"text":"methotrexate","start":173,"end":185,"id":32,"ws":true},{"text":"was","start":186,"end":189,"id":33,"ws":true},{"text":"given","start":190,"end":195,"id":34,"ws":true},{"text":"at","start":196,"end":198,"id":35,"ws":true},{"text":"this","start":199,"end":203,"id":36,"ws":true},{"text":"time","start":204,"end":208,"id":37,"ws":true},{"text":".","start":209,"end":210,"id":38,"ws":false}],"spans":[{"start":77,"end":81,"token_start":13,"token_end":13,"label":"DRUG"},{"start":111,"end":122,"token_start":23,"token_end":23,"label":"DRUG"},{"start":173,"end":185,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8057133/","_input_hash":1591607984,"_task_hash":-814820846,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":13,"child":23,"head_span":{"start":77,"end":81,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":111,"end":122,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":32,"child":23,"head_span":{"start":173,"end":185,"token_start":32,"token_end":32,"label":"DRUG"},"child_span":{"start":111,"end":122,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In first-line treatment of intermediate- to poor-risk patients , the CheckMate 214 study demonstrated a significant survival advantage for nivolumab and ipilimumab versus sunitinib .","paragraph":"<h3><u>A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.</u></h3>The treatment paradigm of advanced renal cell carcinoma (RCC) has changed rapidly in recent years. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>intermediate-</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>poor-risk</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>CheckMate</i></b> <b style='color:DodgerBlue;'><i>214</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The high cost of combined immune-modulating agents warrants an understanding of the combination's value by considering both efficacy and cost. The objective of this study was to estimate the cost-effectiveness of <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> compared with <b style='color:Tomato;'><i>sunitinib</i></b> for first-line treatment of intermediate- to poor-risk advanced RCC from the U.S. payer perspective. ### Materials And Methods A Markov model was developed to compare the costs and effectiveness of <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> with those of <b style='color:Tomato;'><i>sunitinib</i></b> in the first-line treatment of intermediate- to poor-risk advanced RCC. Health outcomes were measured in life-years and quality-adjusted life-years (QALYs). Drug costs were based on Medicare reimbursement rates in 2017. We extrapolated survival beyond the trial closure using Weibull distribution. Model robustness was addressed in univariable and probabilistic sensitivity analyses. ### results The total mean cost per-patient of <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> versus <b style='color:Tomato;'><i>sunitinib</i></b> was $292,308 and $169,287, respectfully. <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> generated a gain of 0.978 QALYs over <b style='color:Tomato;'><i>sunitinib</i></b>. The incremental cost-effectiveness ratio (ICER) for <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> was $125,739/QALY versus <b style='color:Tomato;'><i>sunitinib</i></b>. ### conclusion Our analysis established that the base case ICER in the model for <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> versus <b style='color:Tomato;'><i>sunitinib</i></b> is below what some would consider the upper limit of the theoretical willingness-to-pay threshold in the U.S. ($150,000/QALY) and is thus estimated to be cost-effective. ### Implications For Practice This article assessed the cost-effectiveness of <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> versus <b style='color:Tomato;'><i>sunitinib</i></b> for treatment of patients with intermediate- to poor-risk metastatic kidney cancer, from the U.S. payer perspective. It would cost $125,739 to gain 1 quality-adjusted life-year with <b style='color:Tomato;'><i>nivolumab</i></b> and <b style='color:Tomato;'><i>ipilimumab</i></b> versus <b style='color:Tomato;'><i>sunitinib</i></b> in these patients.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"first-line","start":3,"end":13,"id":1,"ws":true},{"text":"treatment","start":14,"end":23,"id":2,"ws":true},{"text":"of","start":24,"end":26,"id":3,"ws":true},{"text":"intermediate-","start":27,"end":40,"id":4,"ws":true},{"text":"to","start":41,"end":43,"id":5,"ws":true},{"text":"poor-risk","start":44,"end":53,"id":6,"ws":true},{"text":"patients","start":54,"end":62,"id":7,"ws":true},{"text":",","start":63,"end":64,"id":8,"ws":true},{"text":"the","start":65,"end":68,"id":9,"ws":true},{"text":"CheckMate","start":69,"end":78,"id":10,"ws":true},{"text":"214","start":79,"end":82,"id":11,"ws":true},{"text":"study","start":83,"end":88,"id":12,"ws":true},{"text":"demonstrated","start":89,"end":101,"id":13,"ws":true},{"text":"a","start":102,"end":103,"id":14,"ws":true},{"text":"significant","start":104,"end":115,"id":15,"ws":true},{"text":"survival","start":116,"end":124,"id":16,"ws":true},{"text":"advantage","start":125,"end":134,"id":17,"ws":true},{"text":"for","start":135,"end":138,"id":18,"ws":true},{"text":"nivolumab","start":139,"end":148,"id":19,"ws":true},{"text":"and","start":149,"end":152,"id":20,"ws":true},{"text":"ipilimumab","start":153,"end":163,"id":21,"ws":true},{"text":"versus","start":164,"end":170,"id":22,"ws":true},{"text":"sunitinib","start":171,"end":180,"id":23,"ws":true},{"text":".","start":181,"end":182,"id":24,"ws":false}],"spans":[{"start":139,"end":148,"token_start":19,"token_end":19,"label":"DRUG"},{"start":153,"end":163,"token_start":21,"token_end":21,"label":"DRUG"},{"start":171,"end":180,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30710066/","_input_hash":448328555,"_task_hash":136127527,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":19,"child":21,"head_span":{"start":139,"end":148,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":153,"end":163,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In addition , docetaxel has a longer retention time in tumor cells than paclitaxel because of greater uptake and slower efflux .","paragraph":"<h3><u>Preclinical pharmacology of the taxanes: implications of the differences.</u></h3>Taxanes are one of the most powerful classes of compounds among all chemotherapeutic drugs. Only 30 years separate the isolation of the first taxane from the results of direct clinical comparisons in metastatic breast, ovarian, and lung cancer between the two taxanes available in routine clinical practice. These results suggest a more favorable benefit-to-risk ratio for <b style='color:Tomato;'><i>docetaxel</i></b> compared to <b style='color:Tomato;'><i>paclitaxel</i></b> when these drugs are used as single agents or in combination with other chemotherapeutic agents in an every-3-week dosing regimen. Pharmacological data support the difference between the taxanes, likely explaining the clinical results. Considering the molecular pharmacology of the two drugs, <b style='color:Tomato;'><i>docetaxel</i></b> appears to bind to beta-tubulin with greater affinity and has a wider cell cycle activity than <b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:Tomato;'><i>docetaxel</i></b> also appears to have direct antitumoral activity via an apoptotic effect mediated by bcl-2 phosphorylation. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>longer</i></b> <b style='color:DodgerBlue;'><i>retention</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>uptake</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>slower</i></b> <b style='color:DodgerBlue;'><i>efflux</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Pharmacokinetics and pharmacodynamics of the taxanes show both agents to be extensively metabolized in the liver, and <b style='color:Tomato;'><i>paclitaxel</i></b> has a nonlinear pharmacokinetic behavior while <b style='color:Tomato;'><i>docetaxel</i></b> has linear pharmacokinetics. These differences explain the more simple treatment schedule and favorable results for <b style='color:Tomato;'><i>docetaxel</i></b> as a single agent and in combination therapy. Last, but not least, there is a pharmacokinetic interaction between <b style='color:Tomato;'><i>paclitaxel</i></b> and the anthracyclines, an active class of compounds commonly used in the treatment of breast cancer. This pharmacokinetic interaction is associated with greater cardio- and myelotoxicities, which are sequence dependent. These pharmacological data likely explain the different clinical development strategies for the two molecules as well as the different clinical results from individual trials and direct comparisons.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"addition","start":3,"end":11,"id":1,"ws":true},{"text":",","start":12,"end":13,"id":2,"ws":true},{"text":"docetaxel","start":14,"end":23,"id":3,"ws":true},{"text":"has","start":24,"end":27,"id":4,"ws":true},{"text":"a","start":28,"end":29,"id":5,"ws":true},{"text":"longer","start":30,"end":36,"id":6,"ws":true},{"text":"retention","start":37,"end":46,"id":7,"ws":true},{"text":"time","start":47,"end":51,"id":8,"ws":true},{"text":"in","start":52,"end":54,"id":9,"ws":true},{"text":"tumor","start":55,"end":60,"id":10,"ws":true},{"text":"cells","start":61,"end":66,"id":11,"ws":true},{"text":"than","start":67,"end":71,"id":12,"ws":true},{"text":"paclitaxel","start":72,"end":82,"id":13,"ws":true},{"text":"because","start":83,"end":90,"id":14,"ws":true},{"text":"of","start":91,"end":93,"id":15,"ws":true},{"text":"greater","start":94,"end":101,"id":16,"ws":true},{"text":"uptake","start":102,"end":108,"id":17,"ws":true},{"text":"and","start":109,"end":112,"id":18,"ws":true},{"text":"slower","start":113,"end":119,"id":19,"ws":true},{"text":"efflux","start":120,"end":126,"id":20,"ws":true},{"text":".","start":127,"end":128,"id":21,"ws":false}],"spans":[{"start":14,"end":23,"token_start":3,"token_end":3,"label":"DRUG"},{"start":72,"end":82,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15161985/","_input_hash":1766096591,"_task_hash":-393739801,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The total sample size was 103 , consisting of 31 , 23 , and 19 patients in olanzapine , risperidone , and clozapine groups , respectively and 30 controls .","paragraph":"<h3><u>Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia.</u></h3>Sexual dysfunctions have been a major side effect of the second generation anti-psychotic drugs which often affects treatment compliance in patients with schizophrenia. There is no/few systematic review or research addressing sexual dysfunction and their effect on serum prolactin level among different atypical antipsychotics in India. ### aims To determine and compare the frequency of sexual dysfunction associated with <b style='color:Tomato;'><i>olanzapine</i></b>, <b style='color:Tomato;'><i>risperidone</i></b>, and <b style='color:Tomato;'><i>clozapine</i></b> and their effect on serum prolactin level in remitted patients with schizophrenia. ### Settings And Design Cross-sectional hospital-based study. Recruitment by purposive sampling. Estimation of serum prolactin was done using enzyme-linked immunosorbent assay technique. ### Materials And Methods <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>sample</i></b> <b style='color:DodgerBlue;'><i>size</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>103</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>31</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>23</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:MediumOrchid;'><i>olanzapine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>risperidone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clozapine</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>controls</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A Brief Psychiatric Rating Scale, Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale and Sexual Functioning Questionnaire were administered. Analysis of variance was used to compare clinical variables. Chi-square test was used to identify the frequency of sexual dysfunction. Kruskal-Wallis test was used to compare UKU side effect, sexual dysfunction, and blood parameters across the study groups. ### Results And Conclusion Eighty-six percentage reported sexual dysfunction in one or more domains of sexual functioning in <b style='color:Tomato;'><i>risperidone</i></b> group as compared to 48.3% in <b style='color:Tomato;'><i>olanzapine</i></b> and 31% in <b style='color:Tomato;'><i>clozapine</i></b> groups, respectively. Prolactin level elevation was statistically significant in <b style='color:Tomato;'><i>risperidone</i></b> group followed by <b style='color:Tomato;'><i>clozapine</i></b> and <b style='color:Tomato;'><i>olanzapine</i></b> groups, respectively.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"total","start":4,"end":9,"id":1,"ws":true},{"text":"sample","start":10,"end":16,"id":2,"ws":true},{"text":"size","start":17,"end":21,"id":3,"ws":true},{"text":"was","start":22,"end":25,"id":4,"ws":true},{"text":"103","start":26,"end":29,"id":5,"ws":true},{"text":",","start":30,"end":31,"id":6,"ws":true},{"text":"consisting","start":32,"end":42,"id":7,"ws":true},{"text":"of","start":43,"end":45,"id":8,"ws":true},{"text":"31","start":46,"end":48,"id":9,"ws":true},{"text":",","start":49,"end":50,"id":10,"ws":true},{"text":"23","start":51,"end":53,"id":11,"ws":true},{"text":",","start":54,"end":55,"id":12,"ws":true},{"text":"and","start":56,"end":59,"id":13,"ws":true},{"text":"19","start":60,"end":62,"id":14,"ws":true},{"text":"patients","start":63,"end":71,"id":15,"ws":true},{"text":"in","start":72,"end":74,"id":16,"ws":true},{"text":"olanzapine","start":75,"end":85,"id":17,"ws":true},{"text":",","start":86,"end":87,"id":18,"ws":true},{"text":"risperidone","start":88,"end":99,"id":19,"ws":true},{"text":",","start":100,"end":101,"id":20,"ws":true},{"text":"and","start":102,"end":105,"id":21,"ws":true},{"text":"clozapine","start":106,"end":115,"id":22,"ws":true},{"text":"groups","start":116,"end":122,"id":23,"ws":true},{"text":",","start":123,"end":124,"id":24,"ws":true},{"text":"respectively","start":125,"end":137,"id":25,"ws":true},{"text":"and","start":138,"end":141,"id":26,"ws":true},{"text":"30","start":142,"end":144,"id":27,"ws":true},{"text":"controls","start":145,"end":153,"id":28,"ws":true},{"text":".","start":154,"end":155,"id":29,"ws":false}],"spans":[{"start":75,"end":85,"token_start":17,"token_end":17,"label":"DRUG"},{"start":88,"end":99,"token_start":19,"token_end":19,"label":"DRUG"},{"start":106,"end":115,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26816428/","_input_hash":1935711712,"_task_hash":-240299774,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The relative analgesic potency ratios were 0.65 ( 0.56 - 0.76 ) for ropivacaine : bupivacaine , 0.80 ( 0.70 - 0.92 ) for ropivacaine : levobupivacaine , and 0.81 ( 0.69 - 0.94 ) for levobupivacaine : bupivacaine .","paragraph":"<h3><u>Minimum local analgesic doses of ropivacaine, levobupivacaine, and bupivacaine for intrathecal labor analgesia.</u></h3>Doses for intrathecal opioid-local anesthetic mixtures have been arbitrarily chosen. The aim of this study was to compare the analgesic efficacies of intrathecal <b style='color:Tomato;'><i>ropivacaine</i></b>, levo<b style='color:Tomato;'><i>bupivacaine</i></b>, and <b style='color:Tomato;'><i>bupivacaine</i></b> for labor analgesia and to determine the analgesic potency ratios for these three drugs. For this purpose, the authors used the up-down sequential allocation model, which estimates the minimum local analgesic dose for intrathecal local anesthetic. ### methods Ninety-seven nulliparous term parturients in spontaneous labor, requesting combined spinal-epidural analgesia, were randomly allocated to one of three groups to receive 0.25% spinal <b style='color:Tomato;'><i>ropivacaine</i></b>, levo<b style='color:Tomato;'><i>bupivacaine</i></b>, or <b style='color:Tomato;'><i>bupivacaine</i></b>. The initial dose of the local anesthetic drug was chosen to be 2.5 mg, and the testing interval was set at 0.25 mg. The subsequent doses were determined by the response of the previous parturient. Efficacy was accepted if the visual analog pain score decreased to 10 mm or less on a 100-mm scale within 30 min. The minimum local analgesic dose was calculated using the method of Dixon and Massey. ### results The intrathecal minimum local analgesic dose was 3.64 mg (95% confidence interval, 3.33-3.96 mg) for <b style='color:Tomato;'><i>ropivacaine</i></b>, 2.94 (2.73-3.16) mg for levo<b style='color:Tomato;'><i>bupivacaine</i></b>, and 2.37 (2.17-2.58) mg for <b style='color:Tomato;'><i>bupivacaine</i></b>. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>relative</i></b> <b style='color:DodgerBlue;'><i>analgesic</i></b> <b style='color:DodgerBlue;'><i>potency</i></b> <b style='color:DodgerBlue;'><i>ratios</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>0.65</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.56</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>0.76</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>ropivacaine</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>0.80</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.70</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>0.92</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>ropivacaine</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>levobupivacaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>0.81</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0.69</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>0.94</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>levobupivacaine</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> There were significant trends (P </= 0.021) for greater motor block with <b style='color:Tomato;'><i>bupivacaine</i></b> and levo<b style='color:Tomato;'><i>bupivacaine</i></b>. ### conclusions This study suggests a potency hierarchy of spinal <b style='color:Tomato;'><i>bupivacaine</i></b> > levo<b style='color:Tomato;'><i>bupivacaine</i></b> > <b style='color:Tomato;'><i>ropivacaine</i></b>.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"relative","start":4,"end":12,"id":1,"ws":true},{"text":"analgesic","start":13,"end":22,"id":2,"ws":true},{"text":"potency","start":23,"end":30,"id":3,"ws":true},{"text":"ratios","start":31,"end":37,"id":4,"ws":true},{"text":"were","start":38,"end":42,"id":5,"ws":true},{"text":"0.65","start":43,"end":47,"id":6,"ws":true},{"text":"(","start":48,"end":49,"id":7,"ws":true},{"text":"0.56","start":50,"end":54,"id":8,"ws":true},{"text":"-","start":55,"end":56,"id":9,"ws":true},{"text":"0.76","start":57,"end":61,"id":10,"ws":true},{"text":")","start":62,"end":63,"id":11,"ws":true},{"text":"for","start":64,"end":67,"id":12,"ws":true},{"text":"ropivacaine","start":68,"end":79,"id":13,"ws":true},{"text":":","start":80,"end":81,"id":14,"ws":true},{"text":"bupivacaine","start":82,"end":93,"id":15,"ws":true},{"text":",","start":94,"end":95,"id":16,"ws":true},{"text":"0.80","start":96,"end":100,"id":17,"ws":true},{"text":"(","start":101,"end":102,"id":18,"ws":true},{"text":"0.70","start":103,"end":107,"id":19,"ws":true},{"text":"-","start":108,"end":109,"id":20,"ws":true},{"text":"0.92","start":110,"end":114,"id":21,"ws":true},{"text":")","start":115,"end":116,"id":22,"ws":true},{"text":"for","start":117,"end":120,"id":23,"ws":true},{"text":"ropivacaine","start":121,"end":132,"id":24,"ws":true},{"text":":","start":133,"end":134,"id":25,"ws":true},{"text":"levobupivacaine","start":135,"end":150,"id":26,"ws":true},{"text":",","start":151,"end":152,"id":27,"ws":true},{"text":"and","start":153,"end":156,"id":28,"ws":true},{"text":"0.81","start":157,"end":161,"id":29,"ws":true},{"text":"(","start":162,"end":163,"id":30,"ws":true},{"text":"0.69","start":164,"end":168,"id":31,"ws":true},{"text":"-","start":169,"end":170,"id":32,"ws":true},{"text":"0.94","start":171,"end":175,"id":33,"ws":true},{"text":")","start":176,"end":177,"id":34,"ws":true},{"text":"for","start":178,"end":181,"id":35,"ws":true},{"text":"levobupivacaine","start":182,"end":197,"id":36,"ws":true},{"text":":","start":198,"end":199,"id":37,"ws":true},{"text":"bupivacaine","start":200,"end":211,"id":38,"ws":true},{"text":".","start":212,"end":213,"id":39,"ws":false}],"spans":[{"start":68,"end":79,"token_start":13,"token_end":13,"label":"DRUG"},{"start":82,"end":93,"token_start":15,"token_end":15,"label":"DRUG"},{"start":121,"end":132,"token_start":24,"token_end":24,"label":"DRUG"},{"start":135,"end":150,"token_start":26,"token_end":26,"label":"DRUG"},{"start":182,"end":197,"token_start":36,"token_end":36,"label":"DRUG"},{"start":200,"end":211,"token_start":38,"token_end":38,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15731605/","_input_hash":-88937528,"_task_hash":-1639390727,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":68,"end":79,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":82,"end":93,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":24,"child":26,"head_span":{"start":121,"end":132,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":135,"end":150,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":36,"child":38,"head_span":{"start":182,"end":197,"token_start":36,"token_end":36,"label":"DRUG"},"child_span":{"start":200,"end":211,"token_start":38,"token_end":38,"label":"DRUG"},"color":"#c5bdf4","label":"COMB3"}],"radio":[],"answer":"accept"}
{"text":"Lapatinib ( LPT ) could sensitize human epidermal growth factor receptor-2 ( HER-2 ) positive breast cancer to paclitaxel ( PTX ) and induce synergetic action with PTX in preclinical test and phase II/III trial .","paragraph":"<h3><u>A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.</u></h3> <b style='color:MediumOrchid;'><i>Lapatinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LPT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>sensitize</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>epidermal</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>receptor-2</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HER-2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PTX</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>induce</i></b> <b style='color:DodgerBlue;'><i>synergetic</i></b> <b style='color:DodgerBlue;'><i>action</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>PTX</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>preclinical</i></b> <b style='color:DodgerBlue;'><i>test</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II/III</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, LPT-conjugated poly (ethylene glycol) (PEG) and poly (lactic acid) (PLA) (LPT-PEG-PLA) was first synthesized and confirmed with \u00b9H Nuclear Magnetic Resonance and Matrix-Assisted Laser Desorption/ Ionization Time of Flight Mass Spectrometry, which was used for the preparation of a novel PEG-PLA combined micelles of LPT and PTX (PPM-LP). The obtained PPM-LP exhibited uniform, spherical shape with a size of 25.80 \u00b1 0.47 nm and zeta potential of -3.17 \u00b1 0.15 mv. PTX existed in molecular or amorphous forms in the micelles and superficial LPT could better delay PTX release. The cytotoxicity of PPM-LP with LPT conjugation against SKBr-3 cells (HER-2 positive) was found to be significantly increasing as compared with PPM-PTX, whereas there was no significant difference against MDA-MB-231 cells (HER-2 negative). PPM-LP could escape from endosomes and be distributed into cytoplasm and led to cell arrest in G2/M and G1/S phases simultaneously. Results of nucleus staining and flow cytometry confirmed that LPT could remarkably increase antineoplastic effect of PTX against SKBr-3 cells. All these results demonstrated that PPM-LP may be a promising drug delivery system for HER-2 positive breast cancer.","tokens":[{"text":"Lapatinib","start":0,"end":9,"id":0,"ws":true},{"text":"(","start":10,"end":11,"id":1,"ws":true},{"text":"LPT","start":12,"end":15,"id":2,"ws":true},{"text":")","start":16,"end":17,"id":3,"ws":true},{"text":"could","start":18,"end":23,"id":4,"ws":true},{"text":"sensitize","start":24,"end":33,"id":5,"ws":true},{"text":"human","start":34,"end":39,"id":6,"ws":true},{"text":"epidermal","start":40,"end":49,"id":7,"ws":true},{"text":"growth","start":50,"end":56,"id":8,"ws":true},{"text":"factor","start":57,"end":63,"id":9,"ws":true},{"text":"receptor-2","start":64,"end":74,"id":10,"ws":true},{"text":"(","start":75,"end":76,"id":11,"ws":true},{"text":"HER-2","start":77,"end":82,"id":12,"ws":true},{"text":")","start":83,"end":84,"id":13,"ws":true},{"text":"positive","start":85,"end":93,"id":14,"ws":true},{"text":"breast","start":94,"end":100,"id":15,"ws":true},{"text":"cancer","start":101,"end":107,"id":16,"ws":true},{"text":"to","start":108,"end":110,"id":17,"ws":true},{"text":"paclitaxel","start":111,"end":121,"id":18,"ws":true},{"text":"(","start":122,"end":123,"id":19,"ws":true},{"text":"PTX","start":124,"end":127,"id":20,"ws":true},{"text":")","start":128,"end":129,"id":21,"ws":true},{"text":"and","start":130,"end":133,"id":22,"ws":true},{"text":"induce","start":134,"end":140,"id":23,"ws":true},{"text":"synergetic","start":141,"end":151,"id":24,"ws":true},{"text":"action","start":152,"end":158,"id":25,"ws":true},{"text":"with","start":159,"end":163,"id":26,"ws":true},{"text":"PTX","start":164,"end":167,"id":27,"ws":true},{"text":"in","start":168,"end":170,"id":28,"ws":true},{"text":"preclinical","start":171,"end":182,"id":29,"ws":true},{"text":"test","start":183,"end":187,"id":30,"ws":true},{"text":"and","start":188,"end":191,"id":31,"ws":true},{"text":"phase","start":192,"end":197,"id":32,"ws":true},{"text":"II/III","start":198,"end":204,"id":33,"ws":true},{"text":"trial","start":205,"end":210,"id":34,"ws":true},{"text":".","start":211,"end":212,"id":35,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25421492/","_input_hash":-435231815,"_task_hash":-1109865721,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":0,"child":18,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Two of nine patients received 15 mg/kg bevacizumab IV , 90 mg/m(2 ) irinotecan orally for five consecutive days , 100 mg/m(2)/day temozolomide IV for 5 days , and 1.5 mg/m(2 ) vincristine IV , each administered every 21 days .","paragraph":"<h3><u>Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.</u></h3>Chemotherapy for relapsed medulloblastoma has been inadequate, and most patients succumb to disease. ### methods We retrospectively reviewed nine cases of relapsed medulloblastoma treated with <b style='color:Tomato;'><i>bevacizumab</i></b>, <b style='color:Tomato;'><i>irinotecan</i></b>, \u00b1\u2009<b style='color:Tomato;'><i>temozolomide</i></b>. Patients received one to three prior therapeutic regimens. Five patients received 10 mg/kg <b style='color:Tomato;'><i>bevacizumab</i></b> and 125-150 mg/m(2) <b style='color:Tomato;'><i>irinotecan</i></b> IV every 2 weeks, with <b style='color:Tomato;'><i>temozolomide</i></b>, starting at a median dose of 150 mg/m(2) orally for 5 days monthly. Two patients received <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b>, but not <b style='color:Tomato;'><i>temozolomide</i></b>, due to provider preference. <b style='color:DodgerBlue;'><i>Two</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nine</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>90</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m(2)/day</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1.5</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Median time to progression was 11 months. Median overall survival was 13 months. Objective tumor response at 3 months was 67 %, including six patients with partial response (PR) and three patients with stable disease (SD). At 6 months, objective response was 55 %, with two patients with PR and three with complete response. Additionally, one patient had SD and three had PD. Two patients remain alive and progression free at 15 and 55 months; another is alive with disease at 20 months. Toxicities included two patients with grade III neutropenia, two with grade III thrombocytopenia, one with grade III elevation of liver function tests, and one patient with grade III diarrhea. ### conclusions The combination of <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b>, with or without <b style='color:Tomato;'><i>temozolomide</i></b>, produces objective responses with minimal toxicity in children with recurrent medulloblastoma. Prospective clinical trials are needed to evaluate the efficacy of this strategy.","tokens":[{"text":"Two","start":0,"end":3,"id":0,"ws":true},{"text":"of","start":4,"end":6,"id":1,"ws":true},{"text":"nine","start":7,"end":11,"id":2,"ws":true},{"text":"patients","start":12,"end":20,"id":3,"ws":true},{"text":"received","start":21,"end":29,"id":4,"ws":true},{"text":"15","start":30,"end":32,"id":5,"ws":true},{"text":"mg/kg","start":33,"end":38,"id":6,"ws":true},{"text":"bevacizumab","start":39,"end":50,"id":7,"ws":true},{"text":"IV","start":51,"end":53,"id":8,"ws":true},{"text":",","start":54,"end":55,"id":9,"ws":true},{"text":"90","start":56,"end":58,"id":10,"ws":true},{"text":"mg/m(2","start":59,"end":65,"id":11,"ws":true},{"text":")","start":66,"end":67,"id":12,"ws":true},{"text":"irinotecan","start":68,"end":78,"id":13,"ws":true},{"text":"orally","start":79,"end":85,"id":14,"ws":true},{"text":"for","start":86,"end":89,"id":15,"ws":true},{"text":"five","start":90,"end":94,"id":16,"ws":true},{"text":"consecutive","start":95,"end":106,"id":17,"ws":true},{"text":"days","start":107,"end":111,"id":18,"ws":true},{"text":",","start":112,"end":113,"id":19,"ws":true},{"text":"100","start":114,"end":117,"id":20,"ws":true},{"text":"mg/m(2)/day","start":118,"end":129,"id":21,"ws":true},{"text":"temozolomide","start":130,"end":142,"id":22,"ws":true},{"text":"IV","start":143,"end":145,"id":23,"ws":true},{"text":"for","start":146,"end":149,"id":24,"ws":true},{"text":"5","start":150,"end":151,"id":25,"ws":true},{"text":"days","start":152,"end":156,"id":26,"ws":true},{"text":",","start":157,"end":158,"id":27,"ws":true},{"text":"and","start":159,"end":162,"id":28,"ws":true},{"text":"1.5","start":163,"end":166,"id":29,"ws":true},{"text":"mg/m(2","start":167,"end":173,"id":30,"ws":true},{"text":")","start":174,"end":175,"id":31,"ws":true},{"text":"vincristine","start":176,"end":187,"id":32,"ws":true},{"text":"IV","start":188,"end":190,"id":33,"ws":true},{"text":",","start":191,"end":192,"id":34,"ws":true},{"text":"each","start":193,"end":197,"id":35,"ws":true},{"text":"administered","start":198,"end":210,"id":36,"ws":true},{"text":"every","start":211,"end":216,"id":37,"ws":true},{"text":"21","start":217,"end":219,"id":38,"ws":true},{"text":"days","start":220,"end":224,"id":39,"ws":true},{"text":".","start":225,"end":226,"id":40,"ws":false}],"spans":[{"start":39,"end":50,"token_start":7,"token_end":7,"label":"DRUG"},{"start":68,"end":78,"token_start":13,"token_end":13,"label":"DRUG"},{"start":130,"end":142,"token_start":22,"token_end":22,"label":"DRUG"},{"start":176,"end":187,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23296323/","_input_hash":-1934185768,"_task_hash":-1998585097,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":7,"child":13,"head_span":{"start":39,"end":50,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":22,"child":13,"head_span":{"start":130,"end":142,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":32,"child":22,"head_span":{"start":176,"end":187,"token_start":32,"token_end":32,"label":"DRUG"},"child_span":{"start":130,"end":142,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"These findings may help clinicians identify patients for whom acamprosate and naltrexone may be most beneficial .","paragraph":"<h3><u>Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.</u></h3>The COMBINE study evaluated the effects of <b style='color:Tomato;'><i>acamprosate</i></b>, <b style='color:Tomato;'><i>naltrexone</i></b>, and the Combined Behavioral Intervention (CBI). In secondary analyses, our goals were to identify trajectories of any drinking prior to randomization, to characterize subjects in these trajectories, and to assess whether prerandomization trajectories predict drinking outcomes and moderate treatment response. ### methods We analyzed daily indicators of any drinking in 90 days prior to randomization using a trajectory-based approach. General linear models and generalized logistic regression assessed main and interactive effects of prerandomization drinking trajectories and treatment on summary drinking measures during active treatment. ### results We identified five trajectories of any drinking prior to randomization: \"T1: frequent drinkers\", \"T2: very frequent drinkers\", \"T3: nearly daily drinkers\", \"T4: consistent daily drinkers\", and \"T5: daily drinkers stopping early\". During treatment, \"T3: nearly daily drinkers\" and \"T4: consistent daily drinkers\" had significantly worse drinking outcomes than \"T1: frequent drinkers\", while \"T5: daily drinkers stopping early\" had comparable drinking outcomes to \"T1: frequent drinkers\". <b style='color:Tomato;'><i>acamprosate</i></b> significantly increased the chance of abstinence from heavy drinking for the \"T2: very frequent drinking\" trajectory but decreased the chance of abstinence from heavy drinking for \"T5: daily drinkers stopping early\". <b style='color:Tomato;'><i>naltrexone</i></b> differentially improved rates of continuous abstinence for very frequent drinkers. ### conclusions <b style='color:Tomato;'><i>acamprosate</i></b> benefited very frequent drinkers and contrary to expectations was associated with poorer response compared to placebo for consistent daily drinkers who had longer durations of pretreatment abstinence (e.g., \u226514 days). Baseline drinking trajectories also moderated <b style='color:Tomato;'><i>naltrexone</i></b> effects. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>findings</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>help</i></b> <b style='color:DodgerBlue;'><i>clinicians</i></b> <b style='color:DodgerBlue;'><i>identify</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>whom</i></b> <b style='color:MediumOrchid;'><i>acamprosate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>naltrexone</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"findings","start":6,"end":14,"id":1,"ws":true},{"text":"may","start":15,"end":18,"id":2,"ws":true},{"text":"help","start":19,"end":23,"id":3,"ws":true},{"text":"clinicians","start":24,"end":34,"id":4,"ws":true},{"text":"identify","start":35,"end":43,"id":5,"ws":true},{"text":"patients","start":44,"end":52,"id":6,"ws":true},{"text":"for","start":53,"end":56,"id":7,"ws":true},{"text":"whom","start":57,"end":61,"id":8,"ws":true},{"text":"acamprosate","start":62,"end":73,"id":9,"ws":true},{"text":"and","start":74,"end":77,"id":10,"ws":true},{"text":"naltrexone","start":78,"end":88,"id":11,"ws":true},{"text":"may","start":89,"end":92,"id":12,"ws":true},{"text":"be","start":93,"end":95,"id":13,"ws":true},{"text":"most","start":96,"end":100,"id":14,"ws":true},{"text":"beneficial","start":101,"end":111,"id":15,"ws":true},{"text":".","start":112,"end":113,"id":16,"ws":false}],"spans":[{"start":62,"end":73,"token_start":9,"token_end":9,"label":"DRUG"},{"start":78,"end":88,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21143249/","_input_hash":548050658,"_task_hash":-570129931,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":62,"end":73,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":78,"end":88,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"From August 2002 to August 2004 , 42 patients with metastatic breast cancer were recruited for treatment with pegylated liposomal doxorubicin 40 mg/m(2 ) intravenously ( i.v . ) on day 1 and vinorelbine 30 mg/m(2 ) i.v . on days 1 and 15 every 4 weeks .","paragraph":"<h3><u>Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.</u></h3>This multicenter phase II trial was conducted to analyze the clinical activity and toxicity of the combination of pegylated liposomal <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> as first-line treatment in elderly patients with metastatic breast cancer. ### Patients And Methods <b style='color:DodgerBlue;'><i>From</i></b> <b style='color:DodgerBlue;'><i>August</i></b> <b style='color:DodgerBlue;'><i>2002</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>August</i></b> <b style='color:DodgerBlue;'><i>2004</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>42</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>recruited</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>pegylated</i></b> <b style='color:DodgerBlue;'><i>liposomal</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results The median age of the patients in this trial was 68 years (range 60-82). 40% of patients had 2 or more sites of metastasis, 33 (78%) had predominantly visceral metastasis, and 7 (16%) mostly bone metastasis. Just 2 (5%) patients had only lymphogenous or soft tissue metastasis. All patients had an ECOG performance status of 0-1, but 70% of the patients had relevant comorbidities. In an intention-to-treat analysis, the overall clinical response rate was 36%, the complete response rate was 2%, and the rate of partial remissions was 34%; stable disease occurred in 30%, and progressive disease was observed in 36%. Median duration of response was 10 months. Median time to progression was 4 months, and median overall survival time was 24 months. ### conclusion The combination of pegylated liposomal <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> is an active and well tolerated regimen in elderly patients with metastatic breast cancer in first-line treatment.","tokens":[{"text":"From","start":0,"end":4,"id":0,"ws":true},{"text":"August","start":5,"end":11,"id":1,"ws":true},{"text":"2002","start":12,"end":16,"id":2,"ws":true},{"text":"to","start":17,"end":19,"id":3,"ws":true},{"text":"August","start":20,"end":26,"id":4,"ws":true},{"text":"2004","start":27,"end":31,"id":5,"ws":true},{"text":",","start":32,"end":33,"id":6,"ws":true},{"text":"42","start":34,"end":36,"id":7,"ws":true},{"text":"patients","start":37,"end":45,"id":8,"ws":true},{"text":"with","start":46,"end":50,"id":9,"ws":true},{"text":"metastatic","start":51,"end":61,"id":10,"ws":true},{"text":"breast","start":62,"end":68,"id":11,"ws":true},{"text":"cancer","start":69,"end":75,"id":12,"ws":true},{"text":"were","start":76,"end":80,"id":13,"ws":true},{"text":"recruited","start":81,"end":90,"id":14,"ws":true},{"text":"for","start":91,"end":94,"id":15,"ws":true},{"text":"treatment","start":95,"end":104,"id":16,"ws":true},{"text":"with","start":105,"end":109,"id":17,"ws":true},{"text":"pegylated","start":110,"end":119,"id":18,"ws":true},{"text":"liposomal","start":120,"end":129,"id":19,"ws":true},{"text":"doxorubicin","start":130,"end":141,"id":20,"ws":true},{"text":"40","start":142,"end":144,"id":21,"ws":true},{"text":"mg/m(2","start":145,"end":151,"id":22,"ws":true},{"text":")","start":152,"end":153,"id":23,"ws":true},{"text":"intravenously","start":154,"end":167,"id":24,"ws":true},{"text":"(","start":168,"end":169,"id":25,"ws":true},{"text":"i.v","start":170,"end":173,"id":26,"ws":true},{"text":".","start":174,"end":175,"id":27,"ws":true},{"text":")","start":176,"end":177,"id":28,"ws":true},{"text":"on","start":178,"end":180,"id":29,"ws":true},{"text":"day","start":181,"end":184,"id":30,"ws":true},{"text":"1","start":185,"end":186,"id":31,"ws":true},{"text":"and","start":187,"end":190,"id":32,"ws":true},{"text":"vinorelbine","start":191,"end":202,"id":33,"ws":true},{"text":"30","start":203,"end":205,"id":34,"ws":true},{"text":"mg/m(2","start":206,"end":212,"id":35,"ws":true},{"text":")","start":213,"end":214,"id":36,"ws":true},{"text":"i.v","start":215,"end":218,"id":37,"ws":true},{"text":".","start":219,"end":220,"id":38,"ws":true},{"text":"on","start":221,"end":223,"id":39,"ws":true},{"text":"days","start":224,"end":228,"id":40,"ws":true},{"text":"1","start":229,"end":230,"id":41,"ws":true},{"text":"and","start":231,"end":234,"id":42,"ws":true},{"text":"15","start":235,"end":237,"id":43,"ws":true},{"text":"every","start":238,"end":243,"id":44,"ws":true},{"text":"4","start":244,"end":245,"id":45,"ws":true},{"text":"weeks","start":246,"end":251,"id":46,"ws":true},{"text":".","start":252,"end":253,"id":47,"ws":false}],"spans":[{"start":130,"end":141,"token_start":20,"token_end":20,"label":"DRUG"},{"start":191,"end":202,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19209014/","_input_hash":-1438243699,"_task_hash":-1653343456,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":20,"child":33,"head_span":{"start":130,"end":141,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":191,"end":202,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The aim of the present study was to investigate the combined effects of simvastatin and exemestane on MCF-7 human breast cancer cells .","paragraph":"<h3><u>Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells.</u></h3>Breast cancer is associated with high levels of incidence, morbidity and mortality; therefore, the identification of effective chemopreventive strategies is crucial. It is important for clinicians to be able to identify the populations at risk who would benefit from chemoprevention, and the interventions that are effective and safe. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>MCF-7</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The anti-proliferative effects of <b style='color:Tomato;'><i>simvastatin</i></b> and <b style='color:Tomato;'><i>exemestane</i></b>, alone and in combination, on the growth of MCF-7 human breast cancer cells were assessed by MTT assay. The synergism between the two drugs was determined in vitro using the combination index (CI) analysis. Cell cycle distribution and apoptosis were analyzed by flow cytometry, and alterations to the signaling pathway in MCF-7 cells were examined by immunoblotting following treatment with various regimens. The results of the MTT assay indicated that the combined treatment of <b style='color:Tomato;'><i>simvastatin</i></b> and <b style='color:Tomato;'><i>exemestane</i></b> significantly decreased the viability of MCF-7 estrogen receptor-positive (ER+) human breast cancer cells, as compared with those that were treated with the individual drugs (CI<1). In addition, coadministration of <b style='color:Tomato;'><i>exemestane</i></b> and <b style='color:Tomato;'><i>simvastatin</i></b> was shown to result in marked inhibition of tumor cell proliferation, significant cell cycle arrest at G0/G1 phase and induction of apoptosis, as compared with that of the control and individual drug-treated cells. Furthermore, the results of the present study indicated that these synergistic effects may be associated with the B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein apoptotic pathway and the mitogen-activated protein kinase/mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b>/p70S6 kinase growth pathway. The combination of <b style='color:Tomato;'><i>exemestane</i></b> and <b style='color:Tomato;'><i>simvastatin</i></b> generated synergistic effects on MCF-7 ER+ breast cancer cells, indicating that the combination of these drugs may be a potential therapeutic strategy for the treatment of hormone-dependent breast cancer. The combination of the two inhibitors markedly increased the efficacy, as compared with the single-agent treatment, suggesting that combination treatment could become a highly effective approach for breast cancer. The results of the present study suggested that this combination of drugs has therapeutic potential, and requires further mechanistic and biomarker investigations in clinical trials.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"the","start":11,"end":14,"id":3,"ws":true},{"text":"present","start":15,"end":22,"id":4,"ws":true},{"text":"study","start":23,"end":28,"id":5,"ws":true},{"text":"was","start":29,"end":32,"id":6,"ws":true},{"text":"to","start":33,"end":35,"id":7,"ws":true},{"text":"investigate","start":36,"end":47,"id":8,"ws":true},{"text":"the","start":48,"end":51,"id":9,"ws":true},{"text":"combined","start":52,"end":60,"id":10,"ws":true},{"text":"effects","start":61,"end":68,"id":11,"ws":true},{"text":"of","start":69,"end":71,"id":12,"ws":true},{"text":"simvastatin","start":72,"end":83,"id":13,"ws":true},{"text":"and","start":84,"end":87,"id":14,"ws":true},{"text":"exemestane","start":88,"end":98,"id":15,"ws":true},{"text":"on","start":99,"end":101,"id":16,"ws":true},{"text":"MCF-7","start":102,"end":107,"id":17,"ws":true},{"text":"human","start":108,"end":113,"id":18,"ws":true},{"text":"breast","start":114,"end":120,"id":19,"ws":true},{"text":"cancer","start":121,"end":127,"id":20,"ws":true},{"text":"cells","start":128,"end":133,"id":21,"ws":true},{"text":".","start":134,"end":135,"id":22,"ws":false}],"spans":[{"start":72,"end":83,"token_start":13,"token_end":13,"label":"DRUG"},{"start":88,"end":98,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25738757/","_input_hash":620057444,"_task_hash":-1389614691,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":72,"end":83,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":88,"end":98,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Synergy of Omeprazole and Praziquantel In Vitro Treatment against Schistosoma mansoni Adult Worms .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Synergy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Omeprazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Praziquantel</i></b> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>Vitro</i></b> <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>Schistosoma</i></b> <b style='color:DodgerBlue;'><i>mansoni</i></b> <b style='color:DodgerBlue;'><i>Adult</i></b> <b style='color:DodgerBlue;'><i>Worms</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Treatment and morbidity control of schistosomiasis relies on a single drug, <b style='color:Tomato;'><i>praziquantel</i></b> (PZQ), and the selection of resistant worms under repeated treatment is a concern. Therefore, there is a pressing need to understand the molecular effects of PZQ on schistosomes and to investigate alternative or synergistic drugs against schistosomiasis. ### methodology We used a custom-designed Schistosoma mansoni expression microarray to explore the effects of sublethal doses of PZQ on large-scale gene expression of adult paired males and females and unpaired mature females. We also assessed the efficacy of PZQ, <b style='color:Tomato;'><i>omeprazole</i></b> (OMP) or their combination against S. mansoni adult worms with a survival in vitro assay. ### Principal Findings We identified sets of genes that were affected by PZQ in paired and unpaired mature females, however with opposite gene expression patterns (up-regulated in paired and down-regulated in unpaired mature females), indicating that PZQ effects are heavily influenced by the mating status. We also identified genes that were similarly affected by PZQ in males and females. Functional analyses of gene interaction networks were performed with parasite genes that were differentially expressed upon PZQ treatment, searching for proteins encoded by these genes whose human homologs are targets of different drugs used for other diseases. Based on these results, OMP, a widely prescribed proton pump inhibitor known to target the ATP1A2 gene product, was chosen and tested. Sublethal doses of PZQ combined with OMP significantly increased worm mortality in vitro when compared with PZQ or OMP alone, thus evidencing a synergistic effect. ### conclusions Functional analysis of gene interaction networks is an important approach that can point to possible novel synergistic drug candidates. We demonstrated the potential of this strategy by showing that PZQ in combination with OMP displayed increased efficiency against S. mansoni adult worms in vitro when compared with either drug alone.","tokens":[{"text":"Synergy","start":0,"end":7,"id":0,"ws":true},{"text":"of","start":8,"end":10,"id":1,"ws":true},{"text":"Omeprazole","start":11,"end":21,"id":2,"ws":true},{"text":"and","start":22,"end":25,"id":3,"ws":true},{"text":"Praziquantel","start":26,"end":38,"id":4,"ws":true},{"text":"In","start":39,"end":41,"id":5,"ws":true},{"text":"Vitro","start":42,"end":47,"id":6,"ws":true},{"text":"Treatment","start":48,"end":57,"id":7,"ws":true},{"text":"against","start":58,"end":65,"id":8,"ws":true},{"text":"Schistosoma","start":66,"end":77,"id":9,"ws":true},{"text":"mansoni","start":78,"end":85,"id":10,"ws":true},{"text":"Adult","start":86,"end":91,"id":11,"ws":true},{"text":"Worms","start":92,"end":97,"id":12,"ws":true},{"text":".","start":98,"end":99,"id":13,"ws":false}],"spans":[{"start":11,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":26,"end":38,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26402251/","_input_hash":-1559857653,"_task_hash":-512461566,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":11,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":26,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Inclusion criteria were proven infection with evidence of a bacterial strain of PA resistant to all \u03b2-lactams and treated with the association of at least aztreonam plus cefepime .","paragraph":"<h3><u>Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to \u03b2-lactams in ICU patients: A pilot study.</u></h3>Resistance to all \u03b2-lactams is emerging among Pseudomonas aeruginosa (PA) clinical isolates. <b style='color:Tomato;'><i>aztreonam</i></b> and <b style='color:Tomato;'><i>cefepime</i></b> act synergistically in vitro against AmpC overproducing PA isolates. The objective of this study was to evaluate the clinical efficacy of this treatment in ICU patients infected with multidrug-resistant PA. ### Material And Methods Retrospective study (2 years, 2 ICUs) in a tertiary university hospital. <b style='color:DodgerBlue;'><i>Inclusion</i></b> <b style='color:DodgerBlue;'><i>criteria</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>bacterial</i></b> <b style='color:DodgerBlue;'><i>strain</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>PA</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>\u03b2-lactams</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>association</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:MediumOrchid;'><i>aztreonam</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cefepime</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Treatment was considered effective for pneumonia using CPIS scores at the end of treatment and for other infections, using the SOFA score and signs of infection improvement at the end of treatment. Infectious episodes were classified as cure or failure. ### results Thirteen patients were included (10 nosocomial pneumonia, 3 nosocomial intra-abdominal infections). The median [25th-75th percentiles] admission SAPS2 score was 54 [51-69] and the median SOFA score at the beginning of infection was 7 [4-8]. The median CPIS scores for pneumonia at the beginning and end of treatment were 9 [7-10.5] and 2 [0.75-5.5]. The duration of treatment with the combination of <b style='color:Tomato;'><i>aztreonam</i></b> plus <b style='color:Tomato;'><i>cefepime</i></b> was 14 days [9.5-16]. Nine episodes were classified as cures and 4 as failures, indicating a clinical efficacy of 69.2%. Overall mortality was 38.5%. ### discussion These data suggest that the association of <b style='color:Tomato;'><i>cefepime</i></b> plus <b style='color:Tomato;'><i>aztreonam</i></b> could be an attractive alternative in the treatment of infections with multidrug-resistant PA to all \u03b2-lactams with a clinical efficacy rate of 69%.","tokens":[{"text":"Inclusion","start":0,"end":9,"id":0,"ws":true},{"text":"criteria","start":10,"end":18,"id":1,"ws":true},{"text":"were","start":19,"end":23,"id":2,"ws":true},{"text":"proven","start":24,"end":30,"id":3,"ws":true},{"text":"infection","start":31,"end":40,"id":4,"ws":true},{"text":"with","start":41,"end":45,"id":5,"ws":true},{"text":"evidence","start":46,"end":54,"id":6,"ws":true},{"text":"of","start":55,"end":57,"id":7,"ws":true},{"text":"a","start":58,"end":59,"id":8,"ws":true},{"text":"bacterial","start":60,"end":69,"id":9,"ws":true},{"text":"strain","start":70,"end":76,"id":10,"ws":true},{"text":"of","start":77,"end":79,"id":11,"ws":true},{"text":"PA","start":80,"end":82,"id":12,"ws":true},{"text":"resistant","start":83,"end":92,"id":13,"ws":true},{"text":"to","start":93,"end":95,"id":14,"ws":true},{"text":"all","start":96,"end":99,"id":15,"ws":true},{"text":"\u03b2-lactams","start":100,"end":109,"id":16,"ws":true},{"text":"and","start":110,"end":113,"id":17,"ws":true},{"text":"treated","start":114,"end":121,"id":18,"ws":true},{"text":"with","start":122,"end":126,"id":19,"ws":true},{"text":"the","start":127,"end":130,"id":20,"ws":true},{"text":"association","start":131,"end":142,"id":21,"ws":true},{"text":"of","start":143,"end":145,"id":22,"ws":true},{"text":"at","start":146,"end":148,"id":23,"ws":true},{"text":"least","start":149,"end":154,"id":24,"ws":true},{"text":"aztreonam","start":155,"end":164,"id":25,"ws":true},{"text":"plus","start":165,"end":169,"id":26,"ws":true},{"text":"cefepime","start":170,"end":178,"id":27,"ws":true},{"text":".","start":179,"end":180,"id":28,"ws":false}],"spans":[{"start":155,"end":164,"token_start":25,"token_end":25,"label":"DRUG"},{"start":170,"end":178,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26004874/","_input_hash":-164111142,"_task_hash":-1185345343,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":25,"child":27,"head_span":{"start":155,"end":164,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":170,"end":178,"token_start":27,"token_end":27,"label":"DRUG"},",color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Comparison of the additive effects of nipradilol and carteolol to latanoprost in open-angle glaucoma .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Comparison</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>additive</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nipradilol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carteolol</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>latanoprost</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>open-angle</i></b> <b style='color:DodgerBlue;'><i>glaucoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To compare the effects of nipradilol and <b style='color:Tomato;'><i>carteolol</i></b> on intraocular pressure (IOP) when added to <b style='color:Tomato;'><i>latanoprost</i></b> treatment for glaucoma patients. ### methods Fifty patients with primary open-angle glaucoma were treated with <b style='color:Tomato;'><i>latanoprost</i></b> 0.005% once daily for 3 months. Then they were assigned to one of two groups randomly. One group received nipradilol 0.25% twice daily (nipradilol preceding group; n = 25), and the other <b style='color:Tomato;'><i>carteolol</i></b> hydrochloride 2% twice daily (<b style='color:Tomato;'><i>carteolol</i></b> preceding group; n = 25), for 3 months in addition to <b style='color:Tomato;'><i>latanoprost</i></b>. Then, nipradilol and <b style='color:Tomato;'><i>carteolol</i></b> were switched, and the subjects were treated for 3 more months. One eye was selected randomly for analysis. ### results In the nipradilol preceding group, IOP was 21.4 +/- 2.3 mmHg (mean +/- SD) at baseline, and 16.8 +/- 1.9 mmHg at the end of <b style='color:Tomato;'><i>latanoprost</i></b> monotherapy (P < 0.01). The addition of nipradilol decreased IOP to 15.8 +/- 1.7 mmHg, and the change to <b style='color:Tomato;'><i>carteolol</i></b>, to 15.3 +/- 2.0 mmHg. In the <b style='color:Tomato;'><i>carteolol</i></b> preceding group, IOP was 21.2 +/- 2.0 mmHg at baseline, and 17.0 +/- 2.1 mmHg at the end of <b style='color:Tomato;'><i>latanoprost</i></b> monotherapy (P < 0.01). The addition of <b style='color:Tomato;'><i>carteolol</i></b> decreased IOP to 15.4 +/- 1.8 mmHg, and the change to nipradilol, to 16.3 +/- 1.9 mmHg. Additional IOP reduction was greater with <b style='color:Tomato;'><i>carteolol</i></b> than with nipradilol (cross-over analysis of variance; P = 0.0005). ### conclusions Both nipradilol and <b style='color:Tomato;'><i>carteolol</i></b> have additive effects when used in combination with <b style='color:Tomato;'><i>latanoprost</i></b>. <b style='color:Tomato;'><i>carteolol</i></b>, however, may have a more potent effect than nipradilol.","tokens":[{"text":"Comparison","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"the","start":14,"end":17,"id":2,"ws":true},{"text":"additive","start":18,"end":26,"id":3,"ws":true},{"text":"effects","start":27,"end":34,"id":4,"ws":true},{"text":"of","start":35,"end":37,"id":5,"ws":true},{"text":"nipradilol","start":38,"end":48,"id":6,"ws":true},{"text":"and","start":49,"end":52,"id":7,"ws":true},{"text":"carteolol","start":53,"end":62,"id":8,"ws":true},{"text":"to","start":63,"end":65,"id":9,"ws":true},{"text":"latanoprost","start":66,"end":77,"id":10,"ws":true},{"text":"in","start":78,"end":80,"id":11,"ws":true},{"text":"open-angle","start":81,"end":91,"id":12,"ws":true},{"text":"glaucoma","start":92,"end":100,"id":13,"ws":true},{"text":".","start":101,"end":102,"id":14,"ws":false}],"spans":[{"start":38,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":53,"end":62,"token_start":8,"token_end":8,"label":"DRUG"},{"start":66,"end":77,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16453185/","_input_hash":31849482,"_task_hash":1212317438,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":6,"child":10,"head_span":{"start":38,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":66,"end":77,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":10,"head_span":{"start":53,"end":62,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":66,"end":77,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"The poly(ADP-ribose ) polymerase ( PARP ) inhibitor olaparib has recently received approval from the Food and Drug Administration ( FDA ) and European Medicines Agency ( EMA ) , with a second agent ( rucaparib ) likely to be approved in the near future .","paragraph":"<h3><u>Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.</u></h3>: High-grade serous ovarian cancer is characterized by genomic instability, with one half of all tumors displaying defects in the important DNA repair pathway of homologous recombination. Given the action of poly(ADP-ribose) polymerase (PARP) inhibitors in targeting tumors with deficiencies in this repair pathway by loss of BRCA1/2, ovarian tumors could be an attractive population for clinical application of this therapy. PARP inhibitors have moved into clinical practice in the past few years, with approval from the Food and Drug Administration (FDA) and European Medicines Agency (EMA) within the past 2 years. The U.S. FDA approval of <b style='color:Tomato;'><i>olaparib</i></b> applies to fourth line treatment in germline BRCA-mutant ovarian cancer, and European EMA approval to <b style='color:Tomato;'><i>olaparib</i></b> maintenance in both germline and somatic BRCA-mutant platinum-sensitive ovarian cancer. In order to widen the ovarian cancer patient population that would benefit from PARP inhibitors, predictive biomarkers based on a clear understanding of the mechanism of action are required. Additionally, a better understanding of the toxicity profile is needed if PARP inhibitors are to be used in the curative, rather than the palliative, setting. We reviewed the development of PARP inhibitors in phase I-III clinical trials, including combination trials of PARP inhibitors and chemotherapy/antiangiogenics, the approval for these agents, the mechanisms of resistance, and the outstanding issues, including the development of biomarkers and the rate of long-term hematologic toxicities with these agents. ### Implications For Practice <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>poly(ADP-ribose</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>polymerase</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PARP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>olaparib</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>recently</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>approval</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Food</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>Administration</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>European</i></b> <b style='color:DodgerBlue;'><i>Medicines</i></b> <b style='color:DodgerBlue;'><i>Agency</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>EMA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>rucaparib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>likely</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>approved</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>near</i></b> <b style='color:DodgerBlue;'><i>future</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, the patient population with potential benefit from PARP inhibitors is likely wider than that of germline BRCA mutation-associated disease, and biomarkers are in development to enable the selection of patients with the potential for clinical benefit from these agents. Questions remain regarding the toxicities of PARP inhibitors, limiting the use of these agents in the prophylactic or adjuvant setting until more information is available. The indications for <b style='color:Tomato;'><i>olaparib</i></b> as indicated by the FDA and EMA are reviewed.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"poly(ADP-ribose","start":4,"end":19,"id":1,"ws":true},{"text":")","start":20,"end":21,"id":2,"ws":true},{"text":"polymerase","start":22,"end":32,"id":3,"ws":true},{"text":"(","start":33,"end":34,"id":4,"ws":true},{"text":"PARP","start":35,"end":39,"id":5,"ws":true},{"text":")","start":40,"end":41,"id":6,"ws":true},{"text":"inhibitor","start":42,"end":51,"id":7,"ws":true},{"text":"olaparib","start":52,"end":60,"id":8,"ws":true},{"text":"has","start":61,"end":64,"id":9,"ws":true},{"text":"recently","start":65,"end":73,"id":10,"ws":true},{"text":"received","start":74,"end":82,"id":11,"ws":true},{"text":"approval","start":83,"end":91,"id":12,"ws":true},{"text":"from","start":92,"end":96,"id":13,"ws":true},{"text":"the","start":97,"end":100,"id":14,"ws":true},{"text":"Food","start":101,"end":105,"id":15,"ws":true},{"text":"and","start":106,"end":109,"id":16,"ws":true},{"text":"Drug","start":110,"end":114,"id":17,"ws":true},{"text":"Administration","start":115,"end":129,"id":18,"ws":true},{"text":"(","start":130,"end":131,"id":19,"ws":true},{"text":"FDA","start":132,"end":135,"id":20,"ws":true},{"text":")","start":136,"end":137,"id":21,"ws":true},{"text":"and","start":138,"end":141,"id":22,"ws":true},{"text":"European","start":142,"end":150,"id":23,"ws":true},{"text":"Medicines","start":151,"end":160,"id":24,"ws":true},{"text":"Agency","start":161,"end":167,"id":25,"ws":true},{"text":"(","start":168,"end":169,"id":26,"ws":true},{"text":"EMA","start":170,"end":173,"id":27,"ws":true},{"text":")","start":174,"end":175,"id":28,"ws":true},{"text":",","start":176,"end":177,"id":29,"ws":true},{"text":"with","start":178,"end":182,"id":30,"ws":true},{"text":"a","start":183,"end":184,"id":31,"ws":true},{"text":"second","start":185,"end":191,"id":32,"ws":true},{"text":"agent","start":192,"end":197,"id":33,"ws":true},{"text":"(","start":198,"end":199,"id":34,"ws":true},{"text":"rucaparib","start":200,"end":209,"id":35,"ws":true},{"text":")","start":210,"end":211,"id":36,"ws":true},{"text":"likely","start":212,"end":218,"id":37,"ws":true},{"text":"to","start":219,"end":221,"id":38,"ws":true},{"text":"be","start":222,"end":224,"id":39,"ws":true},{"text":"approved","start":225,"end":233,"id":40,"ws":true},{"text":"in","start":234,"end":236,"id":41,"ws":true},{"text":"the","start":237,"end":240,"id":42,"ws":true},{"text":"near","start":241,"end":245,"id":43,"ws":true},{"text":"future","start":246,"end":252,"id":44,"ws":true},{"text":".","start":253,"end":254,"id":45,"ws":false}],"spans":[{"start":52,"end":60,"token_start":8,"token_end":8,"label":"DRUG"},{"start":200,"end":209,"token_start":35,"token_end":35,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27022037/","_input_hash":-735189998,"_task_hash":706383763,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Fluvoxamine is a fairly potent inhibitor of CYP2C19 and it has the potential for causing drug-drug interactions with substrates for CYP2C19 such as imipramine , clomipramine , amitriptyline and diazepam .","paragraph":"<h3><u>Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.</u></h3>The potent CYP1A2 inhibitor <b style='color:Tomato;'><i>fluvoxamine</i></b> has recently been shown also to be an effective inhibitor of the CYP2C19-mediated metabolism of the antimalarial drug <b style='color:Tomato;'><i>proguanil</i></b> in vivo. The purpose of the present study was to confirm this interaction in vitro. ### methods A high-performance liquid chromatography (HPLC) method was developed to assay 4-chlorophenylbiguanide (4-CPBG) and cycloguanil formed from <b style='color:Tomato;'><i>proguanil</i></b> by microsomes prepared from human liver. The limit of detection was 0.08 nmol mg-'. h-I. ### results The formation of 4-CPBG and cycloguanil could be described by one-enzyme kinetics, indicating that the formation of the two metabolites is almost exclusively catalysed by a single enzyme, i.e. CYP2C19 within the concentration range used, or that the contribution of an alternative low-affinity enzyme, probably CYP3A4, is very low. This notion was confirmed by the lack of potent inhibition by four CYP3A4 inhibitors: <b style='color:Tomato;'><i>ketoconazole</i></b>, <b style='color:Tomato;'><i>bromocriptine</i></b>, midazolam and dihydroergotamine. <b style='color:Tomato;'><i>fluvoxamine</i></b> was a very effective inhibitor of the oxidation of <b style='color:Tomato;'><i>proguanil</i></b>, displaying Ki values of 0.69 micromol x l(-1) for the inhibition of cycloguanil formation and 4.7 micromol x l(-1) for the inhibition of 4-CPBG formation. As expected, the CYP2C19 substrate <b style='color:Tomato;'><i>omeprazole</i></b> inhibited the formation of both metabolites with an IC50 of 10 micromol x l(-1). Nor<b style='color:Tomato;'><i>fluoxetine</i></b> and <b style='color:Tomato;'><i>sulfaphenazole</i></b> inhibited <b style='color:Tomato;'><i>proguanil</i></b> oxidation with Ki values of 7.3-16 micromol x l(-1), suggesting that the two compounds are moderate inhibitors of CYP2C19. ### conclusions <b style='color:MediumOrchid;'><i>Fluvoxamine</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fairly</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP2C19</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>causing</i></b> <b style='color:DodgerBlue;'><i>drug-drug</i></b> <b style='color:DodgerBlue;'><i>interactions</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>substrates</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>CYP2C19</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>imipramine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clomipramine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amitriptyline</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>diazepam</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>fluvoxamine</i></b> and <b style='color:Tomato;'><i>proguanil</i></b> can not be recommended.","tokens":[{"text":"Fluvoxamine","start":0,"end":11,"id":0,"ws":true},{"text":"is","start":12,"end":14,"id":1,"ws":true},{"text":"a","start":15,"end":16,"id":2,"ws":true},{"text":"fairly","start":17,"end":23,"id":3,"ws":true},{"text":"potent","start":24,"end":30,"id":4,"ws":true},{"text":"inhibitor","start":31,"end":40,"id":5,"ws":true},{"text":"of","start":41,"end":43,"id":6,"ws":true},{"text":"CYP2C19","start":44,"end":51,"id":7,"ws":true},{"text":"and","start":52,"end":55,"id":8,"ws":true},{"text":"it","start":56,"end":58,"id":9,"ws":true},{"text":"has","start":59,"end":62,"id":10,"ws":true},{"text":"the","start":63,"end":66,"id":11,"ws":true},{"text":"potential","start":67,"end":76,"id":12,"ws":true},{"text":"for","start":77,"end":80,"id":13,"ws":true},{"text":"causing","start":81,"end":88,"id":14,"ws":true},{"text":"drug-drug","start":89,"end":98,"id":15,"ws":true},{"text":"interactions","start":99,"end":111,"id":16,"ws":true},{"text":"with","start":112,"end":116,"id":17,"ws":true},{"text":"substrates","start":117,"end":127,"id":18,"ws":true},{"text":"for","start":128,"end":131,"id":19,"ws":true},{"text":"CYP2C19","start":132,"end":139,"id":20,"ws":true},{"text":"such","start":140,"end":144,"id":21,"ws":true},{"text":"as","start":145,"end":147,"id":22,"ws":true},{"text":"imipramine","start":148,"end":158,"id":23,"ws":true},{"text":",","start":159,"end":160,"id":24,"ws":true},{"text":"clomipramine","start":161,"end":173,"id":25,"ws":true},{"text":",","start":174,"end":175,"id":26,"ws":true},{"text":"amitriptyline","start":176,"end":189,"id":27,"ws":true},{"text":"and","start":190,"end":193,"id":28,"ws":true},{"text":"diazepam","start":194,"end":202,"id":29,"ws":true},{"text":".","start":203,"end":204,"id":30,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":148,"end":158,"token_start":23,"token_end":23,"label":"DRUG"},{"start":161,"end":173,"token_start":25,"token_end":25,"label":"DRUG"},{"start":176,"end":189,"token_start":27,"token_end":27,"label":"DRUG"},{"start":194,"end":202,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9923577/","_input_hash":-879189063,"_task_hash":-193956022,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":0,"child":23,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":148,"end":158,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":0,"child":25,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":161,"end":173,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":0,"child":27,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":176,"end":189,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS20","POS30"],"answer":"accept"}
{"text":"We have compared amphotericin B , flucytosine , ketoconazole and fluconazole susceptibilities of 40 clinical isolates of Candida albicans by broth microdilution in two different media : RPMI 1640 ( RPMI ) and the same medium supplemented with 18 g of glucose per L ( RPMI-2 % glucose ) .","paragraph":"<h3><u>Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>flucytosine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ketoconazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>fluconazole</i></b> <b style='color:DodgerBlue;'><i>susceptibilities</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>isolates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Candida</i></b> <b style='color:DodgerBlue;'><i>albicans</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>broth</i></b> <b style='color:DodgerBlue;'><i>microdilution</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>media</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>RPMI</i></b> <b style='color:DodgerBlue;'><i>1640</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RPMI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>medium</i></b> <b style='color:DodgerBlue;'><i>supplemented</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>g</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>L</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RPMI-2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Preparation of media, drugs and inocula, as well as incubation temperature, followed the recommendations of the National Committee for Clinical Laboratory Standards (Villanova, PA, USA) antifungal agent working group for broth macrodilution tests with antifungal agents. Microtitre plates were agitated for 5 min before spectrophotometric readings were performed with an automatic plate reader. MIC endpoints were defined in three different ways: (i) MIC-100% for <b style='color:Tomato;'><i>amphotericin</i></b> B and <b style='color:Tomato;'><i>flucytosine</i></b>; (ii) MIC-80% for azole-drugs and also for <b style='color:Tomato;'><i>flucytosine</i></b>; (iii) IC1/2 for azole-drugs. The MIC endpoints were compared between the two different media in order to ascertain which was the best criterion. For <b style='color:Tomato;'><i>amphotericin</i></b> B, 100% of strains had a maximum difference of a twofold dilution in both media. For <b style='color:Tomato;'><i>flucytosine</i></b>, MIC values were very similar in both media, irrespective of the MIC endpoint chosen, MIC-100% or MIC-80%. For azole-drugs the (MIC-80%)50 and (MIC-80%)90 in RPMI were higher than those in RPMI-2% glucose. However, (IC1/2)50 and (IC1/2)90 were identical in both media as well as (MIC-80%)50 and (MIC-80%)90 in RPMI-2% glucose, The limited growth of yeasts in RPMI precludes the selection of an azole-MIC-80% endpoint, although the MIC determination was performed with an objective turbidimetric method (spectrophotometric reading plus mathematical MIC calculation). The use of RPMI-2% glucose produces the same MIC whatever methods was used, IC1/2 or MIC-80%. However, some minor discrepancies can be expected between IC1/2 and MIC-80% when strains with higher \"trailing effect\" are being tested. Therefore, we recommended IC1/2 in RPMI-2% glucose as the method of choice for MIC calculation, until more studies correlating in-vitro results with clinical outcome have been performed.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"have","start":3,"end":7,"id":1,"ws":true},{"text":"compared","start":8,"end":16,"id":2,"ws":true},{"text":"amphotericin","start":17,"end":29,"id":3,"ws":true},{"text":"B","start":30,"end":31,"id":4,"ws":true},{"text":",","start":32,"end":33,"id":5,"ws":true},{"text":"flucytosine","start":34,"end":45,"id":6,"ws":true},{"text":",","start":46,"end":47,"id":7,"ws":true},{"text":"ketoconazole","start":48,"end":60,"id":8,"ws":true},{"text":"and","start":61,"end":64,"id":9,"ws":true},{"text":"fluconazole","start":65,"end":76,"id":10,"ws":true},{"text":"susceptibilities","start":77,"end":93,"id":11,"ws":true},{"text":"of","start":94,"end":96,"id":12,"ws":true},{"text":"40","start":97,"end":99,"id":13,"ws":true},{"text":"clinical","start":100,"end":108,"id":14,"ws":true},{"text":"isolates","start":109,"end":117,"id":15,"ws":true},{"text":"of","start":118,"end":120,"id":16,"ws":true},{"text":"Candida","start":121,"end":128,"id":17,"ws":true},{"text":"albicans","start":129,"end":137,"id":18,"ws":true},{"text":"by","start":138,"end":140,"id":19,"ws":true},{"text":"broth","start":141,"end":146,"id":20,"ws":true},{"text":"microdilution","start":147,"end":160,"id":21,"ws":true},{"text":"in","start":161,"end":163,"id":22,"ws":true},{"text":"two","start":164,"end":167,"id":23,"ws":true},{"text":"different","start":168,"end":177,"id":24,"ws":true},{"text":"media","start":178,"end":183,"id":25,"ws":true},{"text":":","start":184,"end":185,"id":26,"ws":true},{"text":"RPMI","start":186,"end":190,"id":27,"ws":true},{"text":"1640","start":191,"end":195,"id":28,"ws":true},{"text":"(","start":196,"end":197,"id":29,"ws":true},{"text":"RPMI","start":198,"end":202,"id":30,"ws":true},{"text":")","start":203,"end":204,"id":31,"ws":true},{"text":"and","start":205,"end":208,"id":32,"ws":true},{"text":"the","start":209,"end":212,"id":33,"ws":true},{"text":"same","start":213,"end":217,"id":34,"ws":true},{"text":"medium","start":218,"end":224,"id":35,"ws":true},{"text":"supplemented","start":225,"end":237,"id":36,"ws":true},{"text":"with","start":238,"end":242,"id":37,"ws":true},{"text":"18","start":243,"end":245,"id":38,"ws":true},{"text":"g","start":246,"end":247,"id":39,"ws":true},{"text":"of","start":248,"end":250,"id":40,"ws":true},{"text":"glucose","start":251,"end":258,"id":41,"ws":true},{"text":"per","start":259,"end":262,"id":42,"ws":true},{"text":"L","start":263,"end":264,"id":43,"ws":true},{"text":"(","start":265,"end":266,"id":44,"ws":true},{"text":"RPMI-2","start":267,"end":273,"id":45,"ws":true},{"text":"%","start":274,"end":275,"id":46,"ws":true},{"text":"glucose","start":276,"end":283,"id":47,"ws":true},{"text":")","start":284,"end":285,"id":48,"ws":true},{"text":".","start":286,"end":287,"id":49,"ws":false}],"spans":[{"start":17,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},{"start":34,"end":45,"token_start":6,"token_end":6,"label":"DRUG"},{"start":48,"end":60,"token_start":8,"token_end":8,"label":"DRUG"},{"start":65,"end":76,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7559186/","_input_hash":2070092889,"_task_hash":2112239501,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Over the past decade , paclitaxel , docetaxel , vinorelbine , gemcitabine , irinotecan , and topotecan have been introduced into the clinic .","paragraph":"<h3><u>Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine.</u></h3>Platinum-based chemotherapy is considered standard treatment for advanced non-small-cell lung cancer (NSCLC). However, toxicity of most platinum-based regimens is substantial and requires close monitoring and supportive care. <b style='color:DodgerBlue;'><i>Over</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>past</i></b> <b style='color:DodgerBlue;'><i>decade</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>introduced</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>clinic</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These newer agents have shown promising activity against NSCLC with a favorable toxicity profile as single agents. For patients with metastatic NSCLC, palliation is the main goal of therapy. Therefore, treatment should be easy to administer on an outpatient basis. We explored a novel combination therapy avoiding platinum. Patients with recurrent or metastatic NSCLC were treated with intravenous (i.v.) <b style='color:Tomato;'><i>topotecan</i></b> (0.5-1.0 mg/m(2)/day x 5) and i.v. <b style='color:Tomato;'><i>vinorelbine</i></b> (20-30 mg/m(2)/day on day 1 and day 5) in 21-day cycles. Dose-limiting toxicity (DLT) was defined separately with or without the addition of granulocyte colony-stimulating factor (G-CSF) support. Twenty-nine patients have been enrolled to date. At i.v. <b style='color:Tomato;'><i>topotecan</i></b> doses of 0.75-1.0 mg/m(2)/day and i.v. <b style='color:Tomato;'><i>vinorelbine</i></b> of 25 mg/m(2)/day, neutropenia was frequent but of short duration (<7 days). The DLT of i.v. <b style='color:Tomato;'><i>topotecan</i></b> (0.85 mg/m(2)) in the absence of G-CSF support was based on myelosuppression with neutropenic fever. With the addition of G-CSF, a DLT has not been reached. Nonhematologic toxicities included mild to moderate fatigue and constipation. An overall clinical response rate of 42% was achieved, with responses noted at all dose levels. At a short median follow-up of 15 months, the median survival for all patients is 13 months. In conclusion, the combination regimen of <b style='color:Tomato;'><i>topotecan</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> is feasible for outpatient administration and is well tolerated with less toxicity than platinum-based regimens. Preliminary response data demonstrate good tumor activity, suggesting that this regimen could make an excellent palliative treatment for advanced NSCLC.","tokens":[{"text":"Over","start":0,"end":4,"id":0,"ws":true},{"text":"the","start":5,"end":8,"id":1,"ws":true},{"text":"past","start":9,"end":13,"id":2,"ws":true},{"text":"decade","start":14,"end":20,"id":3,"ws":true},{"text":",","start":21,"end":22,"id":4,"ws":true},{"text":"paclitaxel","start":23,"end":33,"id":5,"ws":true},{"text":",","start":34,"end":35,"id":6,"ws":true},{"text":"docetaxel","start":36,"end":45,"id":7,"ws":true},{"text":",","start":46,"end":47,"id":8,"ws":true},{"text":"vinorelbine","start":48,"end":59,"id":9,"ws":true},{"text":",","start":60,"end":61,"id":10,"ws":true},{"text":"gemcitabine","start":62,"end":73,"id":11,"ws":true},{"text":",","start":74,"end":75,"id":12,"ws":true},{"text":"irinotecan","start":76,"end":86,"id":13,"ws":true},{"text":",","start":87,"end":88,"id":14,"ws":true},{"text":"and","start":89,"end":92,"id":15,"ws":true},{"text":"topotecan","start":93,"end":102,"id":16,"ws":true},{"text":"have","start":103,"end":107,"id":17,"ws":true},{"text":"been","start":108,"end":112,"id":18,"ws":true},{"text":"introduced","start":113,"end":123,"id":19,"ws":true},{"text":"into","start":124,"end":128,"id":20,"ws":true},{"text":"the","start":129,"end":132,"id":21,"ws":true},{"text":"clinic","start":133,"end":139,"id":22,"ws":true},{"text":".","start":140,"end":141,"id":23,"ws":false}],"spans":[{"start":23,"end":33,"token_start":5,"token_end":5,"label":"DRUG"},{"start":36,"end":45,"token_start":7,"token_end":7,"label":"DRUG"},{"start":48,"end":59,"token_start":9,"token_end":9,"label":"DRUG"},{"start":62,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":76,"end":86,"token_start":13,"token_end":13,"label":"DRUG"},{"start":93,"end":102,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11598413/","_input_hash":370835701,"_task_hash":739658303,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Alternatively , it may be that the adverse effects of pindolol and propranolol are due to the simultaneous blockade of both beta 1- and beta 2-adrenoceptors .","paragraph":"<h3><u>Central propranolol and pindolol, but not atenolol nor metoprolol, inhibit sexual behavior in male rats.</u></h3>Are the anti-sexual effects of <b style='color:Tomato;'><i>propranolol</i></b> and <b style='color:Tomato;'><i>pindolol</i></b> due to actions within the brain? To answer this, these agents were administered directly into the brain ventricular system (ICV). Additionally, <b style='color:Tomato;'><i>atenolol</i></b> and <b style='color:Tomato;'><i>metoprolol</i></b> were evaluated to see whether differential delivery to the brain contributed to the observed lack of effect of systemically administered beta 1-adrenoceptor antagonists. ICV administration of <b style='color:Tomato;'><i>pindolol</i></b> (45 or 90 micrograms) was followed by a suppression of copulation. At 45 micrograms, inhibition was limited to performance aspects of copulation, whereas at 90 micrograms, decrements in motivational and performance aspects of copulation were evident. ICV administration of <b style='color:Tomato;'><i>propranolol</i></b> also suppressed copulatory behavior. At 45 micrograms, no significant effects were observed, whereas at 90 micrograms decrements in motivational and performance aspects of copulation were evident. In contrast, ICV administration of the beta 1-adrenoceptor antagonists, <b style='color:Tomato;'><i>atenolol</i></b> and <b style='color:Tomato;'><i>metoprolol</i></b>, was not associated with any major modifications in copulatory behavior. We suggest that the inhibitory effects of <b style='color:Tomato;'><i>propranolol</i></b> and <b style='color:Tomato;'><i>pindolol</i></b> may involve interactions with 5-HT1A receptors in the CNS. <b style='color:DodgerBlue;'><i>Alternatively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>it</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pindolol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>simultaneous</i></b> <b style='color:DodgerBlue;'><i>blockade</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>beta</i></b> <b style='color:DodgerBlue;'><i>1-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>beta</i></b> <b style='color:DodgerBlue;'><i>2-adrenoceptors</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Alternatively","start":0,"end":13,"id":0,"ws":true},{"text":",","start":14,"end":15,"id":1,"ws":true},{"text":"it","start":16,"end":18,"id":2,"ws":true},{"text":"may","start":19,"end":22,"id":3,"ws":true},{"text":"be","start":23,"end":25,"id":4,"ws":true},{"text":"that","start":26,"end":30,"id":5,"ws":true},{"text":"the","start":31,"end":34,"id":6,"ws":true},{"text":"adverse","start":35,"end":42,"id":7,"ws":true},{"text":"effects","start":43,"end":50,"id":8,"ws":true},{"text":"of","start":51,"end":53,"id":9,"ws":true},{"text":"pindolol","start":54,"end":62,"id":10,"ws":true},{"text":"and","start":63,"end":66,"id":11,"ws":true},{"text":"propranolol","start":67,"end":78,"id":12,"ws":true},{"text":"are","start":79,"end":82,"id":13,"ws":true},{"text":"due","start":83,"end":86,"id":14,"ws":true},{"text":"to","start":87,"end":89,"id":15,"ws":true},{"text":"the","start":90,"end":93,"id":16,"ws":true},{"text":"simultaneous","start":94,"end":106,"id":17,"ws":true},{"text":"blockade","start":107,"end":115,"id":18,"ws":true},{"text":"of","start":116,"end":118,"id":19,"ws":true},{"text":"both","start":119,"end":123,"id":20,"ws":true},{"text":"beta","start":124,"end":128,"id":21,"ws":true},{"text":"1-","start":129,"end":131,"id":22,"ws":true},{"text":"and","start":132,"end":135,"id":23,"ws":true},{"text":"beta","start":136,"end":140,"id":24,"ws":true},{"text":"2-adrenoceptors","start":141,"end":156,"id":25,"ws":true},{"text":".","start":157,"end":158,"id":26,"ws":false}],"spans":[{"start":54,"end":62,"token_start":10,"token_end":10,"label":"DRUG"},{"start":67,"end":78,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8838601/","_input_hash":-206388755,"_task_hash":-555842489,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":54,"end":62,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":67,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"The combinations of irinotecan and mitomycin C or oxaliplatin have given very good results with high objective response rates and good tolerance .","paragraph":"<h3><u>[Irinotecan in combination for colon cancer].</u></h3>As a single agent, <b style='color:Tomato;'><i>irinotecan</i></b> has demonstrated efficacy in metastatic 5FU resistant colorectal metastatic cancer. Chemotherapy with <b style='color:Tomato;'><i>fluorouracil</i></b> (5FU) plus <b style='color:Tomato;'><i>leucovorin</i></b> remains a standard in the treatment of patients with metastatic colorectal cancer. It seemed logical to test the combination of this reference treatment and the new agent. The first trials gave rather disappointing results, suggesting an inhibition of the metabolism of <b style='color:Tomato;'><i>irinotecan</i></b> into SN38 when 5FU was present in the circulation. More recent studies have given totally different results with a very good tolerance and strong efficacy of the combination of weekly folinic acid + 5FU and <b style='color:Tomato;'><i>irinotecan</i></b> or LV5FU2 (the so-called de Gramont regimen) and <b style='color:Tomato;'><i>irinotecan</i></b>. The results were so good that these new schedules are currently developed as first line regimen. Another way to combine 5FU, folinic acid and <b style='color:Tomato;'><i>irinotecan</i></b> is to alternate a cycle of 5FU, folinic acid and a cycle of <b style='color:Tomato;'><i>irinotecan</i></b>. Such an alternated schedule has given encouraging results with an objective response rate greater than 30% and a long median survival time (more than 16 months). It is also very easy to combine <b style='color:Tomato;'><i>irinotecan</i></b> with other drug which have demonstrated activity in the treatment of colorectal cancer. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitomycin</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>good</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>objective</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>good</i></b> <b style='color:DodgerBlue;'><i>tolerance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>irinotecan</i></b> plays now an important part in the treatment of metastatic colorectal cancer. This part becomes larger due to the results of the combination trials already presented which have shown strong efficacy and good tolerance.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combinations","start":4,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"irinotecan","start":20,"end":30,"id":3,"ws":true},{"text":"and","start":31,"end":34,"id":4,"ws":true},{"text":"mitomycin","start":35,"end":44,"id":5,"ws":true},{"text":"C","start":45,"end":46,"id":6,"ws":true},{"text":"or","start":47,"end":49,"id":7,"ws":true},{"text":"oxaliplatin","start":50,"end":61,"id":8,"ws":true},{"text":"have","start":62,"end":66,"id":9,"ws":true},{"text":"given","start":67,"end":72,"id":10,"ws":true},{"text":"very","start":73,"end":77,"id":11,"ws":true},{"text":"good","start":78,"end":82,"id":12,"ws":true},{"text":"results","start":83,"end":90,"id":13,"ws":true},{"text":"with","start":91,"end":95,"id":14,"ws":true},{"text":"high","start":96,"end":100,"id":15,"ws":true},{"text":"objective","start":101,"end":110,"id":16,"ws":true},{"text":"response","start":111,"end":119,"id":17,"ws":true},{"text":"rates","start":120,"end":125,"id":18,"ws":true},{"text":"and","start":126,"end":129,"id":19,"ws":true},{"text":"good","start":130,"end":134,"id":20,"ws":true},{"text":"tolerance","start":135,"end":144,"id":21,"ws":true},{"text":".","start":145,"end":146,"id":22,"ws":false}],"spans":[{"start":20,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},{"start":35,"end":44,"token_start":5,"token_end":5,"label":"DRUG"},{"start":50,"end":61,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9932084/","_input_hash":1058730831,"_task_hash":-1883704268,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":20,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":35,"end":44,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":3,"child":8,"head_span":{"start":20,"end":30,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":50,"end":61,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"The NHB of strategy A was 31.6 QALMs versus strategy C when palbociclib was included in strategy C ; similarly , strategy A had a NHB of 13.8 QALMs versus strategy C when pertuzumab was included in strategy C. Monte-Carlo simulation demonstrated that the main factor influencing NHB of strategy A over strategy C was the cost of systemic therapy .","paragraph":"<h3><u>Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.</u></h3>To estimate the cost-effectiveness of liver resection followed by adjuvant systemic therapy relative to systemic therapy alone for patients with breast cancer liver metastasis. ### background Data on cost-effectiveness of liver resection for advanced breast cancer with liver metastasis are lacking. ### methods A decision-analytic Markov model was constructed to evaluate the cost-effectiveness of liver resection followed by postoperative conventional systemic therapy (strategy A) versus conventional therapy alone (strategy B) versus newer targeted therapy alone (strategy C). The implications of using different chemotherapeutic regimens based on estrogen receptor and human epidermal growth factor receptor 2 status was also assessed. Outcomes included quality-adjusted life months (QALMs), incremental cost-effectiveness ratio, and net health benefit (NHB). ### results NHB of strategy A was 10.9 QALMs compared with strategy B when <b style='color:Tomato;'><i>letrozole</i></b> was used as systemic therapy, whereas it was only 0.3 QALMs when <b style='color:Tomato;'><i>docetaxel</i></b>\u200a+\u200a<b style='color:Tomato;'><i>trastuzumab</i></b> was used as a systemic therapy. The addition of newer biological agents (strategy C) significantly decreased the cost-effectiveness of strategy B (conventional systemic therapy alone). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>NHB</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>31.6</i></b> <b style='color:DodgerBlue;'><i>QALMs</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:MediumOrchid;'><i>palbociclib</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>similarly</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>NHB</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>13.8</i></b> <b style='color:DodgerBlue;'><i>QALMs</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>C.</i></b> <b style='color:DodgerBlue;'><i>Monte-Carlo</i></b> <b style='color:DodgerBlue;'><i>simulation</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>main</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>influencing</i></b> <b style='color:DodgerBlue;'><i>NHB</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>strategy</i></b> <b style='color:DodgerBlue;'><i>C</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cost</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions Liver resection in patients with breast cancer liver metastasis proved to be cost-effective when compared with systemic therapy alone, particularly in estrogen receptor-positive tumors or when newer agents were used.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"NHB","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"strategy","start":11,"end":19,"id":3,"ws":true},{"text":"A","start":20,"end":21,"id":4,"ws":true},{"text":"was","start":22,"end":25,"id":5,"ws":true},{"text":"31.6","start":26,"end":30,"id":6,"ws":true},{"text":"QALMs","start":31,"end":36,"id":7,"ws":true},{"text":"versus","start":37,"end":43,"id":8,"ws":true},{"text":"strategy","start":44,"end":52,"id":9,"ws":true},{"text":"C","start":53,"end":54,"id":10,"ws":true},{"text":"when","start":55,"end":59,"id":11,"ws":true},{"text":"palbociclib","start":60,"end":71,"id":12,"ws":true},{"text":"was","start":72,"end":75,"id":13,"ws":true},{"text":"included","start":76,"end":84,"id":14,"ws":true},{"text":"in","start":85,"end":87,"id":15,"ws":true},{"text":"strategy","start":88,"end":96,"id":16,"ws":true},{"text":"C","start":97,"end":98,"id":17,"ws":true},{"text":";","start":99,"end":100,"id":18,"ws":true},{"text":"similarly","start":101,"end":110,"id":19,"ws":true},{"text":",","start":111,"end":112,"id":20,"ws":true},{"text":"strategy","start":113,"end":121,"id":21,"ws":true},{"text":"A","start":122,"end":123,"id":22,"ws":true},{"text":"had","start":124,"end":127,"id":23,"ws":true},{"text":"a","start":128,"end":129,"id":24,"ws":true},{"text":"NHB","start":130,"end":133,"id":25,"ws":true},{"text":"of","start":134,"end":136,"id":26,"ws":true},{"text":"13.8","start":137,"end":141,"id":27,"ws":true},{"text":"QALMs","start":142,"end":147,"id":28,"ws":true},{"text":"versus","start":148,"end":154,"id":29,"ws":true},{"text":"strategy","start":155,"end":163,"id":30,"ws":true},{"text":"C","start":164,"end":165,"id":31,"ws":true},{"text":"when","start":166,"end":170,"id":32,"ws":true},{"text":"pertuzumab","start":171,"end":181,"id":33,"ws":true},{"text":"was","start":182,"end":185,"id":34,"ws":true},{"text":"included","start":186,"end":194,"id":35,"ws":true},{"text":"in","start":195,"end":197,"id":36,"ws":true},{"text":"strategy","start":198,"end":206,"id":37,"ws":true},{"text":"C.","start":207,"end":209,"id":38,"ws":true},{"text":"Monte-Carlo","start":210,"end":221,"id":39,"ws":true},{"text":"simulation","start":222,"end":232,"id":40,"ws":true},{"text":"demonstrated","start":233,"end":245,"id":41,"ws":true},{"text":"that","start":246,"end":250,"id":42,"ws":true},{"text":"the","start":251,"end":254,"id":43,"ws":true},{"text":"main","start":255,"end":259,"id":44,"ws":true},{"text":"factor","start":260,"end":266,"id":45,"ws":true},{"text":"influencing","start":267,"end":278,"id":46,"ws":true},{"text":"NHB","start":279,"end":282,"id":47,"ws":true},{"text":"of","start":283,"end":285,"id":48,"ws":true},{"text":"strategy","start":286,"end":294,"id":49,"ws":true},{"text":"A","start":295,"end":296,"id":50,"ws":true},{"text":"over","start":297,"end":301,"id":51,"ws":true},{"text":"strategy","start":302,"end":310,"id":52,"ws":true},{"text":"C","start":311,"end":312,"id":53,"ws":true},{"text":"was","start":313,"end":316,"id":54,"ws":true},{"text":"the","start":317,"end":320,"id":55,"ws":true},{"text":"cost","start":321,"end":325,"id":56,"ws":true},{"text":"of","start":326,"end":328,"id":57,"ws":true},{"text":"systemic","start":329,"end":337,"id":58,"ws":true},{"text":"therapy","start":338,"end":345,"id":59,"ws":true},{"text":".","start":346,"end":347,"id":60,"ws":false}],"spans":[{"start":60,"end":71,"token_start":12,"token_end":12,"label":"DRUG"},{"start":171,"end":181,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28266967/","_input_hash":443902227,"_task_hash":-487815903,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In the second study 12 patients with small cell undifferentiated cancers were treated with carboplatin , etoposide and ifosfamide .","paragraph":"<h3><u>Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.</u></h3>Two clinical studies were undertaken to study the toxicity profile and effects of interleukin-3 (rhIL-3) on chemotherapy-induced myelosuppression. Fifteen patients with recurrent ovarian carcinoma were treated with high dose <b style='color:Tomato;'><i>carboplatin</i></b> (800 mg m-2). All patients received 5.0 micrograms/kg/d rhIL-3 subcutaneously but timing and duration of rhIL-3 treatment differed. Constitutional symptoms were the major toxicity and in addition to the <b style='color:Tomato;'><i>carboplatin</i></b>-induced nausea and vomiting the combination was poorly tolerated. In 5/15 patients receiving high dose <b style='color:Tomato;'><i>carboplatin</i></b> rhIL-3 administration was discontinued due to nephrotoxicity (2 x), hypotension, severe malaise and bone pain. In this study, rhIL-3 ameliorated chemotherapy-induced neutropenia as well as thrombocytopenia and reduced the requirement for platelet transfusions in the second cycle of chemotherapy. However, rhIL-3 failed to prevent cumulative platelet toxicity. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>second</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>undifferentiated</i></b> <b style='color:DodgerBlue;'><i>cancers</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Three dose levels of rhIL-3 were explored (0.125, 5.0 and 7.5 micrograms/kg/d). In this study, toxicity of the treatment was mild, however, no beneficial haematologic effects of rhIL-3 could be demonstrated. In conclusion, the haematological effects of rhIL-3 were modest and dependent on the chemotherapeutic regimen, timing and duration of rhIL-3 treatment (in relation to the expected nadir). In general rhIL-3-induced toxicity was mild, but combination with high dose <b style='color:Tomato;'><i>carboplatin</i></b> could be hazardous if rhIL-3 is initiated at 24 h after the cytostatic agent.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"second","start":7,"end":13,"id":2,"ws":true},{"text":"study","start":14,"end":19,"id":3,"ws":true},{"text":"12","start":20,"end":22,"id":4,"ws":true},{"text":"patients","start":23,"end":31,"id":5,"ws":true},{"text":"with","start":32,"end":36,"id":6,"ws":true},{"text":"small","start":37,"end":42,"id":7,"ws":true},{"text":"cell","start":43,"end":47,"id":8,"ws":true},{"text":"undifferentiated","start":48,"end":64,"id":9,"ws":true},{"text":"cancers","start":65,"end":72,"id":10,"ws":true},{"text":"were","start":73,"end":77,"id":11,"ws":true},{"text":"treated","start":78,"end":85,"id":12,"ws":true},{"text":"with","start":86,"end":90,"id":13,"ws":true},{"text":"carboplatin","start":91,"end":102,"id":14,"ws":true},{"text":",","start":103,"end":104,"id":15,"ws":true},{"text":"etoposide","start":105,"end":114,"id":16,"ws":true},{"text":"and","start":115,"end":118,"id":17,"ws":true},{"text":"ifosfamide","start":119,"end":129,"id":18,"ws":true},{"text":".","start":130,"end":131,"id":19,"ws":false}],"spans":[{"start":91,"end":102,"token_start":14,"token_end":14,"label":"DRUG"},{"start":105,"end":114,"token_start":16,"token_end":16,"label":"DRUG"},{"start":119,"end":129,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7692922/","_input_hash":261666132,"_task_hash":378574346,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":91,"end":102,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":105,"end":114,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":18,"child":16,"head_span":{"start":119,"end":129,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":105,"end":114,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"3 . Systemic ( i.v . ) pretreatment with furosemide ( 2 - 10 mg kg-1 ) increased urine volume and dose-dependently inhibited the pressor response to i.c.v . clonidine ( 10 micrograms ) , and a long-lasting depressor response to clonidine was observed .","paragraph":"<h3><u>Furosemide inhibits the centrally-mediated pressor response to clonidine in conscious, normotensive rats.</u></h3>1. The effect of <b style='color:Tomato;'><i>furosemide</i></b> on the pressor response induced by intracerebroventricular (i.c.v.) injection of <b style='color:Tomato;'><i>clonidine</i></b> was investigated in freely moving, normotensive rats with chronically implanted arterial catheters. 2. When injected i.c.v., <b style='color:Tomato;'><i>clonidine</i></b> at doses of 5 and 10 micrograms produced a dose-dependent pressor response and a decrease in heart rate. No depressor response was induced by <b style='color:Tomato;'><i>clonidine</i></b>. <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>Systemic</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>pretreatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>furosemide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>kg-1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>urine</i></b> <b style='color:DodgerBlue;'><i>volume</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>dose-dependently</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pressor</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>i.c.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>micrograms</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>long-lasting</i></b> <b style='color:DodgerBlue;'><i>depressor</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>clonidine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, <b style='color:Tomato;'><i>furosemide</i></b> treatment did not alter the bradycardia produced in response to <b style='color:Tomato;'><i>clonidine</i></b>. 4. The systemic treatment with <b style='color:Tomato;'><i>furosemide</i></b> (10 mg kg-1, i.v.) had no effect on the pressor response to i.v. noradrenaline. 5. These results suggest that reduction of body fluid volume inhibits the centrally-mediated pressor response to <b style='color:Tomato;'><i>clonidine</i></b> and leads to the hypotensive effect. We also suggest that combined treatment with a diuretic increases the hypotensive efficacy of <b style='color:Tomato;'><i>clonidine</i></b>.","tokens":[{"text":"3","start":0,"end":1,"id":0,"ws":true},{"text":".","start":2,"end":3,"id":1,"ws":true},{"text":"Systemic","start":4,"end":12,"id":2,"ws":true},{"text":"(","start":13,"end":14,"id":3,"ws":true},{"text":"i.v","start":15,"end":18,"id":4,"ws":true},{"text":".","start":19,"end":20,"id":5,"ws":true},{"text":")","start":21,"end":22,"id":6,"ws":true},{"text":"pretreatment","start":23,"end":35,"id":7,"ws":true},{"text":"with","start":36,"end":40,"id":8,"ws":true},{"text":"furosemide","start":41,"end":51,"id":9,"ws":true},{"text":"(","start":52,"end":53,"id":10,"ws":true},{"text":"2","start":54,"end":55,"id":11,"ws":true},{"text":"-","start":56,"end":57,"id":12,"ws":true},{"text":"10","start":58,"end":60,"id":13,"ws":true},{"text":"mg","start":61,"end":63,"id":14,"ws":true},{"text":"kg-1","start":64,"end":68,"id":15,"ws":true},{"text":")","start":69,"end":70,"id":16,"ws":true},{"text":"increased","start":71,"end":80,"id":17,"ws":true},{"text":"urine","start":81,"end":86,"id":18,"ws":true},{"text":"volume","start":87,"end":93,"id":19,"ws":true},{"text":"and","start":94,"end":97,"id":20,"ws":true},{"text":"dose-dependently","start":98,"end":114,"id":21,"ws":true},{"text":"inhibited","start":115,"end":124,"id":22,"ws":true},{"text":"the","start":125,"end":128,"id":23,"ws":true},{"text":"pressor","start":129,"end":136,"id":24,"ws":true},{"text":"response","start":137,"end":145,"id":25,"ws":true},{"text":"to","start":146,"end":148,"id":26,"ws":true},{"text":"i.c.v","start":149,"end":154,"id":27,"ws":true},{"text":".","start":155,"end":156,"id":28,"ws":true},{"text":"clonidine","start":157,"end":166,"id":29,"ws":true},{"text":"(","start":167,"end":168,"id":30,"ws":true},{"text":"10","start":169,"end":171,"id":31,"ws":true},{"text":"micrograms","start":172,"end":182,"id":32,"ws":true},{"text":")","start":183,"end":184,"id":33,"ws":true},{"text":",","start":185,"end":186,"id":34,"ws":true},{"text":"and","start":187,"end":190,"id":35,"ws":true},{"text":"a","start":191,"end":192,"id":36,"ws":true},{"text":"long-lasting","start":193,"end":205,"id":37,"ws":true},{"text":"depressor","start":206,"end":215,"id":38,"ws":true},{"text":"response","start":216,"end":224,"id":39,"ws":true},{"text":"to","start":225,"end":227,"id":40,"ws":true},{"text":"clonidine","start":228,"end":237,"id":41,"ws":true},{"text":"was","start":238,"end":241,"id":42,"ws":true},{"text":"observed","start":242,"end":250,"id":43,"ws":true},{"text":".","start":251,"end":252,"id":44,"ws":false}],"spans":[{"start":41,"end":51,"token_start":9,"token_end":9,"label":"DRUG"},{"start":157,"end":166,"token_start":29,"token_end":29,"label":"DRUG"},{"start":228,"end":237,"token_start":41,"token_end":41,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1797326/","_input_hash":732324884,"_task_hash":-2005909752,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":9,"child":29,"head_span":{"start":41,"end":51,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":157,"end":166,"token_start":29,"token_end":29,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"Nine studies connected to the network for the PFS analysis in which necitumumab in combination with gemcitabine and cisplatin was associated with the lowest HR .","paragraph":"<h3><u>First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis.</u></h3>The objectives of this systematic review and meta-analysis were to compare the survival, toxicity, and quality of life of patients treated with <b style='color:Tomato;'><i>necitumumab</i></b> in combination with <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b>. These agents were investigated in published randomized controlled trials (RCTs) of patients with squamous non-small cell lung cancer (NSCLC) in the first-line setting. ### methods The systematic review was executed on January 27, 2015, and updated on August 21, 2016, using a pre-specified search strategy. Searches were conducted using PubMed, Medline, and EMBASE, with supplemental searches using the Evidence Based Medicine Reviews and ClinicalTrials.gov to identify RCTs published in English from 1995-2016 and reporting at least one of the primary outcomes [overall survival (OS), progression-free survival (PFS), toxicity, or quality of life] in patients who received first-line treatment for advanced or metastatic squamous NSCLC. Study quality and risk of bias were assessed using the Physiotherapy Evidence Database (PEDro) scale and Cochrane risk of bias tool, respectively. A Baysian network meta-analysis was performed on the primary outcomes. Hazard ratios (HRs) were evaluated for the primary analysis; secondary analyses were conducted using median OS data. Planned sensitivity analyses were conducted including reanalysis using a Frequentist approach and limiting analyses to subsets based on clinical and demographic covariates. ### results The systematic literature review resulted in identification of 4,016 unique publications; 40 publications (35 unique trials) were eligible for inclusion. Eight studies connected to a common network for the OS analysis using HR data. The majority of studies were not limited to squamous NSCLC, thus analyzable data were limited to a subset of data within the published trials. <b style='color:Tomato;'><i>carboplatin</i></b> + S-1 and <b style='color:Tomato;'><i>necitumumab</i></b> in combination with <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b> were associated with lower HRs for OS versus all other comparators. <b style='color:DodgerBlue;'><i>Nine</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>connected</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>network</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>PFS</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:MediumOrchid;'><i>necitumumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>lowest</i></b> <b style='color:DodgerBlue;'><i>HR</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Data were not available to analyze toxicity or quality of life. ### conclusions Although the results suggest that <b style='color:Tomato;'><i>carboplatin</i></b> + S-1 and <b style='color:Tomato;'><i>necitumumab</i></b> in combination with <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b> may have value in terms of OS versus other comparators, the results should be interpreted with caution due to the limited number of studies (with few focused exclusively on squamous NSCLC) and wide credible intervals.","tokens":[{"text":"Nine","start":0,"end":4,"id":0,"ws":true},{"text":"studies","start":5,"end":12,"id":1,"ws":true},{"text":"connected","start":13,"end":22,"id":2,"ws":true},{"text":"to","start":23,"end":25,"id":3,"ws":true},{"text":"the","start":26,"end":29,"id":4,"ws":true},{"text":"network","start":30,"end":37,"id":5,"ws":true},{"text":"for","start":38,"end":41,"id":6,"ws":true},{"text":"the","start":42,"end":45,"id":7,"ws":true},{"text":"PFS","start":46,"end":49,"id":8,"ws":true},{"text":"analysis","start":50,"end":58,"id":9,"ws":true},{"text":"in","start":59,"end":61,"id":10,"ws":true},{"text":"which","start":62,"end":67,"id":11,"ws":true},{"text":"necitumumab","start":68,"end":79,"id":12,"ws":true},{"text":"in","start":80,"end":82,"id":13,"ws":true},{"text":"combination","start":83,"end":94,"id":14,"ws":true},{"text":"with","start":95,"end":99,"id":15,"ws":true},{"text":"gemcitabine","start":100,"end":111,"id":16,"ws":true},{"text":"and","start":112,"end":115,"id":17,"ws":true},{"text":"cisplatin","start":116,"end":125,"id":18,"ws":true},{"text":"was","start":126,"end":129,"id":19,"ws":true},{"text":"associated","start":130,"end":140,"id":20,"ws":true},{"text":"with","start":141,"end":145,"id":21,"ws":true},{"text":"the","start":146,"end":149,"id":22,"ws":true},{"text":"lowest","start":150,"end":156,"id":23,"ws":true},{"text":"HR","start":157,"end":159,"id":24,"ws":true},{"text":".","start":160,"end":161,"id":25,"ws":false}],"spans":[{"start":68,"end":79,"token_start":12,"token_end":12,"label":"DRUG"},{"start":100,"end":111,"token_start":16,"token_end":16,"label":"DRUG"},{"start":116,"end":125,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30746213/","_input_hash":1477401853,"_task_hash":-1501142073,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":18,"child":12,"head_span":{"start":116,"end":125,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":68,"end":79,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":16,"head_span":{"start":68,"end":79,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":100,"end":111,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"To evaluate the efficacy and toxicities of gemcitabine combined with ifosfamide and anthracycline chemotherapy for recurrent platinum resistant ovarian epithelial cancer .","paragraph":"<h3><u>[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>toxicities</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anthracycline</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>platinum</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods <b style='color:Tomato;'><i>gemcitabine</i></b> 800 mg/m(2) (day 1, 8), <b style='color:Tomato;'><i>ifosfamide</i></b> 1.5 g/m(2) (day 1 - 3), adriamycin 40 mg/m(2) or <b style='color:Tomato;'><i>epirubicin</i></b> 60 mg/m(2) (day 1) or <b style='color:Tomato;'><i>mitoxantrone</i></b> 10 mg/m(2) (day 1, 8) were used in recurrent platinum resistant/refractory ovarian cancer patients, the cycle was repeated at interval of 21 to 28 days. ### results A total of 60 patients received 172 cycles combined chemotherapy. There were no one cases complete response, while partial response 22 (37%, 22/60), stable 23 (38%, 23/60) and progression 15 (25%, 15/60) were observed, with clinical benefit rate 75% (45/60). The median time of progression-free survival was 7 months, and the median overall survival time was 20 months. The main side effect was hematologic toxicity with leukopenia rate of 82% (49/60), among which III-IV accounted for 31% (15/49). Digestive reaction was all in I-II, accounted for 42% (25/60). ### conclusion The regimen of <b style='color:Tomato;'><i>gemcitabine</i></b> combined with <b style='color:Tomato;'><i>ifosfamide</i></b> and anthracycline is feasible, tolerable and effective in patients with recurrent platinum resistant/refractory epithelial ovarian cancer.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"evaluate","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"efficacy","start":16,"end":24,"id":3,"ws":true},{"text":"and","start":25,"end":28,"id":4,"ws":true},{"text":"toxicities","start":29,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"gemcitabine","start":43,"end":54,"id":7,"ws":true},{"text":"combined","start":55,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"ifosfamide","start":69,"end":79,"id":10,"ws":true},{"text":"and","start":80,"end":83,"id":11,"ws":true},{"text":"anthracycline","start":84,"end":97,"id":12,"ws":true},{"text":"chemotherapy","start":98,"end":110,"id":13,"ws":true},{"text":"for","start":111,"end":114,"id":14,"ws":true},{"text":"recurrent","start":115,"end":124,"id":15,"ws":true},{"text":"platinum","start":125,"end":133,"id":16,"ws":true},{"text":"resistant","start":134,"end":143,"id":17,"ws":true},{"text":"ovarian","start":144,"end":151,"id":18,"ws":true},{"text":"epithelial","start":152,"end":162,"id":19,"ws":true},{"text":"cancer","start":163,"end":169,"id":20,"ws":true},{"text":".","start":170,"end":171,"id":21,"ws":false}],"spans":[{"start":43,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"},{"start":84,"end":97,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21211276/","_input_hash":-46406489,"_task_hash":2110540052,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":7,"child":10,"head_span":{"start":43,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":12,"head_span":{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":84,"end":97,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Combination of erlotinib and sorafenib , synergistic in GSC11 , induced apoptosis and autophagic cell death associated with suppressed Akt and ERK signaling pathways and decreased nuclear PKM2 and \u03b2-catenin in vitro , and tended to improve survival of nude mice bearing GSC11 brain tumor .","paragraph":"<h3><u>Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.</u></h3>The majority of glioblastomas have aberrant receptor tyrosine kinase (RTK)/RAS/phosphoinositide 3 kinase (PI3K) signaling pathways and malignant glioma cells are thought to be addicted to these signaling pathways for their survival and proliferation. However, recent studies suggest that monotherapies or inappropriate combination therapies using the molecular targeted drugs have limited efficacy possibly because of tumor heterogeneities, signaling redundancy and crosstalk in intracellular signaling network, indicating necessity of rationale and methods for efficient personalized combination treatments. Here, we evaluated the growth of colonies obtained from glioma tumor-initiating cells (GICs) derived from glioma sphere culture (GSC) in agarose and examined the effects of combination treatments on GICs using targeted drugs that affect the signaling pathways to which most glioma cells are addicted. ### methods Human GICs were cultured in agarose and treated with inhibitors of RTKs, non-receptor kinases or transcription factors. The colony number and volume were analyzed using a colony counter, and Chou-Talalay combination indices were evaluated. Autophagy and apoptosis were also analyzed. Phosphorylation of proteins was evaluated by reverse phase protein array and immunoblotting. ### results Increases of colony number and volume in agarose correlated with the Gompertz function. GICs showed diverse drug sensitivity, but inhibitions of RTK and RAF/MEK or PI3K by combinations such as EGFR inhibitor and MEK inhibitor, <b style='color:Tomato;'><i>sorafenib</i></b> and U0126, <b style='color:Tomato;'><i>erlotinib</i></b> and BKM120, and EGFR inhibitor and <b style='color:Tomato;'><i>sorafenib</i></b> showed synergy in different subtypes of GICs. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>GSC11</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>apoptosis</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>autophagic</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>death</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>suppressed</i></b> <b style='color:DodgerBlue;'><i>Akt</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>ERK</i></b> <b style='color:DodgerBlue;'><i>signaling</i></b> <b style='color:DodgerBlue;'><i>pathways</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>nuclear</i></b> <b style='color:DodgerBlue;'><i>PKM2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>\u03b2-catenin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>tended</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nude</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>bearing</i></b> <b style='color:DodgerBlue;'><i>GSC11</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Reverse phase protein array analysis of the synergistic treatment indicated involvement of not only MEK and PI3K signaling pathways but also others associated with glucose metabolism, fatty acid metabolism, gene transcription, histone methylation, iron transport, stress response, cell cycle, and apoptosis. ### conclusion Inhibiting RTK and RAF/MEK or PI3K could induce synergistic cytotoxicity but personalization is necessary. Examining colonies in agarose initiated by GICs from each patient may be useful for drug sensitivity testing in personalized cancer therapy.","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"of","start":12,"end":14,"id":1,"ws":true},{"text":"erlotinib","start":15,"end":24,"id":2,"ws":true},{"text":"and","start":25,"end":28,"id":3,"ws":true},{"text":"sorafenib","start":29,"end":38,"id":4,"ws":true},{"text":",","start":39,"end":40,"id":5,"ws":true},{"text":"synergistic","start":41,"end":52,"id":6,"ws":true},{"text":"in","start":53,"end":55,"id":7,"ws":true},{"text":"GSC11","start":56,"end":61,"id":8,"ws":true},{"text":",","start":62,"end":63,"id":9,"ws":true},{"text":"induced","start":64,"end":71,"id":10,"ws":true},{"text":"apoptosis","start":72,"end":81,"id":11,"ws":true},{"text":"and","start":82,"end":85,"id":12,"ws":true},{"text":"autophagic","start":86,"end":96,"id":13,"ws":true},{"text":"cell","start":97,"end":101,"id":14,"ws":true},{"text":"death","start":102,"end":107,"id":15,"ws":true},{"text":"associated","start":108,"end":118,"id":16,"ws":true},{"text":"with","start":119,"end":123,"id":17,"ws":true},{"text":"suppressed","start":124,"end":134,"id":18,"ws":true},{"text":"Akt","start":135,"end":138,"id":19,"ws":true},{"text":"and","start":139,"end":142,"id":20,"ws":true},{"text":"ERK","start":143,"end":146,"id":21,"ws":true},{"text":"signaling","start":147,"end":156,"id":22,"ws":true},{"text":"pathways","start":157,"end":165,"id":23,"ws":true},{"text":"and","start":166,"end":169,"id":24,"ws":true},{"text":"decreased","start":170,"end":179,"id":25,"ws":true},{"text":"nuclear","start":180,"end":187,"id":26,"ws":true},{"text":"PKM2","start":188,"end":192,"id":27,"ws":true},{"text":"and","start":193,"end":196,"id":28,"ws":true},{"text":"\u03b2-catenin","start":197,"end":206,"id":29,"ws":true},{"text":"in","start":207,"end":209,"id":30,"ws":true},{"text":"vitro","start":210,"end":215,"id":31,"ws":true},{"text":",","start":216,"end":217,"id":32,"ws":true},{"text":"and","start":218,"end":221,"id":33,"ws":true},{"text":"tended","start":222,"end":228,"id":34,"ws":true},{"text":"to","start":229,"end":231,"id":35,"ws":true},{"text":"improve","start":232,"end":239,"id":36,"ws":true},{"text":"survival","start":240,"end":248,"id":37,"ws":true},{"text":"of","start":249,"end":251,"id":38,"ws":true},{"text":"nude","start":252,"end":256,"id":39,"ws":true},{"text":"mice","start":257,"end":261,"id":40,"ws":true},{"text":"bearing","start":262,"end":269,"id":41,"ws":true},{"text":"GSC11","start":270,"end":275,"id":42,"ws":true},{"text":"brain","start":276,"end":281,"id":43,"ws":true},{"text":"tumor","start":282,"end":287,"id":44,"ws":true},{"text":".","start":288,"end":289,"id":45,"ws":false}],"spans":[{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":29,"end":38,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26861698/","_input_hash":-2015905784,"_task_hash":-127037352,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":29,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In the first trial , paclitaxel and doxorubicin were alternated every 3 weeks in doses of 200 mg/m2 and 75 mg/m2 , respectively , for patients who had received no more than one prior chemotherapeutic regimen .","paragraph":"<h3><u>Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.</u></h3><b style='color:Tomato;'><i>paclitaxel</i></b> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), the first taxane to enter routine clinical practice, has aroused considerable interest due to its novel mechanism of action and its significant activity in metastatic breast cancer. Given this activity, it seemed logical to attempt to combine <b style='color:Tomato;'><i>paclitaxel</i></b> with <b style='color:Tomato;'><i>doxorubicin</i></b>, the other most active single agent in metastatic breast cancer. The Eastern Cooperative Oncology Group performed two trials investigating <b style='color:Tomato;'><i>paclitaxel</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b> combinations in patients with advanced breast cancer in an attempt to identify a tolerable dose and schedule of the combination. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>alternated</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>chemotherapeutic</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Therapy was well tolerated in this setting. At these doses, <b style='color:Tomato;'><i>paclitaxel</i></b> induced more granulocytopenia and less thrombocytopenia than did <b style='color:Tomato;'><i>doxorubicin</i></b>. Objective responses (complete and partial responses) were seen in seven of 12 patients; two other patients had improved disease (relief of pain in bony metastases). A second limited-institution Eastern Cooperative Oncology Group trial evaluated <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b> given in combination. In this phase I trial, <b style='color:Tomato;'><i>doxorubicin</i></b> was given as an intravenous push and <b style='color:Tomato;'><i>paclitaxel</i></b> as a 24-hour continuous infusion. The sequence of drug administration (D-->P or P-->D) was alternated both between and within patients, so that we might evaluate the effect of administration schedule on toxicity. Therapy was begun at an initial <b style='color:Tomato;'><i>paclitaxel</i></b> dose of 150 mg/m2 and an initial <b style='color:Tomato;'><i>doxorubicin</i></b> dose of 50 mg/m2 in six patients, with a subsequent six patients receiving 175 and 60 mg/m2, respectively, of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>doxorubicin</i></b>. In addition, patients received granulocyte colony-stimulating factor 5 micrograms/kg/d. While therapy at the initial dose level was well tolerated, dose-limiting mucositis was seen at the second dose level, although only when <b style='color:Tomato;'><i>paclitaxel</i></b> preceded <b style='color:Tomato;'><i>doxorubicin</i></b>. This suggests that sequence of drug administration in <b style='color:Tomato;'><i>paclitaxel</i></b>-based regimens may play an important role as a determinant of toxicity and (perhaps) efficacy, a finding similar to that seen when <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b> were combined in patients with ovarian cancer. Based on this study, we identified the sequence of <b style='color:Tomato;'><i>doxorubicin</i></b> (50 mg/m2) followed by <b style='color:Tomato;'><i>paclitaxel</i></b> (150 mg/m2) to be the maximum tolerated dose. This combination is currently being compared with <b style='color:Tomato;'><i>paclitaxel</i></b> alone and <b style='color:Tomato;'><i>doxorubicin</i></b> alone in patients with advanced breast cancer in an intergroup trial led by the Eastern Cooperative Oncology Group.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"first","start":7,"end":12,"id":2,"ws":true},{"text":"trial","start":13,"end":18,"id":3,"ws":true},{"text":",","start":19,"end":20,"id":4,"ws":true},{"text":"paclitaxel","start":21,"end":31,"id":5,"ws":true},{"text":"and","start":32,"end":35,"id":6,"ws":true},{"text":"doxorubicin","start":36,"end":47,"id":7,"ws":true},{"text":"were","start":48,"end":52,"id":8,"ws":true},{"text":"alternated","start":53,"end":63,"id":9,"ws":true},{"text":"every","start":64,"end":69,"id":10,"ws":true},{"text":"3","start":70,"end":71,"id":11,"ws":true},{"text":"weeks","start":72,"end":77,"id":12,"ws":true},{"text":"in","start":78,"end":80,"id":13,"ws":true},{"text":"doses","start":81,"end":86,"id":14,"ws":true},{"text":"of","start":87,"end":89,"id":15,"ws":true},{"text":"200","start":90,"end":93,"id":16,"ws":true},{"text":"mg/m2","start":94,"end":99,"id":17,"ws":true},{"text":"and","start":100,"end":103,"id":18,"ws":true},{"text":"75","start":104,"end":106,"id":19,"ws":true},{"text":"mg/m2","start":107,"end":112,"id":20,"ws":true},{"text":",","start":113,"end":114,"id":21,"ws":true},{"text":"respectively","start":115,"end":127,"id":22,"ws":true},{"text":",","start":128,"end":129,"id":23,"ws":true},{"text":"for","start":130,"end":133,"id":24,"ws":true},{"text":"patients","start":134,"end":142,"id":25,"ws":true},{"text":"who","start":143,"end":146,"id":26,"ws":true},{"text":"had","start":147,"end":150,"id":27,"ws":true},{"text":"received","start":151,"end":159,"id":28,"ws":true},{"text":"no","start":160,"end":162,"id":29,"ws":true},{"text":"more","start":163,"end":167,"id":30,"ws":true},{"text":"than","start":168,"end":172,"id":31,"ws":true},{"text":"one","start":173,"end":176,"id":32,"ws":true},{"text":"prior","start":177,"end":182,"id":33,"ws":true},{"text":"chemotherapeutic","start":183,"end":199,"id":34,"ws":true},{"text":"regimen","start":200,"end":207,"id":35,"ws":true},{"text":".","start":208,"end":209,"id":36,"ws":false}],"spans":[{"start":21,"end":31,"token_start":5,"token_end":5,"label":"DRUG"},{"start":36,"end":47,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7939756/","_input_hash":453768740,"_task_hash":669278767,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":21,"end":31,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":36,"end":47,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Thirty-one patients with histologically proven small cell lung cancer were treated with cyclophosphamide 1 g m-2 and etoposide ( VP16 - 213 ) 125 mg m-2 both intravenously on day 1 followed by etoposide 250 mg m-2 orally on days 2 - 3 for a maximum of six courses at 3 weekly intervals .","paragraph":"<h3><u>Combination cyclophosphamide and etoposide in treatment of small cell lung cancer.</u></h3> <b style='color:DodgerBlue;'><i>Thirty-one</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>histologically</i></b> <b style='color:DodgerBlue;'><i>proven</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>g</i></b> <b style='color:DodgerBlue;'><i>m-2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VP16</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>213</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>125</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>m-2</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>250</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>m-2</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>courses</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Fourteen patients had limited and 17 patients had extensive disease. Twenty-five patients were evaluable for response. Objective response was observed in 18 patients (58%) with 6 (19%) complete and 12 (39%) partial responses. Median survival of the entire group of patients was 30 weeks. There was significant survival benefit among the responders (P less than 0.005) when compared with non-responders. One patient (3.3%) developed grade 4 while 60% of patients developed grade 1-2 haematological toxicity. Other side effects were relatively mild. We conclude that combination <b style='color:Tomato;'><i>cyclophosphamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b> was active in small cell lung cancer and relatively well tolerated.","tokens":[{"text":"Thirty-one","start":0,"end":10,"id":0,"ws":true},{"text":"patients","start":11,"end":19,"id":1,"ws":true},{"text":"with","start":20,"end":24,"id":2,"ws":true},{"text":"histologically","start":25,"end":39,"id":3,"ws":true},{"text":"proven","start":40,"end":46,"id":4,"ws":true},{"text":"small","start":47,"end":52,"id":5,"ws":true},{"text":"cell","start":53,"end":57,"id":6,"ws":true},{"text":"lung","start":58,"end":62,"id":7,"ws":true},{"text":"cancer","start":63,"end":69,"id":8,"ws":true},{"text":"were","start":70,"end":74,"id":9,"ws":true},{"text":"treated","start":75,"end":82,"id":10,"ws":true},{"text":"with","start":83,"end":87,"id":11,"ws":true},{"text":"cyclophosphamide","start":88,"end":104,"id":12,"ws":true},{"text":"1","start":105,"end":106,"id":13,"ws":true},{"text":"g","start":107,"end":108,"id":14,"ws":true},{"text":"m-2","start":109,"end":112,"id":15,"ws":true},{"text":"and","start":113,"end":116,"id":16,"ws":true},{"text":"etoposide","start":117,"end":126,"id":17,"ws":true},{"text":"(","start":127,"end":128,"id":18,"ws":true},{"text":"VP16","start":129,"end":133,"id":19,"ws":true},{"text":"-","start":134,"end":135,"id":20,"ws":true},{"text":"213","start":136,"end":139,"id":21,"ws":true},{"text":")","start":140,"end":141,"id":22,"ws":true},{"text":"125","start":142,"end":145,"id":23,"ws":true},{"text":"mg","start":146,"end":148,"id":24,"ws":true},{"text":"m-2","start":149,"end":152,"id":25,"ws":true},{"text":"both","start":153,"end":157,"id":26,"ws":true},{"text":"intravenously","start":158,"end":171,"id":27,"ws":true},{"text":"on","start":172,"end":174,"id":28,"ws":true},{"text":"day","start":175,"end":178,"id":29,"ws":true},{"text":"1","start":179,"end":180,"id":30,"ws":true},{"text":"followed","start":181,"end":189,"id":31,"ws":true},{"text":"by","start":190,"end":192,"id":32,"ws":true},{"text":"etoposide","start":193,"end":202,"id":33,"ws":true},{"text":"250","start":203,"end":206,"id":34,"ws":true},{"text":"mg","start":207,"end":209,"id":35,"ws":true},{"text":"m-2","start":210,"end":213,"id":36,"ws":true},{"text":"orally","start":214,"end":220,"id":37,"ws":true},{"text":"on","start":221,"end":223,"id":38,"ws":true},{"text":"days","start":224,"end":228,"id":39,"ws":true},{"text":"2","start":229,"end":230,"id":40,"ws":true},{"text":"-","start":231,"end":232,"id":41,"ws":true},{"text":"3","start":233,"end":234,"id":42,"ws":true},{"text":"for","start":235,"end":238,"id":43,"ws":true},{"text":"a","start":239,"end":240,"id":44,"ws":true},{"text":"maximum","start":241,"end":248,"id":45,"ws":true},{"text":"of","start":249,"end":251,"id":46,"ws":true},{"text":"six","start":252,"end":255,"id":47,"ws":true},{"text":"courses","start":256,"end":263,"id":48,"ws":true},{"text":"at","start":264,"end":266,"id":49,"ws":true},{"text":"3","start":267,"end":268,"id":50,"ws":true},{"text":"weekly","start":269,"end":275,"id":51,"ws":true},{"text":"intervals","start":276,"end":285,"id":52,"ws":true},{"text":".","start":286,"end":287,"id":53,"ws":false}],"spans":[{"start":88,"end":104,"token_start":12,"token_end":12,"label":"DRUG"},{"start":117,"end":126,"token_start":17,"token_end":17,"label":"DRUG"},{"start":193,"end":202,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2160034/","_input_hash":-665126207,"_task_hash":598669028,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":17,"child":12,"head_span":{"start":117,"end":126,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":88,"end":104,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Pemetrexed plus carboplatin followed by pemetrexed , docetaxel , atezolizumab and S-1 were performed in sequence .","paragraph":"<h3><u>Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.</u></h3>In non-small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR-tyrosine kinase inhibitors. <b style='color:Tomato;'><i>afatinib</i></b>, a second-generation EGFR-tyrosine kinase inhibitor, has been shown to be effective in patients with uncommon mutations. <b style='color:Tomato;'><i>dacomitinib</i></b>, another second-generation EGFR-tyrosine kinase inhibitor, has not previously been shown to be effective in patients with uncommon mutations. Here, we report the efficacy of <b style='color:Tomato;'><i>dacomitinib</i></b> for uncommon EGFR mutations in a 71-year-old woman diagnosed with metastatic lung adenocarcinoma with uncommon EGFR mutation (Ex18 G719A). <b style='color:Tomato;'><i>afatinib</i></b> was administered as the first-line treatment, and a remarkable antitumor effect was observed. However, the tumor grew after 14\u2009months. <b style='color:MediumOrchid;'><i>Pemetrexed</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>atezolizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>S-1</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>sequence</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Although approximately four years had passed since the start of treatment, her physical condition was good. The patient started <b style='color:Tomato;'><i>dacomitinib</i></b> as the sixth-line treatment. Lesions were markedly reduced and treatment with <b style='color:Tomato;'><i>dacomitinib</i></b> was continued for 7.8 months. <b style='color:Tomato;'><i>dacomitinib</i></b> is a possible treatment option for NSCLC with uncommon mutations.","tokens":[{"text":"Pemetrexed","start":0,"end":10,"id":0,"ws":true},{"text":"plus","start":11,"end":15,"id":1,"ws":true},{"text":"carboplatin","start":16,"end":27,"id":2,"ws":true},{"text":"followed","start":28,"end":36,"id":3,"ws":true},{"text":"by","start":37,"end":39,"id":4,"ws":true},{"text":"pemetrexed","start":40,"end":50,"id":5,"ws":true},{"text":",","start":51,"end":52,"id":6,"ws":true},{"text":"docetaxel","start":53,"end":62,"id":7,"ws":true},{"text":",","start":63,"end":64,"id":8,"ws":true},{"text":"atezolizumab","start":65,"end":77,"id":9,"ws":true},{"text":"and","start":78,"end":81,"id":10,"ws":true},{"text":"S-1","start":82,"end":85,"id":11,"ws":true},{"text":"were","start":86,"end":90,"id":12,"ws":true},{"text":"performed","start":91,"end":100,"id":13,"ws":true},{"text":"in","start":101,"end":103,"id":14,"ws":true},{"text":"sequence","start":104,"end":112,"id":15,"ws":true},{"text":".","start":113,"end":114,"id":16,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":40,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},{"start":53,"end":62,"token_start":7,"token_end":7,"label":"DRUG"},{"start":65,"end":77,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33651475/","_input_hash":-2006697010,"_task_hash":203791512,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":2,"child":0,"head_span":{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":2,"head_span":{"start":40,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":7,"child":2,"head_span":{"start":53,"end":62,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":2,"head_span":{"start":65,"end":77,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The initial response ( IR ) was sustained for a mean ( s.d . ) of 309 ( 244 ) days with vildagliptin versus 270 ( 223 ) days for glimepiride ( p < 0.001 ) ( IR = nadir HbA1c where change from baseline > or = 0.5 % or HbA1c < or = 6.5 % within the first six months of treatment .","paragraph":"<h3><u>Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.</u></h3>To show that <b style='color:Tomato;'><i>vildagliptin</i></b> added to <b style='color:Tomato;'><i>metformin</i></b> is non-inferior to <b style='color:Tomato;'><i>glimepiride</i></b> in reducing HbA1c levels from baseline over 2 years. ### methods A randomized, double-blind, active-comparator study of patients with type 2 diabetes mellitus inadequately controlled (HbA1c 6.5-8.5%) by <b style='color:Tomato;'><i>metformin</i></b> monotherapy. Patients received <b style='color:Tomato;'><i>vildagliptin</i></b> (50 mg twice daily) or <b style='color:Tomato;'><i>glimepiride</i></b> (up to 6 mg/day) added to <b style='color:Tomato;'><i>metformin</i></b>. ### results In all, 3118 patients were randomized (<b style='color:Tomato;'><i>vildagliptin</i></b>, n = 1562; <b style='color:Tomato;'><i>glimepiride</i></b>, n = 1556). From similar baseline values (7.3%), after 2 years adjusted mean (s.e.) change in HbA1c was comparable between <b style='color:Tomato;'><i>vildagliptin</i></b> and <b style='color:Tomato;'><i>glimepiride</i></b> treatment: -0.1% (0.0%) and -0.1% (0.0%), respectively. The primary objective of non-inferiority was met. A similar proportion of patients reached HbA1c <7% (36.9 and 38.3%, respectively), but with <b style='color:Tomato;'><i>vildagliptin</i></b> more patients reached this target without hypoglycaemia (36.0% vs. 28.8%; p = 0.004). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>sustained</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>s.d</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>309</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>244</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vildagliptin</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:DodgerBlue;'><i>270</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>223</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>glimepiride</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>IR</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>nadir</i></b> <b style='color:DodgerBlue;'><i>HbA1c</i></b> <b style='color:DodgerBlue;'><i>where</i></b> <b style='color:DodgerBlue;'><i>change</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>></i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>0.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>HbA1c</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>6.5</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>within</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After IR was detected, sustained response = time between nadir and an increase of >0.3% above IR). Independent of disease duration, age was a predictor of effect sustainability. Fewer patients experienced hypoglycaemia with <b style='color:Tomato;'><i>vildagliptin</i></b> (2.3% vs. 18.2% with <b style='color:Tomato;'><i>glimepiride</i></b>) with a 14-fold difference in the number of hypoglycaemic events (59 vs. 838). <b style='color:Tomato;'><i>vildagliptin</i></b> had a beneficial effect on body weight [mean (s.e.) change from baseline -0.3 (0.1) kg; between-group difference -1.5 kg; p < 0.001]. Overall, both treatments were well tolerated and displayed similar safety profiles. ### conclusions <b style='color:Tomato;'><i>vildagliptin</i></b> add-on has similar efficacy to <b style='color:Tomato;'><i>glimepiride</i></b> after 2 years' treatment, with markedly reduced hypoglycaemia risk and no weight gain.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"initial","start":4,"end":11,"id":1,"ws":true},{"text":"response","start":12,"end":20,"id":2,"ws":true},{"text":"(","start":21,"end":22,"id":3,"ws":true},{"text":"IR","start":23,"end":25,"id":4,"ws":true},{"text":")","start":26,"end":27,"id":5,"ws":true},{"text":"was","start":28,"end":31,"id":6,"ws":true},{"text":"sustained","start":32,"end":41,"id":7,"ws":true},{"text":"for","start":42,"end":45,"id":8,"ws":true},{"text":"a","start":46,"end":47,"id":9,"ws":true},{"text":"mean","start":48,"end":52,"id":10,"ws":true},{"text":"(","start":53,"end":54,"id":11,"ws":true},{"text":"s.d","start":55,"end":58,"id":12,"ws":true},{"text":".","start":59,"end":60,"id":13,"ws":true},{"text":")","start":61,"end":62,"id":14,"ws":true},{"text":"of","start":63,"end":65,"id":15,"ws":true},{"text":"309","start":66,"end":69,"id":16,"ws":true},{"text":"(","start":70,"end":71,"id":17,"ws":true},{"text":"244","start":72,"end":75,"id":18,"ws":true},{"text":")","start":76,"end":77,"id":19,"ws":true},{"text":"days","start":78,"end":82,"id":20,"ws":true},{"text":"with","start":83,"end":87,"id":21,"ws":true},{"text":"vildagliptin","start":88,"end":100,"id":22,"ws":true},{"text":"versus","start":101,"end":107,"id":23,"ws":true},{"text":"270","start":108,"end":111,"id":24,"ws":true},{"text":"(","start":112,"end":113,"id":25,"ws":true},{"text":"223","start":114,"end":117,"id":26,"ws":true},{"text":")","start":118,"end":119,"id":27,"ws":true},{"text":"days","start":120,"end":124,"id":28,"ws":true},{"text":"for","start":125,"end":128,"id":29,"ws":true},{"text":"glimepiride","start":129,"end":140,"id":30,"ws":true},{"text":"(","start":141,"end":142,"id":31,"ws":true},{"text":"p","start":143,"end":144,"id":32,"ws":true},{"text":"<","start":145,"end":146,"id":33,"ws":true},{"text":"0.001","start":147,"end":152,"id":34,"ws":true},{"text":")","start":153,"end":154,"id":35,"ws":true},{"text":"(","start":155,"end":156,"id":36,"ws":true},{"text":"IR","start":157,"end":159,"id":37,"ws":true},{"text":"=","start":160,"end":161,"id":38,"ws":true},{"text":"nadir","start":162,"end":167,"id":39,"ws":true},{"text":"HbA1c","start":168,"end":173,"id":40,"ws":true},{"text":"where","start":174,"end":179,"id":41,"ws":true},{"text":"change","start":180,"end":186,"id":42,"ws":true},{"text":"from","start":187,"end":191,"id":43,"ws":true},{"text":"baseline","start":192,"end":200,"id":44,"ws":true},{"text":">","start":201,"end":202,"id":45,"ws":true},{"text":"or","start":203,"end":205,"id":46,"ws":true},{"text":"=","start":206,"end":207,"id":47,"ws":true},{"text":"0.5","start":208,"end":211,"id":48,"ws":true},{"text":"%","start":212,"end":213,"id":49,"ws":true},{"text":"or","start":214,"end":216,"id":50,"ws":true},{"text":"HbA1c","start":217,"end":222,"id":51,"ws":true},{"text":"<","start":223,"end":224,"id":52,"ws":true},{"text":"or","start":225,"end":227,"id":53,"ws":true},{"text":"=","start":228,"end":229,"id":54,"ws":true},{"text":"6.5","start":230,"end":233,"id":55,"ws":true},{"text":"%","start":234,"end":235,"id":56,"ws":true},{"text":"within","start":236,"end":242,"id":57,"ws":true},{"text":"the","start":243,"end":246,"id":58,"ws":true},{"text":"first","start":247,"end":252,"id":59,"ws":true},{"text":"six","start":253,"end":256,"id":60,"ws":true},{"text":"months","start":257,"end":263,"id":61,"ws":true},{"text":"of","start":264,"end":266,"id":62,"ws":true},{"text":"treatment","start":267,"end":276,"id":63,"ws":true},{"text":".","start":277,"end":278,"id":64,"ws":false}],"spans":[{"start":88,"end":100,"token_start":22,"token_end":22,"label":"DRUG"},{"start":129,"end":140,"token_start":30,"token_end":30,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20649630/","_input_hash":-1877299602,"_task_hash":-171138069,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The aim of this phase I study was to determine the maximum tolerated dose of a 3-h infusion of paclitaxel , combined with carboplatin at a fixed AUC of 7 mg ml-1 min every 4 weeks for up to six cycles and to evaluate any possible pharmacokinetic interaction .","paragraph":"<h3><u>A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>maximum</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>3-h</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>fixed</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>ml-1</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>possible</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twelve chemonaive patients with ovarian cancer were treated with <b style='color:Tomato;'><i>paclitaxel</i></b> followed by a 30-min infusion of <b style='color:Tomato;'><i>carboplatin</i></b>. <b style='color:Tomato;'><i>paclitaxel</i></b> dose was escalated from 150 mg m-2 to 225 mg m-2 in cohorts of three patients. <b style='color:Tomato;'><i>carboplatin</i></b> dose was based on renal function. Pharmacokinetic studies were performed in nine patients (at least two at each dose level). A total of 66 courses were evaluable for assessment. Grade 3 or 4 neutropenia was seen in 70% of the courses, however hospitalization was not required. Grade 3 or 4 thrombocytopenia occurred in 24% of the courses. Alopecia, myalgia and peripheral neuropathy were common but rarely severe. The pharmacokinetics of <b style='color:Tomato;'><i>paclitaxel</i></b> was non-linear and did not appear to be influenced by co-administration of <b style='color:Tomato;'><i>carboplatin</i></b>. The AUC of <b style='color:Tomato;'><i>carboplatin</i></b> was 7.0 +/- 1.4 mg ml-1 min, indicating that there was no pharmacokinetic interaction. The combination of <b style='color:Tomato;'><i>carboplatin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> may be administered as first-line treatment for advanced ovarian cancer. Although myelosuppression is the dose-limiting toxicity of the component drugs, the severity of thrombocytopenia was less than anticipated. The results of this study, with only a small number of patients, need to be confirmed in future investigations.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"this","start":11,"end":15,"id":3,"ws":true},{"text":"phase","start":16,"end":21,"id":4,"ws":true},{"text":"I","start":22,"end":23,"id":5,"ws":true},{"text":"study","start":24,"end":29,"id":6,"ws":true},{"text":"was","start":30,"end":33,"id":7,"ws":true},{"text":"to","start":34,"end":36,"id":8,"ws":true},{"text":"determine","start":37,"end":46,"id":9,"ws":true},{"text":"the","start":47,"end":50,"id":10,"ws":true},{"text":"maximum","start":51,"end":58,"id":11,"ws":true},{"text":"tolerated","start":59,"end":68,"id":12,"ws":true},{"text":"dose","start":69,"end":73,"id":13,"ws":true},{"text":"of","start":74,"end":76,"id":14,"ws":true},{"text":"a","start":77,"end":78,"id":15,"ws":true},{"text":"3-h","start":79,"end":82,"id":16,"ws":true},{"text":"infusion","start":83,"end":91,"id":17,"ws":true},{"text":"of","start":92,"end":94,"id":18,"ws":true},{"text":"paclitaxel","start":95,"end":105,"id":19,"ws":true},{"text":",","start":106,"end":107,"id":20,"ws":true},{"text":"combined","start":108,"end":116,"id":21,"ws":true},{"text":"with","start":117,"end":121,"id":22,"ws":true},{"text":"carboplatin","start":122,"end":133,"id":23,"ws":true},{"text":"at","start":134,"end":136,"id":24,"ws":true},{"text":"a","start":137,"end":138,"id":25,"ws":true},{"text":"fixed","start":139,"end":144,"id":26,"ws":true},{"text":"AUC","start":145,"end":148,"id":27,"ws":true},{"text":"of","start":149,"end":151,"id":28,"ws":true},{"text":"7","start":152,"end":153,"id":29,"ws":true},{"text":"mg","start":154,"end":156,"id":30,"ws":true},{"text":"ml-1","start":157,"end":161,"id":31,"ws":true},{"text":"min","start":162,"end":165,"id":32,"ws":true},{"text":"every","start":166,"end":171,"id":33,"ws":true},{"text":"4","start":172,"end":173,"id":34,"ws":true},{"text":"weeks","start":174,"end":179,"id":35,"ws":true},{"text":"for","start":180,"end":183,"id":36,"ws":true},{"text":"up","start":184,"end":186,"id":37,"ws":true},{"text":"to","start":187,"end":189,"id":38,"ws":true},{"text":"six","start":190,"end":193,"id":39,"ws":true},{"text":"cycles","start":194,"end":200,"id":40,"ws":true},{"text":"and","start":201,"end":204,"id":41,"ws":true},{"text":"to","start":205,"end":207,"id":42,"ws":true},{"text":"evaluate","start":208,"end":216,"id":43,"ws":true},{"text":"any","start":217,"end":220,"id":44,"ws":true},{"text":"possible","start":221,"end":229,"id":45,"ws":true},{"text":"pharmacokinetic","start":230,"end":245,"id":46,"ws":true},{"text":"interaction","start":246,"end":257,"id":47,"ws":true},{"text":".","start":258,"end":259,"id":48,"ws":false}],"spans":[{"start":95,"end":105,"token_start":19,"token_end":19,"label":"DRUG"},{"start":122,"end":133,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9010040/","_input_hash":-1442875809,"_task_hash":1218200973,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":23,"child":19,"head_span":{"start":122,"end":133,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":95,"end":105,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Efficacy of tramadol in combination with doxepin or venlafaxine in inhibition of nociceptive process in the rat model of neuropathic pain : an isobolographic analysis .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tramadol</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>doxepin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>venlafaxine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>nociceptive</i></b> <b style='color:DodgerBlue;'><i>process</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>neuropathic</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>isobolographic</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Neuropathic pain constitutes a serious therapeutic problem. In most cases polytherapy is necessary. <b style='color:Tomato;'><i>tramadol</i></b> and antidepressants have common mechanisms of action and are frequently used together in clinical practice, thus interaction between them is very important. In the present study isobolographic analysis for equivalent doses of drugs was applied to examine the nature of interaction between <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> or <b style='color:Tomato;'><i>venlafaxine</i></b> in a neuropathic pain model in rats. Allodynia and hyperalgesia were assessed after intraperitoneal administration of each drug alone or in combination. Dose response curves were obtained and ED(50) doses were calculated. All drugs were effective in reducing thermal hyperalgesia and mechanical allodynia, however <b style='color:Tomato;'><i>doxepin</i></b> was more effective than <b style='color:Tomato;'><i>venlafaxine</i></b>. Combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> demonstrated synergistic action in reducing thermal hyperalgesia and additive action in reducing mechanical allodynia. Combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>venlafaxine</i></b> showed additive action in reducing hyperalgesia and allodynia. Moreover, combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> was more effective than combined administration of <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>venlafaxine</i></b>. The experiments demonstrated that the nature of interaction between <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>doxepin</i></b> is synergistic, which is not the case for <b style='color:Tomato;'><i>tramadol</i></b> and <b style='color:Tomato;'><i>venlafaxine</i></b>, what provides a valuable information referring to clinical practice, rationalizing administration of such drug combination.","tokens":[{"text":"Efficacy","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"tramadol","start":12,"end":20,"id":2,"ws":true},{"text":"in","start":21,"end":23,"id":3,"ws":true},{"text":"combination","start":24,"end":35,"id":4,"ws":true},{"text":"with","start":36,"end":40,"id":5,"ws":true},{"text":"doxepin","start":41,"end":48,"id":6,"ws":true},{"text":"or","start":49,"end":51,"id":7,"ws":true},{"text":"venlafaxine","start":52,"end":63,"id":8,"ws":true},{"text":"in","start":64,"end":66,"id":9,"ws":true},{"text":"inhibition","start":67,"end":77,"id":10,"ws":true},{"text":"of","start":78,"end":80,"id":11,"ws":true},{"text":"nociceptive","start":81,"end":92,"id":12,"ws":true},{"text":"process","start":93,"end":100,"id":13,"ws":true},{"text":"in","start":101,"end":103,"id":14,"ws":true},{"text":"the","start":104,"end":107,"id":15,"ws":true},{"text":"rat","start":108,"end":111,"id":16,"ws":true},{"text":"model","start":112,"end":117,"id":17,"ws":true},{"text":"of","start":118,"end":120,"id":18,"ws":true},{"text":"neuropathic","start":121,"end":132,"id":19,"ws":true},{"text":"pain","start":133,"end":137,"id":20,"ws":true},{"text":":","start":138,"end":139,"id":21,"ws":true},{"text":"an","start":140,"end":142,"id":22,"ws":true},{"text":"isobolographic","start":143,"end":157,"id":23,"ws":true},{"text":"analysis","start":158,"end":166,"id":24,"ws":true},{"text":".","start":167,"end":168,"id":25,"ws":false}],"spans":[{"start":12,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},{"start":41,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":52,"end":63,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20065499/","_input_hash":-922832735,"_task_hash":-1117305017,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":2,"child":6,"head_span":{"start":12,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":41,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":2,"child":8,"head_span":{"start":12,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":52,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"All those treated with mefloquine plus artemether survived and their parasite clearance time and fever clearance time were significantly shorter than those of patients receiving quinine .","paragraph":"<h3><u>The effect of mefloquine-artemether compared with quinine on patients with complicated falciparum malaria.</u></h3>30 pairs of patients with complicated Plasmodium falciparum malaria (with anaemia, hyperpyrexia, jaundice or more than 5% of erythrocytes parasitized) were studied. Patients with cerebral signs and symptoms were excluded. One group of patients was treated with oral <b style='color:Tomato;'><i>mefloquine</i></b> (750 mg) and <b style='color:Tomato;'><i>artemether</i></b> (600 mg by injection, 200 mg initially and 100 mg every 12 h). The second group of patients was treated with <b style='color:Tomato;'><i>quinine</i></b> (10 mg/kg orally every 8 h for 7 d). All patients were admitted to hospital for 7 d and examined subsequently on days 14, 21 and 28. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>mefloquine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>artemether</i></b> <b style='color:DodgerBlue;'><i>survived</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>parasite</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>fever</i></b> <b style='color:DodgerBlue;'><i>clearance</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>shorter</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>quinine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> 2 patients treated with <b style='color:Tomato;'><i>quinine</i></b> died. There was no recrudescence in any patient of either group.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"those","start":4,"end":9,"id":1,"ws":true},{"text":"treated","start":10,"end":17,"id":2,"ws":true},{"text":"with","start":18,"end":22,"id":3,"ws":true},{"text":"mefloquine","start":23,"end":33,"id":4,"ws":true},{"text":"plus","start":34,"end":38,"id":5,"ws":true},{"text":"artemether","start":39,"end":49,"id":6,"ws":true},{"text":"survived","start":50,"end":58,"id":7,"ws":true},{"text":"and","start":59,"end":62,"id":8,"ws":true},{"text":"their","start":63,"end":68,"id":9,"ws":true},{"text":"parasite","start":69,"end":77,"id":10,"ws":true},{"text":"clearance","start":78,"end":87,"id":11,"ws":true},{"text":"time","start":88,"end":92,"id":12,"ws":true},{"text":"and","start":93,"end":96,"id":13,"ws":true},{"text":"fever","start":97,"end":102,"id":14,"ws":true},{"text":"clearance","start":103,"end":112,"id":15,"ws":true},{"text":"time","start":113,"end":117,"id":16,"ws":true},{"text":"were","start":118,"end":122,"id":17,"ws":true},{"text":"significantly","start":123,"end":136,"id":18,"ws":true},{"text":"shorter","start":137,"end":144,"id":19,"ws":true},{"text":"than","start":145,"end":149,"id":20,"ws":true},{"text":"those","start":150,"end":155,"id":21,"ws":true},{"text":"of","start":156,"end":158,"id":22,"ws":true},{"text":"patients","start":159,"end":167,"id":23,"ws":true},{"text":"receiving","start":168,"end":177,"id":24,"ws":true},{"text":"quinine","start":178,"end":185,"id":25,"ws":true},{"text":".","start":186,"end":187,"id":26,"ws":false}],"spans":[{"start":23,"end":33,"token_start":4,"token_end":4,"label":"DRUG"},{"start":39,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},{"start":178,"end":185,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3075350/","_input_hash":-2408159,"_task_hash":779874448,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":23,"end":33,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":39,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"Currently available adrenal steroidogenesis inhibitors , including ketoconazole , metyrapone , etomidate , and mitotane , have variable efficacy and significant side effects , and none are approved by the US Food and Drug Administration for CS .","paragraph":"<h3><u>Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.</u></h3>Endogenous Cushing's syndrome (CS) is a rare disease that results from exposure to high levels of cortisol; Cushing's disease (CD) is the most frequent form of CS. Patients with CS suffer from a variety of comorbidities that increase the risk of mortality. Surgical resection of the disease-causing lesion is generally the first-line treatment of CS. However, some patients may not be eligible for surgery due to comorbidities, and approximately 25\u00a0% of patients, especially those with CD, have recurrent disease. For these patients, adrenal steroidogenesis inhibitors may control cortisol elevation and subsequent symptomatology. CS is rare overall, and clinical studies of adrenal steroidogenesis inhibitors are often small and, in many cases, data are limited regarding the efficacy and safety of these treatments. Our aim was to better characterize the profiles of efficacy and safety of currently available adrenal steroidogenesis inhibitors, including drugs currently in development. ### methods We performed a systematic review of the literature regarding adrenal steroidogenesis inhibitors, focusing on novel drugs. ### results <b style='color:DodgerBlue;'><i>Currently</i></b> <b style='color:DodgerBlue;'><i>available</i></b> <b style='color:DodgerBlue;'><i>adrenal</i></b> <b style='color:DodgerBlue;'><i>steroidogenesis</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>ketoconazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>metyrapone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>etomidate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>mitotane</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>variable</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>side</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>none</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>approved</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>US</i></b> <b style='color:DodgerBlue;'><i>Food</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>Administration</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>CS</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Therefore, there is a clear need for novel, prospectively studied agents that have greater efficacy and a low rate of adverse side effects. Efficacy and safety data of current and emerging adrenal steroidogenesis inhibitors, including osilodrostat (LCI699) and levo<b style='color:Tomato;'><i>ketoconazole</i></b> (COR-003), show promising results that will have to be confirmed in larger-scale phase 3 studies (currently ongoing). ### conclusions The management of CS, and particularly CD, remains challenging. Adrenal steroidogenesis inhibitors can be of major interest to control the hypercortisolism at any time point, either before or after surgery, as discussed in this review.","tokens":[{"text":"Currently","start":0,"end":9,"id":0,"ws":true},{"text":"available","start":10,"end":19,"id":1,"ws":true},{"text":"adrenal","start":20,"end":27,"id":2,"ws":true},{"text":"steroidogenesis","start":28,"end":43,"id":3,"ws":true},{"text":"inhibitors","start":44,"end":54,"id":4,"ws":true},{"text":",","start":55,"end":56,"id":5,"ws":true},{"text":"including","start":57,"end":66,"id":6,"ws":true},{"text":"ketoconazole","start":67,"end":79,"id":7,"ws":true},{"text":",","start":80,"end":81,"id":8,"ws":true},{"text":"metyrapone","start":82,"end":92,"id":9,"ws":true},{"text":",","start":93,"end":94,"id":10,"ws":true},{"text":"etomidate","start":95,"end":104,"id":11,"ws":true},{"text":",","start":105,"end":106,"id":12,"ws":true},{"text":"and","start":107,"end":110,"id":13,"ws":true},{"text":"mitotane","start":111,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"have","start":122,"end":126,"id":16,"ws":true},{"text":"variable","start":127,"end":135,"id":17,"ws":true},{"text":"efficacy","start":136,"end":144,"id":18,"ws":true},{"text":"and","start":145,"end":148,"id":19,"ws":true},{"text":"significant","start":149,"end":160,"id":20,"ws":true},{"text":"side","start":161,"end":165,"id":21,"ws":true},{"text":"effects","start":166,"end":173,"id":22,"ws":true},{"text":",","start":174,"end":175,"id":23,"ws":true},{"text":"and","start":176,"end":179,"id":24,"ws":true},{"text":"none","start":180,"end":184,"id":25,"ws":true},{"text":"are","start":185,"end":188,"id":26,"ws":true},{"text":"approved","start":189,"end":197,"id":27,"ws":true},{"text":"by","start":198,"end":200,"id":28,"ws":true},{"text":"the","start":201,"end":204,"id":29,"ws":true},{"text":"US","start":205,"end":207,"id":30,"ws":true},{"text":"Food","start":208,"end":212,"id":31,"ws":true},{"text":"and","start":213,"end":216,"id":32,"ws":true},{"text":"Drug","start":217,"end":221,"id":33,"ws":true},{"text":"Administration","start":222,"end":236,"id":34,"ws":true},{"text":"for","start":237,"end":240,"id":35,"ws":true},{"text":"CS","start":241,"end":243,"id":36,"ws":true},{"text":".","start":244,"end":245,"id":37,"ws":false}],"spans":[{"start":67,"end":79,"token_start":7,"token_end":7,"label":"DRUG"},{"start":82,"end":92,"token_start":9,"token_end":9,"label":"DRUG"},{"start":95,"end":104,"token_start":11,"token_end":11,"label":"DRUG"},{"start":111,"end":119,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27600150/","_input_hash":-132880978,"_task_hash":1756656753,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The differential effects of haloperidol and methamphetamine on time estimation in the rat .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>differential</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>haloperidol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>estimation</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Forty rats were trained to make a left lever response if a signal (white noise) was 2.5s and to make a right lever response if the signal was 6.3s. When seven intermediate signal durations, to which responses were not reinforced, were randomly interspersed the probability of a right-lever ('long') response increased as a function of signal duration. <b style='color:Tomato;'><i>methamphetamine</i></b> shifted this psychometric function leftward and decreased its slope: <b style='color:Tomato;'><i>haloperidol</i></b> also decreased the slope but shifted the function rightward. A combination of <b style='color:Tomato;'><i>haloperidol</i></b> and <b style='color:Tomato;'><i>methamphetamine</i></b> led to a function similar to the saline control function. The leftward shift probably reflects an increase in the speed of an internal clock, and the rightward shift probably reflects a decrease in its speed. Since <b style='color:Tomato;'><i>methamphetamine</i></b> releases several catecholamines, including dopamine, and <b style='color:Tomato;'><i>haloperidol</i></b> blocks dopamine receptors, it is plausible that the horizontal location of the psychometric function (the speed of the clock) is related to the effective level of dopamine.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"differential","start":4,"end":16,"id":1,"ws":true},{"text":"effects","start":17,"end":24,"id":2,"ws":true},{"text":"of","start":25,"end":27,"id":3,"ws":true},{"text":"haloperidol","start":28,"end":39,"id":4,"ws":true},{"text":"and","start":40,"end":43,"id":5,"ws":true},{"text":"methamphetamine","start":44,"end":59,"id":6,"ws":true},{"text":"on","start":60,"end":62,"id":7,"ws":true},{"text":"time","start":63,"end":67,"id":8,"ws":true},{"text":"estimation","start":68,"end":78,"id":9,"ws":true},{"text":"in","start":79,"end":81,"id":10,"ws":true},{"text":"the","start":82,"end":85,"id":11,"ws":true},{"text":"rat","start":86,"end":89,"id":12,"ws":true},{"text":".","start":90,"end":91,"id":13,"ws":false}],"spans":[{"start":28,"end":39,"token_start":4,"token_end":4,"label":"DRUG"},{"start":44,"end":59,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6403957/","_input_hash":-432926380,"_task_hash":169142185,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":28,"end":39,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":44,"end":59,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"In the present study , we evaluated the efficacy and safety of the weekly combination of etoposide , leucovorin ( LV ) and 5-fluorouracil ( 5-FU ) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer ( ACC ) , previously treated with weekly LV+5-FU .","paragraph":"<h3><u>Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer.</u></h3> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>LV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>relapsed/refractory</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ACC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:DodgerBlue;'><i>LV+5-FU</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>etoposide</i></b> was administered at 3 different dose levels (DLs), in 3 groups of 20 patients each (total: 60); DL-I: <b style='color:Tomato;'><i>etoposide</i></b> 80 mg/m2, DL-II: <b style='color:Tomato;'><i>etoposide</i></b> 120 mg/m2, and DL-III: <b style='color:Tomato;'><i>etoposide</i></b> 180 mg/m2, in 45 min i.v. infusion, and followed in all levels by LV 100 mg/m2 i.v. over 1 hour and 5-FU 500 mg/m2 i.v. bolus. Treatment was administered weekly until disease progression or unacceptable toxicity. No patients at DL-I responded, while 2 patients at DL-II and 3 at DL-III had a partial response (PR). Stable disease (SD) rates were as follows; at DL-I: 2, DL-II: 8 and DL-III: 9. More patients in DL-I progressed (n = 19) compared to DL-II (n=10) and DL-II (n = 8) (p < 0.0007). Time to progression was for DL-I, -II, -III: 17, 15, and 14 weeks, respectively. Median survival was DL-I, -II, -III: 30, 30, and 32.5 weeks, respectively. Toxicity consisted mainly of neutropenia, diarrhea and mucositis at all DLs, and was significantly more severe in DL-III. No difference was noted in responses between DL-II and DL-III. The authors conclude that the combination of <b style='color:Tomato;'><i>etoposide</i></b> with LV+5-FU has limited activity when administered after failure of weekly LV+5-FU in patients with ACC and should not be recommended for further evaluation.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"study","start":15,"end":20,"id":3,"ws":true},{"text":",","start":21,"end":22,"id":4,"ws":true},{"text":"we","start":23,"end":25,"id":5,"ws":true},{"text":"evaluated","start":26,"end":35,"id":6,"ws":true},{"text":"the","start":36,"end":39,"id":7,"ws":true},{"text":"efficacy","start":40,"end":48,"id":8,"ws":true},{"text":"and","start":49,"end":52,"id":9,"ws":true},{"text":"safety","start":53,"end":59,"id":10,"ws":true},{"text":"of","start":60,"end":62,"id":11,"ws":true},{"text":"the","start":63,"end":66,"id":12,"ws":true},{"text":"weekly","start":67,"end":73,"id":13,"ws":true},{"text":"combination","start":74,"end":85,"id":14,"ws":true},{"text":"of","start":86,"end":88,"id":15,"ws":true},{"text":"etoposide","start":89,"end":98,"id":16,"ws":true},{"text":",","start":99,"end":100,"id":17,"ws":true},{"text":"leucovorin","start":101,"end":111,"id":18,"ws":true},{"text":"(","start":112,"end":113,"id":19,"ws":true},{"text":"LV","start":114,"end":116,"id":20,"ws":true},{"text":")","start":117,"end":118,"id":21,"ws":true},{"text":"and","start":119,"end":122,"id":22,"ws":true},{"text":"5-fluorouracil","start":123,"end":137,"id":23,"ws":true},{"text":"(","start":138,"end":139,"id":24,"ws":true},{"text":"5-FU","start":140,"end":144,"id":25,"ws":true},{"text":")","start":145,"end":146,"id":26,"ws":true},{"text":"when","start":147,"end":151,"id":27,"ws":true},{"text":"administered","start":152,"end":164,"id":28,"ws":true},{"text":"as","start":165,"end":167,"id":29,"ws":true},{"text":"second-line","start":168,"end":179,"id":30,"ws":true},{"text":"chemotherapy","start":180,"end":192,"id":31,"ws":true},{"text":"in","start":193,"end":195,"id":32,"ws":true},{"text":"patients","start":196,"end":204,"id":33,"ws":true},{"text":"with","start":205,"end":209,"id":34,"ws":true},{"text":"relapsed/refractory","start":210,"end":229,"id":35,"ws":true},{"text":"advanced","start":230,"end":238,"id":36,"ws":true},{"text":"colorectal","start":239,"end":249,"id":37,"ws":true},{"text":"cancer","start":250,"end":256,"id":38,"ws":true},{"text":"(","start":257,"end":258,"id":39,"ws":true},{"text":"ACC","start":259,"end":262,"id":40,"ws":true},{"text":")","start":263,"end":264,"id":41,"ws":true},{"text":",","start":265,"end":266,"id":42,"ws":true},{"text":"previously","start":267,"end":277,"id":43,"ws":true},{"text":"treated","start":278,"end":285,"id":44,"ws":true},{"text":"with","start":286,"end":290,"id":45,"ws":true},{"text":"weekly","start":291,"end":297,"id":46,"ws":true},{"text":"LV+5-FU","start":298,"end":305,"id":47,"ws":true},{"text":".","start":306,"end":307,"id":48,"ws":false}],"spans":[{"start":89,"end":98,"token_start":16,"token_end":16,"label":"DRUG"},{"start":101,"end":111,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12420860/","_input_hash":19588298,"_task_hash":-577091587,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":16,"child":18,"head_span":{"start":89,"end":98,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":101,"end":111,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":18,"child":23,"head_span":{"start":101,"end":111,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":123,"end":137,"token_start":23,"token_end":23,"label":null},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Diazoxide , nifedipine and 2-deoxy glucose suppressed ( p < 0.05 ) glucose stimulated insulin secretion in AtT20HI-GLUT2-GK-6 cells .","paragraph":"<h3><u>Cellular characterization of pituitary adenoma cell line (AtT20 cell) transfected with insulin, glucose transporter type 2 (GLUT2) and glucokinase genes: insulin secretion in response to physiological concentrations of glucose.</u></h3>We investigated the mechanisms of insulin secretion by transfecting into a pituitary adenoma cell line (AtT20) a combination of genes encoding human insulin (HI), glucose transporter type 2 (GLUT2) and glucokinase (GK), followed by studying the characteristics of these cells. In static incubation, a cell line transfected with insulin gene alone (AtT20HI) secreted mature human insulin but this was not in a glucose-dependent manner. Other cell lines transfected with insulin and GLUT2 genes (AtT20HI-GLUT2-3) or with insulin and GK genes (AtT20HI-GK-1) secreted insulin in response to glucose concentrations of only less than 1 mmol/l. In contrast, cell lines transfected with insulin, GLUT2 and GK genes (AtT20HI-GLUT2-GK-6, AtT20HI-GLUT2-GK-7 and AtT20HI-GLUT2-GK-10) showed a glucose-dependent insulin secretion up to 25 mmol/l glucose. Glucose utilization and oxidation were increased in AtT20HI-GLUT2-GK cell lines but not in AtT20HI, AtT20HI-GLUT2-3 and AtT20HI-GK-1 cells at physiological glucose concentrations, compared with AtT20 cells. <b style='color:MediumOrchid;'><i>Diazoxide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nifedipine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2-deoxy</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>suppressed</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>stimulated</i></b> <b style='color:DodgerBlue;'><i>insulin</i></b> <b style='color:DodgerBlue;'><i>secretion</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>AtT20HI-GLUT2-GK-6</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Glibenclamide, KCl or <b style='color:Tomato;'><i>corticotropin</i></b> releasing factor (CRF) stimulated (p < 0.05) insulin secretion both in AtT20HI and AtT20HI-GLUT2-GK-6 cells. Insulin secretion stimulated by glibenclamide, KCl or CRF was further enhanced by the addition of 25 mmol/l glucose in AtT20HI-GLUT2-GK-6 cells but not in AtT20HI cells. In perifusion experiments, a stepwise increase in glucose concentration from 5 to 25 mmol/l stimulated insulin secretion in AtT20HI-GLUT2-GK cell lines but the response lacked a clear first phase of insulin secretion. Our results suggest that both GLUT2 and glucokinase are necessary for the glucose stimulated insulin secretion in at least rodent cell lines, and that other element(s) are necessary for a biphasic insulin secretion typically observed in beta cells.","tokens":[{"text":"Diazoxide","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"nifedipine","start":12,"end":22,"id":2,"ws":true},{"text":"and","start":23,"end":26,"id":3,"ws":true},{"text":"2-deoxy","start":27,"end":34,"id":4,"ws":true},{"text":"glucose","start":35,"end":42,"id":5,"ws":true},{"text":"suppressed","start":43,"end":53,"id":6,"ws":true},{"text":"(","start":54,"end":55,"id":7,"ws":true},{"text":"p","start":56,"end":57,"id":8,"ws":true},{"text":"<","start":58,"end":59,"id":9,"ws":true},{"text":"0.05","start":60,"end":64,"id":10,"ws":true},{"text":")","start":65,"end":66,"id":11,"ws":true},{"text":"glucose","start":67,"end":74,"id":12,"ws":true},{"text":"stimulated","start":75,"end":85,"id":13,"ws":true},{"text":"insulin","start":86,"end":93,"id":14,"ws":true},{"text":"secretion","start":94,"end":103,"id":15,"ws":true},{"text":"in","start":104,"end":106,"id":16,"ws":true},{"text":"AtT20HI-GLUT2-GK-6","start":107,"end":125,"id":17,"ws":true},{"text":"cells","start":126,"end":131,"id":18,"ws":true},{"text":".","start":132,"end":133,"id":19,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":12,"end":22,"token_start":2,"token_end":2,"label":"DRUG"},{"start":27,"end":42,"token_start":4,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9867217/","_input_hash":1226126973,"_task_hash":392157566,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":12,"end":22,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":2,"child":5,"head_span":{"start":12,"end":22,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":27,"end":42,"token_start":4,"token_end":5,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Reducing the duration of medication use postoperatively may also minimize the possible side effects of ketorolac and codeine , which could develop with extended periods of use .","paragraph":"<h3><u>Evaluation of ketorolac (Toradol) with varying amounts of codeine for postoperative extraction pain control.</u></h3>This study analyzes the combination of oral <b style='color:Tomato;'><i>ketorolac</i></b> 10 mg with varying amounts of <b style='color:Tomato;'><i>codeine</i></b> phosphate, and the postoperative pain relief that developed from these combinations. Five groups of patients were administered the <b style='color:Tomato;'><i>codeine</i></b>/<b style='color:Tomato;'><i>ketorolac</i></b> combinations. Variations of the combinations were analyzed to ascertain if an optimal analgesic ratio existed. All controllable variables involved with the surgical procedure were held constant to allow for better evaluation of postoperative pain. Results obtained from 67 patients indicated that the best pain relief was achieved with a combination of 10 mg <b style='color:Tomato;'><i>ketorolac</i></b> and 15 mg <b style='color:Tomato;'><i>codeine</i></b> phosphate. <b style='color:Tomato;'><i>codeine</i></b> alone provided adequate analgesia, but the addition of <b style='color:Tomato;'><i>ketorolac</i></b> reduced the patients' perceived side effects. The presence of <b style='color:Tomato;'><i>codeine</i></b> in the analgesic combination was also shown to reduce the number of days that the patient required the medication postoperatively. <b style='color:DodgerBlue;'><i>Reducing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>duration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>medication</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>postoperatively</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>minimize</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>possible</i></b> <b style='color:DodgerBlue;'><i>side</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ketorolac</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>codeine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>could</i></b> <b style='color:DodgerBlue;'><i>develop</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>extended</i></b> <b style='color:DodgerBlue;'><i>periods</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Reducing","start":0,"end":8,"id":0,"ws":true},{"text":"the","start":9,"end":12,"id":1,"ws":true},{"text":"duration","start":13,"end":21,"id":2,"ws":true},{"text":"of","start":22,"end":24,"id":3,"ws":true},{"text":"medication","start":25,"end":35,"id":4,"ws":true},{"text":"use","start":36,"end":39,"id":5,"ws":true},{"text":"postoperatively","start":40,"end":55,"id":6,"ws":true},{"text":"may","start":56,"end":59,"id":7,"ws":true},{"text":"also","start":60,"end":64,"id":8,"ws":true},{"text":"minimize","start":65,"end":73,"id":9,"ws":true},{"text":"the","start":74,"end":77,"id":10,"ws":true},{"text":"possible","start":78,"end":86,"id":11,"ws":true},{"text":"side","start":87,"end":91,"id":12,"ws":true},{"text":"effects","start":92,"end":99,"id":13,"ws":true},{"text":"of","start":100,"end":102,"id":14,"ws":true},{"text":"ketorolac","start":103,"end":112,"id":15,"ws":true},{"text":"and","start":113,"end":116,"id":16,"ws":true},{"text":"codeine","start":117,"end":124,"id":17,"ws":true},{"text":",","start":125,"end":126,"id":18,"ws":true},{"text":"which","start":127,"end":132,"id":19,"ws":true},{"text":"could","start":133,"end":138,"id":20,"ws":true},{"text":"develop","start":139,"end":146,"id":21,"ws":true},{"text":"with","start":147,"end":151,"id":22,"ws":true},{"text":"extended","start":152,"end":160,"id":23,"ws":true},{"text":"periods","start":161,"end":168,"id":24,"ws":true},{"text":"of","start":169,"end":171,"id":25,"ws":true},{"text":"use","start":172,"end":175,"id":26,"ws":true},{"text":".","start":176,"end":177,"id":27,"ws":false}],"spans":[{"start":103,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},{"start":117,"end":124,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12190134/","_input_hash":-1280865924,"_task_hash":-1776961753,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":17,"child":15,"head_span":{"start":117,"end":124,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":103,"end":112,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma .","paragraph":"<h3><u>Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.</u></h3> <b style='color:MediumOrchid;'><i>Lenalidomide</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>reference</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>relapsed</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>myeloma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of the proteasome inhibitor <b style='color:Tomato;'><i>carfilzomib</i></b> with <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. ### methods We randomly assigned 792 patients with relapsed multiple myeloma to <b style='color:Tomato;'><i>carfilzomib</i></b> with <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> (<b style='color:Tomato;'><i>carfilzomib</i></b> group) or <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> alone (control group). The primary end point was progression-free survival. ### results Progression-free survival was significantly improved with <b style='color:Tomato;'><i>carfilzomib</i></b> (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the <b style='color:Tomato;'><i>carfilzomib</i></b> and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the <b style='color:Tomato;'><i>carfilzomib</i></b> and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the <b style='color:Tomato;'><i>carfilzomib</i></b> and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the <b style='color:Tomato;'><i>carfilzomib</i></b> group reported superior health-related quality of life. ### conclusions In patients with relapsed multiple myeloma, the addition of <b style='color:Tomato;'><i>carfilzomib</i></b> to <b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).","tokens":[{"text":"Lenalidomide","start":0,"end":12,"id":0,"ws":true},{"text":"plus","start":13,"end":17,"id":1,"ws":true},{"text":"dexamethasone","start":18,"end":31,"id":2,"ws":true},{"text":"is","start":32,"end":34,"id":3,"ws":true},{"text":"a","start":35,"end":36,"id":4,"ws":true},{"text":"reference","start":37,"end":46,"id":5,"ws":true},{"text":"treatment","start":47,"end":56,"id":6,"ws":true},{"text":"for","start":57,"end":60,"id":7,"ws":true},{"text":"relapsed","start":61,"end":69,"id":8,"ws":true},{"text":"multiple","start":70,"end":78,"id":9,"ws":true},{"text":"myeloma","start":79,"end":86,"id":10,"ws":true},{"text":".","start":87,"end":88,"id":11,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":18,"end":31,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25482145/","_input_hash":-942881164,"_task_hash":-1758155141,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":18,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Following definitive treatment , patients were randomized to either cyclophosphamide 1 g/m2 intravenously every 3 weeks for 2 years , estramustine phosphate 600 mg/m2 orally daily for 2 years or to observation only .","paragraph":"<h3><u>Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation.</u></h3>Because of efficacy demonstrated with chemotherapy in patients with metastatic disease, the National Prostate Cancer Project in 1978 initiated two protocols evaluating adjuvant therapy following surgery (Protocol 900) and irradiation (Protocol 1000) for patients with localized disease at high risk for relapse. ### methods All patients underwent staging pelvic lymph node dissection. <b style='color:DodgerBlue;'><i>Following</i></b> <b style='color:DodgerBlue;'><i>definitive</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>g/m2</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>estramustine</i></b> <b style='color:DodgerBlue;'><i>phosphate</i></b> <b style='color:DodgerBlue;'><i>600</i></b> <b style='color:DodgerBlue;'><i>mg/m2</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>observation</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Accession closed in 1985 and included 184 patients in Protocol 900 (170 evaluable) and 253 in Protocol 1000 (233 evaluable). ### results Nodal involvement was identified in 198 patients (49% of total): 29% in Protocol 900 and 63% in protocol 1000. Median progression-free survival (PFS) and survival have been greater for patients in Protocol 900 regardless of adjuvant, reflecting their lower pathologic stage. Median PFS is significantly greater for patients in Protocol 1000 receiving <b style='color:Tomato;'><i>estramustine</i></b> (52.2 months) compared to <b style='color:Tomato;'><i>cyclophosphamide</i></b> (35.0 months). Median PFS for patients with nodal involvement in Protocol 1000 receiving <b style='color:Tomato;'><i>estramustine</i></b> is increased (43.5 months) compared to no treatment (21.5 months). Patients with limited nodal involvement in Protocol 1000 have a longer median PFS (45.6 months) compared to patients with extensive disease (23.6 months). But in the latter group patients receiving <b style='color:Tomato;'><i>estramustine</i></b> experienced a significantly longer median PFS (43.5 months) compared to <b style='color:Tomato;'><i>cyclophosphamide</i></b> (29.1 months) or no adjuvant (13.5 months). Increased PFS with <b style='color:Tomato;'><i>estramustine</i></b> adjuvant was also noted in stage C patients (only Protocol 900) and in those with high-grade (grade 3) tumors (both protocols). ### conclusions With now over 10 years mean follow-up for this series of patients, we conclude that adjuvant <b style='color:Tomato;'><i>estramustine</i></b> is beneficial for prostate cancer patients receiving definitive irradiation. This benefit is particularly noted in those patients with extensive nodal involvement (N+, D-1).","tokens":[{"text":"Following","start":0,"end":9,"id":0,"ws":true},{"text":"definitive","start":10,"end":20,"id":1,"ws":true},{"text":"treatment","start":21,"end":30,"id":2,"ws":true},{"text":",","start":31,"end":32,"id":3,"ws":true},{"text":"patients","start":33,"end":41,"id":4,"ws":true},{"text":"were","start":42,"end":46,"id":5,"ws":true},{"text":"randomized","start":47,"end":57,"id":6,"ws":true},{"text":"to","start":58,"end":60,"id":7,"ws":true},{"text":"either","start":61,"end":67,"id":8,"ws":true},{"text":"cyclophosphamide","start":68,"end":84,"id":9,"ws":true},{"text":"1","start":85,"end":86,"id":10,"ws":true},{"text":"g/m2","start":87,"end":91,"id":11,"ws":true},{"text":"intravenously","start":92,"end":105,"id":12,"ws":true},{"text":"every","start":106,"end":111,"id":13,"ws":true},{"text":"3","start":112,"end":113,"id":14,"ws":true},{"text":"weeks","start":114,"end":119,"id":15,"ws":true},{"text":"for","start":120,"end":123,"id":16,"ws":true},{"text":"2","start":124,"end":125,"id":17,"ws":true},{"text":"years","start":126,"end":131,"id":18,"ws":true},{"text":",","start":132,"end":133,"id":19,"ws":true},{"text":"estramustine","start":134,"end":146,"id":20,"ws":true},{"text":"phosphate","start":147,"end":156,"id":21,"ws":true},{"text":"600","start":157,"end":160,"id":22,"ws":true},{"text":"mg/m2","start":161,"end":166,"id":23,"ws":true},{"text":"orally","start":167,"end":173,"id":24,"ws":true},{"text":"daily","start":174,"end":179,"id":25,"ws":true},{"text":"for","start":180,"end":183,"id":26,"ws":true},{"text":"2","start":184,"end":185,"id":27,"ws":true},{"text":"years","start":186,"end":191,"id":28,"ws":true},{"text":"or","start":192,"end":194,"id":29,"ws":true},{"text":"to","start":195,"end":197,"id":30,"ws":true},{"text":"observation","start":198,"end":209,"id":31,"ws":true},{"text":"only","start":210,"end":214,"id":32,"ws":true},{"text":".","start":215,"end":216,"id":33,"ws":false}],"spans":[{"start":68,"end":84,"token_start":9,"token_end":9,"label":"DRUG"},{"start":134,"end":146,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8791049/","_input_hash":1773548335,"_task_hash":-1919144287,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The authors report on anemia observed during preoperative paclitaxel and carboplatin chemotherapy in patients with advanced head and neck carcinoma and discuss how the use of recombinant human erythropoietin ( r-HuEPO ) ameliorates this anemia , reducing the need for subsequent packed red blood cell ( PRBC ) transfusions .","paragraph":"<h3><u>Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>authors</i></b> <b style='color:DodgerBlue;'><i>report</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>anemia</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>preoperative</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>head</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neck</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>discuss</i></b> <b style='color:DodgerBlue;'><i>how</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:MediumOrchid;'><i>erythropoietin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>r-HuEPO</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>ameliorates</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>anemia</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>reducing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>need</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>subsequent</i></b> <b style='color:DodgerBlue;'><i>packed</i></b> <b style='color:DodgerBlue;'><i>red</i></b> <b style='color:DodgerBlue;'><i>blood</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PRBC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>transfusions</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Response to r-HuEPO was defined as reduced hemoglobin fall during preoperative chemotherapy and reduced transfusion requirements during surgery. Thirty-six patients with advanced head and neck carcinoma were evaluable after treatment with preoperative chemotherapy using <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>. Group 1 was comprised of 14 patients who empirically received r-HuEPO at a dose of 150 U/kg 3 times per week for 3 weeks; in patients deemed nonresponders, the dose was increased to 300 U/kg and 450 U/kg in the subsequent courses. Group 2 was comprised of 22 patients who did not receive r-HuEPO. ### results During preoperative chemotherapy, the mean hemoglobin fall was 0.5 g/dL in Group 1 (P = 0.40). In Group 2 there was a statistically significant mean hemoglobin fall of 3.3 g/dL (P < 0.0001). There was also a nonstatistically significant trend toward fewer PRBC transfusions: none of 14 patients (0%) in Group 1 versus 4 of 22 patients (18%) in Group 2 (P = 0.141). ### conclusions A significant fall in hemoglobin and an increase in the need for transfusions were observed in head and neck carcinoma patients receiving <b style='color:Tomato;'><i>carboplatin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy prior to surgery. Empiric r-HuEPO therapy appeared to prevent anemia and reduced the need for PRBC transfusions.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"authors","start":4,"end":11,"id":1,"ws":true},{"text":"report","start":12,"end":18,"id":2,"ws":true},{"text":"on","start":19,"end":21,"id":3,"ws":true},{"text":"anemia","start":22,"end":28,"id":4,"ws":true},{"text":"observed","start":29,"end":37,"id":5,"ws":true},{"text":"during","start":38,"end":44,"id":6,"ws":true},{"text":"preoperative","start":45,"end":57,"id":7,"ws":true},{"text":"paclitaxel","start":58,"end":68,"id":8,"ws":true},{"text":"and","start":69,"end":72,"id":9,"ws":true},{"text":"carboplatin","start":73,"end":84,"id":10,"ws":true},{"text":"chemotherapy","start":85,"end":97,"id":11,"ws":true},{"text":"in","start":98,"end":100,"id":12,"ws":true},{"text":"patients","start":101,"end":109,"id":13,"ws":true},{"text":"with","start":110,"end":114,"id":14,"ws":true},{"text":"advanced","start":115,"end":123,"id":15,"ws":true},{"text":"head","start":124,"end":128,"id":16,"ws":true},{"text":"and","start":129,"end":132,"id":17,"ws":true},{"text":"neck","start":133,"end":137,"id":18,"ws":true},{"text":"carcinoma","start":138,"end":147,"id":19,"ws":true},{"text":"and","start":148,"end":151,"id":20,"ws":true},{"text":"discuss","start":152,"end":159,"id":21,"ws":true},{"text":"how","start":160,"end":163,"id":22,"ws":true},{"text":"the","start":164,"end":167,"id":23,"ws":true},{"text":"use","start":168,"end":171,"id":24,"ws":true},{"text":"of","start":172,"end":174,"id":25,"ws":true},{"text":"recombinant","start":175,"end":186,"id":26,"ws":true},{"text":"human","start":187,"end":192,"id":27,"ws":true},{"text":"erythropoietin","start":193,"end":207,"id":28,"ws":true},{"text":"(","start":208,"end":209,"id":29,"ws":true},{"text":"r-HuEPO","start":210,"end":217,"id":30,"ws":true},{"text":")","start":218,"end":219,"id":31,"ws":true},{"text":"ameliorates","start":220,"end":231,"id":32,"ws":true},{"text":"this","start":232,"end":236,"id":33,"ws":true},{"text":"anemia","start":237,"end":243,"id":34,"ws":true},{"text":",","start":244,"end":245,"id":35,"ws":true},{"text":"reducing","start":246,"end":254,"id":36,"ws":true},{"text":"the","start":255,"end":258,"id":37,"ws":true},{"text":"need","start":259,"end":263,"id":38,"ws":true},{"text":"for","start":264,"end":267,"id":39,"ws":true},{"text":"subsequent","start":268,"end":278,"id":40,"ws":true},{"text":"packed","start":279,"end":285,"id":41,"ws":true},{"text":"red","start":286,"end":289,"id":42,"ws":true},{"text":"blood","start":290,"end":295,"id":43,"ws":true},{"text":"cell","start":296,"end":300,"id":44,"ws":true},{"text":"(","start":301,"end":302,"id":45,"ws":true},{"text":"PRBC","start":303,"end":307,"id":46,"ws":true},{"text":")","start":308,"end":309,"id":47,"ws":true},{"text":"transfusions","start":310,"end":322,"id":48,"ws":true},{"text":".","start":323,"end":324,"id":49,"ws":false}],"spans":[{"start":58,"end":68,"token_start":8,"token_end":8,"label":"DRUG"},{"start":73,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},{"start":193,"end":207,"token_start":28,"token_end":28,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9118049/","_input_hash":-115747160,"_task_hash":-1156151995,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":58,"end":68,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":73,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":28,"child":10,"head_span":{"start":193,"end":207,"token_start":28,"token_end":28,"label":"DRUG"},"child_span":{"start":73,"end":84,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>fluconazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>flucytosine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>murine</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cryptococcal</i></b> <b style='color:DodgerBlue;'><i>meningitis</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This study elucidates the role of combined <b style='color:Tomato;'><i>fluconazole</i></b> and <b style='color:Tomato;'><i>flucytosine</i></b> as therapy for cryptococcosis in the murine model of meningitis. Three strains of Cryptococcus neoformans for which the range of <b style='color:Tomato;'><i>fluconazole</i></b> MICs was wide--2 microg/ml (susceptible strain), 8 microg/ml (moderately susceptible strain), and 32 microg/ml (resistant strain)--were used for infection. One day postinfection, the mice were randomized into eight treatment groups: placebo; <b style='color:Tomato;'><i>flucytosine</i></b> (40 mg/kg of body weight/day); <b style='color:Tomato;'><i>fluconazole</i></b> at 3 mg/kg/day (low dosage), 10 mg/kg/day (moderate dosage), or 20 mg/kg/day (high dosage); and combined <b style='color:Tomato;'><i>flucytosine</i></b> and <b style='color:Tomato;'><i>fluconazole</i></b> at low, moderate, or high doses of <b style='color:Tomato;'><i>fluconazole</i></b>. Three major findings were demonstrated: (i) correlation between the MICs for the isolates and the in vivo effectiveness of <b style='color:Tomato;'><i>fluconazole</i></b> as assessed by the reduction in cryptococcal brain burden, (ii) a dose-response curve (a higher dose of <b style='color:Tomato;'><i>fluconazole</i></b> was significantly more efficacious than a lower dose [P < 0.001]), and (iii) synergism between <b style='color:Tomato;'><i>fluconazole</i></b> and <b style='color:Tomato;'><i>flucytosine</i></b> (therapy with a combination of <b style='color:Tomato;'><i>fluconazole</i></b> and <b style='color:Tomato;'><i>flucytosine</i></b> was superior to therapy with either agent alone [P < 0.01]).","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"therapy","start":12,"end":19,"id":1,"ws":true},{"text":"with","start":20,"end":24,"id":2,"ws":true},{"text":"fluconazole","start":25,"end":36,"id":3,"ws":true},{"text":"and","start":37,"end":40,"id":4,"ws":true},{"text":"flucytosine","start":41,"end":52,"id":5,"ws":true},{"text":"in","start":53,"end":55,"id":6,"ws":true},{"text":"the","start":56,"end":59,"id":7,"ws":true},{"text":"murine","start":60,"end":66,"id":8,"ws":true},{"text":"model","start":67,"end":72,"id":9,"ws":true},{"text":"of","start":73,"end":75,"id":10,"ws":true},{"text":"cryptococcal","start":76,"end":88,"id":11,"ws":true},{"text":"meningitis","start":89,"end":99,"id":12,"ws":true},{"text":".","start":100,"end":101,"id":13,"ws":false}],"spans":[{"start":25,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":52,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9145879/","_input_hash":1182230001,"_task_hash":1415328540,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":25,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":41,"end":52,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The consumption of meropenem or doripenem was calculated using the Anatomic Therapeutic Chemical classification and defined daily doses methodology .","paragraph":"<h3><u>Correlation between the consumption of meropenem or doripenem and meropenem susceptibility of Pseudomonas aeruginosa in a university hospital in Japan.</u></h3>The appropriate use of carbapenems is essential in order to prevent resistance in Pseudomonas aeruginosa. We investigated the correlation between the consumption of <b style='color:Tomato;'><i>meropenem</i></b> or <b style='color:Tomato;'><i>doripenem</i></b> and the susceptibility of P. aeruginosa to <b style='color:Tomato;'><i>meropenem</i></b> in a Japanese university hospital from 2004 to 2009. The susceptibility data of P. aeruginosa and the annual consumption of <b style='color:Tomato;'><i>meropenem</i></b> or <b style='color:Tomato;'><i>doripenem</i></b> were analyzed. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>consumption</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>meropenem</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>doripenem</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>calculated</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Anatomic</i></b> <b style='color:DodgerBlue;'><i>Therapeutic</i></b> <b style='color:DodgerBlue;'><i>Chemical</i></b> <b style='color:DodgerBlue;'><i>classification</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>defined</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>methodology</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>meropenem</i></b> consumption decreased and <b style='color:Tomato;'><i>doripenem</i></b> consumption increased and throughout the entire investigation period, total consumption of <b style='color:Tomato;'><i>meropenem</i></b> plus <b style='color:Tomato;'><i>doripenem</i></b> was stable. Although the annual number of isolated P. aeruginosa has not changed, the annual number of isolated multidrug resistant P. aeruginosa decreased by measures against nosocomial infection. The rate of <b style='color:Tomato;'><i>meropenem</i></b> resistant P. aeruginosa decreased in a time-dependent manner. <b style='color:Tomato;'><i>meropenem</i></b> consumption was positively correlated with the <b style='color:Tomato;'><i>meropenem</i></b> resistance rate among P. aeruginosa (r = 0.9455, p<0.01). The total consumption of <b style='color:Tomato;'><i>meropenem</i></b> and <b style='color:Tomato;'><i>doripenem</i></b> was not correlated with the <b style='color:Tomato;'><i>meropenem</i></b> resistance rate (r = -0.6601, p>0.1). These results suggested that even if the total consumption of <b style='color:Tomato;'><i>meropenem</i></b> plus <b style='color:Tomato;'><i>doripenem</i></b> was not changed, <b style='color:Tomato;'><i>meropenem</i></b> susceptibility among P. aeruginosa improved by the decrease of <b style='color:Tomato;'><i>meropenem</i></b> consumption. Although <b style='color:Tomato;'><i>meropenem</i></b> and <b style='color:Tomato;'><i>doripenem</i></b> have been suggested to show cross-resistance with each other, the reduction of <b style='color:Tomato;'><i>meropenem</i></b> consumption might be effective for preventing an increase of <b style='color:Tomato;'><i>meropenem</i></b>-resistant P. aeruginosa.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"consumption","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"meropenem","start":19,"end":28,"id":3,"ws":true},{"text":"or","start":29,"end":31,"id":4,"ws":true},{"text":"doripenem","start":32,"end":41,"id":5,"ws":true},{"text":"was","start":42,"end":45,"id":6,"ws":true},{"text":"calculated","start":46,"end":56,"id":7,"ws":true},{"text":"using","start":57,"end":62,"id":8,"ws":true},{"text":"the","start":63,"end":66,"id":9,"ws":true},{"text":"Anatomic","start":67,"end":75,"id":10,"ws":true},{"text":"Therapeutic","start":76,"end":87,"id":11,"ws":true},{"text":"Chemical","start":88,"end":96,"id":12,"ws":true},{"text":"classification","start":97,"end":111,"id":13,"ws":true},{"text":"and","start":112,"end":115,"id":14,"ws":true},{"text":"defined","start":116,"end":123,"id":15,"ws":true},{"text":"daily","start":124,"end":129,"id":16,"ws":true},{"text":"doses","start":130,"end":135,"id":17,"ws":true},{"text":"methodology","start":136,"end":147,"id":18,"ws":true},{"text":".","start":148,"end":149,"id":19,"ws":false}],"spans":[{"start":19,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},{"start":32,"end":41,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22687536/","_input_hash":1114884058,"_task_hash":380056829,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"After successful phase II studies , recent phase III trials established combinations of chlorambucil with anti-CD20 antibodies such as rituximab , ofatumumab and obinutuzumab as a valuable treatment option for these patients .","paragraph":"<h3><u>Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.</u></h3>For many decades, <b style='color:Tomato;'><i>chlorambucil</i></b> was the standard of care for chronic lymphocytic leukemia (CLL), but meanwhile has been replaced by purine analog-based chemoimmunotherapy. Monotherapy with the alkylator only retained significance in the treatment of older patients unfit for standard treatment. <b style='color:DodgerBlue;'><i>After</i></b> <b style='color:DodgerBlue;'><i>successful</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>recent</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>chlorambucil</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anti-CD20</i></b> <b style='color:DodgerBlue;'><i>antibodies</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ofatumumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>obinutuzumab</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>valuable</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>option</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Today, <b style='color:Tomato;'><i>chlorambucil</i></b> therefore should be used as a chemotherapy backbone for antibody-based chemoimmunotherapy in this patient population rather than as monotherapy. Starting from the past role of <b style='color:Tomato;'><i>chlorambucil</i></b> in CLL treatment, we here review the most recent efforts to elaborate <b style='color:Tomato;'><i>chlorambucil</i></b>-based chemoimmunotherapy in CLL and discuss clinically relevant questions that arise from this approach.","tokens":[{"text":"After","start":0,"end":5,"id":0,"ws":true},{"text":"successful","start":6,"end":16,"id":1,"ws":true},{"text":"phase","start":17,"end":22,"id":2,"ws":true},{"text":"II","start":23,"end":25,"id":3,"ws":true},{"text":"studies","start":26,"end":33,"id":4,"ws":true},{"text":",","start":34,"end":35,"id":5,"ws":true},{"text":"recent","start":36,"end":42,"id":6,"ws":true},{"text":"phase","start":43,"end":48,"id":7,"ws":true},{"text":"III","start":49,"end":52,"id":8,"ws":true},{"text":"trials","start":53,"end":59,"id":9,"ws":true},{"text":"established","start":60,"end":71,"id":10,"ws":true},{"text":"combinations","start":72,"end":84,"id":11,"ws":true},{"text":"of","start":85,"end":87,"id":12,"ws":true},{"text":"chlorambucil","start":88,"end":100,"id":13,"ws":true},{"text":"with","start":101,"end":105,"id":14,"ws":true},{"text":"anti-CD20","start":106,"end":115,"id":15,"ws":true},{"text":"antibodies","start":116,"end":126,"id":16,"ws":true},{"text":"such","start":127,"end":131,"id":17,"ws":true},{"text":"as","start":132,"end":134,"id":18,"ws":true},{"text":"rituximab","start":135,"end":144,"id":19,"ws":true},{"text":",","start":145,"end":146,"id":20,"ws":true},{"text":"ofatumumab","start":147,"end":157,"id":21,"ws":true},{"text":"and","start":158,"end":161,"id":22,"ws":true},{"text":"obinutuzumab","start":162,"end":174,"id":23,"ws":true},{"text":"as","start":175,"end":177,"id":24,"ws":true},{"text":"a","start":178,"end":179,"id":25,"ws":true},{"text":"valuable","start":180,"end":188,"id":26,"ws":true},{"text":"treatment","start":189,"end":198,"id":27,"ws":true},{"text":"option","start":199,"end":205,"id":28,"ws":true},{"text":"for","start":206,"end":209,"id":29,"ws":true},{"text":"these","start":210,"end":215,"id":30,"ws":true},{"text":"patients","start":216,"end":224,"id":31,"ws":true},{"text":".","start":225,"end":226,"id":32,"ws":false}],"spans":[{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},{"start":135,"end":144,"token_start":19,"token_end":19,"label":"DRUG"},{"start":147,"end":157,"token_start":21,"token_end":21,"label":"DRUG"},{"start":162,"end":174,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25219593/","_input_hash":217161781,"_task_hash":564488024,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":19,"child":13,"head_span":{"start":135,"end":144,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":21,"child":13,"head_span":{"start":147,"end":157,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":23,"child":13,"head_span":{"start":162,"end":174,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS10","POS20","POS30"],"answer":"accept"}
{"text":"Unorthodox antibiotic combinations including ciprofloxacin against high-level gentamicin resistant enterococci .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Unorthodox</i></b> <b style='color:DodgerBlue;'><i>antibiotic</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>high-level</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>enterococci</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Development of high-level <b style='color:Tomato;'><i>gentamicin</i></b> resistance among enterococci represents a serious therapeutic problem as it precludes synergy between aminoglycosides and cell-wall active agents. As part of a search for active antibiotic combinations against enterococci with high-level <b style='color:Tomato;'><i>gentamicin</i></b> resistance, we tested by the time kill curve method the efficacy of <b style='color:Tomato;'><i>ciprofloxacin</i></b> combined with <b style='color:Tomato;'><i>ampicillin</i></b>, <b style='color:Tomato;'><i>trimethoprim</i></b>-sulphamethoxazole, <b style='color:Tomato;'><i>vancomycin</i></b> or <b style='color:Tomato;'><i>teicoplanin</i></b> against ten isolates of Enterococcus faecium, three of Enterococcus casseliflavus and 13 of Enterococcus faecalis that exhibited a MIC of <b style='color:Tomato;'><i>gentamicin</i></b> > or = 2000 mg/L. Most of the E. faecium were also resistant to <b style='color:Tomato;'><i>ampicillin</i></b> and to <b style='color:Tomato;'><i>ciprofloxacin</i></b>. The combination of <b style='color:Tomato;'><i>ciprofloxacin</i></b> with <b style='color:Tomato;'><i>ampicillin</i></b> was bactericidal against five of seven E. faecium strains that exhibited a <b style='color:Tomato;'><i>ciprofloxacin</i></b> MIC < or = 4 mg/L, but was inactive against the three E. faecium that were highly resistant to <b style='color:Tomato;'><i>ciprofloxacin</i></b>. This combination was also bactericidal against the E. casseliflavus and all the E. faecalis strains. The combination of <b style='color:Tomato;'><i>ciprofloxacin</i></b> with <b style='color:Tomato;'><i>trimethoprim</i></b>-sulphamethoxazole was bactericidal against five of the seven E. faecium and seven of the nine E. faecalis strains with a <b style='color:Tomato;'><i>ciprofloxacin</i></b> MIC < or = 4 mg/L. No bactericidal activity of this combination was seen against the enterococci that were highly resistant to either <b style='color:Tomato;'><i>ciprofloxacin</i></b> or to <b style='color:Tomato;'><i>trimethoprim</i></b>-sulphamethoxazole. The combination of <b style='color:Tomato;'><i>ciprofloxacin</i></b> with glycopeptides was inactive against E. faecium and E. casseliflavus and against E. faecalis, it was either ineffective or antagonistic; in only one case it was bactericidal. Five strains of E. faecium were resistant to all antibiotic combinations tested.","tokens":[{"text":"Unorthodox","start":0,"end":10,"id":0,"ws":true},{"text":"antibiotic","start":11,"end":21,"id":1,"ws":true},{"text":"combinations","start":22,"end":34,"id":2,"ws":true},{"text":"including","start":35,"end":44,"id":3,"ws":true},{"text":"ciprofloxacin","start":45,"end":58,"id":4,"ws":true},{"text":"against","start":59,"end":66,"id":5,"ws":true},{"text":"high-level","start":67,"end":77,"id":6,"ws":true},{"text":"gentamicin","start":78,"end":88,"id":7,"ws":true},{"text":"resistant","start":89,"end":98,"id":8,"ws":true},{"text":"enterococci","start":99,"end":110,"id":9,"ws":true},{"text":".","start":111,"end":112,"id":10,"ws":false}],"spans":[{"start":45,"end":58,"token_start":4,"token_end":4,"label":"DRUG"},{"start":78,"end":88,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8722538/","_input_hash":2130018385,"_task_hash":-985602480,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma : CALGB 50401 ( Alliance ) .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Randomized</i></b> <b style='color:DodgerBlue;'><i>Trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Lenalidomide</i></b> <b style='color:DodgerBlue;'><i>Alone</i></b> <b style='color:DodgerBlue;'><i>Versus</i></b> <b style='color:MediumOrchid;'><i>Lenalidomide</i></b> <b style='color:DodgerBlue;'><i>Plus</i></b> <b style='color:MediumOrchid;'><i>Rituximab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:DodgerBlue;'><i>Recurrent</i></b> <b style='color:DodgerBlue;'><i>Follicular</i></b> <b style='color:DodgerBlue;'><i>Lymphoma</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>CALGB</i></b> <b style='color:DodgerBlue;'><i>50401</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Alliance</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>lenalidomide</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> (LR) are active agents in follicular lymphoma (FL). Combination regimens have not been previously assessed in randomized studies. ### Patients And Methods The Cancer and Leukemia Group B (Alliance) 50401 trial is a randomized phase II trial studying <b style='color:Tomato;'><i>rituximab</i></b> (375 mg/m(2) weekly for 4 weeks), <b style='color:Tomato;'><i>lenalidomide</i></b> (15 mg per day on days 1 to 21, followed by 7 days of rest, in cycle 1 and then 20 mg per day on days 1 to 21, followed by 7 days of rest, in cycles 2 to 12), or LR. The <b style='color:Tomato;'><i>rituximab</i></b>-alone arm was discontinued as a result of poor accrual. Eligibility included recurrent FL and prior <b style='color:Tomato;'><i>rituximab</i></b> with time to progression of \u2265 6 months from last dose. <b style='color:Tomato;'><i>aspirin</i></b> or <b style='color:Tomato;'><i>heparin</i></b> was recommended for patients at high thrombosis risk. ### results Ninety-one patients (<b style='color:Tomato;'><i>lenalidomide</i></b>, n = 45; LR, n = 46) received treatment; median age was 63 years (range, 34 to 89 years), and 58% were intermediate or high risk according to the Follicular Lymphoma International Prognostic Index. In the <b style='color:Tomato;'><i>lenalidomide</i></b> and LR arms, grade 3 to 4 adverse events occurred in 58% and 53% of patients, with 9% and 11% of patients experiencing grade 4 toxicity, respectively; grade 3 to 4 adverse events included neutropenia (16% v 20%, respectively), fatigue (9% v 13%, respectively), and thrombosis (16% [n = 7] v 4% [n = 2], respectively; P = .157). Thirty-six percent of <b style='color:Tomato;'><i>lenalidomide</i></b> patients and 63% of LR patients completed 12 cycles. <b style='color:Tomato;'><i>lenalidomide</i></b> alone was associated with more treatment failures, with 22% of patients discontinuing treatment as a result of adverse events. Dose-intensity exceeded 80% in both arms. Overall response rate was 53% (20% complete response) and 76% (39% complete response) for <b style='color:Tomato;'><i>lenalidomide</i></b> alone and LR, respectively (P = .029). At the median follow-up of 2.5 years, median time to progression was 1.1 year for <b style='color:Tomato;'><i>lenalidomide</i></b> alone and 2 years for LR (P = .0023). ### conclusion LR is more active than <b style='color:Tomato;'><i>lenalidomide</i></b> alone in recurrent FL with similar toxicity, warranting further study in B-cell non-Hodgkin lymphoma as a platform for addition of novel agents.","tokens":[{"text":"Randomized","start":0,"end":10,"id":0,"ws":true},{"text":"Trial","start":11,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"Lenalidomide","start":20,"end":32,"id":3,"ws":true},{"text":"Alone","start":33,"end":38,"id":4,"ws":true},{"text":"Versus","start":39,"end":45,"id":5,"ws":true},{"text":"Lenalidomide","start":46,"end":58,"id":6,"ws":true},{"text":"Plus","start":59,"end":63,"id":7,"ws":true},{"text":"Rituximab","start":64,"end":73,"id":8,"ws":true},{"text":"in","start":74,"end":76,"id":9,"ws":true},{"text":"Patients","start":77,"end":85,"id":10,"ws":true},{"text":"With","start":86,"end":90,"id":11,"ws":true},{"text":"Recurrent","start":91,"end":100,"id":12,"ws":true},{"text":"Follicular","start":101,"end":111,"id":13,"ws":true},{"text":"Lymphoma","start":112,"end":120,"id":14,"ws":true},{"text":":","start":121,"end":122,"id":15,"ws":true},{"text":"CALGB","start":123,"end":128,"id":16,"ws":true},{"text":"50401","start":129,"end":134,"id":17,"ws":true},{"text":"(","start":135,"end":136,"id":18,"ws":true},{"text":"Alliance","start":137,"end":145,"id":19,"ws":true},{"text":")","start":146,"end":147,"id":20,"ws":true},{"text":".","start":148,"end":149,"id":21,"ws":false}],"spans":[{"start":20,"end":32,"token_start":3,"token_end":3,"label":"DRUG"},{"start":46,"end":58,"token_start":6,"token_end":6,"label":"DRUG"},{"start":64,"end":73,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26304886/","_input_hash":-2053138454,"_task_hash":544291367,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":46,"end":58,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":64,"end":73,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis : implications for future clinical trials .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Potential</i></b> <b style='color:DodgerBlue;'><i>cost-effectiveness</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rifampin</i></b> <b style='color:DodgerBlue;'><i>vs.</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>latent</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>implications</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>future</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Standard treatment for latent tuberculosis infection (LTBI) is 9 months daily <b style='color:Tomato;'><i>isoniazid</i></b> (9INH). An alternative is 4 months daily <b style='color:Tomato;'><i>rifampin</i></b> (4RMP), associated with better completion and less toxicity; however, its efficacy remains uncertain. ### objectives To assess the cost-effectiveness of these regimens for treating LTBI in human immunodeficiency virus negative persons, using results from a recent clinical trial, plus different scenarios for 4RMP efficacy, and to estimate the costs of an adequately powered noninferiority trial and resulting savings from substitution with 4RMP. ### design A decision-analysis model tracked TB contacts and lower-risk tuberculin reactors receiving 9INH, 4RMP or no treatment. For different 4RMP efficacy scenarios, we estimated the cost-effectiveness, sample size and cost of non-inferiority trials, and potential cost savings substituting 4RMP for 9INH for 10 years in Canada. ### results With an assumed 4RMP efficacy of 60%, 9INH was more effective but slightly more expensive. Above a threshold efficacy of 69%, 4RMP was cheaper and more effective than 9INH. If the true efficacy of 4RMP is \u226575%, a trial powered to detect non-inferiority with a lower limit of 60% estimated efficacy (~20 000 subjects) may lead to cost savings within 10 years, even with the extreme assumption that Canada bears the entire cost. ### conclusion 4RMP may be a reasonable alternative to 9INH. Costs of a large-scale non-inferiority trial may be offset by subsequent savings.","tokens":[{"text":"Potential","start":0,"end":9,"id":0,"ws":true},{"text":"cost-effectiveness","start":10,"end":28,"id":1,"ws":true},{"text":"of","start":29,"end":31,"id":2,"ws":true},{"text":"rifampin","start":32,"end":40,"id":3,"ws":true},{"text":"vs.","start":41,"end":44,"id":4,"ws":true},{"text":"isoniazid","start":45,"end":54,"id":5,"ws":true},{"text":"for","start":55,"end":58,"id":6,"ws":true},{"text":"latent","start":59,"end":65,"id":7,"ws":true},{"text":"tuberculosis","start":66,"end":78,"id":8,"ws":true},{"text":":","start":79,"end":80,"id":9,"ws":true},{"text":"implications","start":81,"end":93,"id":10,"ws":true},{"text":"for","start":94,"end":97,"id":11,"ws":true},{"text":"future","start":98,"end":104,"id":12,"ws":true},{"text":"clinical","start":105,"end":113,"id":13,"ws":true},{"text":"trials","start":114,"end":120,"id":14,"ws":true},{"text":".","start":121,"end":122,"id":15,"ws":false}],"spans":[{"start":32,"end":40,"token_start":3,"token_end":3,"label":"DRUG"},{"start":45,"end":54,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22283892/","_input_hash":965071236,"_task_hash":1293090769,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Treatments included once daily erlotinib , which was given alone for the first 7 days of treatments , then in combination with once daily sirolimus .","paragraph":"<h3><u>A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.</u></h3>In order to achieve higher dosages than previously used in clinical trials, we conducted a phase I trial to determine the maximum tolerated dose (MTD) for the combination of <b style='color:Tomato;'><i>erlotinib</i></b> and <b style='color:Tomato;'><i>sirolimus</i></b> for the treatments of recurrent malignant gliomas. Patients with pathologically proven World Health Organization (WHO) grade III glioma and grade IV glioblastoma and radiographically proven tumor recurrence were eligible for this study. <b style='color:DodgerBlue;'><i>Treatments</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:MediumOrchid;'><i>erlotinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatments</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>then</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>once</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:MediumOrchid;'><i>sirolimus</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>sirolimus</i></b> was given with a loading dose on day 8 followed by a maintenance dose starting on day 9. Dose-limiting toxicity (DLT) was determined over the first 28 days of treatments, and the MTD was determined in a 3 + 3 classic study design. 19 patients were enrolled, and 13 patients were eligible for MTD determination. The MTD was determined to be 150 mg daily for <b style='color:Tomato;'><i>erlotinib</i></b> and 5 mg daily (after a 15 mg loading dose) for <b style='color:Tomato;'><i>sirolimus</i></b>. The DLTs included rash and mucositis (despite maximal medical managements), hypophosphatemia, altered mental status, and neutropenia. The combination of <b style='color:Tomato;'><i>erlotinib</i></b> and <b style='color:Tomato;'><i>sirolimus</i></b> is difficult to tolerate at dosages higher than previously reported in phase II trials.","tokens":[{"text":"Treatments","start":0,"end":10,"id":0,"ws":true},{"text":"included","start":11,"end":19,"id":1,"ws":true},{"text":"once","start":20,"end":24,"id":2,"ws":true},{"text":"daily","start":25,"end":30,"id":3,"ws":true},{"text":"erlotinib","start":31,"end":40,"id":4,"ws":true},{"text":",","start":41,"end":42,"id":5,"ws":true},{"text":"which","start":43,"end":48,"id":6,"ws":true},{"text":"was","start":49,"end":52,"id":7,"ws":true},{"text":"given","start":53,"end":58,"id":8,"ws":true},{"text":"alone","start":59,"end":64,"id":9,"ws":true},{"text":"for","start":65,"end":68,"id":10,"ws":true},{"text":"the","start":69,"end":72,"id":11,"ws":true},{"text":"first","start":73,"end":78,"id":12,"ws":true},{"text":"7","start":79,"end":80,"id":13,"ws":true},{"text":"days","start":81,"end":85,"id":14,"ws":true},{"text":"of","start":86,"end":88,"id":15,"ws":true},{"text":"treatments","start":89,"end":99,"id":16,"ws":true},{"text":",","start":100,"end":101,"id":17,"ws":true},{"text":"then","start":102,"end":106,"id":18,"ws":true},{"text":"in","start":107,"end":109,"id":19,"ws":true},{"text":"combination","start":110,"end":121,"id":20,"ws":true},{"text":"with","start":122,"end":126,"id":21,"ws":true},{"text":"once","start":127,"end":131,"id":22,"ws":true},{"text":"daily","start":132,"end":137,"id":23,"ws":true},{"text":"sirolimus","start":138,"end":147,"id":24,"ws":true},{"text":".","start":148,"end":149,"id":25,"ws":false}],"spans":[{"start":31,"end":40,"token_start":4,"token_end":4,"label":"DRUG"},{"start":138,"end":147,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22918789/","_input_hash":-139977506,"_task_hash":-1888720374,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":4,"child":24,"head_span":{"start":31,"end":40,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":138,"end":147,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Cabazitaxel effectively killed PC-3R cells , and MDR1 knockdown improved the sensitivity of PC-3R cells to docetaxel but not to cabazitaxel .","paragraph":"<h3><u>Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.</u></h3><b style='color:Tomato;'><i>docetaxel</i></b> is used as the first-line chemotherapy for castration-resistant prostate cancer (CRPC), but <b style='color:Tomato;'><i>docetaxel</i></b> resistance occurs in part owing to induction of P-glycoprotein (P-gp) encoded by multidrug resistance protein 1 (MDR1) gene. A recently developed taxane-<b style='color:Tomato;'><i>cabazitaxel</i></b>-has poor affinity for P-gp and is thereby effective in <b style='color:Tomato;'><i>docetaxel</i></b>-resistant CRPC. It has been recently demonstrated that exosomes in the body fluids could serve as a diagnostic marker because they contain proteins and RNAs specific to the cells from which they are derived. In this study, we aimed to investigate if P-gp in blood exosomes could be a marker to diagnose <b style='color:Tomato;'><i>docetaxel</i></b> resistance and select a taxoid for patients with CRPC. ### Methods And Materials Exosomes were isolated by differential centrifugation from <b style='color:Tomato;'><i>docetaxel</i></b>-resistant prostate cancer (PC-3) cells (PC-3R) and their parental PC-3 cells and from the serum of patients. Silencing of P-gp was performed by small interfering RNA transfection. Protein expression was examined by Western blot analysis. Viability of cells treated with <b style='color:Tomato;'><i>docetaxel</i></b> or <b style='color:Tomato;'><i>cabazitaxel</i></b> was determined by water soluble tetrazolium salt (WST) assay. ### results The level of P-gp was higher in exosomes as well as cell lysates from PC-3R cells than in those from PC-3 cells. <b style='color:MediumOrchid;'><i>Cabazitaxel</i></b> <b style='color:DodgerBlue;'><i>effectively</i></b> <b style='color:DodgerBlue;'><i>killed</i></b> <b style='color:DodgerBlue;'><i>PC-3R</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>MDR1</i></b> <b style='color:DodgerBlue;'><i>knockdown</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>sensitivity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>PC-3R</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>cabazitaxel</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The P-gp level in blood exosomes was relatively higher in clinically <b style='color:Tomato;'><i>docetaxel</i></b>-resistant patients than in therapy-na\u00efve patients. ### conclusions Our results suggest that detection of P-gp in blood exosomes, which is involved in resistance to <b style='color:Tomato;'><i>docetaxel</i></b> but not to <b style='color:Tomato;'><i>cabazitaxel</i></b>, could be useful to diagnose <b style='color:Tomato;'><i>docetaxel</i></b> resistance and select an appropriate taxoid for patients with CRPC-<b style='color:Tomato;'><i>docetaxel</i></b> or <b style='color:Tomato;'><i>cabazitaxel</i></b>.","tokens":[{"text":"Cabazitaxel","start":0,"end":11,"id":0,"ws":true},{"text":"effectively","start":12,"end":23,"id":1,"ws":true},{"text":"killed","start":24,"end":30,"id":2,"ws":true},{"text":"PC-3R","start":31,"end":36,"id":3,"ws":true},{"text":"cells","start":37,"end":42,"id":4,"ws":true},{"text":",","start":43,"end":44,"id":5,"ws":true},{"text":"and","start":45,"end":48,"id":6,"ws":true},{"text":"MDR1","start":49,"end":53,"id":7,"ws":true},{"text":"knockdown","start":54,"end":63,"id":8,"ws":true},{"text":"improved","start":64,"end":72,"id":9,"ws":true},{"text":"the","start":73,"end":76,"id":10,"ws":true},{"text":"sensitivity","start":77,"end":88,"id":11,"ws":true},{"text":"of","start":89,"end":91,"id":12,"ws":true},{"text":"PC-3R","start":92,"end":97,"id":13,"ws":true},{"text":"cells","start":98,"end":103,"id":14,"ws":true},{"text":"to","start":104,"end":106,"id":15,"ws":true},{"text":"docetaxel","start":107,"end":116,"id":16,"ws":true},{"text":"but","start":117,"end":120,"id":17,"ws":true},{"text":"not","start":121,"end":124,"id":18,"ws":true},{"text":"to","start":125,"end":127,"id":19,"ws":true},{"text":"cabazitaxel","start":128,"end":139,"id":20,"ws":true},{"text":".","start":140,"end":141,"id":21,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":107,"end":116,"token_start":16,"token_end":16,"label":"DRUG"},{"start":128,"end":139,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26027763/","_input_hash":2074706082,"_task_hash":-1323763211,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The results suggest that rational therapy for severe CHF includes addition of the aldosterone antagonist spironolactone to low doses of captopril ( or another ACE inhibitor ) and high doses of loop diuretics , provided renal function is adequate .","paragraph":"<h3><u>Captopril and spironolactone therapy for refractory congestive heart failure.</u></h3>Short- and long-term clinical effects of the angiotensin-converting enzyme (ACE) inhibitor <b style='color:Tomato;'><i>captopril</i></b> in severe congestive heart failure (CHF) were evaluated during a 3-year open study of 124 inpatients with New York Heart Association (NYHA) functional class III or IV CHF refractory to treatment with cardiac glycosides and high doses of loop diuretics. <b style='color:Tomato;'><i>captopril</i></b> was added to each patient's regimen, which comprised combinations of <b style='color:Tomato;'><i>furosemide</i></b> (124 patients), digitalis (117 patients), and <b style='color:Tomato;'><i>spironolactone</i></b> (90 patients). By the end of the first month of <b style='color:Tomato;'><i>captopril</i></b> administration, improvement in NYHA functional class was seen in 89 patients (72%). During the first year of <b style='color:Tomato;'><i>captopril</i></b> treatment, the number of hospital admissions and hospital days declined significantly (p < 0.001) and functional class improved significantly (p < 0.001). Although most patients tolerated <b style='color:Tomato;'><i>captopril</i></b> well, 44% experienced hypotension, which in 10% of patients necessitated termination of <b style='color:Tomato;'><i>captopril</i></b> therapy. Although mean serum potassium levels tended to increase, serious hyperkalemia did not occur. After 1 year, a subset of 30 patients who had not initially received <b style='color:Tomato;'><i>spironolactone</i></b> deteriorated clinically and manifested increasing urinary aldosterone levels. Hypotension precluded increasing the <b style='color:Tomato;'><i>captopril</i></b> dose, but introduction of <b style='color:Tomato;'><i>spironolactone</i></b> improved clinical status in this cohort. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>rational</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>CHF</i></b> <b style='color:DodgerBlue;'><i>includes</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>aldosterone</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:MediumOrchid;'><i>spironolactone</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>another</i></b> <b style='color:DodgerBlue;'><i>ACE</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>loop</i></b> <b style='color:DodgerBlue;'><i>diuretics</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>provided</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>adequate</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"results","start":4,"end":11,"id":1,"ws":true},{"text":"suggest","start":12,"end":19,"id":2,"ws":true},{"text":"that","start":20,"end":24,"id":3,"ws":true},{"text":"rational","start":25,"end":33,"id":4,"ws":true},{"text":"therapy","start":34,"end":41,"id":5,"ws":true},{"text":"for","start":42,"end":45,"id":6,"ws":true},{"text":"severe","start":46,"end":52,"id":7,"ws":true},{"text":"CHF","start":53,"end":56,"id":8,"ws":true},{"text":"includes","start":57,"end":65,"id":9,"ws":true},{"text":"addition","start":66,"end":74,"id":10,"ws":true},{"text":"of","start":75,"end":77,"id":11,"ws":true},{"text":"the","start":78,"end":81,"id":12,"ws":true},{"text":"aldosterone","start":82,"end":93,"id":13,"ws":true},{"text":"antagonist","start":94,"end":104,"id":14,"ws":true},{"text":"spironolactone","start":105,"end":119,"id":15,"ws":true},{"text":"to","start":120,"end":122,"id":16,"ws":true},{"text":"low","start":123,"end":126,"id":17,"ws":true},{"text":"doses","start":127,"end":132,"id":18,"ws":true},{"text":"of","start":133,"end":135,"id":19,"ws":true},{"text":"captopril","start":136,"end":145,"id":20,"ws":true},{"text":"(","start":146,"end":147,"id":21,"ws":true},{"text":"or","start":148,"end":150,"id":22,"ws":true},{"text":"another","start":151,"end":158,"id":23,"ws":true},{"text":"ACE","start":159,"end":162,"id":24,"ws":true},{"text":"inhibitor","start":163,"end":172,"id":25,"ws":true},{"text":")","start":173,"end":174,"id":26,"ws":true},{"text":"and","start":175,"end":178,"id":27,"ws":true},{"text":"high","start":179,"end":183,"id":28,"ws":true},{"text":"doses","start":184,"end":189,"id":29,"ws":true},{"text":"of","start":190,"end":192,"id":30,"ws":true},{"text":"loop","start":193,"end":197,"id":31,"ws":true},{"text":"diuretics","start":198,"end":207,"id":32,"ws":true},{"text":",","start":208,"end":209,"id":33,"ws":true},{"text":"provided","start":210,"end":218,"id":34,"ws":true},{"text":"renal","start":219,"end":224,"id":35,"ws":true},{"text":"function","start":225,"end":233,"id":36,"ws":true},{"text":"is","start":234,"end":236,"id":37,"ws":true},{"text":"adequate","start":237,"end":245,"id":38,"ws":true},{"text":".","start":246,"end":247,"id":39,"ws":false}],"spans":[{"start":105,"end":119,"token_start":15,"token_end":15,"label":"DRUG"},{"start":136,"end":145,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8422001/","_input_hash":502076918,"_task_hash":-2120561096,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":20,"child":15,"head_span":{"start":136,"end":145,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":105,"end":119,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The MICs of erythromycin and clindamycin for most of the LAB were within the normal range of susceptibility .","paragraph":"<h3><u>Antibiotic resistance in lactic acid bacteria isolated from some pharmaceutical and dairy products.</u></h3>A total of 244 lactic acid bacteria (LAB) strains were isolated from 180 dairy and pharmaceutical products that were collected from different areas in Minia governorate, Egypt. LAB were identified phenotypically on basis of morphological, physiological and biochemical characteristics. Lactobacillus isolates were further confirmed using PCR-based assay. By combination of phenotypic with molecular identification Lactobacillus spp. were found to be the dominant genus (138, 76.7%) followed by Streptococcus spp. (65, 36.1%) and Lactococcus spp. (27, 15%). Some contaminant organisms such as (Staphylococcus spp., Escherichia coli, Salmonella spp., mould and yeast) were isolated from the collected dairy samples but pharmaceutical products were free of such contaminants. Susceptibility of LAB isolates to antibiotics representing all major classes was tested by agar dilution method. Generally, LAB were highly susceptible to Beta-lactams except penicillin. Lactobacilli were resistant to <b style='color:Tomato;'><i>vancomycin</i></b>, however lactococci and streptococci proved to be very susceptible. Most strains were susceptible to <b style='color:Tomato;'><i>tetracycline</i></b> and showed a wide range of <b style='color:Tomato;'><i>streptomycin</i></b> MICs. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>MICs</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>erythromycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clindamycin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>LAB</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>within</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>normal</i></b> <b style='color:DodgerBlue;'><i>range</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>susceptibility</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Sixteen Lactobacillus, 8 Lactococcus and 8 Streptococcus isolates including all <b style='color:Tomato;'><i>tetracycline</i></b> and/or <b style='color:Tomato;'><i>erythromycin</i></b> resistant strains were tested for the presence of <b style='color:Tomato;'><i>tetracycline</i></b> and/or <b style='color:Tomato;'><i>erythromycin</i></b> resistant genes [tet(M) and/or erm(B)]. PCR assays shows that some resistant strains harbor tet(M) and/or erm(B) resistance genes.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"MICs","start":4,"end":8,"id":1,"ws":true},{"text":"of","start":9,"end":11,"id":2,"ws":true},{"text":"erythromycin","start":12,"end":24,"id":3,"ws":true},{"text":"and","start":25,"end":28,"id":4,"ws":true},{"text":"clindamycin","start":29,"end":40,"id":5,"ws":true},{"text":"for","start":41,"end":44,"id":6,"ws":true},{"text":"most","start":45,"end":49,"id":7,"ws":true},{"text":"of","start":50,"end":52,"id":8,"ws":true},{"text":"the","start":53,"end":56,"id":9,"ws":true},{"text":"LAB","start":57,"end":60,"id":10,"ws":true},{"text":"were","start":61,"end":65,"id":11,"ws":true},{"text":"within","start":66,"end":72,"id":12,"ws":true},{"text":"the","start":73,"end":76,"id":13,"ws":true},{"text":"normal","start":77,"end":83,"id":14,"ws":true},{"text":"range","start":84,"end":89,"id":15,"ws":true},{"text":"of","start":90,"end":92,"id":16,"ws":true},{"text":"susceptibility","start":93,"end":107,"id":17,"ws":true},{"text":".","start":108,"end":109,"id":18,"ws":false}],"spans":[{"start":12,"end":24,"token_start":3,"token_end":3,"label":"DRUG"},{"start":29,"end":40,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24948910/","_input_hash":1103413111,"_task_hash":1587683157,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Based on HRs for RFS/DFS , the risk of recurrence with nivolumab was similar to that of pembrolizumab and lower than that of ipilimumab 3 mg/kg , ipilimumab 10 mg/kg , or interferon .","paragraph":"<h3><u>Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.</u></h3>Immune checkpoint inhibitors and targeted therapies are approved for adjuvant treatment of patients with resected melanoma; however, they have not been compared in randomized controlled trials (RCTs). We compared the efficacy and safety of adjuvant <b style='color:Tomato;'><i>nivolumab</i></b> with other approved treatments using available evidence from RCTs in a Bayesian network meta-analysis (NMA). ### methods A systematic literature review was conducted through May 2019 to identify relevant RCTs evaluating approved adjuvant treatments. Outcomes of interest included recurrence-free survival (RFS)/disease-free survival (DFS), distant metastasis-free survival (DMFS), all-cause grade 3/4 adverse events (AEs), discontinuations, and discontinuations due to AEs. Time-to-event outcomes (RFS/DFS and DMFS) were analyzed both assuming that hazard ratios (HRs) are constant over time and that they vary. ### results Of 26 identified RCTs, 19 were included in the NMA following a feasibility assessment. <b style='color:DodgerBlue;'><i>Based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>HRs</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>RFS/DFS</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>interferon</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Risk of recurrence with <b style='color:Tomato;'><i>nivolumab</i></b> was similar to that of <b style='color:Tomato;'><i>dabrafenib</i></b> plus <b style='color:Tomato;'><i>trametinib</i></b> at 12\u2009months, however, was lower beyond 12\u2009months (HR [95% credible interval] at 24\u2009months, 0.46 [0.27-0.78]; at 36\u2009months, 0.28 [0.14-0.59]). Based on HRs for DMFS, the risk of developing distant metastases was lower with <b style='color:Tomato;'><i>nivolumab</i></b> than with <b style='color:Tomato;'><i>ipilimumab</i></b> 10\u2009mg/kg or interferon and was similar to <b style='color:Tomato;'><i>dabrafenib</i></b> plus <b style='color:Tomato;'><i>trametinib</i></b>. ### conclusion Adjuvant therapy with <b style='color:Tomato;'><i>nivolumab</i></b> provides an effective treatment option with a promising risk-benefit profile.","tokens":[{"text":"Based","start":0,"end":5,"id":0,"ws":true},{"text":"on","start":6,"end":8,"id":1,"ws":true},{"text":"HRs","start":9,"end":12,"id":2,"ws":true},{"text":"for","start":13,"end":16,"id":3,"ws":true},{"text":"RFS/DFS","start":17,"end":24,"id":4,"ws":true},{"text":",","start":25,"end":26,"id":5,"ws":true},{"text":"the","start":27,"end":30,"id":6,"ws":true},{"text":"risk","start":31,"end":35,"id":7,"ws":true},{"text":"of","start":36,"end":38,"id":8,"ws":true},{"text":"recurrence","start":39,"end":49,"id":9,"ws":true},{"text":"with","start":50,"end":54,"id":10,"ws":true},{"text":"nivolumab","start":55,"end":64,"id":11,"ws":true},{"text":"was","start":65,"end":68,"id":12,"ws":true},{"text":"similar","start":69,"end":76,"id":13,"ws":true},{"text":"to","start":77,"end":79,"id":14,"ws":true},{"text":"that","start":80,"end":84,"id":15,"ws":true},{"text":"of","start":85,"end":87,"id":16,"ws":true},{"text":"pembrolizumab","start":88,"end":101,"id":17,"ws":true},{"text":"and","start":102,"end":105,"id":18,"ws":true},{"text":"lower","start":106,"end":111,"id":19,"ws":true},{"text":"than","start":112,"end":116,"id":20,"ws":true},{"text":"that","start":117,"end":121,"id":21,"ws":true},{"text":"of","start":122,"end":124,"id":22,"ws":true},{"text":"ipilimumab","start":125,"end":135,"id":23,"ws":true},{"text":"3","start":136,"end":137,"id":24,"ws":true},{"text":"mg/kg","start":138,"end":143,"id":25,"ws":true},{"text":",","start":144,"end":145,"id":26,"ws":true},{"text":"ipilimumab","start":146,"end":156,"id":27,"ws":true},{"text":"10","start":157,"end":159,"id":28,"ws":true},{"text":"mg/kg","start":160,"end":165,"id":29,"ws":true},{"text":",","start":166,"end":167,"id":30,"ws":true},{"text":"or","start":168,"end":170,"id":31,"ws":true},{"text":"interferon","start":171,"end":181,"id":32,"ws":true},{"text":".","start":182,"end":183,"id":33,"ws":false}],"spans":[{"start":55,"end":64,"token_start":11,"token_end":11,"label":"DRUG"},{"start":88,"end":101,"token_start":17,"token_end":17,"label":"DRUG"},{"start":125,"end":135,"token_start":23,"token_end":23,"label":"DRUG"},{"start":146,"end":156,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33402121/","_input_hash":1093190495,"_task_hash":214136276,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Combination therapy of infliximab and methotrexate is more effective in reducing clinical and biochemical disease activity than gold with methylprednisolone treatment in RA patients during 22 weeks of treatment , especially in the first 6 weeks .","paragraph":"<h3><u>[Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis].</u></h3>The objective of the paper was compare the effects and tolerability of combined therapy of multiple intravenous infusions of anti-tumour necrosis factor-alfa (TNF-alfa) monoclonal antibody (Remicade) with <b style='color:Tomato;'><i>methotrexate</i></b> versus treatment with sodium aurothiomalate and intramuscular depot <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> in rheumatoid arthritis (RA). We investigate also the interval necessary to obtain the improvement in both treatment groups. 36 patients commencing intramuscular sodium aurothiomalate therapy with intramuscular depot <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> acetate at weeks 0, 4, 8 and 12 in addition to chrysotherapy were compared in retrospective analysis with 32 patients starting with multiple intravenous infusions of <b style='color:Tomato;'><i>infliximab</i></b>, anti-TNF-alfa monoclonal antibody (Remicade) and <b style='color:Tomato;'><i>methotrexate</i></b> at a stable dose. Patients were assessed by composite clinical score (DAS 28) and C-reactive protein during 22 weeks of therapy. At week 2 and 6 a significantly greater percentage of <b style='color:Tomato;'><i>infliximab</i></b>-treated than gold-treated RA patients achieved improvement in each clinical measurement of disease activity. At 22 week of treatment moderate and good response according to EULAR criteria was achieved in 91% of <b style='color:Tomato;'><i>infliximab</i></b>-treated patients and 58% gold treated patients (p < 0.001). Adverse events were more frequently observed in <b style='color:Tomato;'><i>infliximab</i></b>-treated patients, but only gold-treated patients discontinued treatment because adverse events (2 patients due to proteinuria, 2 patients due to mucocutaneous changes and one patient due to leucopenia). The higher percentage of adverse events in <b style='color:Tomato;'><i>infliximab</i></b>-treated patients was caused mainly by the occurrence of infusion reactions (23 reactions out of 160 infusions); most of them were mild (somnolentia and headache) and transient. Viral infections (including herpes simplex and zoster) were more common in patients treated with <b style='color:Tomato;'><i>infliximab</i></b> and <b style='color:Tomato;'><i>methotrexate</i></b>. <b style='color:DodgerBlue;'><i>Combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>infliximab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>reducing</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>biochemical</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>gold</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>RA</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>22</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>especially</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Combination","start":0,"end":11,"id":0,"ws":true},{"text":"therapy","start":12,"end":19,"id":1,"ws":true},{"text":"of","start":20,"end":22,"id":2,"ws":true},{"text":"infliximab","start":23,"end":33,"id":3,"ws":true},{"text":"and","start":34,"end":37,"id":4,"ws":true},{"text":"methotrexate","start":38,"end":50,"id":5,"ws":true},{"text":"is","start":51,"end":53,"id":6,"ws":true},{"text":"more","start":54,"end":58,"id":7,"ws":true},{"text":"effective","start":59,"end":68,"id":8,"ws":true},{"text":"in","start":69,"end":71,"id":9,"ws":true},{"text":"reducing","start":72,"end":80,"id":10,"ws":true},{"text":"clinical","start":81,"end":89,"id":11,"ws":true},{"text":"and","start":90,"end":93,"id":12,"ws":true},{"text":"biochemical","start":94,"end":105,"id":13,"ws":true},{"text":"disease","start":106,"end":113,"id":14,"ws":true},{"text":"activity","start":114,"end":122,"id":15,"ws":true},{"text":"than","start":123,"end":127,"id":16,"ws":true},{"text":"gold","start":128,"end":132,"id":17,"ws":true},{"text":"with","start":133,"end":137,"id":18,"ws":true},{"text":"methylprednisolone","start":138,"end":156,"id":19,"ws":true},{"text":"treatment","start":157,"end":166,"id":20,"ws":true},{"text":"in","start":167,"end":169,"id":21,"ws":true},{"text":"RA","start":170,"end":172,"id":22,"ws":true},{"text":"patients","start":173,"end":181,"id":23,"ws":true},{"text":"during","start":182,"end":188,"id":24,"ws":true},{"text":"22","start":189,"end":191,"id":25,"ws":true},{"text":"weeks","start":192,"end":197,"id":26,"ws":true},{"text":"of","start":198,"end":200,"id":27,"ws":true},{"text":"treatment","start":201,"end":210,"id":28,"ws":true},{"text":",","start":211,"end":212,"id":29,"ws":true},{"text":"especially","start":213,"end":223,"id":30,"ws":true},{"text":"in","start":224,"end":226,"id":31,"ws":true},{"text":"the","start":227,"end":230,"id":32,"ws":true},{"text":"first","start":231,"end":236,"id":33,"ws":true},{"text":"6","start":237,"end":238,"id":34,"ws":true},{"text":"weeks","start":239,"end":244,"id":35,"ws":true},{"text":".","start":245,"end":246,"id":36,"ws":false}],"spans":[{"start":23,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":38,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},{"start":138,"end":156,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12685246/","_input_hash":-102465531,"_task_hash":-582924133,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":23,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":38,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Serum homocysteine , cholesterol , retinol , alpha-tocopherol , glycosylated hemoglobin and inflammatory response during therapy with bevacizumab , oxaliplatin , 5-fluorouracil and leucovorin .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Serum</i></b> <b style='color:DodgerBlue;'><i>homocysteine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>retinol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alpha-tocopherol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>glycosylated</i></b> <b style='color:DodgerBlue;'><i>hemoglobin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>inflammatory</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Targeted agents present with a new spectrum of side-effects, including toxicities that negatively impact the risk of atherosclerosis. The aim of the present study was to evaluate the effect of the combination of targeted therapy and chemotherapy on serum homocysteine and other laboratory parameters of cardiovascular risk in patients with metastatic colorectal carcinoma. ### Patients And Methods Thirty-one patients with metastatic colorectal carcinoma treated with the combination of <b style='color:Tomato;'><i>bevacizumab</i></b>, <b style='color:Tomato;'><i>oxaliplatin</i></b>, 5-<b style='color:Tomato;'><i>fluorouracil</i></b> and <b style='color:Tomato;'><i>leucovorin</i></b> were studied before and during the therapy. ### results Serum homocysteine decreased significantly throughout the course of treatment. Total cholesterol and low-density lipoprotein cholesterol also decreased significantly during the first month of therapy. In contrast, serum retinol significantly increased during the second and third months of treatment. A significant increase in glycosylated hemoglobin was also observed. After an initial rise, serum C-reactive protein (CRP) and carcinoembryonic antigen (CEA) were significantly lower compared to baseline throughout the course of treatment. Serum ferritin increased throughout most of the course of treatment. A significant correlation was observed between CRP and high-density lipoprotein cholesterol, retinol, ferritin, and CEA. CEA correlated with hemoglobin, retinol, and ferritin. Retinol correlated significantly with hemoglobin. ### conclusion Tumor control, reflected in lower CEA, resulted in suppression of the acute phase response and generally in favorable effects on laboratory parameters indicative of risk factors of atherosclerosis, including lower homocysteine concentrations, and lower total and LDL cholesterol.","tokens":[{"text":"Serum","start":0,"end":5,"id":0,"ws":true},{"text":"homocysteine","start":6,"end":18,"id":1,"ws":true},{"text":",","start":19,"end":20,"id":2,"ws":true},{"text":"cholesterol","start":21,"end":32,"id":3,"ws":true},{"text":",","start":33,"end":34,"id":4,"ws":true},{"text":"retinol","start":35,"end":42,"id":5,"ws":true},{"text":",","start":43,"end":44,"id":6,"ws":true},{"text":"alpha-tocopherol","start":45,"end":61,"id":7,"ws":true},{"text":",","start":62,"end":63,"id":8,"ws":true},{"text":"glycosylated","start":64,"end":76,"id":9,"ws":true},{"text":"hemoglobin","start":77,"end":87,"id":10,"ws":true},{"text":"and","start":88,"end":91,"id":11,"ws":true},{"text":"inflammatory","start":92,"end":104,"id":12,"ws":true},{"text":"response","start":105,"end":113,"id":13,"ws":true},{"text":"during","start":114,"end":120,"id":14,"ws":true},{"text":"therapy","start":121,"end":128,"id":15,"ws":true},{"text":"with","start":129,"end":133,"id":16,"ws":true},{"text":"bevacizumab","start":134,"end":145,"id":17,"ws":true},{"text":",","start":146,"end":147,"id":18,"ws":true},{"text":"oxaliplatin","start":148,"end":159,"id":19,"ws":true},{"text":",","start":160,"end":161,"id":20,"ws":true},{"text":"5-fluorouracil","start":162,"end":176,"id":21,"ws":true},{"text":"and","start":177,"end":180,"id":22,"ws":true},{"text":"leucovorin","start":181,"end":191,"id":23,"ws":true},{"text":".","start":192,"end":193,"id":24,"ws":false}],"spans":[{"start":134,"end":145,"token_start":17,"token_end":17,"label":"DRUG"},{"start":148,"end":159,"token_start":19,"token_end":19,"label":"DRUG"},{"start":162,"end":176,"token_start":21,"token_end":21,"label":"DRUG"},{"start":181,"end":191,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20032440/","_input_hash":626081300,"_task_hash":-2050444588,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":17,"child":19,"head_span":{"start":134,"end":145,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":148,"end":159,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":21,"child":23,"head_span":{"start":162,"end":176,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":181,"end":191,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":21,"child":19,"head_span":{"start":162,"end":176,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":148,"end":159,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Reversal of drug resistance by planetary ball milled ( PBM ) nanoparticle loaded with resveratrol and docetaxel in prostate cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Reversal</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>planetary</i></b> <b style='color:DodgerBlue;'><i>ball</i></b> <b style='color:DodgerBlue;'><i>milled</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PBM</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>nanoparticle</i></b> <b style='color:DodgerBlue;'><i>loaded</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>resveratrol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The folate receptor (FR) is a valued target that is highly expressed in various cancers, which will expedite the development of ligand-receptor binding based cancer therapeutics. In the present investigation, through tissue microarray analysis, we report higher levels of folate receptor expression in prostate cancer (PCa) tissue derived from patients, which were minimal in normal tissue. For folate-receptor based targeted therapy of PCa, we generated novel planetary ball milled (PBM) nanoparticles (NPs) encapsulated with <b style='color:Tomato;'><i>resveratrol</i></b> (RES), and in combination with <b style='color:Tomato;'><i>docetaxel</i></b> (DTX) and conjugated with folic acid (FA) on the surface. The cytotoxic effect of FA-conjugated DTX-nanoparticles was found effectual that reduced the concentration of free drug (DTX) to 28 times. Flow cytometry analysis showed a significant increase in the number of apoptotic cells by 30.92% and 65.9% in the FA-conjugated RES and in combination with DTX nanoparticle formulation respectively. However, only 8.9% apoptotic cells were found with control (empty NP). The expressions of NF-kB p65, COX-2, pro (BAX, BAK) and anti-apoptotic (BCL-2, BCL-XL) genes were significantly reduced after treatment with FA-RES\u00a0+\u00a0DTX-NP. In addition, the FA-conjugated DTX formulation exhibited additional cytotoxic effects with the down-regulation of survivin and an increased expression of Cleaved Caspase-3 in PCa cells. Further, we observed that treating DTX resistant PCa cells with FA-RES\u00a0+\u00a0DTX-NP exhibited a reversal of the ABC-transporter markers thereby limiting the multidrug resistance phenotype of the cancer cells. Our results strongly suggested that FA conjugated nanoparticle drugs acted as effective inhibitors of drug efflux that effectually enhances the intracellular concentration of the drug to exhibit their cytotoxic effect.","tokens":[{"text":"Reversal","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"drug","start":12,"end":16,"id":2,"ws":true},{"text":"resistance","start":17,"end":27,"id":3,"ws":true},{"text":"by","start":28,"end":30,"id":4,"ws":true},{"text":"planetary","start":31,"end":40,"id":5,"ws":true},{"text":"ball","start":41,"end":45,"id":6,"ws":true},{"text":"milled","start":46,"end":52,"id":7,"ws":true},{"text":"(","start":53,"end":54,"id":8,"ws":true},{"text":"PBM","start":55,"end":58,"id":9,"ws":true},{"text":")","start":59,"end":60,"id":10,"ws":true},{"text":"nanoparticle","start":61,"end":73,"id":11,"ws":true},{"text":"loaded","start":74,"end":80,"id":12,"ws":true},{"text":"with","start":81,"end":85,"id":13,"ws":true},{"text":"resveratrol","start":86,"end":97,"id":14,"ws":true},{"text":"and","start":98,"end":101,"id":15,"ws":true},{"text":"docetaxel","start":102,"end":111,"id":16,"ws":true},{"text":"in","start":112,"end":114,"id":17,"ws":true},{"text":"prostate","start":115,"end":123,"id":18,"ws":true},{"text":"cancer","start":124,"end":130,"id":19,"ws":true},{"text":".","start":131,"end":132,"id":20,"ws":false}],"spans":[{"start":86,"end":97,"token_start":14,"token_end":14,"label":"DRUG"},{"start":102,"end":111,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29678549/","_input_hash":1903734758,"_task_hash":-393600527,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":86,"end":97,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":102,"end":111,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Records of 63 patients diagnosis of IHCC who received Gemcitabine and Carboplatin ( G-C Regimen ) chemotherapy as a first line were retrospectively reviewed .","paragraph":"<h3><u>Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: A study from North India Cancer Centre.</u></h3><b style='color:Tomato;'><i>gemcitabine</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b> has been established as a standard chemotherapy regimen for advanced biliary tract cancers (BTCs) based on the phase III UK ABC-02 study, which included all types of biliary cancers. There is very limited data regarding the effectiveness of known chemotherapeutic regimens especially in IHCC. ### methods <b style='color:DodgerBlue;'><i>Records</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>63</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>diagnosis</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>IHCC</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>Gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Carboplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>G-C</i></b> <b style='color:DodgerBlue;'><i>Regimen</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>retrospectively</i></b> <b style='color:DodgerBlue;'><i>reviewed</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary aim of this study was to assess the response rate of <b style='color:Tomato;'><i>gemcitabine</i></b> <b style='color:Tomato;'><i>carboplatin</i></b>-based chemotherapy as a first line therapy in advanced intrahepatic cholangiocarcinoma (IHCC). The secondary objectives were to assess toxicity, progression free survival and overall survival. ### results There were 38 men and 25 women in our study with a median age of 56.75 years (range 31-78 years). Of the 38+25= 63 patients, 21 patients (33.8%) progressed, 5 patients (8.06%) had complete response, 25 patients (40.3%) had partial response, 12 patients (19.3%) had stable disease. Overall response rate was 48.36% and tumor control rate was 67.6%. Progression free survival was 5.3 months and overall survival of 10.3 months was seen. The most common grade 3-4 toxicities were anemia, neutropenia, and thrombocytopenia. Most common nonhematological toxicity was fatigue. ### conclusion <b style='color:Tomato;'><i>gemcitabine</i></b> in combination with <b style='color:Tomato;'><i>carboplatin</i></b> has activity against advanced IHCC. Our results are comparable with other <b style='color:Tomato;'><i>gemcitabine</i></b> <b style='color:Tomato;'><i>carboplatin</i></b> studies as well as <b style='color:Tomato;'><i>gemcitabine</i></b> <b style='color:Tomato;'><i>cisplatin</i></b>-based studies.","tokens":[{"text":"Records","start":0,"end":7,"id":0,"ws":true},{"text":"of","start":8,"end":10,"id":1,"ws":true},{"text":"63","start":11,"end":13,"id":2,"ws":true},{"text":"patients","start":14,"end":22,"id":3,"ws":true},{"text":"diagnosis","start":23,"end":32,"id":4,"ws":true},{"text":"of","start":33,"end":35,"id":5,"ws":true},{"text":"IHCC","start":36,"end":40,"id":6,"ws":true},{"text":"who","start":41,"end":44,"id":7,"ws":true},{"text":"received","start":45,"end":53,"id":8,"ws":true},{"text":"Gemcitabine","start":54,"end":65,"id":9,"ws":true},{"text":"and","start":66,"end":69,"id":10,"ws":true},{"text":"Carboplatin","start":70,"end":81,"id":11,"ws":true},{"text":"(","start":82,"end":83,"id":12,"ws":true},{"text":"G-C","start":84,"end":87,"id":13,"ws":true},{"text":"Regimen","start":88,"end":95,"id":14,"ws":true},{"text":")","start":96,"end":97,"id":15,"ws":true},{"text":"chemotherapy","start":98,"end":110,"id":16,"ws":true},{"text":"as","start":111,"end":113,"id":17,"ws":true},{"text":"a","start":114,"end":115,"id":18,"ws":true},{"text":"first","start":116,"end":121,"id":19,"ws":true},{"text":"line","start":122,"end":126,"id":20,"ws":true},{"text":"were","start":127,"end":131,"id":21,"ws":true},{"text":"retrospectively","start":132,"end":147,"id":22,"ws":true},{"text":"reviewed","start":148,"end":156,"id":23,"ws":true},{"text":".","start":157,"end":158,"id":24,"ws":false}],"spans":[{"start":54,"end":65,"token_start":9,"token_end":9,"label":"DRUG"},{"start":70,"end":81,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30693882/","_input_hash":-1298190503,"_task_hash":785351110,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":54,"end":65,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":70,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Drugs most commonly implicated in ADRs were amoxicillin + clavulanate ( 21.87 % ) followed by ceftriaxone ( 20.31 % ) .","paragraph":"<h3><u>Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective Observational Study.</u></h3>To determine the incidence, pattern, causality, preventability, severity and predictors of adverse drug reactions (ADRs) in pediatric population. ### methods It was a prospective, observational study that included patients of either sex, of any age treated in the pediatric wards of a tertiary care hospital. Study patients were followed throughout their hospital stay. Whenever an ADR was detected, all the required data was collected and analyzed. Data was analyzed for incidence, causality (by using WHO Probability scale and Naranjo's algorithm), preventability (by using Modified Shumock and Thornton scale), severity (by using Modified Hartwig and Siegel scale) and predictors of ADRs. ### results Of the 1775 children admitted in the pediatrics ward, 1082 patients met study criteria and were enrolled into the study. A total of 64 ADRs were identified from 54 patients. The incidence of ADRs was 4.99\u00a0%. Male patients experienced majority (68.52\u00a0%) of ADRs. <b style='color:DodgerBlue;'><i>Drugs</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>commonly</i></b> <b style='color:DodgerBlue;'><i>implicated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>ADRs</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>clavulanate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>21.87</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>ceftriaxone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20.31</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Most (51.56\u00a0%) of the ADRs reported belonged to the system organ class, gastrointestinal system disorders. Among the ADRs reported, 82.85\u00a0% of ADRs were mild. Majority (87.5\u00a0%) of the ADRs were of 'probable' causality category and 96.9\u00a0% were not preventable. There was a significant association between occurrence of ADRs and the use of \u22654 number of medications, age (infants) and gender (male). ### conclusions Among the pediatric population, infants, male gender and those receiving \u22654 number of medications are at risk of developing ADRs. Constant monitoring is required to address the safety issue in pediatric population especially in infants and patients receiving \u22654 drugs.","tokens":[{"text":"Drugs","start":0,"end":5,"id":0,"ws":true},{"text":"most","start":6,"end":10,"id":1,"ws":true},{"text":"commonly","start":11,"end":19,"id":2,"ws":true},{"text":"implicated","start":20,"end":30,"id":3,"ws":true},{"text":"in","start":31,"end":33,"id":4,"ws":true},{"text":"ADRs","start":34,"end":38,"id":5,"ws":true},{"text":"were","start":39,"end":43,"id":6,"ws":true},{"text":"amoxicillin","start":44,"end":55,"id":7,"ws":true},{"text":"+","start":56,"end":57,"id":8,"ws":true},{"text":"clavulanate","start":58,"end":69,"id":9,"ws":true},{"text":"(","start":70,"end":71,"id":10,"ws":true},{"text":"21.87","start":72,"end":77,"id":11,"ws":true},{"text":"%","start":78,"end":79,"id":12,"ws":true},{"text":")","start":80,"end":81,"id":13,"ws":true},{"text":"followed","start":82,"end":90,"id":14,"ws":true},{"text":"by","start":91,"end":93,"id":15,"ws":true},{"text":"ceftriaxone","start":94,"end":105,"id":16,"ws":true},{"text":"(","start":106,"end":107,"id":17,"ws":true},{"text":"20.31","start":108,"end":113,"id":18,"ws":true},{"text":"%","start":114,"end":115,"id":19,"ws":true},{"text":")","start":116,"end":117,"id":20,"ws":true},{"text":".","start":118,"end":119,"id":21,"ws":false}],"spans":[{"start":44,"end":55,"token_start":7,"token_end":7,"label":"DRUG"},{"start":94,"end":105,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26916890/","_input_hash":1802714067,"_task_hash":1007422582,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Dexamethasone and piroxicam provided in the diet were found to significantly inhibit lung tumors induced by 60 mg/kg vinyl carbamate at 24 weeks whereas myo-inositol also provided in the diet , did not significantly inhibit tumor formation .","paragraph":"<h3><u>Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice.</u></h3>The ability of potential chemopreventive agents to prevent vinyl carbamate-induced lung tumors was determined in 2 different experiments. Female strain A mice administered intraperitoneally either a single injection of 60 mg/kg vinyl carbamate that induced 24.0 +/- 1.72 tumors/mouse at 24 weeks or 2 injections of 16 mg/kg vinyl carbamate each (32 mg/kg total dose) that induced 43.2 +/- 3.2 tumors/mouse at 20 weeks. Lung carcinomas were found as early as 16 weeks. <b style='color:MediumOrchid;'><i>Dexamethasone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>piroxicam</i></b> <b style='color:DodgerBlue;'><i>provided</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>diet</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>inhibit</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>vinyl</i></b> <b style='color:DodgerBlue;'><i>carbamate</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:DodgerBlue;'><i>myo-inositol</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>provided</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>diet</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>inhibit</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>formation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In animals given 6 16-mg/kg doses of vinyl carbamate, tumor multiplicity was reduced roughly 25% by alpha-difluoromethylornithine and green tea and reduced 50% by <b style='color:Tomato;'><i>dexamethasone</i></b> and <b style='color:Tomato;'><i>piroxicam</i></b>. Combinations of these agents were also tested using a total dose of 32 mg/kg of vinyl carbamate. Although alpha-difluoromethylornithine and green tea did not result in a significant inhibition of lung tumor formation if used alone, the combination of alpha-difluoromethylornithine and green tea resulted in a significant reduction of tumor multiplicity. The combinations of alpha-difluoromethylornithine or green tea with either <b style='color:Tomato;'><i>dexamethasone</i></b> or <b style='color:Tomato;'><i>piroxicam</i></b> or the combination of <b style='color:Tomato;'><i>dexamethasone</i></b> and <b style='color:Tomato;'><i>piroxicam</i></b> did not decrease tumor multiplicity greater than achieved by <b style='color:Tomato;'><i>dexamethasone</i></b> and <b style='color:Tomato;'><i>piroxicam</i></b> alone. In summary, selected chemopreventive agents previously shown to inhibit lung tumors by other chemical carcinogens also inhibited vinyl carbamate-induced lung tumors.","tokens":[{"text":"Dexamethasone","start":0,"end":13,"id":0,"ws":true},{"text":"and","start":14,"end":17,"id":1,"ws":true},{"text":"piroxicam","start":18,"end":27,"id":2,"ws":true},{"text":"provided","start":28,"end":36,"id":3,"ws":true},{"text":"in","start":37,"end":39,"id":4,"ws":true},{"text":"the","start":40,"end":43,"id":5,"ws":true},{"text":"diet","start":44,"end":48,"id":6,"ws":true},{"text":"were","start":49,"end":53,"id":7,"ws":true},{"text":"found","start":54,"end":59,"id":8,"ws":true},{"text":"to","start":60,"end":62,"id":9,"ws":true},{"text":"significantly","start":63,"end":76,"id":10,"ws":true},{"text":"inhibit","start":77,"end":84,"id":11,"ws":true},{"text":"lung","start":85,"end":89,"id":12,"ws":true},{"text":"tumors","start":90,"end":96,"id":13,"ws":true},{"text":"induced","start":97,"end":104,"id":14,"ws":true},{"text":"by","start":105,"end":107,"id":15,"ws":true},{"text":"60","start":108,"end":110,"id":16,"ws":true},{"text":"mg/kg","start":111,"end":116,"id":17,"ws":true},{"text":"vinyl","start":117,"end":122,"id":18,"ws":true},{"text":"carbamate","start":123,"end":132,"id":19,"ws":true},{"text":"at","start":133,"end":135,"id":20,"ws":true},{"text":"24","start":136,"end":138,"id":21,"ws":true},{"text":"weeks","start":139,"end":144,"id":22,"ws":true},{"text":"whereas","start":145,"end":152,"id":23,"ws":true},{"text":"myo-inositol","start":153,"end":165,"id":24,"ws":true},{"text":"also","start":166,"end":170,"id":25,"ws":true},{"text":"provided","start":171,"end":179,"id":26,"ws":true},{"text":"in","start":180,"end":182,"id":27,"ws":true},{"text":"the","start":183,"end":186,"id":28,"ws":true},{"text":"diet","start":187,"end":191,"id":29,"ws":true},{"text":",","start":192,"end":193,"id":30,"ws":true},{"text":"did","start":194,"end":197,"id":31,"ws":true},{"text":"not","start":198,"end":201,"id":32,"ws":true},{"text":"significantly","start":202,"end":215,"id":33,"ws":true},{"text":"inhibit","start":216,"end":223,"id":34,"ws":true},{"text":"tumor","start":224,"end":229,"id":35,"ws":true},{"text":"formation","start":230,"end":239,"id":36,"ws":true},{"text":".","start":240,"end":241,"id":37,"ws":false}],"spans":[{"start":0,"end":13,"token_start":0,"token_end":0,"label":"DRUG"},{"start":18,"end":27,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11195469/","_input_hash":-368672526,"_task_hash":1275930704,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":13,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":18,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"We identified 938 patients with RCC who had initially been treated with sunitinib ( n = 554 ) or sorafenib ( n = 384 ) .","paragraph":"<h3><u>Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.</u></h3>To characterize the contemporary use of oral-targeted therapies (ie, <b style='color:Tomato;'><i>sunitinib</i></b>, <b style='color:Tomato;'><i>sorafenib</i></b>) among patients with renal cell carcinoma (RCC) and to assess the factors associated with short-term and sequential treatment. ### methods We used an administrative claims database of privately insured patients to evaluate oral-targeted therapy use among patients with RCC from 2006 to 2007. After identifying patients with RCC who had received <b style='color:Tomato;'><i>sunitinib</i></b> and/or <b style='color:Tomato;'><i>sorafenib</i></b>, we determined the prevalence of patients treated with short-term and/or sequential therapy. We performed bivariate and multivariate analyses to estimate the associations between the patient characteristics and receipt of short-term and/or sequential treatment regimens. ### results <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>identified</i></b> <b style='color:DodgerBlue;'><i>938</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>RCC</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>554</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>384</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this group, 36% and 23% of patients had received short-term or sequential therapy, respectively. Most patients (61%) who had received sequential therapy had undergone short-term treatment with \u22651 drugs, with second-line <b style='color:Tomato;'><i>sorafenib</i></b> more likely to be given as short-term therapy than <b style='color:Tomato;'><i>sunitinib</i></b> (63% vs 34%, P < .001). Short-term therapy was more common in female patients (odds ratio 1.53, 95% confidence interval 1.12-2.09) and patients in the Southern United States (odds ratio 1.71, 95% confidence interval 1.05-2.80). Sequential therapy was more common among patients receiving <b style='color:Tomato;'><i>sorafenib</i></b> first (odds ratio 2.30, 95% confidence interval 1.64-3.21). ### conclusions Short-term and sequential oral targeted therapy use was relatively prevalent among patients with RCC. For patients treated with <b style='color:Tomato;'><i>sunitinib</i></b> and <b style='color:Tomato;'><i>sorafenib</i></b>, the patterns of short-term use varied by the sequence of medications, suggesting differences in the effectiveness or tolerability of each regimen. These findings highlight the need for future studies to characterize the \"real-world\" clinical outcomes and economic effect associated with these treatment courses.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"identified","start":3,"end":13,"id":1,"ws":true},{"text":"938","start":14,"end":17,"id":2,"ws":true},{"text":"patients","start":18,"end":26,"id":3,"ws":true},{"text":"with","start":27,"end":31,"id":4,"ws":true},{"text":"RCC","start":32,"end":35,"id":5,"ws":true},{"text":"who","start":36,"end":39,"id":6,"ws":true},{"text":"had","start":40,"end":43,"id":7,"ws":true},{"text":"initially","start":44,"end":53,"id":8,"ws":true},{"text":"been","start":54,"end":58,"id":9,"ws":true},{"text":"treated","start":59,"end":66,"id":10,"ws":true},{"text":"with","start":67,"end":71,"id":11,"ws":true},{"text":"sunitinib","start":72,"end":81,"id":12,"ws":true},{"text":"(","start":82,"end":83,"id":13,"ws":true},{"text":"n","start":84,"end":85,"id":14,"ws":true},{"text":"=","start":86,"end":87,"id":15,"ws":true},{"text":"554","start":88,"end":91,"id":16,"ws":true},{"text":")","start":92,"end":93,"id":17,"ws":true},{"text":"or","start":94,"end":96,"id":18,"ws":true},{"text":"sorafenib","start":97,"end":106,"id":19,"ws":true},{"text":"(","start":107,"end":108,"id":20,"ws":true},{"text":"n","start":109,"end":110,"id":21,"ws":true},{"text":"=","start":111,"end":112,"id":22,"ws":true},{"text":"384","start":113,"end":116,"id":23,"ws":true},{"text":")","start":117,"end":118,"id":24,"ws":true},{"text":".","start":119,"end":120,"id":25,"ws":false}],"spans":[{"start":72,"end":81,"token_start":12,"token_end":12,"label":"DRUG"},{"start":97,"end":106,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21256539/","_input_hash":1229048412,"_task_hash":-2045860467,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"( 3 ) Observed facilitatory effects of caerulein on the hypothalamic defensive attack were very similar to those observed with dopamine ( DA ) agonists such as methamphetamine and apomorphine and opposite to those with DA antagonists such as haloperidol and chlorpromazine .","paragraph":"<h3><u>Facilitatory effects of caerulein on hypothalamic defensive attack in cats.</u></h3>Effects of intraventricularly microinjected caerulein (0.1, 1.0 and 10.0 micrograms) on the thresholds for hypothalamically elicited defensive attack and influences of <b style='color:Tomato;'><i>haloperidol</i></b> (0.5 mg/kg, i.p.) on the effects were studied in chronic cats. Directed attack and hissing were selected for threshold determination, and thresholds for these responses were measured under two situations: one with provocations by a human, and the other without such provocation. Results were as follows. (1) Caerulein lowered all thresholds in generally equal decrements and in a dose-related manner, accompanied by a general behavioral arousal. (2) Prior injection of <b style='color:Tomato;'><i>haloperidol</i></b> prevented the effects of caerulein, suggesting an antagonism-like interaction between <b style='color:Tomato;'><i>haloperidol</i></b> and caerulein. <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>Observed</i></b> <b style='color:DodgerBlue;'><i>facilitatory</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>caerulein</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>hypothalamic</i></b> <b style='color:DodgerBlue;'><i>defensive</i></b> <b style='color:DodgerBlue;'><i>attack</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>dopamine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>agonists</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>apomorphine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>opposite</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>DA</i></b> <b style='color:DodgerBlue;'><i>antagonists</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>haloperidol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>chlorpromazine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These findings suggest that caerulein exerts its facilitatory effects on the excitability of the ventromedial hypothalamic nucleus through its synergistic interaction with DA.","tokens":[{"text":"(","start":0,"end":1,"id":0,"ws":true},{"text":"3","start":2,"end":3,"id":1,"ws":true},{"text":")","start":4,"end":5,"id":2,"ws":true},{"text":"Observed","start":6,"end":14,"id":3,"ws":true},{"text":"facilitatory","start":15,"end":27,"id":4,"ws":true},{"text":"effects","start":28,"end":35,"id":5,"ws":true},{"text":"of","start":36,"end":38,"id":6,"ws":true},{"text":"caerulein","start":39,"end":48,"id":7,"ws":true},{"text":"on","start":49,"end":51,"id":8,"ws":true},{"text":"the","start":52,"end":55,"id":9,"ws":true},{"text":"hypothalamic","start":56,"end":68,"id":10,"ws":true},{"text":"defensive","start":69,"end":78,"id":11,"ws":true},{"text":"attack","start":79,"end":85,"id":12,"ws":true},{"text":"were","start":86,"end":90,"id":13,"ws":true},{"text":"very","start":91,"end":95,"id":14,"ws":true},{"text":"similar","start":96,"end":103,"id":15,"ws":true},{"text":"to","start":104,"end":106,"id":16,"ws":true},{"text":"those","start":107,"end":112,"id":17,"ws":true},{"text":"observed","start":113,"end":121,"id":18,"ws":true},{"text":"with","start":122,"end":126,"id":19,"ws":true},{"text":"dopamine","start":127,"end":135,"id":20,"ws":true},{"text":"(","start":136,"end":137,"id":21,"ws":true},{"text":"DA","start":138,"end":140,"id":22,"ws":true},{"text":")","start":141,"end":142,"id":23,"ws":true},{"text":"agonists","start":143,"end":151,"id":24,"ws":true},{"text":"such","start":152,"end":156,"id":25,"ws":true},{"text":"as","start":157,"end":159,"id":26,"ws":true},{"text":"methamphetamine","start":160,"end":175,"id":27,"ws":true},{"text":"and","start":176,"end":179,"id":28,"ws":true},{"text":"apomorphine","start":180,"end":191,"id":29,"ws":true},{"text":"and","start":192,"end":195,"id":30,"ws":true},{"text":"opposite","start":196,"end":204,"id":31,"ws":true},{"text":"to","start":205,"end":207,"id":32,"ws":true},{"text":"those","start":208,"end":213,"id":33,"ws":true},{"text":"with","start":214,"end":218,"id":34,"ws":true},{"text":"DA","start":219,"end":221,"id":35,"ws":true},{"text":"antagonists","start":222,"end":233,"id":36,"ws":true},{"text":"such","start":234,"end":238,"id":37,"ws":true},{"text":"as","start":239,"end":241,"id":38,"ws":true},{"text":"haloperidol","start":242,"end":253,"id":39,"ws":true},{"text":"and","start":254,"end":257,"id":40,"ws":true},{"text":"chlorpromazine","start":258,"end":272,"id":41,"ws":true},{"text":".","start":273,"end":274,"id":42,"ws":false}],"spans":[{"start":160,"end":175,"token_start":27,"token_end":27,"label":"DRUG"},{"start":242,"end":253,"token_start":39,"token_end":39,"label":"DRUG"},{"start":258,"end":272,"token_start":41,"token_end":41,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3179708/","_input_hash":-1263621431,"_task_hash":2078413213,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The NIBIT-MESO-1 study demonstrated the efficacy and safety of tremelimumab combined with durvalumab in patient with unresectable mesothelioma followed up for a median of 52 months [ IQR 49 - 53 ] .","paragraph":"<h3><u>Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>NIBIT-MESO-1</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tremelimumab</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>durvalumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>mesothelioma</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>up</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>52</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>IQR</i></b> <b style='color:DodgerBlue;'><i>49</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>53</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Here, we report 4-year survival and outcomes after retreatment, and the role of tumour mutational burden (TMB) in identifying patients who might have a better outcome in response to combined therapy. ### methods NIBIT-MESO-1 was an open-label, non-randomised, phase 2 trial of patients with unresectable pleural or peritoneal mesothelioma who received intravenous <b style='color:Tomato;'><i>tremelimumab</i></b> (1 mg/kg bodyweight) and <b style='color:Tomato;'><i>durvalumab</i></b> (20 mg/kg bodyweight) every 4 weeks for four doses, followed by maintenance intravenous <b style='color:Tomato;'><i>durvalumab</i></b> at the same dose and schedule for nine doses. In this follow-up study, patients with disease progression following initial clinical benefit-ie, a partial repsonse or stable disease-were eligible for retreatment and with the same doses and schedules for <b style='color:Tomato;'><i>tremelimumab</i></b> and <b style='color:Tomato;'><i>durvalumab</i></b> as used in the NIBIT-MESO-1 trial. The primary endpoint, immune-related objective response rate, was evaluated per immune-related modified Response Evaluation Criteria in Solid Tumors (RECIST) or immune-related RECIST 1.1 criteria for patients with pleural or peritoneal malignant mesothelioma, respectively. Key secondary endpoints were overall survival and safety, and TMB was also evaluated post hoc in patients who had tumour tissue available before treatment. The intention-to-treat population was used for analysis of all efficacy endpoints. This study is registered with ClinicalTrials.gov, number NCT02588131. ### findings 40 patients were enrolled in the NIBIT-MESO-1 study between Oct 30, 2015, and Oct 12, 2016. At data cut-off, April 30, 2020, five (13%) of 40 patients were alive, and 35 (88%) patients had died of progressive disease. At a median follow-up of 52 months (IQR 49-53), median overall survival was 16\u00b75 months (95% CI 13\u00b77-19\u00b72). Survival was 20% (eight of 40 patients) at 36 months and 15% (six of 40 patients) and 48 months. 17 (43%) of 40 patients met the criteria for enrolment in the retreatment study and were retreated with at least one dose of <b style='color:Tomato;'><i>tremelimumab</i></b> and <b style='color:Tomato;'><i>durvalumab</i></b>. No immune-related objective responses were observed in the 17 retreated patients. Seven (41%) of 17 patients achieved immune-related stable disease. From the start of retreatment to a median follow-up of 24 months (22\u00b70-25\u00b70), median overall survival was 12\u00b75 months (95% CI 0\u00b70-25\u00b78), and survival at 12 months was 52\u00b79%, at 18 months was 35\u00b73%, and at 24 months was 23\u00b75%. There were no grade 3-4 immune-related adverse events in the retreatment cohort. In a post-hoc analysis of 28 patients for whom tumour tissue before treatment was available, patients with a TMB higher than the median value of 8\u00b73 mutations per Mb had a higher median overall survival compared with patients with TMB below the median value, but this difference was non-significant. Moreover, when patients were additionally stratified for ICI retreatment (n=13), there was a significant difference in survival between those with a TMB higher than the median of 8\u00b73 mutations per Mb and those with TMB lower than the median in the retreated cohort (41\u00b73 months vs 17\u00b74 months; p=0\u00b702). ### interpretation <b style='color:Tomato;'><i>tremelimumab</i></b> combined with <b style='color:Tomato;'><i>durvalumab</i></b> was associated with long-term survival in patients with mesothelioma. Retreatment was safe and resulted in clinically meaningful outcomes, thus suggesting its potential application in the clinical practice of mesothalioma patients. ### funding NIBIT Foundation, Fondazione AIRC, AstraZeneca.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"NIBIT-MESO-1","start":4,"end":16,"id":1,"ws":true},{"text":"study","start":17,"end":22,"id":2,"ws":true},{"text":"demonstrated","start":23,"end":35,"id":3,"ws":true},{"text":"the","start":36,"end":39,"id":4,"ws":true},{"text":"efficacy","start":40,"end":48,"id":5,"ws":true},{"text":"and","start":49,"end":52,"id":6,"ws":true},{"text":"safety","start":53,"end":59,"id":7,"ws":true},{"text":"of","start":60,"end":62,"id":8,"ws":true},{"text":"tremelimumab","start":63,"end":75,"id":9,"ws":true},{"text":"combined","start":76,"end":84,"id":10,"ws":true},{"text":"with","start":85,"end":89,"id":11,"ws":true},{"text":"durvalumab","start":90,"end":100,"id":12,"ws":true},{"text":"in","start":101,"end":103,"id":13,"ws":true},{"text":"patient","start":104,"end":111,"id":14,"ws":true},{"text":"with","start":112,"end":116,"id":15,"ws":true},{"text":"unresectable","start":117,"end":129,"id":16,"ws":true},{"text":"mesothelioma","start":130,"end":142,"id":17,"ws":true},{"text":"followed","start":143,"end":151,"id":18,"ws":true},{"text":"up","start":152,"end":154,"id":19,"ws":true},{"text":"for","start":155,"end":158,"id":20,"ws":true},{"text":"a","start":159,"end":160,"id":21,"ws":true},{"text":"median","start":161,"end":167,"id":22,"ws":true},{"text":"of","start":168,"end":170,"id":23,"ws":true},{"text":"52","start":171,"end":173,"id":24,"ws":true},{"text":"months","start":174,"end":180,"id":25,"ws":true},{"text":"[","start":181,"end":182,"id":26,"ws":true},{"text":"IQR","start":183,"end":186,"id":27,"ws":true},{"text":"49","start":187,"end":189,"id":28,"ws":true},{"text":"-","start":190,"end":191,"id":29,"ws":true},{"text":"53","start":192,"end":194,"id":30,"ws":true},{"text":"]","start":195,"end":196,"id":31,"ws":true},{"text":".","start":197,"end":198,"id":32,"ws":false}],"spans":[{"start":63,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},{"start":90,"end":100,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33844995/","_input_hash":-592658905,"_task_hash":-448978464,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":9,"child":12,"head_span":{"start":63,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":90,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Sorafenib has been the standard of care for a decade , and promising results for regorafenib as a second-line and lenvatinib as a first-line treatment were reported only 1 or 2 years ago .","paragraph":"<h3><u>Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.</u></h3>Hepatocellular carcinoma (HCC) is the most common malignancy worldwide, and is especially common in China. A total of 70%-80% of patients are diagnosed at an advanced stage and can receive only palliative care. <b style='color:MediumOrchid;'><i>Sorafenib</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>care</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>decade</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>promising</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:MediumOrchid;'><i>regorafenib</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>lenvatinib</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>ago</i></b> <b style='color:DodgerBlue;'><i>.</i></b> FOLFOX4 was recently recommended as a clinical practice guideline by the China Food and Drug Administration. All approved systemic therapies remain unsatisfactory, with limited objective response rates and poor overall survival. Immune checkpoint inhibitors (CPIs) offer great promise in the treatment of a rapidly expanding spectrum of solid tumors. Immune checkpoint molecules are involved in almost the whole process of viral-related hepatitis with cirrhosis and HCC and in the most important resistance mechanism of <b style='color:Tomato;'><i>sorafenib</i></b>. The approval of <b style='color:Tomato;'><i>nivolumab</i></b> by the U.S. Food and Drug Administration on September 23, 2017, for the treatment of patients with HCC, based only on a phase I/II clinical trial, is a strong hint that immunotherapy will introduce a new era of HCC therapy. CPI-based strategies will soon be a main approach in anticancer treatment for HCC, and we will observe the rapid advances in the therapeutic use of CPIs, even in an adjuvant setting, with great interest. How shall we face the opportunities and challenges? Can we dramatically improve the prognosis of patients with HCC? This review may provide some informed guidance. IMPLICATIONS FOR PRACTICE: Immune checkpoint molecules are involved in almost the whole process of viral-related hepatitis with cirrhosis and hepatocellular carcinoma (HCC) and in the most important resistance mechanism of <b style='color:Tomato;'><i>sorafenib</i></b>. As all approved systemic therapies in HCC remain unsatisfactory, checkpoint inhibitor (CPI)-based strategies will soon be a main approach in anticancer treatment for advanced stage of HCC, even in an adjuvant setting. In virus-related HCC, especially hepatitis B virus-related HCC, whether CPIs can control virus relapse should be further investigated. Combination strategies involving conventional therapies and immunotherapies are needed to increase clinical benefit and minimize adverse toxicities with regard to the underlying liver disease.","tokens":[{"text":"Sorafenib","start":0,"end":9,"id":0,"ws":true},{"text":"has","start":10,"end":13,"id":1,"ws":true},{"text":"been","start":14,"end":18,"id":2,"ws":true},{"text":"the","start":19,"end":22,"id":3,"ws":true},{"text":"standard","start":23,"end":31,"id":4,"ws":true},{"text":"of","start":32,"end":34,"id":5,"ws":true},{"text":"care","start":35,"end":39,"id":6,"ws":true},{"text":"for","start":40,"end":43,"id":7,"ws":true},{"text":"a","start":44,"end":45,"id":8,"ws":true},{"text":"decade","start":46,"end":52,"id":9,"ws":true},{"text":",","start":53,"end":54,"id":10,"ws":true},{"text":"and","start":55,"end":58,"id":11,"ws":true},{"text":"promising","start":59,"end":68,"id":12,"ws":true},{"text":"results","start":69,"end":76,"id":13,"ws":true},{"text":"for","start":77,"end":80,"id":14,"ws":true},{"text":"regorafenib","start":81,"end":92,"id":15,"ws":true},{"text":"as","start":93,"end":95,"id":16,"ws":true},{"text":"a","start":96,"end":97,"id":17,"ws":true},{"text":"second-line","start":98,"end":109,"id":18,"ws":true},{"text":"and","start":110,"end":113,"id":19,"ws":true},{"text":"lenvatinib","start":114,"end":124,"id":20,"ws":true},{"text":"as","start":125,"end":127,"id":21,"ws":true},{"text":"a","start":128,"end":129,"id":22,"ws":true},{"text":"first-line","start":130,"end":140,"id":23,"ws":true},{"text":"treatment","start":141,"end":150,"id":24,"ws":true},{"text":"were","start":151,"end":155,"id":25,"ws":true},{"text":"reported","start":156,"end":164,"id":26,"ws":true},{"text":"only","start":165,"end":169,"id":27,"ws":true},{"text":"1","start":170,"end":171,"id":28,"ws":true},{"text":"or","start":172,"end":174,"id":29,"ws":true},{"text":"2","start":175,"end":176,"id":30,"ws":true},{"text":"years","start":177,"end":182,"id":31,"ws":true},{"text":"ago","start":183,"end":186,"id":32,"ws":true},{"text":".","start":187,"end":188,"id":33,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":81,"end":92,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":124,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30819826/","_input_hash":-1632316519,"_task_hash":-2109845674,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The addition of trastuzumab , pertuzumab , bevacizumab , or lapatinib to chemotherapy significantly ( P < .05 ) improved objective response rate ( ORR ) , time to failure ( TTF ) , and overall survival ( OS ) in patients with HER2-positive ( HER2(+ ) ) disease .","paragraph":"<h3><u>Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.</u></h3>Breast cancer is the most common cancer and the most frequent cause of death in women. Targeted therapies offer a possibility of effective and individualized therapy based on the molecular profile of the tumor. The aim of this systematic review was to evaluate the efficacy and safety of targeted agents added to chemotherapy or endocrine therapy in patients with previously untreated metastatic breast cancer (MBC) depending on their human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status (positive or negative). The systematic literature search was performed in PubMed, EMBASE, and the Cochrane Library to identify randomized controlled trials (RCTs). Thirteen trials were included. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>pertuzumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lapatinib</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>objective</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ORR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>failure</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TTF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>OS</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER2-positive</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HER2(+</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>trastuzumab</i></b> or <b style='color:Tomato;'><i>lapatinib</i></b> combined with endocrine therapy significantly (P < .05) improved ORR, time to progression (TTP), and progression-free survival (PFS) in patients with HER2(+) and HR(+) disease. In patients with HER2-negative (HER2(-)) cancer, <b style='color:Tomato;'><i>bevacizumab</i></b> or <b style='color:Tomato;'><i>lapatinib</i></b> added to chemotherapy significantly (P < .05), improved ORR but did not prolong PFS and OS (P > .05). In patients with HER2(-) and HR(-) disease, <b style='color:Tomato;'><i>trastuzumab</i></b> combined with chemotherapy did not significantly improve (P > .05) ORR or PFS. Targeted therapies also increased the overall risk of adverse events. So far, there is a lack of published results for <b style='color:Tomato;'><i>everolimus</i></b> and <b style='color:Tomato;'><i>trastuzumab</i></b> <b style='color:Tomato;'><i>emtansine</i></b> trials in patients with previously untreated MBC. The addition of targeted therapy to chemotherapy or endocrine therapy using HER2 and HR status significantly improved ORR, PFS, and OS in patients with previously untreated MBC.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"addition","start":4,"end":12,"id":1,"ws":true},{"text":"of","start":13,"end":15,"id":2,"ws":true},{"text":"trastuzumab","start":16,"end":27,"id":3,"ws":true},{"text":",","start":28,"end":29,"id":4,"ws":true},{"text":"pertuzumab","start":30,"end":40,"id":5,"ws":true},{"text":",","start":41,"end":42,"id":6,"ws":true},{"text":"bevacizumab","start":43,"end":54,"id":7,"ws":true},{"text":",","start":55,"end":56,"id":8,"ws":true},{"text":"or","start":57,"end":59,"id":9,"ws":true},{"text":"lapatinib","start":60,"end":69,"id":10,"ws":true},{"text":"to","start":70,"end":72,"id":11,"ws":true},{"text":"chemotherapy","start":73,"end":85,"id":12,"ws":true},{"text":"significantly","start":86,"end":99,"id":13,"ws":true},{"text":"(","start":100,"end":101,"id":14,"ws":true},{"text":"P","start":102,"end":103,"id":15,"ws":true},{"text":"<","start":104,"end":105,"id":16,"ws":true},{"text":".05","start":106,"end":109,"id":17,"ws":true},{"text":")","start":110,"end":111,"id":18,"ws":true},{"text":"improved","start":112,"end":120,"id":19,"ws":true},{"text":"objective","start":121,"end":130,"id":20,"ws":true},{"text":"response","start":131,"end":139,"id":21,"ws":true},{"text":"rate","start":140,"end":144,"id":22,"ws":true},{"text":"(","start":145,"end":146,"id":23,"ws":true},{"text":"ORR","start":147,"end":150,"id":24,"ws":true},{"text":")","start":151,"end":152,"id":25,"ws":true},{"text":",","start":153,"end":154,"id":26,"ws":true},{"text":"time","start":155,"end":159,"id":27,"ws":true},{"text":"to","start":160,"end":162,"id":28,"ws":true},{"text":"failure","start":163,"end":170,"id":29,"ws":true},{"text":"(","start":171,"end":172,"id":30,"ws":true},{"text":"TTF","start":173,"end":176,"id":31,"ws":true},{"text":")","start":177,"end":178,"id":32,"ws":true},{"text":",","start":179,"end":180,"id":33,"ws":true},{"text":"and","start":181,"end":184,"id":34,"ws":true},{"text":"overall","start":185,"end":192,"id":35,"ws":true},{"text":"survival","start":193,"end":201,"id":36,"ws":true},{"text":"(","start":202,"end":203,"id":37,"ws":true},{"text":"OS","start":204,"end":206,"id":38,"ws":true},{"text":")","start":207,"end":208,"id":39,"ws":true},{"text":"in","start":209,"end":211,"id":40,"ws":true},{"text":"patients","start":212,"end":220,"id":41,"ws":true},{"text":"with","start":221,"end":225,"id":42,"ws":true},{"text":"HER2-positive","start":226,"end":239,"id":43,"ws":true},{"text":"(","start":240,"end":241,"id":44,"ws":true},{"text":"HER2(+","start":242,"end":248,"id":45,"ws":true},{"text":")","start":249,"end":250,"id":46,"ws":true},{"text":")","start":251,"end":252,"id":47,"ws":true},{"text":"disease","start":253,"end":260,"id":48,"ws":true},{"text":".","start":261,"end":262,"id":49,"ws":false}],"spans":[{"start":16,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},{"start":43,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},{"start":60,"end":69,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25441421/","_input_hash":-1048615256,"_task_hash":-433153419,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The feasibility and efficacy of an intensified procarbazine-free consolidation regimen VECOPA ( vinblastine , etoposide , cyclophosphamide , vincristine , prednisone , doxorubicin ) were investigated .","paragraph":"<h3><u>Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial.</u></h3>The GPOH-HD (Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie-Hodgkin Disease) strategy for children and adolescents with intermediate and advanced stage Hodgkin lymphoma is based on two induction cycles of OEPA (<b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>etoposide</i></b>, <b style='color:Tomato;'><i>prednisone</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>) followed by COPP (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>procarbazine</i></b>, <b style='color:Tomato;'><i>prednisone</i></b>) or COPDAC (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>prednisone</i></b>, <b style='color:Tomato;'><i>dacarbazine</i></b>) consolidation. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>feasibility</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>intensified</i></b> <b style='color:DodgerBlue;'><i>procarbazine-free</i></b> <b style='color:DodgerBlue;'><i>consolidation</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>VECOPA</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Following two OEPA and one or two VECOPA cycles, involved field radiotherapy was applied. The main endpoint was feasibility. Secondary endpoints were toxicity, proportion of delayed cycles, granulocyte-colony stimulating factor use, and event-free and overall survival. The regimen was well tolerated with mostly hematotoxicity exceeding Common Toxicity Criteria grade 2. In most patients with advanced stage the second VECOPA cycle was delayed despite hematopoietic recovery and absence of serious adverse events. Event-free survival at 36 months was 0.86 (95% confidence interval 0.70-1). The VECOPA regimen is effective and tolerable. However, its time-intensification was not fully exploited within this trial.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"feasibility","start":4,"end":15,"id":1,"ws":true},{"text":"and","start":16,"end":19,"id":2,"ws":true},{"text":"efficacy","start":20,"end":28,"id":3,"ws":true},{"text":"of","start":29,"end":31,"id":4,"ws":true},{"text":"an","start":32,"end":34,"id":5,"ws":true},{"text":"intensified","start":35,"end":46,"id":6,"ws":true},{"text":"procarbazine-free","start":47,"end":64,"id":7,"ws":true},{"text":"consolidation","start":65,"end":78,"id":8,"ws":true},{"text":"regimen","start":79,"end":86,"id":9,"ws":true},{"text":"VECOPA","start":87,"end":93,"id":10,"ws":true},{"text":"(","start":94,"end":95,"id":11,"ws":true},{"text":"vinblastine","start":96,"end":107,"id":12,"ws":true},{"text":",","start":108,"end":109,"id":13,"ws":true},{"text":"etoposide","start":110,"end":119,"id":14,"ws":true},{"text":",","start":120,"end":121,"id":15,"ws":true},{"text":"cyclophosphamide","start":122,"end":138,"id":16,"ws":true},{"text":",","start":139,"end":140,"id":17,"ws":true},{"text":"vincristine","start":141,"end":152,"id":18,"ws":true},{"text":",","start":153,"end":154,"id":19,"ws":true},{"text":"prednisone","start":155,"end":165,"id":20,"ws":true},{"text":",","start":166,"end":167,"id":21,"ws":true},{"text":"doxorubicin","start":168,"end":179,"id":22,"ws":true},{"text":")","start":180,"end":181,"id":23,"ws":true},{"text":"were","start":182,"end":186,"id":24,"ws":true},{"text":"investigated","start":187,"end":199,"id":25,"ws":true},{"text":".","start":200,"end":201,"id":26,"ws":false}],"spans":[{"start":96,"end":107,"token_start":12,"token_end":12,"label":"DRUG"},{"start":110,"end":119,"token_start":14,"token_end":14,"label":"DRUG"},{"start":122,"end":138,"token_start":16,"token_end":16,"label":"DRUG"},{"start":141,"end":152,"token_start":18,"token_end":18,"label":"DRUG"},{"start":155,"end":165,"token_start":20,"token_end":20,"label":"DRUG"},{"start":168,"end":179,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25204374/","_input_hash":-1137194698,"_task_hash":-273439235,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":96,"end":107,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":110,"end":119,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":14,"child":16,"head_span":{"start":110,"end":119,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":122,"end":138,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":16,"child":18,"head_span":{"start":122,"end":138,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":141,"end":152,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":18,"child":20,"head_span":{"start":141,"end":152,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":155,"end":165,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":20,"child":22,"head_span":{"start":155,"end":165,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":168,"end":179,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The combination regimen of nivolumab plus ipilimumab demonstrates activity in metastatic uveal melanoma , with deep and sustained confirmed responses .","paragraph":"<h3><u>Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.</u></h3>Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options. Studies of single-agent immunotherapy regimens have shown minimal benefit. There is the potential for improved responses with the use of combination immunotherapy. ### Patients And Methods We conducted a phase II study of <b style='color:Tomato;'><i>nivolumab</i></b> with <b style='color:Tomato;'><i>ipilimumab</i></b> in patients with metastatic uveal melanoma. Any number of prior treatments was permitted. Patients received <b style='color:Tomato;'><i>nivolumab</i></b> 1 mg/kg and <b style='color:Tomato;'><i>ipilimumab</i></b> 3 mg/kg for four cycles, followed by <b style='color:Tomato;'><i>nivolumab</i></b> maintenance therapy for up to 2 years. The primary outcome of the study was overall response rate (ORR) as determined by RECIST 1.1 criteria. Progression-free survival (PFS), OS, and adverse events were also assessed. ### results Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy. The ORR was 18%, including one confirmed complete response and five confirmed partial responses. The median PFS was 5.5 months (95% CI, 3.4 to 9.5 months), and the median OS was 19.1 months (95% CI, 9.6 months to NR). Forty percent of patients experienced a grade 3-4 treatment-related adverse event. ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>demonstrates</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>uveal</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>deep</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>sustained</i></b> <b style='color:DodgerBlue;'><i>confirmed</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"regimen","start":16,"end":23,"id":2,"ws":true},{"text":"of","start":24,"end":26,"id":3,"ws":true},{"text":"nivolumab","start":27,"end":36,"id":4,"ws":true},{"text":"plus","start":37,"end":41,"id":5,"ws":true},{"text":"ipilimumab","start":42,"end":52,"id":6,"ws":true},{"text":"demonstrates","start":53,"end":65,"id":7,"ws":true},{"text":"activity","start":66,"end":74,"id":8,"ws":true},{"text":"in","start":75,"end":77,"id":9,"ws":true},{"text":"metastatic","start":78,"end":88,"id":10,"ws":true},{"text":"uveal","start":89,"end":94,"id":11,"ws":true},{"text":"melanoma","start":95,"end":103,"id":12,"ws":true},{"text":",","start":104,"end":105,"id":13,"ws":true},{"text":"with","start":106,"end":110,"id":14,"ws":true},{"text":"deep","start":111,"end":115,"id":15,"ws":true},{"text":"and","start":116,"end":119,"id":16,"ws":true},{"text":"sustained","start":120,"end":129,"id":17,"ws":true},{"text":"confirmed","start":130,"end":139,"id":18,"ws":true},{"text":"responses","start":140,"end":149,"id":19,"ws":true},{"text":".","start":150,"end":151,"id":20,"ws":false}],"spans":[{"start":27,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},{"start":42,"end":52,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33125309/","_input_hash":-1960347536,"_task_hash":1596022185,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":27,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":42,"end":52,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The FDA reviewed data in electronic format from a randomized controlled clinical trial of 1106 adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase , comparing imatinib with the combination of IFN-alpha and cytarabine .","paragraph":"<h3><u>Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.</u></h3>The purpose is to describe the Food and Drug Administration (FDA) review and approval of <b style='color:Tomato;'><i>imatinib</i></b> (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in chronic phase. ### Experimental Design <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>reviewed</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>electronic</i></b> <b style='color:DodgerBlue;'><i>format</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>controlled</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>1106</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>newly</i></b> <b style='color:DodgerBlue;'><i>diagnosed</i></b> <b style='color:DodgerBlue;'><i>Philadelphia</i></b> <b style='color:DodgerBlue;'><i>chromosome-positive</i></b> <b style='color:DodgerBlue;'><i>CML</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>IFN-alpha</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results <b style='color:Tomato;'><i>imatinib</i></b> showed clinically and statistically significantly better results for time-to-progression to accelerated phase or blast crisis, progression-free survival, complete hematological response rate, and cytogenetic response rate. With a median follow-up of 14 months, a maximum follow-up of 19.5 months, and an expected median survival of 5-6 years on the IFN-alpha/<b style='color:Tomato;'><i>cytarabine</i></b> control arm, few of the expected progressions to accelerated or blast phase or deaths have occurred. <b style='color:Tomato;'><i>imatinib</i></b> was also better tolerated. Edema, nausea, rigors, neutropenia, and headache were more frequent in women. Only 57% of the IFN-alpha target dose was administered, and only 68% of patients received any <b style='color:Tomato;'><i>cytarabine</i></b>. However, this does not appear to adequately explain the superiority of <b style='color:Tomato;'><i>imatinib</i></b> observed in this trial. Results of a population pharmacokinetic study in a subgroup of 371 patients and a separate <b style='color:Tomato;'><i>rifampin</i></b>-<b style='color:Tomato;'><i>imatinib</i></b> drug-drug interaction study in healthy volunteers are presented. ### conclusions On December 20, 2002, <b style='color:Tomato;'><i>imatinib</i></b> was granted accelerated approval under subpart H, rather than regular approval. Follow-up is short compared with the natural history of chronic phase CML or more mature results with established therapies such as IFN-alpha or transplantation. If <b style='color:Tomato;'><i>imatinib</i></b> should stop working after 1.5-2 years, the results could be importantly different from the present analysis. As a Phase IV postmarketing commitment, the applicant has agreed to provide follow-up reports on this <b style='color:Tomato;'><i>imatinib</i></b> study annually for the next 6 years.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"FDA","start":4,"end":7,"id":1,"ws":true},{"text":"reviewed","start":8,"end":16,"id":2,"ws":true},{"text":"data","start":17,"end":21,"id":3,"ws":true},{"text":"in","start":22,"end":24,"id":4,"ws":true},{"text":"electronic","start":25,"end":35,"id":5,"ws":true},{"text":"format","start":36,"end":42,"id":6,"ws":true},{"text":"from","start":43,"end":47,"id":7,"ws":true},{"text":"a","start":48,"end":49,"id":8,"ws":true},{"text":"randomized","start":50,"end":60,"id":9,"ws":true},{"text":"controlled","start":61,"end":71,"id":10,"ws":true},{"text":"clinical","start":72,"end":80,"id":11,"ws":true},{"text":"trial","start":81,"end":86,"id":12,"ws":true},{"text":"of","start":87,"end":89,"id":13,"ws":true},{"text":"1106","start":90,"end":94,"id":14,"ws":true},{"text":"adult","start":95,"end":100,"id":15,"ws":true},{"text":"patients","start":101,"end":109,"id":16,"ws":true},{"text":"with","start":110,"end":114,"id":17,"ws":true},{"text":"newly","start":115,"end":120,"id":18,"ws":true},{"text":"diagnosed","start":121,"end":130,"id":19,"ws":true},{"text":"Philadelphia","start":131,"end":143,"id":20,"ws":true},{"text":"chromosome-positive","start":144,"end":163,"id":21,"ws":true},{"text":"CML","start":164,"end":167,"id":22,"ws":true},{"text":"in","start":168,"end":170,"id":23,"ws":true},{"text":"chronic","start":171,"end":178,"id":24,"ws":true},{"text":"phase","start":179,"end":184,"id":25,"ws":true},{"text":",","start":185,"end":186,"id":26,"ws":true},{"text":"comparing","start":187,"end":196,"id":27,"ws":true},{"text":"imatinib","start":197,"end":205,"id":28,"ws":true},{"text":"with","start":206,"end":210,"id":29,"ws":true},{"text":"the","start":211,"end":214,"id":30,"ws":true},{"text":"combination","start":215,"end":226,"id":31,"ws":true},{"text":"of","start":227,"end":229,"id":32,"ws":true},{"text":"IFN-alpha","start":230,"end":239,"id":33,"ws":true},{"text":"and","start":240,"end":243,"id":34,"ws":true},{"text":"cytarabine","start":244,"end":254,"id":35,"ws":true},{"text":".","start":255,"end":256,"id":36,"ws":false}],"spans":[{"start":197,"end":205,"token_start":28,"token_end":28,"label":"DRUG"},{"start":244,"end":254,"token_start":35,"token_end":35,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12796358/","_input_hash":-2061684921,"_task_hash":117573876,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":33,"child":35,"head_span":{"start":230,"end":239,"token_start":33,"token_end":33,"label":null},"child_span":{"start":244,"end":254,"token_start":35,"token_end":35,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"A total of 164 patients with recurrent ovarian cancer were selected and randomly divided into two groups : experimental group ( n=82 , BEV + paclitaxel + carboplatin ) and control group ( n=82 , paclitaxel + carboplatin ) .","paragraph":"<h3><u>Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer.</u></h3>To observe the clinical efficacy and safety of <b style='color:Tomato;'><i>bevacizumab</i></b> (BEV) combined with <b style='color:Tomato;'><i>paclitaxel</i></b> on recurrent ovarian cancer. ### methods <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>164</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>selected</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>divided</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=82</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>BEV</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n=82</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The clinical therapeutic effects including objective response rate (ORR), complete response (CR) rate, partial response (PR) rate, stable disease (SD), progressive disease (PD), progression free survival (PFS) and overall survival (OS) were evaluated, together with the adverse clinical reactions and improvement of quality of life (QoL). Immunohistochemistry was used to detect the expression of phosphate and tension homology deleted on chromosome ten (PTEN). ### results The PFS, OS and ORR of patients in the experimental group were significantly higher than those in the control group (p<0.05). In addition, the incidence rates of allergy, gastrointestinal reactions and leukopenia were significantly lower in the experimental group compared with those in the control group (p<0.05). There was no significant difference in QoL score between the two groups before treatment (p>0.05). However, after treatment, the QoL score in the experimental group was increased significantly compared with the control group (p<0.05). Moreover, the expression of PTEN in PR, SD and PD patients was lower, with significant difference between the two groups (p<0.05). ### conclusion The clinical therapeutic effect of BEV combined with <b style='color:Tomato;'><i>paclitaxel</i></b> in patients with recurrent ovarian cancer was improved, suggesting it might be beneficial for the treatment of ovarian cancer.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"total","start":2,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"164","start":11,"end":14,"id":3,"ws":true},{"text":"patients","start":15,"end":23,"id":4,"ws":true},{"text":"with","start":24,"end":28,"id":5,"ws":true},{"text":"recurrent","start":29,"end":38,"id":6,"ws":true},{"text":"ovarian","start":39,"end":46,"id":7,"ws":true},{"text":"cancer","start":47,"end":53,"id":8,"ws":true},{"text":"were","start":54,"end":58,"id":9,"ws":true},{"text":"selected","start":59,"end":67,"id":10,"ws":true},{"text":"and","start":68,"end":71,"id":11,"ws":true},{"text":"randomly","start":72,"end":80,"id":12,"ws":true},{"text":"divided","start":81,"end":88,"id":13,"ws":true},{"text":"into","start":89,"end":93,"id":14,"ws":true},{"text":"two","start":94,"end":97,"id":15,"ws":true},{"text":"groups","start":98,"end":104,"id":16,"ws":true},{"text":":","start":105,"end":106,"id":17,"ws":true},{"text":"experimental","start":107,"end":119,"id":18,"ws":true},{"text":"group","start":120,"end":125,"id":19,"ws":true},{"text":"(","start":126,"end":127,"id":20,"ws":true},{"text":"n=82","start":128,"end":132,"id":21,"ws":true},{"text":",","start":133,"end":134,"id":22,"ws":true},{"text":"BEV","start":135,"end":138,"id":23,"ws":true},{"text":"+","start":139,"end":140,"id":24,"ws":true},{"text":"paclitaxel","start":141,"end":151,"id":25,"ws":true},{"text":"+","start":152,"end":153,"id":26,"ws":true},{"text":"carboplatin","start":154,"end":165,"id":27,"ws":true},{"text":")","start":166,"end":167,"id":28,"ws":true},{"text":"and","start":168,"end":171,"id":29,"ws":true},{"text":"control","start":172,"end":179,"id":30,"ws":true},{"text":"group","start":180,"end":185,"id":31,"ws":true},{"text":"(","start":186,"end":187,"id":32,"ws":true},{"text":"n=82","start":188,"end":192,"id":33,"ws":true},{"text":",","start":193,"end":194,"id":34,"ws":true},{"text":"paclitaxel","start":195,"end":205,"id":35,"ws":true},{"text":"+","start":206,"end":207,"id":36,"ws":true},{"text":"carboplatin","start":208,"end":219,"id":37,"ws":true},{"text":")","start":220,"end":221,"id":38,"ws":true},{"text":".","start":222,"end":223,"id":39,"ws":false}],"spans":[{"start":141,"end":151,"token_start":25,"token_end":25,"label":"DRUG"},{"start":154,"end":165,"token_start":27,"token_end":27,"label":"DRUG"},{"start":195,"end":205,"token_start":35,"token_end":35,"label":"DRUG"},{"start":208,"end":219,"token_start":37,"token_end":37,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31424654/","_input_hash":255029221,"_task_hash":-611066734,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":23,"child":25,"head_span":{"start":135,"end":138,"token_start":23,"token_end":23,"label":null},"child_span":{"start":141,"end":151,"token_start":25,"token_end":25,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":25,"child":27,"head_span":{"start":141,"end":151,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":154,"end":165,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide , vincristine , and prednisone .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Successful</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>adult</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Kasabach-Merritt</i></b> <b style='color:DodgerBlue;'><i>syndrome</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Kasabach-Merritt syndrome is a rare disease that mainly occurs in infants and adolescents. It usually manifests as disseminated intravascular coagulation and severe bleeding, and is associated with high mortality. However, its low incidence and clinical rarity in adults mean that there is currently no well-verified treatment regimen for this disease. We report on an effective novel therapeutic regimen in a patient with Kasabach-Merritt syndrome. ### methods A woman with Kasabach-Merritt syndrome presented with a recurrent subcutaneous mass and disseminated intravascular coagulation, and was treated with <b style='color:Tomato;'><i>prednisone</i></b>, <b style='color:Tomato;'><i>vincristine</i></b> and <b style='color:Tomato;'><i>thalidomide</i></b>. ### results This treatment regimen successfully resolved the patient's symptoms, with tumor regression. The patient remained disease-free after 6 years of follow-up. ### conclusions <b style='color:Tomato;'><i>prednisone</i></b> combined with <b style='color:Tomato;'><i>vincristine</i></b> and <b style='color:Tomato;'><i>thalidomide</i></b> may be an effective treatment for Kasabach-Merritt syndrome, but further studies are needed to verify the use of this regimen.","tokens":[{"text":"Successful","start":0,"end":10,"id":0,"ws":true},{"text":"treatment","start":11,"end":20,"id":1,"ws":true},{"text":"of","start":21,"end":23,"id":2,"ws":true},{"text":"an","start":24,"end":26,"id":3,"ws":true},{"text":"adult","start":27,"end":32,"id":4,"ws":true},{"text":"with","start":33,"end":37,"id":5,"ws":true},{"text":"Kasabach-Merritt","start":38,"end":54,"id":6,"ws":true},{"text":"syndrome","start":55,"end":63,"id":7,"ws":true},{"text":"using","start":64,"end":69,"id":8,"ws":true},{"text":"thalidomide","start":70,"end":81,"id":9,"ws":true},{"text":",","start":82,"end":83,"id":10,"ws":true},{"text":"vincristine","start":84,"end":95,"id":11,"ws":true},{"text":",","start":96,"end":97,"id":12,"ws":true},{"text":"and","start":98,"end":101,"id":13,"ws":true},{"text":"prednisone","start":102,"end":112,"id":14,"ws":true},{"text":".","start":113,"end":114,"id":15,"ws":false}],"spans":[{"start":70,"end":81,"token_start":9,"token_end":9,"label":"DRUG"},{"start":84,"end":95,"token_start":11,"token_end":11,"label":"DRUG"},{"start":102,"end":112,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30806107/","_input_hash":1375470345,"_task_hash":1785747830,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":11,"child":9,"head_span":{"start":84,"end":95,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":70,"end":81,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":14,"child":11,"head_span":{"start":102,"end":112,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":84,"end":95,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Superiority of sirolimus ( rapamycin ) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Superiority</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sirolimus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>augmenting</i></b> <b style='color:DodgerBlue;'><i>allograft</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>xenograft</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>mice</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>antilymphocyte</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>donor-specific</i></b> <b style='color:DodgerBlue;'><i>bone</i></b> <b style='color:DodgerBlue;'><i>marrow</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>sirolimus</i></b> is a potent immunosuppressive agent with great therapeutic potential. The objective of our study was to evaluate the efficacy of <b style='color:Tomato;'><i>sirolimus</i></b> versus <b style='color:Tomato;'><i>cyclosporin</i></b>e in augmenting the unresponsiveness induced by an antilymphocyte serum (ALS)/donor-specific bone marrow (BM)-based regimen across three levels of histoincompatibility: class I and II disparate (DBA/2 to B6AF1), complete mismatch (AKR to C57BL/6), and xenograft (ACI rat to B6AF1). ### methods Full-thickness skin grafts were taken from donors and placed on recipients in standard fashion. Seven groups of recipient mice (n=10-28) received various combinations of the following treatment protocols: <b style='color:Tomato;'><i>sirolimus</i></b>, 1.5 mg/kg (3.0 mg/kg for xenografts) every other day from day 0 to day 12; <b style='color:Tomato;'><i>cyclosporin</i></b>e, 50 mg/kg every other day from day 10 through 22; ALS, 0.5 ml on days -1 and 2 for allografts and days -1, 2, and 4 for xenografts; and BM, 25 million donor-specific cells IV on day 7. ### results The administration of ALS or ALS/BM resulted in modest but significant prolongation of skin graft survival in all combinations tested. <b style='color:Tomato;'><i>cyclosporin</i></b>e combined with ALS or ALS/BM significantly extended allograft survival compared with ALS or ALS/BM alone (P<0.05) but had no effect on xenograft survival. In contrast, the combination of <b style='color:Tomato;'><i>sirolimus</i></b> with ALS or ALS/BM resulted in a two- to threefold increase in allograft survival and over a fourfold increase in xenograft survival when compared with the comparable <b style='color:Tomato;'><i>cyclosporin</i></b>e-based regimen. Additionally, lymphocytes isolated from class I and II incompatible mice with skin grafts surviving >100 days demonstrated markedly reduced interleukin 2 and interferon-gamma secretion in response to irradiated donor-specific lymphocytes in culture. ### conclusions In the regimens tested, <b style='color:Tomato;'><i>sirolimus</i></b> was superior to <b style='color:Tomato;'><i>cyclosporin</i></b>e in augmenting donor BM-induced skin graft prolongation in ALS-treated mice across all levels of histoincompatibility.","tokens":[{"text":"Superiority","start":0,"end":11,"id":0,"ws":true},{"text":"of","start":12,"end":14,"id":1,"ws":true},{"text":"sirolimus","start":15,"end":24,"id":2,"ws":true},{"text":"(","start":25,"end":26,"id":3,"ws":true},{"text":"rapamycin","start":27,"end":36,"id":4,"ws":true},{"text":")","start":37,"end":38,"id":5,"ws":true},{"text":"over","start":39,"end":43,"id":6,"ws":true},{"text":"cyclosporine","start":44,"end":56,"id":7,"ws":true},{"text":"in","start":57,"end":59,"id":8,"ws":true},{"text":"augmenting","start":60,"end":70,"id":9,"ws":true},{"text":"allograft","start":71,"end":80,"id":10,"ws":true},{"text":"and","start":81,"end":84,"id":11,"ws":true},{"text":"xenograft","start":85,"end":94,"id":12,"ws":true},{"text":"survival","start":95,"end":103,"id":13,"ws":true},{"text":"in","start":104,"end":106,"id":14,"ws":true},{"text":"mice","start":107,"end":111,"id":15,"ws":true},{"text":"treated","start":112,"end":119,"id":16,"ws":true},{"text":"with","start":120,"end":124,"id":17,"ws":true},{"text":"antilymphocyte","start":125,"end":139,"id":18,"ws":true},{"text":"serum","start":140,"end":145,"id":19,"ws":true},{"text":"and","start":146,"end":149,"id":20,"ws":true},{"text":"donor-specific","start":150,"end":164,"id":21,"ws":true},{"text":"bone","start":165,"end":169,"id":22,"ws":true},{"text":"marrow","start":170,"end":176,"id":23,"ws":true},{"text":".","start":177,"end":178,"id":24,"ws":false}],"spans":[{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":27,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},{"start":44,"end":56,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9039923/","_input_hash":164148955,"_task_hash":800843899,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Profiling of drug-metabolizing enzymes/transporters in CD33 + acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine , Cytarabine and Idarubicin .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Profiling</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>drug-metabolizing</i></b> <b style='color:DodgerBlue;'><i>enzymes/transporters</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>CD33</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>Gemtuzumab-Ozogamicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Fludarabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Idarubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Genetic heterogeneity in drug-metabolizing enzyme/transporter (DMET) genes affects specific drug-related cancer phenotypes. To investigate the relationships between genetic variation and response to treatment in acute myeloid leukemia (AML), we genotyped 1931 variants on DMET genes in 94 CD33-positive AML patients enrolled in a phase III multicenter clinical trial combining Gemtuzumab-<b style='color:Tomato;'><i>ozogamicin</i></b> (GO) with <b style='color:Tomato;'><i>fludarabine</i></b>-<b style='color:Tomato;'><i>cytarabine</i></b>-<b style='color:Tomato;'><i>idarubicin</i></b> (FLAI) regimen, with the DMET Plus platform. Two ADH1A variants showed statistically significant differences (odds ratio (OR)=5.68, P=0.0006; OR=5.35, P=0.0009) in allele frequencies between patients in complete/partial remission and patients without response, two substitutions on CYP2E1 (OR=0.13, P=0.001; OR=0.09, P=0.003) and one on SLCO1B1 (OR=4.68, P=0.002) were found to differently influence liver toxicity, and two nucleotide changes on SULTB1 and SLC22A12 genes correlated with response to GO (OR=0.24, P=0.0009; OR=2.75, P=0.0029). Genetic variants were thus found for the first time to be potentially associated with differential response and toxicity in AML patients treated with a combination of GO-FLAI regimen.","tokens":[{"text":"Profiling","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"drug-metabolizing","start":13,"end":30,"id":2,"ws":true},{"text":"enzymes/transporters","start":31,"end":51,"id":3,"ws":true},{"text":"in","start":52,"end":54,"id":4,"ws":true},{"text":"CD33","start":55,"end":59,"id":5,"ws":true},{"text":"+","start":60,"end":61,"id":6,"ws":true},{"text":"acute","start":62,"end":67,"id":7,"ws":true},{"text":"myeloid","start":68,"end":75,"id":8,"ws":true},{"text":"leukemia","start":76,"end":84,"id":9,"ws":true},{"text":"patients","start":85,"end":93,"id":10,"ws":true},{"text":"treated","start":94,"end":101,"id":11,"ws":true},{"text":"with","start":102,"end":106,"id":12,"ws":true},{"text":"Gemtuzumab-Ozogamicin","start":107,"end":128,"id":13,"ws":true},{"text":"and","start":129,"end":132,"id":14,"ws":true},{"text":"Fludarabine","start":133,"end":144,"id":15,"ws":true},{"text":",","start":145,"end":146,"id":16,"ws":true},{"text":"Cytarabine","start":147,"end":157,"id":17,"ws":true},{"text":"and","start":158,"end":161,"id":18,"ws":true},{"text":"Idarubicin","start":162,"end":172,"id":19,"ws":true},{"text":".","start":173,"end":174,"id":20,"ws":false}],"spans":[{"start":133,"end":144,"token_start":15,"token_end":15,"label":"DRUG"},{"start":147,"end":157,"token_start":17,"token_end":17,"label":"DRUG"},{"start":162,"end":172,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22584460/","_input_hash":-1106265043,"_task_hash":609859858,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":107,"end":128,"token_start":13,"token_end":13,"label":null},"child_span":{"start":133,"end":144,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":17,"head_span":{"start":133,"end":144,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":147,"end":157,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":17,"child":19,"head_span":{"start":147,"end":157,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":162,"end":172,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"In addition , anti-PCSK9 drugs ( evolocumab and alirocumab ) provide an effective solution for patients with familial hypercholesterolemia ( FH ) and statin intolerance at very high cardiovascular risk .","paragraph":"<h3><u>Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs.</u></h3>Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, as they have been shown to reduce the risk of major vascular events by lowering low-density lipoprotein cholesterol (LDL-C). However, due to adherence to statin therapy or statin resistance, many patients do not reach LDL-C target levels. <b style='color:Tomato;'><i>ezetimibe</i></b>, fibrates, and nicotinic acid represent the second-choice drugs to be used in combination with statins if lipid targets cannot be reached. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>anti-PCSK9</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>evolocumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>alirocumab</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>provide</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>solution</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>familial</i></b> <b style='color:DodgerBlue;'><i>hypercholesterolemia</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FH</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>statin</i></b> <b style='color:DodgerBlue;'><i>intolerance</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Recently, studies demonstrated the effects of two novel lipid-lowering agents (<b style='color:Tomato;'><i>lomitapide</i></b> and mipomersen) for the management of homozygous FH by decreasing LDL-C values and reducing cardiovascular events. However, the costs for these new therapies made the cost-effectiveness debate more complicated.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"addition","start":3,"end":11,"id":1,"ws":true},{"text":",","start":12,"end":13,"id":2,"ws":true},{"text":"anti-PCSK9","start":14,"end":24,"id":3,"ws":true},{"text":"drugs","start":25,"end":30,"id":4,"ws":true},{"text":"(","start":31,"end":32,"id":5,"ws":true},{"text":"evolocumab","start":33,"end":43,"id":6,"ws":true},{"text":"and","start":44,"end":47,"id":7,"ws":true},{"text":"alirocumab","start":48,"end":58,"id":8,"ws":true},{"text":")","start":59,"end":60,"id":9,"ws":true},{"text":"provide","start":61,"end":68,"id":10,"ws":true},{"text":"an","start":69,"end":71,"id":11,"ws":true},{"text":"effective","start":72,"end":81,"id":12,"ws":true},{"text":"solution","start":82,"end":90,"id":13,"ws":true},{"text":"for","start":91,"end":94,"id":14,"ws":true},{"text":"patients","start":95,"end":103,"id":15,"ws":true},{"text":"with","start":104,"end":108,"id":16,"ws":true},{"text":"familial","start":109,"end":117,"id":17,"ws":true},{"text":"hypercholesterolemia","start":118,"end":138,"id":18,"ws":true},{"text":"(","start":139,"end":140,"id":19,"ws":true},{"text":"FH","start":141,"end":143,"id":20,"ws":true},{"text":")","start":144,"end":145,"id":21,"ws":true},{"text":"and","start":146,"end":149,"id":22,"ws":true},{"text":"statin","start":150,"end":156,"id":23,"ws":true},{"text":"intolerance","start":157,"end":168,"id":24,"ws":true},{"text":"at","start":169,"end":171,"id":25,"ws":true},{"text":"very","start":172,"end":176,"id":26,"ws":true},{"text":"high","start":177,"end":181,"id":27,"ws":true},{"text":"cardiovascular","start":182,"end":196,"id":28,"ws":true},{"text":"risk","start":197,"end":201,"id":29,"ws":true},{"text":".","start":202,"end":203,"id":30,"ws":false}],"spans":[{"start":33,"end":43,"token_start":6,"token_end":6,"label":"DRUG"},{"start":48,"end":58,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29361723/","_input_hash":1233389599,"_task_hash":-754149707,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Likewise , emotional , functional well-being , and QoL aspects specifically related to lung cancer were better improved in the Gefitinib group than in the Pemetrexed group ( P<0.05 ) .","paragraph":"<h3><u>[A randomized clinical study of Gefitinib and pemetrexed as second line therapy for advanced non-squamous non-small cell lung cancer].</u></h3><b style='color:Tomato;'><i>gefitinib</i></b> and <b style='color:Tomato;'><i>pemetrexed</i></b> are drugs used as second-line therapy for advanced non-small cell lung cancer (NSCLC), although studies comparing the two drugs are limited. The aim of this study is to explore the effects, safety, and quality of life (QoL) of <b style='color:Tomato;'><i>gefitinib</i></b> and <b style='color:Tomato;'><i>pemetrexed</i></b> on patients with advanced non-squamous NSCLC. ### methods Forty-six advanced non-squamous NSCLC patients who failed to first-line therapy were randomly divided into two groups with 23 patients each, one using oral <b style='color:Tomato;'><i>gefitinib</i></b> (<b style='color:Tomato;'><i>gefitinib</i></b> group) and the other using intravenous injection <b style='color:Tomato;'><i>pemetrexed</i></b> (<b style='color:Tomato;'><i>pemetrexed</i></b> group). The effects, safety, and QoL were determined and analyzed. ### results For the <b style='color:Tomato;'><i>pemetrexed</i></b> group, objective response rate (ORR) was 13.0% (3/23), disease control rate (DCR) was 30.4% (7/23), and median progression-free survival (mPFS) was 3.1 months. In the <b style='color:Tomato;'><i>gefitinib</i></b> group, ORR was 17.3% (4/23), DCR was 39.1% (9/23), and mPFS was 4.4 months. Compared with the <b style='color:Tomato;'><i>pemetrexed</i></b> group, the ORR, DCR, and mPFS in the <b style='color:Tomato;'><i>gefitinib</i></b> group exhibited no statistical significance (P>0.05). Furthermore, the most common toxicities in the <b style='color:Tomato;'><i>pemetrexed</i></b> group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in <b style='color:Tomato;'><i>gefitinib</i></b> group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%). Compared with baseline, the QoL improved in both groups but to different degrees. <b style='color:DodgerBlue;'><i>Likewise</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>emotional</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>functional</i></b> <b style='color:DodgerBlue;'><i>well-being</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>QoL</i></b> <b style='color:DodgerBlue;'><i>aspects</i></b> <b style='color:DodgerBlue;'><i>specifically</i></b> <b style='color:DodgerBlue;'><i>related</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>better</i></b> <b style='color:DodgerBlue;'><i>improved</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>Gefitinib</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>Pemetrexed</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>P<0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions The effects of <b style='color:Tomato;'><i>pemetrexed</i></b> and <b style='color:Tomato;'><i>gefitinib</i></b> as second line therapy were similar, although with different AEs. Both drugs could improve the QoL, but <b style='color:Tomato;'><i>gefitinib</i></b> showed better overall results than <b style='color:Tomato;'><i>pemetrexed</i></b>.","tokens":[{"text":"Likewise","start":0,"end":8,"id":0,"ws":true},{"text":",","start":9,"end":10,"id":1,"ws":true},{"text":"emotional","start":11,"end":20,"id":2,"ws":true},{"text":",","start":21,"end":22,"id":3,"ws":true},{"text":"functional","start":23,"end":33,"id":4,"ws":true},{"text":"well-being","start":34,"end":44,"id":5,"ws":true},{"text":",","start":45,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"QoL","start":51,"end":54,"id":8,"ws":true},{"text":"aspects","start":55,"end":62,"id":9,"ws":true},{"text":"specifically","start":63,"end":75,"id":10,"ws":true},{"text":"related","start":76,"end":83,"id":11,"ws":true},{"text":"to","start":84,"end":86,"id":12,"ws":true},{"text":"lung","start":87,"end":91,"id":13,"ws":true},{"text":"cancer","start":92,"end":98,"id":14,"ws":true},{"text":"were","start":99,"end":103,"id":15,"ws":true},{"text":"better","start":104,"end":110,"id":16,"ws":true},{"text":"improved","start":111,"end":119,"id":17,"ws":true},{"text":"in","start":120,"end":122,"id":18,"ws":true},{"text":"the","start":123,"end":126,"id":19,"ws":true},{"text":"Gefitinib","start":127,"end":136,"id":20,"ws":true},{"text":"group","start":137,"end":142,"id":21,"ws":true},{"text":"than","start":143,"end":147,"id":22,"ws":true},{"text":"in","start":148,"end":150,"id":23,"ws":true},{"text":"the","start":151,"end":154,"id":24,"ws":true},{"text":"Pemetrexed","start":155,"end":165,"id":25,"ws":true},{"text":"group","start":166,"end":171,"id":26,"ws":true},{"text":"(","start":172,"end":173,"id":27,"ws":true},{"text":"P<0.05","start":174,"end":180,"id":28,"ws":true},{"text":")","start":181,"end":182,"id":29,"ws":true},{"text":".","start":183,"end":184,"id":30,"ws":false}],"spans":[{"start":127,"end":136,"token_start":20,"token_end":20,"label":"DRUG"},{"start":155,"end":165,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23945243/","_input_hash":1859641829,"_task_hash":1091363367,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"To determine efficacy and safety of the association of IL-1 receptor antagonist anakinra plus methylprednisolone in severe COVID-19 pneumonia with hyperinflammation .","paragraph":"<h3><u>Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.</u></h3>Immunomodulants have been proposed to mitigate SARS-Cov-2-induced cytokine storm, which drives acute respiratory distress syndrome in COVID-19. ### objective <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>determine</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>association</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>IL-1</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>antagonist</i></b> <b style='color:MediumOrchid;'><i>anakinra</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>severe</i></b> <b style='color:DodgerBlue;'><i>COVID-19</i></b> <b style='color:DodgerBlue;'><i>pneumonia</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>hyperinflammation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Secondary analysis of prospective observational cohort studies at an Italian tertiary health-care facility. COVID-19 patients consecutively hospitalized (02/25/2020 to 03/30/2020), with hyperinflammation (ferritin \u22651000ng/mL and/or C-reactive protein >10mg/dL) and respiratory failure (oxygen therapy from 0.4 FiO2 Venturi mask to invasive mechanical ventilation) were evaluated to investigate the effect of high-dose <b style='color:Tomato;'><i>anakinra</i></b> plus <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> on survival. Patients were followed from study inclusion to day 28 or death. Crude and adjusted (sex, age, baseline PaO ### results 120 COVID-19 patients with hyperinflammation (median age 62 years, 80.0% males, median PaO ### conclusions Treatment with <b style='color:Tomato;'><i>anakinra</i></b> plus <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> may be a valid therapeutic option in COVID-19 patients with hyperinflammation and respiratory failure, also on mechanical ventilation. Randomized, controlled trials including use of either agent alone are needed to confirm these results.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"determine","start":3,"end":12,"id":1,"ws":true},{"text":"efficacy","start":13,"end":21,"id":2,"ws":true},{"text":"and","start":22,"end":25,"id":3,"ws":true},{"text":"safety","start":26,"end":32,"id":4,"ws":true},{"text":"of","start":33,"end":35,"id":5,"ws":true},{"text":"the","start":36,"end":39,"id":6,"ws":true},{"text":"association","start":40,"end":51,"id":7,"ws":true},{"text":"of","start":52,"end":54,"id":8,"ws":true},{"text":"IL-1","start":55,"end":59,"id":9,"ws":true},{"text":"receptor","start":60,"end":68,"id":10,"ws":true},{"text":"antagonist","start":69,"end":79,"id":11,"ws":true},{"text":"anakinra","start":80,"end":88,"id":12,"ws":true},{"text":"plus","start":89,"end":93,"id":13,"ws":true},{"text":"methylprednisolone","start":94,"end":112,"id":14,"ws":true},{"text":"in","start":113,"end":115,"id":15,"ws":true},{"text":"severe","start":116,"end":122,"id":16,"ws":true},{"text":"COVID-19","start":123,"end":131,"id":17,"ws":true},{"text":"pneumonia","start":132,"end":141,"id":18,"ws":true},{"text":"with","start":142,"end":146,"id":19,"ws":true},{"text":"hyperinflammation","start":147,"end":164,"id":20,"ws":true},{"text":".","start":165,"end":166,"id":21,"ws":false}],"spans":[{"start":80,"end":88,"token_start":12,"token_end":12,"label":"DRUG"},{"start":94,"end":112,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33220354/","_input_hash":-84801278,"_task_hash":-1044793918,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":80,"end":88,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":94,"end":112,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"When rats were given Li for 3 days , followed by a single injection of imipramine , the concentrations of desipramine in the brain and serum were higher than those in the vehicle-treated rat , although the imipramine concentrations in both tissues did not differ in Li- and in vehicle-treated rats .","paragraph":"<h3><u>Effects of lithium on alterations of pharmacokinetics of imipramine and on the related changes of monoamines in rat brain.</u></h3>Rats were given chronically i.p. <b style='color:Tomato;'><i>imipramine</i></b> (20 mg/kg), LiCl (1 mg/kg) or both drugs to examine the effects of lithium (Li) on the alterations of <b style='color:Tomato;'><i>imipramine</i></b> pharmacokinetics in the whole brain and on the <b style='color:Tomato;'><i>imipramine</i></b>-related changes of nor<b style='color:Tomato;'><i>epinephrine</i></b> (NE) and serotonin (5-HT) levels in the brain. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>Li</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>injection</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>imipramine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>desipramine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>vehicle-treated</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>although</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>imipramine</i></b> <b style='color:DodgerBlue;'><i>concentrations</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>tissues</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>differ</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Li-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vehicle-treated</i></b> <b style='color:DodgerBlue;'><i>rats</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In rats receiving both drugs for 10 days, the steady state levels of <b style='color:Tomato;'><i>imipramine</i></b> and <b style='color:Tomato;'><i>desipramine</i></b> in the brain were the same as those in the vehicle-treated rats but the steady state level of <b style='color:Tomato;'><i>desipramine</i></b> was reached earlier with Li treatments presumably because of the enhanced demethylation of <b style='color:Tomato;'><i>imipramine</i></b>. Consequently, the <b style='color:Tomato;'><i>desipramine</i></b>-dependent alterations of NE and 3-methoxy-4-hydroxyphenylglycol levels in the brain appeared to be induced earlier and more markedly when Li was given simultaneously. As the 5-hydroxyindole acetic acid (5-HIAA) levels were elevated in the brains of Li-treated rats and reduced in brains of <b style='color:Tomato;'><i>imipramine</i></b>-treated rats as compared with the level in vehicle-treated rats, the 5-HIAA level in rats receiving both drugs was equivalent to that in vehicle-treated rats.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"rats","start":5,"end":9,"id":1,"ws":true},{"text":"were","start":10,"end":14,"id":2,"ws":true},{"text":"given","start":15,"end":20,"id":3,"ws":true},{"text":"Li","start":21,"end":23,"id":4,"ws":true},{"text":"for","start":24,"end":27,"id":5,"ws":true},{"text":"3","start":28,"end":29,"id":6,"ws":true},{"text":"days","start":30,"end":34,"id":7,"ws":true},{"text":",","start":35,"end":36,"id":8,"ws":true},{"text":"followed","start":37,"end":45,"id":9,"ws":true},{"text":"by","start":46,"end":48,"id":10,"ws":true},{"text":"a","start":49,"end":50,"id":11,"ws":true},{"text":"single","start":51,"end":57,"id":12,"ws":true},{"text":"injection","start":58,"end":67,"id":13,"ws":true},{"text":"of","start":68,"end":70,"id":14,"ws":true},{"text":"imipramine","start":71,"end":81,"id":15,"ws":true},{"text":",","start":82,"end":83,"id":16,"ws":true},{"text":"the","start":84,"end":87,"id":17,"ws":true},{"text":"concentrations","start":88,"end":102,"id":18,"ws":true},{"text":"of","start":103,"end":105,"id":19,"ws":true},{"text":"desipramine","start":106,"end":117,"id":20,"ws":true},{"text":"in","start":118,"end":120,"id":21,"ws":true},{"text":"the","start":121,"end":124,"id":22,"ws":true},{"text":"brain","start":125,"end":130,"id":23,"ws":true},{"text":"and","start":131,"end":134,"id":24,"ws":true},{"text":"serum","start":135,"end":140,"id":25,"ws":true},{"text":"were","start":141,"end":145,"id":26,"ws":true},{"text":"higher","start":146,"end":152,"id":27,"ws":true},{"text":"than","start":153,"end":157,"id":28,"ws":true},{"text":"those","start":158,"end":163,"id":29,"ws":true},{"text":"in","start":164,"end":166,"id":30,"ws":true},{"text":"the","start":167,"end":170,"id":31,"ws":true},{"text":"vehicle-treated","start":171,"end":186,"id":32,"ws":true},{"text":"rat","start":187,"end":190,"id":33,"ws":true},{"text":",","start":191,"end":192,"id":34,"ws":true},{"text":"although","start":193,"end":201,"id":35,"ws":true},{"text":"the","start":202,"end":205,"id":36,"ws":true},{"text":"imipramine","start":206,"end":216,"id":37,"ws":true},{"text":"concentrations","start":217,"end":231,"id":38,"ws":true},{"text":"in","start":232,"end":234,"id":39,"ws":true},{"text":"both","start":235,"end":239,"id":40,"ws":true},{"text":"tissues","start":240,"end":247,"id":41,"ws":true},{"text":"did","start":248,"end":251,"id":42,"ws":true},{"text":"not","start":252,"end":255,"id":43,"ws":true},{"text":"differ","start":256,"end":262,"id":44,"ws":true},{"text":"in","start":263,"end":265,"id":45,"ws":true},{"text":"Li-","start":266,"end":269,"id":46,"ws":true},{"text":"and","start":270,"end":273,"id":47,"ws":true},{"text":"in","start":274,"end":276,"id":48,"ws":true},{"text":"vehicle-treated","start":277,"end":292,"id":49,"ws":true},{"text":"rats","start":293,"end":297,"id":50,"ws":true},{"text":".","start":298,"end":299,"id":51,"ws":false}],"spans":[{"start":21,"end":23,"token_start":4,"token_end":4,"label":"DRUG"},{"start":71,"end":81,"token_start":15,"token_end":15,"label":"DRUG"},{"start":106,"end":117,"token_start":20,"token_end":20,"label":"DRUG"},{"start":206,"end":216,"token_start":37,"token_end":37,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2625134/","_input_hash":-386093514,"_task_hash":-1278757705,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":4,"child":15,"head_span":{"start":21,"end":23,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":71,"end":81,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Using population-based data from the province of Ontario , the benefit of first-line ipilimumab was estimated by comparing outcomes of patients treated with first-line dacarbazine over the period 2007 - 2009 with patients treated over the period 2010 - 2015 with first-line ipilimumab .","paragraph":"<h3><u>A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.</u></h3><b style='color:Tomato;'><i>ipilimumab</i></b> is an anti-CTLA4 monoclonal antibody with demonstrated efficacy for metastatic melanoma in randomized controlled trials, including in the first-line setting. Population-based outcomes directly compared with historic chemotherapy treatment in metastatic or unresectable melanoma are lacking. <b style='color:DodgerBlue;'><i>Using</i></b> <b style='color:DodgerBlue;'><i>population-based</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>province</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Ontario</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>estimated</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>period</i></b> <b style='color:DodgerBlue;'><i>2007</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2009</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>period</i></b> <b style='color:DodgerBlue;'><i>2010</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>2015</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Cutaneous and noncutaneous cases were included. The administrative data set utilized was high-dimensional; meaning, there was a large number of variables relative to the sample size. To adjust for important confounders among the many available variables, we utilized a double-selection method, a modified machine learning algorithm to extract the important variables that were related to both survival times and treatment usage. Time-dependent treatment modeling was utilized. Among the 2793 melanoma patients receiving palliative treatment (systemic therapy, surgery, or radiation) in Ontario (2007-2015), there were 289 patients treated with first-line <b style='color:Tomato;'><i>ipilimumab</i></b> (2010-2015) and 175 patients treated with first-line <b style='color:Tomato;'><i>dacarbazine</i></b> (2007-2009). For first-line <b style='color:Tomato;'><i>ipilimumab</i></b>, the adjusted hazard ratio compared with <b style='color:Tomato;'><i>dacarbazine</i></b> for overall survival (OS) was 0.63 (95% confidence interval: 0.47-0.84) with a 1-year survival of 46.5 versus 18.9% with <b style='color:Tomato;'><i>dacarbazine</i></b>. In subgroup analysis, <b style='color:Tomato;'><i>ipilimumab</i></b> was associated with improved OS across groups (age, sex, comorbidity, income quintile, previous interferon). First-line <b style='color:Tomato;'><i>ipilimumab</i></b> was found to have a significant OS benefit compared with historical controls in a population including those patients not routinely included in clinical trials. The treatment effect was similar to randomized controlled trials, suggesting a meaningful benefit when utilized in a population-based setting.","tokens":[{"text":"Using","start":0,"end":5,"id":0,"ws":true},{"text":"population-based","start":6,"end":22,"id":1,"ws":true},{"text":"data","start":23,"end":27,"id":2,"ws":true},{"text":"from","start":28,"end":32,"id":3,"ws":true},{"text":"the","start":33,"end":36,"id":4,"ws":true},{"text":"province","start":37,"end":45,"id":5,"ws":true},{"text":"of","start":46,"end":48,"id":6,"ws":true},{"text":"Ontario","start":49,"end":56,"id":7,"ws":true},{"text":",","start":57,"end":58,"id":8,"ws":true},{"text":"the","start":59,"end":62,"id":9,"ws":true},{"text":"benefit","start":63,"end":70,"id":10,"ws":true},{"text":"of","start":71,"end":73,"id":11,"ws":true},{"text":"first-line","start":74,"end":84,"id":12,"ws":true},{"text":"ipilimumab","start":85,"end":95,"id":13,"ws":true},{"text":"was","start":96,"end":99,"id":14,"ws":true},{"text":"estimated","start":100,"end":109,"id":15,"ws":true},{"text":"by","start":110,"end":112,"id":16,"ws":true},{"text":"comparing","start":113,"end":122,"id":17,"ws":true},{"text":"outcomes","start":123,"end":131,"id":18,"ws":true},{"text":"of","start":132,"end":134,"id":19,"ws":true},{"text":"patients","start":135,"end":143,"id":20,"ws":true},{"text":"treated","start":144,"end":151,"id":21,"ws":true},{"text":"with","start":152,"end":156,"id":22,"ws":true},{"text":"first-line","start":157,"end":167,"id":23,"ws":true},{"text":"dacarbazine","start":168,"end":179,"id":24,"ws":true},{"text":"over","start":180,"end":184,"id":25,"ws":true},{"text":"the","start":185,"end":188,"id":26,"ws":true},{"text":"period","start":189,"end":195,"id":27,"ws":true},{"text":"2007","start":196,"end":200,"id":28,"ws":true},{"text":"-","start":201,"end":202,"id":29,"ws":true},{"text":"2009","start":203,"end":207,"id":30,"ws":true},{"text":"with","start":208,"end":212,"id":31,"ws":true},{"text":"patients","start":213,"end":221,"id":32,"ws":true},{"text":"treated","start":222,"end":229,"id":33,"ws":true},{"text":"over","start":230,"end":234,"id":34,"ws":true},{"text":"the","start":235,"end":238,"id":35,"ws":true},{"text":"period","start":239,"end":245,"id":36,"ws":true},{"text":"2010","start":246,"end":250,"id":37,"ws":true},{"text":"-","start":251,"end":252,"id":38,"ws":true},{"text":"2015","start":253,"end":257,"id":39,"ws":true},{"text":"with","start":258,"end":262,"id":40,"ws":true},{"text":"first-line","start":263,"end":273,"id":41,"ws":true},{"text":"ipilimumab","start":274,"end":284,"id":42,"ws":true},{"text":".","start":285,"end":286,"id":43,"ws":false}],"spans":[{"start":85,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},{"start":168,"end":179,"token_start":24,"token_end":24,"label":"DRUG"},{"start":274,"end":284,"token_start":42,"token_end":42,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30789386/","_input_hash":-1307283051,"_task_hash":-848490144,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In the present study the combination of tamoxifen and bromocriptine was tried for the suppression of prolactin in prolactin secreting adenomas which were resistant to suppression with bromoergocriptine alone .","paragraph":"<h3><u>[Bromocriptine and tamoxifen--a new therapeutic approach in suppression-resistant prolactin-secreting adenomas].</u></h3> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bromocriptine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>tried</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>suppression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>prolactin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>prolactin</i></b> <b style='color:DodgerBlue;'><i>secreting</i></b> <b style='color:DodgerBlue;'><i>adenomas</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>suppression</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>bromoergocriptine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> 10 women under treatment with 2.5-10 mg of parlodel (<b style='color:Tomato;'><i>bromocriptine</i></b>) for pituitary tumours of various sizes were additionally treated with <b style='color:Tomato;'><i>tamoxifen</i></b> 10-20 mg. (nolvadex) daily. Two patients had a previous incomplete resection for chromophobe adenomas. The other patients refused operation. Two women were also studied who did not tolerate a bromoergocriptine therapy because of side effects. In 6 of the 10 women with combination treatment a satisfactory suppression of the prolactin was observed. Four women were cleared of their amenorrhoea and galactorrhoea. One woman conceived. One woman lost her frigidity. Three women, among those the two with severe side effects from bromoergocriptine, tolerated the combined treatment well. Four women showed no success with the combined treatment. The effectiveness of the combined treatment was not correlated with the size of the tumour nor the clinical or biochemical baseline. The results lead to the conclusion that <b style='color:Tomato;'><i>tamoxifen</i></b> is capable of improving the suppression of prolactin or render the adenomas suppressible in a large number of cases.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"study","start":15,"end":20,"id":3,"ws":true},{"text":"the","start":21,"end":24,"id":4,"ws":true},{"text":"combination","start":25,"end":36,"id":5,"ws":true},{"text":"of","start":37,"end":39,"id":6,"ws":true},{"text":"tamoxifen","start":40,"end":49,"id":7,"ws":true},{"text":"and","start":50,"end":53,"id":8,"ws":true},{"text":"bromocriptine","start":54,"end":67,"id":9,"ws":true},{"text":"was","start":68,"end":71,"id":10,"ws":true},{"text":"tried","start":72,"end":77,"id":11,"ws":true},{"text":"for","start":78,"end":81,"id":12,"ws":true},{"text":"the","start":82,"end":85,"id":13,"ws":true},{"text":"suppression","start":86,"end":97,"id":14,"ws":true},{"text":"of","start":98,"end":100,"id":15,"ws":true},{"text":"prolactin","start":101,"end":110,"id":16,"ws":true},{"text":"in","start":111,"end":113,"id":17,"ws":true},{"text":"prolactin","start":114,"end":123,"id":18,"ws":true},{"text":"secreting","start":124,"end":133,"id":19,"ws":true},{"text":"adenomas","start":134,"end":142,"id":20,"ws":true},{"text":"which","start":143,"end":148,"id":21,"ws":true},{"text":"were","start":149,"end":153,"id":22,"ws":true},{"text":"resistant","start":154,"end":163,"id":23,"ws":true},{"text":"to","start":164,"end":166,"id":24,"ws":true},{"text":"suppression","start":167,"end":178,"id":25,"ws":true},{"text":"with","start":179,"end":183,"id":26,"ws":true},{"text":"bromoergocriptine","start":184,"end":201,"id":27,"ws":true},{"text":"alone","start":202,"end":207,"id":28,"ws":true},{"text":".","start":208,"end":209,"id":29,"ws":false}],"spans":[{"start":40,"end":49,"token_start":7,"token_end":7,"label":"DRUG"},{"start":54,"end":67,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6924910/","_input_hash":712663056,"_task_hash":1607711575,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":40,"end":49,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":54,"end":67,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The present case suggests that combination therapy with thalidomide and dexamethasone is still an alternative treatment regimen for resistant extramedullary plasmacytoma with a plasmablastic morphology .","paragraph":"<h3><u>Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone.</u></h3>A 74-year-old man with multiple myeloma was refractory to <b style='color:Tomato;'><i>melphalan</i></b>/<b style='color:Tomato;'><i>prednisolone</i></b> (MP), high-dose <b style='color:Tomato;'><i>dexamethasone</i></b> and VAD chemotherapy. He had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells. Combination therapy with <b style='color:Tomato;'><i>thalidomide</i></b> and <b style='color:Tomato;'><i>dexamethasone</i></b> resulted in a rapid response and a partial remission despite his multiple poor prognostic factors. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>case</i></b> <b style='color:DodgerBlue;'><i>suggests</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>thalidomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>still</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>alternative</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>extramedullary</i></b> <b style='color:DodgerBlue;'><i>plasmacytoma</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>plasmablastic</i></b> <b style='color:DodgerBlue;'><i>morphology</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"present","start":4,"end":11,"id":1,"ws":true},{"text":"case","start":12,"end":16,"id":2,"ws":true},{"text":"suggests","start":17,"end":25,"id":3,"ws":true},{"text":"that","start":26,"end":30,"id":4,"ws":true},{"text":"combination","start":31,"end":42,"id":5,"ws":true},{"text":"therapy","start":43,"end":50,"id":6,"ws":true},{"text":"with","start":51,"end":55,"id":7,"ws":true},{"text":"thalidomide","start":56,"end":67,"id":8,"ws":true},{"text":"and","start":68,"end":71,"id":9,"ws":true},{"text":"dexamethasone","start":72,"end":85,"id":10,"ws":true},{"text":"is","start":86,"end":88,"id":11,"ws":true},{"text":"still","start":89,"end":94,"id":12,"ws":true},{"text":"an","start":95,"end":97,"id":13,"ws":true},{"text":"alternative","start":98,"end":109,"id":14,"ws":true},{"text":"treatment","start":110,"end":119,"id":15,"ws":true},{"text":"regimen","start":120,"end":127,"id":16,"ws":true},{"text":"for","start":128,"end":131,"id":17,"ws":true},{"text":"resistant","start":132,"end":141,"id":18,"ws":true},{"text":"extramedullary","start":142,"end":156,"id":19,"ws":true},{"text":"plasmacytoma","start":157,"end":169,"id":20,"ws":true},{"text":"with","start":170,"end":174,"id":21,"ws":true},{"text":"a","start":175,"end":176,"id":22,"ws":true},{"text":"plasmablastic","start":177,"end":190,"id":23,"ws":true},{"text":"morphology","start":191,"end":201,"id":24,"ws":true},{"text":".","start":202,"end":203,"id":25,"ws":false}],"spans":[{"start":56,"end":67,"token_start":8,"token_end":8,"label":"DRUG"},{"start":72,"end":85,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19834276/","_input_hash":1939938823,"_task_hash":1642536107,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":56,"end":67,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":72,"end":85,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Among 788 eligible patients , the median ( SD ) age was 59 ( 22 - 74 ) years ; 263 patients were assigned to doxorubicin plus cisplatin treatment , 263 patients to docetaxel plus cisplatin treatment , and 262 patients to paclitaxel plus carboplatin treatment .","paragraph":"<h3><u>Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.</u></h3>The efficacy of taxane plus platinum regimens has been demonstrated for advanced or recurrent endometrial cancer; however, it has not been assessed in postoperative adjuvant chemotherapy for endometrial cancer. ### objective To evaluate the clinical benefit of taxane plus platinum compared with standard <b style='color:Tomato;'><i>doxorubicin</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b> as postoperative adjuvant chemotherapy in endometrial cancer. ### Design Setting And Participants In this multicenter, open-label, phase 3 randomized clinical trial, patients with endometrial cancer at high-risk stage I or II or stage III or IV that did not extend beyond the abdominal cavity and had 2 cm or greater residual tumor were included from 118 institutions in Japan from November 24, 2006, to January 7, 2011. Data was analyzed from March 15, 2017, to June 30, 2017. ### interventions Eligible patients were randomly assigned (1:1:1) to receive 6 cycles of <b style='color:Tomato;'><i>doxorubicin</i></b>, 60 mg/m2, plus <b style='color:Tomato;'><i>cisplatin</i></b>, 50 mg/m2, on day 1; <b style='color:Tomato;'><i>docetaxel</i></b>, 70 mg/m2, plus <b style='color:Tomato;'><i>cisplatin</i></b>, 60 mg/m2, on day 1; or <b style='color:Tomato;'><i>paclitaxel</i></b>, 180 mg/m2, plus <b style='color:Tomato;'><i>carboplatin</i></b> (area under the curve, 6.0 mg/mL\u2009\u00d7\u2009min) on day 1 every 3 weeks. ### Main Outcomes And Measures The primary end point was progression-free survival. Secondary end points were overall survival, occurrence of adverse events, tolerability, and status of lymph node dissection. ### results <b style='color:DodgerBlue;'><i>Among</i></b> <b style='color:DodgerBlue;'><i>788</i></b> <b style='color:DodgerBlue;'><i>eligible</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>SD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>59</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>22</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>74</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>263</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>263</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>262</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The number of patients who did not complete 6 cycles was 53 (20.1%) for the <b style='color:Tomato;'><i>doxorubicin</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b> group, 45 (17.1%) for the <b style='color:Tomato;'><i>docetaxel</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b> group, and 63 (24.0%) for the <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b> group. Tolerability of these regimens were not statistically different. After a median follow-up period of 7 years, there was no statistical difference of progression-free survival (<b style='color:Tomato;'><i>doxorubicin</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b>, 191; <b style='color:Tomato;'><i>docetaxel</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b>, 208; <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b>, 187; P\u2009=\u2009.12) or overall survival (<b style='color:Tomato;'><i>doxorubicin</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b>, 217; <b style='color:Tomato;'><i>docetaxel</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b>, 223; <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b>, 215; P\u2009=\u2009.67) among the 3 groups. The 5-year progression-free survival rate was 73.3% for the <b style='color:Tomato;'><i>doxorubicin</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b> group, 79.0% for the <b style='color:Tomato;'><i>docetaxel</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b> group, and 73.9% for the <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b> group, while the 5-year overall survival rates were 82.7%, 88.1%, and 86.1%, respectively. ### Conclusions And Relevance There was no significant difference of survival among patients receiving <b style='color:Tomato;'><i>doxorubicin</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b>, <b style='color:Tomato;'><i>docetaxel</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b>, or <b style='color:Tomato;'><i>paclitaxel</i></b> plus <b style='color:Tomato;'><i>carboplatin</i></b> as postoperative adjuvant chemotherapy for endometrial cancer. Because each regimen showed adequate tolerability but different toxic effects, taxane plus platinum regimens may be a reasonable alternative to treatment with <b style='color:Tomato;'><i>doxorubicin</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b>. ### Trial Registration UMIN-CTR identifier: UMIN000000522.","tokens":[{"text":"Among","start":0,"end":5,"id":0,"ws":true},{"text":"788","start":6,"end":9,"id":1,"ws":true},{"text":"eligible","start":10,"end":18,"id":2,"ws":true},{"text":"patients","start":19,"end":27,"id":3,"ws":true},{"text":",","start":28,"end":29,"id":4,"ws":true},{"text":"the","start":30,"end":33,"id":5,"ws":true},{"text":"median","start":34,"end":40,"id":6,"ws":true},{"text":"(","start":41,"end":42,"id":7,"ws":true},{"text":"SD","start":43,"end":45,"id":8,"ws":true},{"text":")","start":46,"end":47,"id":9,"ws":true},{"text":"age","start":48,"end":51,"id":10,"ws":true},{"text":"was","start":52,"end":55,"id":11,"ws":true},{"text":"59","start":56,"end":58,"id":12,"ws":true},{"text":"(","start":59,"end":60,"id":13,"ws":true},{"text":"22","start":61,"end":63,"id":14,"ws":true},{"text":"-","start":64,"end":65,"id":15,"ws":true},{"text":"74","start":66,"end":68,"id":16,"ws":true},{"text":")","start":69,"end":70,"id":17,"ws":true},{"text":"years","start":71,"end":76,"id":18,"ws":true},{"text":";","start":77,"end":78,"id":19,"ws":true},{"text":"263","start":79,"end":82,"id":20,"ws":true},{"text":"patients","start":83,"end":91,"id":21,"ws":true},{"text":"were","start":92,"end":96,"id":22,"ws":true},{"text":"assigned","start":97,"end":105,"id":23,"ws":true},{"text":"to","start":106,"end":108,"id":24,"ws":true},{"text":"doxorubicin","start":109,"end":120,"id":25,"ws":true},{"text":"plus","start":121,"end":125,"id":26,"ws":true},{"text":"cisplatin","start":126,"end":135,"id":27,"ws":true},{"text":"treatment","start":136,"end":145,"id":28,"ws":true},{"text":",","start":146,"end":147,"id":29,"ws":true},{"text":"263","start":148,"end":151,"id":30,"ws":true},{"text":"patients","start":152,"end":160,"id":31,"ws":true},{"text":"to","start":161,"end":163,"id":32,"ws":true},{"text":"docetaxel","start":164,"end":173,"id":33,"ws":true},{"text":"plus","start":174,"end":178,"id":34,"ws":true},{"text":"cisplatin","start":179,"end":188,"id":35,"ws":true},{"text":"treatment","start":189,"end":198,"id":36,"ws":true},{"text":",","start":199,"end":200,"id":37,"ws":true},{"text":"and","start":201,"end":204,"id":38,"ws":true},{"text":"262","start":205,"end":208,"id":39,"ws":true},{"text":"patients","start":209,"end":217,"id":40,"ws":true},{"text":"to","start":218,"end":220,"id":41,"ws":true},{"text":"paclitaxel","start":221,"end":231,"id":42,"ws":true},{"text":"plus","start":232,"end":236,"id":43,"ws":true},{"text":"carboplatin","start":237,"end":248,"id":44,"ws":true},{"text":"treatment","start":249,"end":258,"id":45,"ws":true},{"text":".","start":259,"end":260,"id":46,"ws":false}],"spans":[{"start":109,"end":120,"token_start":25,"token_end":25,"label":"DRUG"},{"start":126,"end":135,"token_start":27,"token_end":27,"label":"DRUG"},{"start":164,"end":173,"token_start":33,"token_end":33,"label":"DRUG"},{"start":179,"end":188,"token_start":35,"token_end":35,"label":"DRUG"},{"start":221,"end":231,"token_start":42,"token_end":42,"label":"DRUG"},{"start":237,"end":248,"token_start":44,"token_end":44,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30896757/","_input_hash":-1594167191,"_task_hash":-548868786,"_session_id":"drug_drug_test_set_3-dana_a","_view_id":"blocks","relations":[{"head":25,"child":27,"head_span":{"start":109,"end":120,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":126,"end":135,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":33,"child":35,"head_span":{"start":164,"end":173,"token_start":33,"token_end":33,"label":"DRUG"},"child_span":{"start":179,"end":188,"token_start":35,"token_end":35,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":42,"child":44,"head_span":{"start":221,"end":231,"token_start":42,"token_end":42,"label":"DRUG"},"child_span":{"start":237,"end":248,"token_start":44,"token_end":44,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS11","POS21","POS31"],"answer":"accept"}
